

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: November 6, 2004, 23:33:52 ; Search time 406 seconds
(without alignments)
3038.458 Million cell updates/sec

Title: US-09-914-053A-5

Perfect score: 1241

Sequence: 1 MSWTSGRTSSSVRHDEKRN.....MVKLTQYLSLCCRIQRINR 235

Scoring table: BLCSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 8269772

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Command line parameters:

-MODE=frame+p2n.model -DEV=xlp
-Q=/cgn2.1/USPTO.spool.p/US0914053/runat_04112004.183921.18210/app.query.fasta_1.391
-DB=N_Geneseq_23Sep04 -CFMR=fastap -SUFFIX=ring -MINMATCH=0.1 -LOOPEXT=0
-LOOPEXT=0 -UNIT=bits -START=1 -END=1 -MATRIX=biosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR SCORE=pt -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pt -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US0914053 @CGN 1.1.708 @runat_04112004.183921.18210 -NCPU=6 -ICPU=3
-NO MAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N_Geneseq_23Sep04:*

- 1: Geneseqn1980s:*
- 2: Geneseqn1990s:*
- 3: Geneseqn2000s:*
- 4: Geneseqn2001as:*
- 5: Geneseqn2001bs:*
- 6: Geneseqn2002as:*
- 7: Geneseqn2002bs:*
- 8: Geneseqn2003as:*
- 9: Geneseqn2003bs:*
- 10: Geneseqn2003cs:*
- 11: Geneseqn2003ds:*
- 12: Geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1235	99.5	1184	AAF27991	Aaf27991 Human cal
2	1228	99.0	1300	AAZ51632	Aaz51632 Human mem
3	1216	98.0	707	AAZ75011	Aaz75011 DNA encod
4	1012	81.5	2098	AAZ63355	Aaz63355 Human sec
5	1012	81.5	2098	ADA39669	Ada39669 Human sec
6	1012	81.5	2098	ADA55858	Ada55858 Gene encod

7	1012	81.5	2098	12	ADL71416	Adl71416 Novel hum
8	481.5	38.8	1246	2	AAZ11912	Aaz11912 Human pot
9	481	38.8	558	4	ABA09433	Aba09433 Human K c
10	478.5	38.6	1237	4	AAF27992	Aaf27992 Human cal
11	478	38.5	1111	2	AAZ11913	Aaz11913 Human pot
12	477.5	38.5	1144	4	AAK52128	Aak52128 Human pot
13	477.5	38.5	1251	4	ABA09214	Aba09214 Human Ca-
14	477.5	38.5	1251	4	AAK53112	Aak53112 Human pol
15	474	38.2	1296	4	AAZ75009	Aaz75009 DNA encod
16	474	38.2	1296	4	AAF27995	Aaf27995 Human cal
17	474	38.2	1632	4	AAF27993	Aaf27993 Human cal
18	464.5	37.4	1759	4	AAF27994	Aaf27994 Human cal
19	421	33.9	1106	2	AAK06477	Aak06477 Human cal
20	421	33.9	1277	6	ABL69681	Abi69681 Prostate
21	421	33.9	1277	10	ADD14749	Adi14749 Human src
22	383	30.9	2238	2	AAK06476	Aac06476 Bovine ca
23	352	28.4	608	4	AAK02267	Aai02267 Human rep
24	319	25.7	1228	2	AAK82099	Aax82099 Human cal
25	318	25.6	1501	3	AAK75815	Aak75815 Human ORF
26	318	25.6	1608	3	AAZ22298	Aaz22298 Human pot
27	316	25.5	633	3	AAK75010	Aak75010 DNA encod
C 28	207	16.7	11000	12	ADO34927_0	Ado34927 Human vol
C 29	195	15.7	7045	4	ABA07292	Aba07292 Human pan
C 30	195	15.7	7045	4	AAK89937	Aak89937 Human dig
31	195	15.7	7045	4	AAK37429	Aal37429 Human mus
32	195	15.7	7045	8	ABX60417	Abx60417 cDNA enco
33	195	15.7	7045	12	ADJ31167	Adj31167 Human mus
34	177	14.3	394	3	AAK03613	Aac03613 Human sec
35	151.5	12.2	898	6	ABQ25377	Abq25377 Oligonucl
C 36	151.5	12.2	898	6	ABQ25376	Abq25376 Oligonucl
37	150	12.1	285	2	AAK22677	Aat22677 Human gen
38	148	11.9	898	6	ABQ25374	Abq25374 Oligonucl
C 39	148	11.9	898	6	ABQ25375	Abq25375 Oligonucl
40	138.5	11.2	48000	4	AAF27996	Aaf27996 Human cal
41	132	10.6	188	3	AAK07442	Aac07442 Human sec
42	125.5	10.1	2787	5	AAK77593	Aas77593 DNA encod
43	125.5	10.1	2787	5	AAK82312	Aas82312 DNA encod
44	125.5	10.1	2787	5	AAK77413	Aas77413 DNA encod
C 45	120.5	9.7	345	12	ADO35048	Ado35048 Human KCh

ALIGNMENTS

RESULT 1
AAF27991
ID AAF27991 standard; DNA; 1184 BP.
XX
AC AAF27991;
XX
DT 08-MAY-2001 (first entry)
XX
DE Human calcium sensitive potassium channel beta2 subunit coding sequence.
XX
KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;
KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;
KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;
KW irritable bowel syndrome; Alzheimer's disease; ds.
XX
OS Homo sapiens.
XX
PN WO200105828-A1.
XX
PD 25-JAN-2001.
XX
PF 18-JUL-2000; 2000WO-US019585.
XX
PR 20-JUL-1999; 99US-0144764P.
XX
PA (MERI) MERCK & CO INC.
XX
PI Uebele V, Swanson R, Liu Y, Lagrutta A;
XX
DR WPI; 2001-159514/16.

DR P-ESDB; AAB35301.

XX Novel human calcium sensitive potassium channel subunits for identifying
PT inhibitors and agonists of the potassium channel for use in treating
PT conditions such as asthma, hypertension, memory disorders, depression.

XX Claim 3; Fig 1A; 89pp; English.

XX The present invention provides the protein and coding sequences of the
CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c
CC and beta3d subunits. These can be used to identify inhibitors and
CC activators of the channels, which can be used in the treatment of
CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,
CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,
CC incontinence, migraine and irritable bowel syndrome. The coding sequences
CC are found at human chromosome 3q23-ter. The present sequence is the beta2
CC subunit coding sequence

XX Sequence 1184 BP; 356 A; 260 C; 255 G; 313 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 5.92e-134 Length: 1184
Score: 1235.00 Matches: 234
Percent Similarity: 99.57% Conservative: 1
Best Local Similarity: 99.57% Mismatches: 0
Query Match: 99.52% Indels: 0
DB: 4 Gaps: 0

US-09-914-053A-5 (1-235) x AAF27991 (1-1184)

QY 1 MetSerIleTrpThrSerGlyArgThrSerSerTyrArgHisAspGluLysArgAsn 20
DB 271 ATGTTTATATGACGACGTCGCGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 330
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
DB 331 ATTTACCAGAAATCAGGGACCATGCTCTCTGGACAAAAGGAAACAGTCACGACACTG 390
QY 41 LysAlaGlyGluAspArgAlaIleLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 391 AAGCAGAGAGAGACGACGATTTCTCTGGAGCTGCTATGATGGTGCTCCATCATG 450
QY 61 MetTyrPheLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80
DB 451 ATGTTATTTCTGCTGGGAATCACACTCTCTGCTCATACATGACAGCGTGTGGACCGAA 510
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAenCysSerPheSer 100
DB 511 GAGTCTCAATGACCTTGCTGAATGCTGCATCATCGGAAACATTTAACTGCTCTCTCAGC 570
QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
DB 571 TGTGTCAGACTGCTGAAACTTCTCAGTACCTGCTCCAGGTGTACGTTAACCTG 630
QY 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
DB 631 ACTTCTTCCGGGAAAAGCTCTCTCTACACACAGAGACAAATAAAATCAATCAG 690
QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
DB 691 AAGTGCTCTTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTCGTGAAT 750
QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
DB 751 GTTGTCTAGGAAAATCTCAGGAAGTATCAACACTTCTCGTATTTCTGACCCAGAGGA 810
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
DB 811 AACAGAGAGAGTGTATCTTACCAAACTCTACAGTTCACAGTGTCTGTTCCATTCACTC 870
QY 201 PheTrpProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
DB 871 TTCTGGCCAACTGATGATGGCTGGGGGTGTGGCAATTGTTGCCATGTTGAAACTTACA 930

QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
DB 931 CAGTACCTCTCCCTACTATGTGAGAGGATCCACGGATCAATAGA 975

RESULT 2

AAZ51632
ID AAZ51632 standard; cDNA; 1300 BP.

XX AAZ51632;

XX 21-JUN-2000 (first entry)

DE Human membrane channel protein-16 (MECHP-16) cDNA.

XX Membrane channel protein-16; MECHP-16; diagnosis; treatment; lymphoma;
KW cell proliferative disorder; bursitis; atherosclerosis; cancer; sarcoma;
KW inflammatory disorder; AIDS; Addison's disease; cystic fibrosis; asthma;
KW diabetes mellitus; osmoregulatory disorder; diarrhoea; renal failure;
KW muscular disorder; myocarditis; Duchenne's muscular dystrophy; nontropic;
KW cardiovascular disorder; hypertension; bronchitis; vasculitis; cardiac;
KW neurological disorder; Alzheimer's disease; Parkinson's disease; human;
KW Huntington's disease; antiarteriosclerotic; hepatotropic; cytostatic;
KW anti-HIV; antianaemic; neuroprotective; immunomodulator; antidiabetic;
KW hypertensive; vasotropic; antiasthmatic; antiinflammatory; antidepressant;
KW anticonvulsant; thrombolytic; antiParkinsonian; immunostimulant; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 378..1085

XX /*tag= a

XX /product= "MECHP-16"

XX /note= "Shows homology to human beta subunit of Ca²⁺

XX misc_binding

XX activated K⁺ channel"

XX 381..425

XX /*tag= b

XX /bound_moiety= "Primer or Probe"

XX WO200012711-A2.

XX 09-MAR-2000.

XX 02-SEP-1999; 99WO-US020468.

XX 02-SEP-1998; 98US-0155226P.

XX 12-NOV-1998; 98US-00191283.

XX 09-DEC-1998; 98US-0155225P.

XX 26-JAN-1999; 99US-0155211P.

XX 10-FEB-1999; 99US-0155263P.

XX (INCY-) INCYTE PHARM INC.

XX Au-Young J, Bandman O, Tang YT, Reddy R, Hillman JL, Yue H;

XX Lal P, Corley NC, Guegler KJ, Gorgone G, Baughn MR, Azimzai Y;

XX WPI; 2000-256643/22.

XX P-PSDB; AAY70466.

XX Novel human membrane channel protein and polynucleotide useful for
PT diagnosing and treating cell proliferative, inflammatory, secretory,
PT osmoregulatory, muscular, cardiovascular and neurological disorders.

XX Claim 9; Page 128-129; 140pp; English.

XX The present sequence is a cDNA identified in Incyte clone 2069907 derived
CC from ISITN01 cDNA library. It encodes human membrane channel protein-16
CC (MECHP-16), which is expressed in nervous tissues. Anti-MECHP antibodies
CC can be used as therapeutic antagonists and reagents for diagnosis and
CC monitoring diseases. MECHP cDNA can be used for diagnosis of MECHP-
CC related diseases and gene mapping. MECHP can be used for treatment of
CC cell proliferative disorders such as bursitis and atherosclerosis,
CC cancers like lymphoma and sarcoma, inflammatory disorders like AIDS and

CC	Addison's disease, transport/secretory disorders like cystic fibrosis and
CC	diabetes mellitus, osmoregulatory disorders like diarrhoea and renal
CC	failure, muscular disorders like myocarditis and Duchenne's muscular
CC	dystrophy, cardiovascular disorders like hypertension and vasculitis,
CC	congenital lung anomalies like bronchitis and asthma and neurological
CC	disorders like Alzheimer's disease, Parkinson's disease and Huntington's
CC	disease
XX	
SQL	Sequence 1300 BP; 381 A; 288 C; 279 G; 352 T; 0 U; 0 Other;
Alignment Scores:	
Pred. No.:	4.48e-133 Length: 1300
Score:	1228.00 Matches: 233
Percent Similarity:	99.15% Conservative: 0
Best Local Similarity:	99.15% Mismatches: 2
Query Match:	98.95% Indels: 0
DB:	3 Gaps: 0
US-09-914-053A-5 (1-235) x AAZ51632 (1-1300)	
QY	1 MetSerIleTrpThrSerGlyArgThrSerSerSerTyArgHisAspGluLysArgAsn 20
Db	378 ATGTTTATATGGACAGTGGCGGACCTTCCTCATCTTATGACATGATGAAAAAAGAAT 437
QY	21 ILeTyRGlNLSyIleArGAsPHiAspLeuLeuAspLysArGLysThrValThrAlaLeu 40
Db	438 ATTTPACAGAAAAATCAGGACCATGACCTCTCGACAAAAGAAAAACAGTCACAGCAGT 497
QY	41 LysNlaGlyGluAspArgAlaIleLeuLeuLeuLylLeuAlaMetMetValCysSerIleMet 60
Db	498 AAGCAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG 557
QY	61 MetTyRPhelLeuLeuGlyIleTheLeuLeuArgSerTyRMetGlnSerValTrpThrGlu 80
Db	558 ATGTATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGAGAGGGTGTGGACCGAA 617
QY	81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db	618 GAGTCTCAATGACCTTGCTGAATGCGTCCATCATCGGAAAAATTTAACTGCTCCTTCAGC 677
QY	101 CysGlyProAspCysTrpLysLeuSerGlnTyRProCysLeuGlnValTyRValAsnLeu 120
Db	678 TGTGCTCAGACTGCTGAAACTTCTCAGTACCCTGCCCTCCAGGTGTAGCTTAACCTG 737
QY	121 ThrSerSerGlyGluLysLeuLeuLeuTyRHisThrGluGluThrIleLysIleAsnGln 140
Db	738 ACTTCTTCGGGGAAAAAGCTCTCTCTACACACAGAGAGAGACAATAAATAATCAATCAG 797
QY	141 LysCysSerTyRlleProLysCysGlyLysAsnPhelGluSerMetSerLeuValAsn 160
Db	798 AAGTGCTCCTATATACCTAAATATGGAAAAAATTTGAAGAAATCCATGTCCCTGGTGAAT 857
QY	161 ValValMetGluAsnPhelArgLysTyRGlnHisPheSerCysTyRSerAspProGluGly 180
Db	858 GTTGTCATGAAACCTTCAGGAAGTATCAACACTTCTCTCTGCTATCTGACCCAGAGGA 917
QY	181 AsnGlnLysSerValIleLeuThrLysLeuTyRSerSerAsnValLeuPheHisSerLeu 200
Db	918 AACACAGAAGAGTGTATCCTAACCAAACTCTACAGTTCCAACGTGCTGTTCCTCATTCATC 977
QY	201 PheTrpProThrCysMetMetAlaGlyClyValAlaIleValAlaMetValLysLeuThr 220
Db	978 TTCGGGCACCTGTATGATGCTTGGGGGTGGCAATTTGTGCCATGTGGAAACTTACA 1037
QY	221 GlnTyRLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db	1038 CAGTACCTCTCCCTACTATGTGAGAGGATCCAAACGGATCAATAGA 1082
RESULT 3	
AAAY5011	
ID	AAAY5011 standard; DNA; 707 BP.
XX	
AC	AAAY5011;

Db 1 ATGTCGATATGACACGACGTCGGCGGACCTCTTCATCTTATAGACATGATGATGAAAAAGAAAT 60
 Qy 21 IletyGlnLysIleAsgAHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
 Db 61 ATTTACCAAGAAATCAGGACCATGCTCTCTGGACAAAGGAAACAGTCACAGCACTG 120
 Qy 41 LysAlaGlyGluAspAsgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
 Db 121 AAGGACGAGAGAGACCGAGCTATTCTCTGGACTGGCTATGATGGTGTCTCCATCATG 180
 Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80
 Db 181 ATGATATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAA 240
 Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
 Db 241 GAGTCTCAATGCACTGCTGCTGAATGCGTCCATCAGGAAACATTTAATGCTCTCTTCAGC 300
 Qy 101 CysGlyProAspCysTyrPheLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
 Db 301 TGTGGTCCAGACTGCTGGAACTTCTCAGTACCCCTGCTCCAGGTTGACGTTAACCTG 360
 Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140
 Db 361 ACTTCTCTCCGGGAAAAAGCTCTCTCTACACAGAGAGACAATAAAAATCAATCAG 420
 Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
 Db 421 AAGTCTCTCTATATACCTAATATGGAATAATTTGAGAAATCCATGTCCTCTGGTGAAT 480
 Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
 Db 481 GTTGTCTGGAATACTTTCAGGAAGTATACACTTCTCTCTCTCTCTCTCTCTCTCTCTCT 540
 Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
 Db 541 AACGAGAGAGTGTATCTTACCAAACTCTACAGTTCCACGTCGTGTTCCATTCTCTC 600
 Qy 201 PheTyrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
 Db 601 TTTGCGCCACCTGATGATGGCTGGGGTGTGGCAATTGTCATGTTGGTGAACCTTACA 660
 Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
 Db 661 CAGTACTCTCTCTACTATGTGAGAGATCCA-CGGATCAATAGA 704

RESULT 4
 ID AAA26355
 XX AAA26355 standard; cDNA; 2098 BP.
 AC AAA26355;
 XX
 DT 29-JUN-2000 (first entry)
 XX
 DE Human secreted protein gene 10 SEQ ID NO:20.
 XX
 KW Human; secreted protein; diagnosis; cytostatic; immunosuppressive;
 KW antiHIV; antineoplastic; neurotrophic; neuroprotective; antiallergic;
 KW osteoporosis; antithrombotic; antidiabetic; antidiabetic; antidiabetic;
 KW antipsoriasis; cardiant; gene therapy; cancer; neurological disorder;
 KW immune disease; inflammation; blood disorder; tumour; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200006698-A1.
 XX
 PD 10-FEB-2000.
 XX
 PF 29-JUL-1999; 99WO-US017130.
 XX
 PR 30-JUL-1998; 98US-0094657P.
 PR 05-AUG-1998; 98US-0095486P.
 PR 05-AUG-1998; 98US-0095454P.
 PR

PR 06-AUG-1998; 98US-0095455P.
 PR 12-AUG-1998; 98US-0096319P.
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX Komatsoulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y;
 PI Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA;
 PI Soppet DR, Endress GA, Ebner R, Olsen HS, Mucenski M;
 XX WPI; 2000-195282/17.
 DR P-PSDB; AAY91460.
 XX
 PT New isolated human genes and the secreted polypeptides they encode,
 PT useful for diagnosis and treatment of e.g. cancers, neurological
 PT disorders, immune diseases, inflammation or blood disorders.
 XX
 PS Claim 1; Page 378-379; 634pp; English.
 XX
 CC The polynucleotide sequences given in AAA26346 to AAA26458 encode the
 CC human secreted proteins given in AAY91451 to AAY91691. The human secreted
 CC proteins can have activities based on the tissues and cells they are
 CC expressed in. Examples of the activities are: cytostatic;
 CC immunosuppressive; antiHIV; antineoplastic; neurotrophic; neuroprotective;
 CC antiallergic; osteoporosis; antithrombotic; antidiabetic; antidiabetic;
 CC antipsoriasis; cardiant; and cardiant. The polynucleotides and their
 CC ameliorating medical conditions, e.g. by protein or gene therapy. Also
 CC pathological conditions can be diagnosed by determining the amount of the
 CC proteins in a sample or by determining the presence of mutations in the
 CC polynucleotides. Specific uses are described for each of the
 CC polynucleotides, based on which tissues they are most highly expressed
 CC in, and include developing products for the diagnosis or treatment of
 CC cancer, tumours, neurodegenerative disorders, developmental abnormalities
 CC and foetal deficiencies, blood disorders, diseases of the immune system,
 CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,
 CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,
 CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,
 CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,
 CC reproductive disorders, gastrointestinal disorders, respiratory disorders
 CC and metabolic disorders. The proteins or polynucleotides can also be used
 CC as food additives or preservatives. The proteins are also useful for
 CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are
 CC sequences used in the exemplification of the present invention
 XX
 XX Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.6e-107 Length: 2098
 Score: 1012.00 Matches: 191
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 81.55% Indels: 0
 DB: 3 Gaps: 0
 US-09-914-053A-5 (1-235) x AAA26355 (1-2098)
 Qy 45 AspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMetMetTyrPheLeu 64
 Db 10 GACCGAGCTATTCTCTGGACTGGCTATGATGGTGTCTCCATCATGATGATTTCTG 69
 Qy 65 LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGluLysSerGlnCys 84
 Db 70 CTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAAGAGTCTCAATGC 129
 Qy 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104
 Db 130 ACCTTGTGATGCGTCTCATACAGGAAACATTTAATGCTCTCTTCAGTGTGGTCCAGAC 189
 Qy 105 CysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124
 Db 190 TGTGGAAACTTTCTCAGTACCTCTCCCTGCTCCAGGTTAGCTTAACCTGACTTCTCCGGG 249
 Qy 125 GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr 144

Db 250 GAAGAAGCTCTCTTACCCACAGAGACAAATAAATAATCAATCAGAAAGTCTCTCTAT 309
 Qy 145 IleProLysCysGlyLysAsnPhelGluSerMetSerLeuValAsnValMetGlu 164
 Db 310 ATACCTAAATGTGGAATAATTTGAAGATCCATGCTCCCTGGTGAATGTGTGATGGA 369
 Qy 165 AsnPhelArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184
 Db 370 AACTTCAGGAAGTATCAACACTTCTCTGCTATCTTGACCCAGAGAAACCAAGAGAGT 429
 Qy 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTyrProThr 204
 Db 430 GTTATCTCAACAAACTCTACAGTCCACAGTGTGTCTTCACTCTTCTGCGCAACC 489
 Qy 205 CysMetMetAlaGlyGlyValAlaIleValAlaValMetValLysLeuThrGlnTyrLeuSer 224
 Db 490 TGTATGATGGCTGGGGGTGGCAATTTGGCCATGGTGAACCTTACACAGTACCTCTCC 549
 Qy 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235
 Db 550 CTACTATGTGAGAGATCCACCGATCAATAGA 582

RESULT 5

ADA39669
 ID ADA39669 standard; cDNA; 2098 BP.

AC ADA39669;

XX 20-NOV-2003 (first entry)

XX Human secreted protein encoding cDNA.

XX Human; secreted protein; cancer; hyperproliferative disorder;
 KW rheumatoid arthritis; autoimmune disorder; haematopoietic disorder;
 KW anaemia; allergic reaction; asthma; cardiovascular disorder;
 KW wound healing; cytostatic; immunosuppressive; neutropenic; neuroprotective;
 KW antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory;
 KW vulnervary; cardiac; gene therapy; ss.

XX Homo sapiens.

XX WO2002102993-A2.

XX 27-DEC-2002.

XX 19-MAR-2002; 2002WO-US008123.

XX 21-MAR-2001; 2001US-0277340P.

XX 19-JUL-2001; 2001US-0306171P.

XX 13-NOV-2001; 2001US-0331287P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Rosen CA, Ruben SM;

XX WPI; 2003-175238/17.

XX New human secreted proteins and nucleic acid molecules, useful for
 PT preparing a diagnostic or pharmaceutical composition for diagnosing,
 PT preventing or treating cancer or other hyperproliferative disorder,
 PT asthma, allergies or AIDS.

XX Claim 9; SEQ ID NO 51; 3205pp; English.

XX The invention relates to novel genes ADA39629-ADA40565 and proteins
 CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,
 CC treating or ameliorating medical conditions e.g. by protein or gene
 CC therapy. The polypeptides, nucleic acid molecules, antibodies or their
 CC fragments, and agonists or antagonists that bind to the polypeptide are
 CC useful for preparing a diagnostic or pharmaceutical composition for
 CC diagnosing or treating cancer or other hyperproliferative disorder. The
 CC polypeptides and nucleic acid molecules are also useful for detecting,

CC preventing, diagnosing, prognosticating, treating or ameliorating cancer
 CC or other hyperproliferative disorders including neoplasms, autoimmune
 CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus
 CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic
 CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,
 CC thrombocytopenia), allergic reactions including asthma or eczema,
 CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory
 CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.
 CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders
 CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,
 CC fungal or viral infections including HIV/AIDS), or wound healing and
 CC disorders of epithelial cell proliferation. The nucleic acids are also
 CC useful for chromosome identification, radiation hybrid mapping or long-
 CC range restriction mapping, as molecular weight markers, or as
 CC hybridization or diagnostic probes. The polypeptides and antibodies are
 CC useful for providing immunological probes for differential identification
 CC of the tissues immunohistochemistry assays. Note: the sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX
 SQ Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.6e-107 Length: 2098
 Score: 1012.00 Matches: 191
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 81.55% Indels: 0
 DB: 8 Gaps: 0

US-09-914-053A-5 (1-235) x ADA39669 (1-2098)

Qy 45 AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64
 Db 10 GACCGAGTATCTCTCTGGACTGCTATGATGGTGTCTCCATCATGATGATTTCTG 69
 Qy 65 LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGluGluSerGlnCys 84
 Db 70 CTGGGAATCACACTCTCTCGCTCATACATGACAGCGGTGGACCAAGAGTCTCAATGC 129
 Qy 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104
 Db 130 ACCTTGCTGAATGCGTCCATCAGGAAACATTAATTCCTCTCCTCAGTGTGGTCCAG 189
 Qy 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124
 Db 190 TGCTGAAACTTCTCAGTACCCCTCCCTCCAGGTGTACGTAACTGACATCTCTCCGG 249
 Qy 125 GluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyr 144
 Db 250 GAAAGAGTCTCTCTACACACAGAGACAAATAAAATCAATCAGAAGTGTCTCTAT 309
 Qy 145 IleProLysCysGlyLysAsnPhelGluSerMetSerLeuValAsnValValMetGlu 164
 Db 310 ATACCTAAATGTGGAATAATTTTGAAGATCCATGTCCTGGTGAATGTTGTATGGA 369
 Qy 165 AsnPhelArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184
 Db 370 AACTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGAGAAACCAAGAGAGT 429
 Qy 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTyrProThr 204
 Db 430 GTTATCTCAACAAACTCTACAGTCCACAGTGTGTCTTCACTCTCTTCTGCGCAACC 489
 Qy 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224
 Db 490 TGTATGATGGCTGGGGGTGTGGCAATTTGTCATGTTGGTGAACCTTACACAGTACCTCTCC 549
 Qy 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235
 Db 550 CTACTATGTGAGAGATCCACCGATCAATAGA 582

RESULT 6

ADA55858
ID ADA55858 standard; DNA; 2098 BP.

XX AC ADA55858;
XX 20-NOV-2003 (first entry)
XX Gene encoding human secreted protein #37.
XX immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;
XX cytotatic; cerebroprotective; neuroprotective; nootropic;
XX cardiovascular; antiarteriosclerotic; gene therapy;
XX human secreted protein; immune disorder; inflammation;
XX respiratory disorder; cancer; CNS disorder; neurodegenerative disorders;
XX inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;
XX multiple sclerosis; ischaemic brain injury; Parkinson's disease;
XX Alzheimer's disease; atherosclerosis; myocarditis; chromosome mapping;
XX triple helix formation; antisense gene therapy; forensic biology; ds;
XX gene.
XX Homo sapiens.
XX WO2002102994-A2.
XX 27-DEC-2002.
XX 19-MAR-2002; 2002WO-US008278.
XX 21-MAR-2001; 2001US-0277340P.
XX 19-JUL-2001; 2001US-0306171P.
XX 13-NOV-2001; 2001US-0331287P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Ruben SM;
XX WPI; 2003-167512/16.
XX P-PSDB; ADA56755.

XX New human secreted polypeptides and polynucleotides, useful for
PT diagnosing, treating or preventing e.g. immune disorders, inflammatory
PT conditions, respiratory disorders, cancers, CNS disorders, or
PT neurodegenerative disorders.

PS Claim 21; SEQ ID NO 47; 1754bp; English.

XX The invention relates to 592 new human secreted polypeptides useful for
CC diagnosing, treating or preventing e.g. immune disorders, inflammatory
CC conditions, respiratory disorders, cancers, CNS disorders, or
CC neurodegenerative disorders, or polypeptides comprising an amino acid
CC sequence at least 95% identical to the new sequences. The polypeptides,
CC antibodies or antibody fragments that bind to the polypeptides, nucleic
CC acids encoding the polypeptides, agonists or antagonists that binds to
CC the polypeptide, are useful in preparing diagnostic or pharmaceutical
CC compositions for diagnosing, treating or preventing an e.g. immune
CC disorders, inflammatory conditions (e.g. inflammatory bowel disease,
CC nephritis or Crohn's disease), respiratory disorders (e.g. asthma and
CC allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders
CC (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative
CC disorders (e.g. Parkinson's disease or Alzheimer's disease), and
CC cardiovascular disorders (e.g. atherosclerosis or myocarditis). The
CC polynucleotides are useful for chromosome identification, chromosome
CC mapping, for controlling gene expression through triple helix formation
CC or antisense DNA or RNA, in gene therapy, for identifying individuals
CC from minute biological samples, in forensic biology, and as hybridization
CC probes. The polypeptides are useful for as molecular weight markers on
CC sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
CC gels, to raise antibodies, for testing biological activities, and for
CC treating or preventing neural disorders, immune system disorders,
CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
CC renal, proliferative and/or cancerous diseases. This sequence corresponds
CC to a gene encoding one of the polypeptide of the invention. Note: The

CC sequence data for this patent did form part of the printed specification,
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

Alignment Scores: 1.6e-107 Length: 2098
Pred. No.: 1012.00 Matches: 191
Score: 1012.00 Conservative: 0
Percent Similarity: 100.00%
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 81.55% Indels: 0
DB: 10 Gaps: 0

US-09-914-053A-5 (1-235) x ADA55858 (1-2098)

QY 45 AspArgAlaileLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64
Db 10 GACCGAGCTATTCTCTGGAGCTGCTATGATGGTGTGCTCCATCATGATGATTTCTG 69
QY 65 LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTTrpThrGluGlnSerGlnCys 84
Db 70 CTGGGAATCACACTCTCTGGCTCATACATGACAGCGGTGGAGGAGTCTCAATGC 129
QY 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104
Db 130 ACCTTGCTGATGCTCCATCAGGAAACATTTAATTGCTCTTCAGCTGTGGTCCAGAC 189
QY 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124
Db 190 TGCTGGAACTTTCTCAGTACCCCTGCTCCAGGTGACGTAACTGACTTCCTTCGGG 249
QY 125 GluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyr 144
Db 250 GAAAGCTCTCTCTTACCACACAGAGAGACAATAAATAATCAATCAGAGTGTCTCTAT 309
QY 145 IleProLysCysGlyLysAsnPheGluGlnSerMetSerLeuValAsnValValMetGlu 164
Db 310 ATACCTTAATGTGGAATAATTTGAAGAATCCATGTCCTGGTGAATGTTGTCTATGAA 369
QY 165 AsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184
Db 370 ACCTTCAGAGAGTATCAACACTTCTCTGCTATTCTGACCCAGAGAAACAGAGAGT 429
QY 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTrpProThr 204
Db 430 GTTATCTTAACAAAACCTTACAGTTCACAGTGTGTTCCATTCCTCTCTGCGCAACC 489
QY 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224
Db 490 TGTAATGATGGCTGGGGGTGGCAATTTGTCATGGTGAACACTTACACAGTACCTCTCC 549
QY 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db 550 CTATATGTGAGAGGATCCACGGATCAATAGA 582

RESULT 7

ADL71416
ID ADL71416 standard; cDNA; 2098 BP.

XX AC ADL71416;

XX 20-MAY-2004 (first entry)

XX Novel human secreted protein cDNA seqid 20.

XX antinflammatory; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; antilipemic; CNS; gynaecological; antiarthritic;
KW antiasthmatic; anti-HIV; virucide; endocrine; cytostatic;
KW immunosuppressive; antiallergic; cardiovascular; respiratory;
KW dermatological; antimicrobial; gastrointestinal; gene therapy;
KW neurodegenerative disease; behavioral disorder; inflammatory condition;
KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;

KW Huntington's disease; metabolic disorder; Tay-Sach's disease;
KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;
KW arthritis; asthma; AIDS; endocrine disorder; immune disorder;
KW Hodgkin's lymphoma; haematopoietic disorder; muscular disorder;
KW leukaemia; autoimmune disorder; allergy; cancer; cardiovascular disorder;
KW respiratory disorder; pulmonary disorder; connective tissue disorder;
KW skin disorder; CNS disorder; congenital disorder; infectious disorder;
KW gastrointestinal disorder; human; secreted protein; gene; ss.
XX Homo sapiens.
XX US2004034196-A1.
XX 19-FEB-2004.
XX 27-JAN-2003; 2003US-00351334.
XX 30-JUL-1998; 98US-0094557P.
XX 03-AUG-1998; 98US-0095486P.
XX 06-AUG-1998; 98US-0095454P.
XX 08-AUG-1998; 98US-0095455P.
XX 12-AUG-1998; 98US-0096319P.
XX 29-JUL-1999; 99WO-US017130.
XX 24-JAN-2000; 2000US-00489847.
XX 25-JAN-2002; 2002US-0350898P.
XX (KOMA/) KOMATSOULIS G A.
XX (ROSE/) ROSEN C A.
XX (RUBE/) RUBEN S M.
XX (DUAN/) DUAN D R.
XX (MOOR/) MOORE P A.
XX (SHIY/) SHI Y.
XX (LAFLE/) LAFLEUR D W.
XX (WEIY/) WEI Y.
XX Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;
PI Lafleur DW, Wei Y;
PI WFI; 2004-180094/17.
DR P-PSDB; ADL71532.
XX New human secreted nucleic acid, useful for diagnosing and treating
PT neurodegenerative, inflammatory, hyperproliferative, metabolic,
PT reproductive, cardiovascular, respiratory or immunological disorders or
PT diseases.
XX Claim 1; SEQ ID NO 20; 234pp; English.
XX The invention describes an isolated human nucleic acid molecule (I)
CC comprising a polynucleotide having a nucleotide sequence at least 95%
CC identical to a sequence polynucleotide fragment of SEQ ID NO: X or of
CC the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable
CC to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or
CC epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA
CC sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID
CC NO: X, having a biological activity. The nucleic acids and polypeptides,
CC pharmaceutical formulations and kits are useful in diagnosing and
CC treating neurodegenerative diseases states, behavioral disorders,
CC inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's
CC disease, Parkinson's disease or Huntington's disease), metabolic
CC disorders (e.g. Tay-Sach's disease or Leash-Nyhan syndrome), reproductive
CC disorders, immunological disorders (e.g. arthritis, asthma or AIDS),
CC endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic
CC or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy,
CC cancer, cardiovascular, respiratory or pulmonary disorders, disorders or
CC conditions afflicting connective tissue, skin disorders, CNS disorders,
CC congenital disorders, infectious disorders and gastrointestinal
CC disorders. This sequence encodes a novel human secreted protein of the
CC invention. Note: This sequence does not appear in the printed
CC specification but is available in electronic format from the US patent
CC office at ftp.seqdata.uspto.gov/seqdata.html?DocID=20040034196.

Sequence 2098 BP; 545 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.6e-107 Length: 2098
Score: 1012.00 Matches: 191
Percent Similarity: 100.00% Conservatives: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 81.55% Indels: 0
DB: 12 Gaps: 0

US-09-914-053A-5 (1-235) x ADL71416 (1-2098)

QY	45	AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu	64
DB	10	GACCGAGCTATTCTCTCGGGACTGGCTATGATGGTGGTCCATCATGATGATTTCTG	69
QY	65	LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGluGluSerGlnCys	84
DB	70	CTGGGAATCACACTCTCTCGGCTCATACATGCAGAGCGGTGGACCGAAGAGTCTCAATGC	129
QY	85	ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp	104
DB	130	ACCTTGCTGGAATGGCTCCATCACGAAACATTTAATTGCTCTCTCAGCTGGTCCAGAC	189
QY	105	CysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly	124
DB	190	TGCTGGAACCTTCTCAGTACCCCTGCTCCAGGTGACGTACCTGACTTCTTCCGGG	249
QY	125	GluLysLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr	144
DB	250	GAAGAAGCTCTCTCTACACACAGAGACAAATAAATCAATCAGAGAGTGTCTCTAT	309
QY	145	IleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValMetGlu	164
DB	310	ATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTCTGGTGAATGTTGTATGAA	369
QY	165	AsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer	184
DB	370	AACCTTCAGGAAGTATCAACACTTCTCTGCTGCTATCTGACCCAGAGGAACACAGAAGAGT	429
QY	185	ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTrpProThr	204
DB	430	GTAATCTTCAACAAACTCTACAGTTCACAGCTGTTTCCATTCACTTCTTGGCCAAACC	489
QY	205	CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer	224
DB	490	TGTATGATGGCTGGGGGTGTGGCAATTGTCGATGGTGAAACTTACACAGTACCTCTCC	549
QY	225	LeuLeuCysGluArgIleGlnArgIleAsnArg	235
DB	550	CTACTATGTGAGAGGATCCAAACGGATCAATAGA	582

RESULT 8

AAZ11912 standard; cDNA; 1246 BP.

AAZ11912;

30-NOV-1999 (first entry)

Human potassium channel K-Hnov44 cDNA (splice variant 1).

Potassium channel; ataxia; arrhythmia; epilepsy; Bartter's syndrome;
cardiovascular disorder; CNS disorder; renal disorder; ds.

Homo sapiens.

Location/Qualifiers

432..1094

/*tag= a

/product= "Human K-Hnov44 potassium channel"

WO9943696-A1.

XX

XX WPI; 2001-457740/49.
DR P-PSDB; ABB12189.
XX Human proteins and DNA encoding sequences useful for preventing, treating
PT or ameliorating a medical condition in a mammalian subject e.g. arthritis
PT and cancer.
XX
PS Claim 1; Page 945; 1963pp; English.
XX
CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
CC invention also relates to vectors and recombinant host cells comprising a
CC nucleotide of the invention, methods of producing the novel polypeptides,
CC antibodies against the polypeptides, methods of detecting the nucleotides
CC or polypeptides in a sample, and methods of identifying compounds which
CC bind to polypeptides of the invention. Although novel, many of the
CC polypeptides of the invention have homology to known proteins, thereby
CC giving an insight into their probable biological activities, and hence
CC potential therapeutic applications. The polypeptides of the invention may
CC have various activities, including cytokine, cell proliferation or cell
CC differentiation activities; stem cell growth factor activity;
CC haematopoiesis regulatory activity; tissue growth activity;
CC immunomodulatory activity; activin- or inhibin-related activities;
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or
CC thrombolytic activities; receptor or ligand activities; or may be
CC involved in oncogenesis, cancer cell proliferation or metastasis.
CC Depending on their biological activities, polypeptides and nucleotides of
CC the invention are useful for preventing, treating or ameliorating medical
CC conditions, e.g., by protein or gene therapy. Such conditions include
CC cancers, haematopoietic disorders (e.g. myeloid or lymphoid cell
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
CC proliferative retinopathy, atherosclerosis, coronary heart disease,
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
CC vascular growth. Polypeptides involved with tissue regeneration and
CC repair (or nucleic acids encoding them) may be used to promote wound
CC healing (e.g., of burns, incisions and ulcers), while those with
CC immunomodulatory activities may be used in the treatment of viral,
CC bacterial and fungal infections in addition to immune disorders.
CC Polypeptides with growth factor activity may be used in cell cultures to
CC promote cell growth. For example, such polypeptides may be used to
CC manipulate stem cells in culture to give rise to neuroepithelial cells
CC that can be used to augment or replace cells damaged by illness,
CC autoimmune disease or accidental damage, the polypeptides and nucleotides
CC may also be used in the diagnosis of the above conditions, and in drug
CC screening techniques. The present sequence represents a cDNA encoding a
CC novel human polypeptide of the invention
XX
SQ Sequence 558 BP; 165 A; 128 C; 144 G; 121 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 2,46e-46 Length: 558
Score: 481.00 Matches: 94
Percent Similarity: 97.94% Conservative: 1
Best Local Similarity: 96.91% Mismatches: 2
Query Match: 38.76% Indels: 0
DB: 4 Gaps: 0

US-09-914-053A-5 (1-235) x ABA09433 (1-558)

Qy 1 MetSerIleThrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
Db 268 ATGTCGATATGGACAGTCGGCGGACCTCTTCATCTTATAGACATGATGAAAGAGAAAT 327
Qy 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db 328 ATTTACAGAGAAATCAGGACCATGACCTCTCGACAAAGAAAGAAACAGTCACAGCACTG 387
Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
Db 388 AAGCAGGAGAGGACCGAGCTATTCTACTGGGACTGCTATGATGATGCTGCTCCATCATG 447
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrThrGlu 80

Db 448 ATGTAATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGCAGAGCGTGTGACCGGA 507
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCys 97
Db 508 GAGTCTCATGCACTTGCTGTAATGGCTCATCATCGGAACATTTACTGC 558
RESULT 10
AAF27992
ID AAF27992 standard; DNA; 1237 BP.
XX
AC AAF27992;
XX
XX 08-MAY-2001 (first entry)
DT
DE Human calcium sensitive potassium channel beta3a subunit coding sequence.
XX
KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;
KW beta3a subunit; beta3b subunit; beta3c subunit; diabetes;
KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;
KW irritable bowel syndrome; Alzheimer's disease; ds.
XX
OS Homo sapiens.
XX
PN WC200105828-A1.
XX
PD 25-JAN-2001.
XX
PF 18-JUL-2000; 2000WO-US019585.
XX
PR 20-JUL-1999; 99US-0144764P.
XX (MERI) MERCK & CO INC.
XX
XX Debele V, Swanson R, Liu Y, Lagrutta A;
PI WPI; 2001-159514/16.
DR P-PSDB; AAB35302.
XX
XX Novel human calcium sensitive potassium channel subunits for identifying
PT inhibitors and agonists of the potassium channel for use in treating
PT conditions such as asthma, hypertension, memory disorders, depression.
XX
PS Claim 3; Fig 2A; 89pp; English.
XX
CC The present invention provides the protein and coding sequences of the
CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c
CC and beta3d subunits. These can be used to identify inhibitors and
CC activators of the channels, which can be used in the treatment of
CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,
CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,
CC incontinence, migraine and irritable bowel syndrome. The coding sequences
CC are found at human chromosome 3q23-ter. The present sequence is the
CC beta3a subunit coding sequence
XX
SQ Sequence 1237 BP; 314 A; 312 C; 324 G; 287 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.6e-45 Length: 1237
Score: 478.50 Matches: 97
Percent Similarity: 60.00% Conservative: 44
Best Local Similarity: 41.28% Mismatches: 81
Query Match: 38.56% Indels: 13
DB: 4 Gaps: 5

US-09-914-053A-5 (1-235) x AAF27992 (1-1237)

Qy 7 GlyArgThrSerSerSerTyrArgHisAspGluLysArgAsnIleTyrGlnLysIleArg 26
Db 398 GGGAGGACAGCCCTTCTCTCCCTCAGGAGAGAGAGAGACAGACTACAGT----- 448
Qy 27 AspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAlaGlyGluAspArg 46

Db 449 GATGAGACCCACTAGATGTGTGCACAAAGAGGCTGCCATCC---AGTACTGGAGAGGACCGA 505
 QY 47 AlalileuLeuGlyLeuAlaMetMetValCysSerIleMetTyrPheLeuLeuGly 66
 Db 506 GCCGTGATGCTGGGTTTGCATGATGGCTTCTCAGTCCCTAAATGTTCTTCTCTCGGA 565
 QY 67 IleThrLeuLeuArgSerTyrMetGlnSerValThrTrpThrGluGluSerGlnCysThrLeu 86
 Db 566 ACAACCATCTTAAGCCCTTTATGCTCAGCATTCAGAGAGAAGATCGACCTGCACCTGCC 625
 QY 87 LeuAsnAlaSerIleThrGluThrPhe---AsnCysSerPheSerCysGlyProAspCys 105
 Db 626 ATCCACAGATATCATGAGACACTGGCTGGACTGTGCTTCACTGTGGTGTGCACCTGC 685
 QY 106 TrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGlyGlu 125
 Db 686 CACGGTCAGGGAGTAGTACCGGTCTTCAGGTGTTTGTGAACCTCAGCCATCCAGGTCAG 745
 QY 126 LysLeuLeuLeuTyrHisThrGluGluThrIleLysLeuGlnLysCysSerTyrIle 145
 Db 746 AARGCTCTCTACATTATATCAAGAGGCTGTCCAGATAAATCCCAAGTGTCTTTACACA 805
 QY 146 ProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValValMetGluAsn 165
 Db 806 CCTAAGTGC-----CACCAAGATAGAGTGTGTTGTCAACAGCTGCTCGACATA 856
 QY 166 PheArgLysTyrGlnHis-----PheSerCysTyrSerAspProGluGly 180
 Db 857 AAGAATTTCTTCGATCAAAAATGGAACCCCTTTTCATGCTTCTACAGTCCAGCCAGC 916
 QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
 Db 917 CAATCTGAGATGTCATTTATATAAAGATGATGACCAATGCTATCTTCCACTGTGTTA 976
 QY 201 PheTrpProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
 Db 977 TTTGGCCTTCAGTGACTCTCTAGTGTGGTCCCTGATTTGTGTCATGGTGAGATTAA 1036
 QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
 Db 1037 CAACACTGTCTCTTACTGTGTGAAAAATATAGCACTGTAGTCAGA 1081

RESULT 11
 AAZ11913
 ID AAZ11913 standard; cDNA; 1111 BP.
 AC AAZ11913;
 XX
 DT 30-NOV-1999 (first entry)
 XX
 DE Human potassium channel K-Hnov44 cDNA (splice variant 2).
 XX
 KW Potassium channel; ataxia; arrhythmia; epilepsy; Bartter's syndrome;
 XX cardiovascular disorder; CNS disorder; renal disorder; ds.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 297..959
 FT /*tag=a
 FT /product= "Human K-Hnov44 potassium channel"
 XX
 FN W09943696-A1.
 XX
 PD 02-SEP-1999.
 XX
 PF 22-FEB-1999; 99WO-US0003826.
 XX
 PR 25-FEB-1998; 98US-0076697P.
 PR 07-AUG-1998; 98US-0095836P.
 PR 19-JAN-1999; 99US-0116448P.
 XX
 PA (AXIS-) AXIS PHARM INC.

XX
 PI
 XX
 DR WFI; 1999-527591/44.
 DR P-PSDB; AAV34131.
 XX
 PT New nucleic acids encoding mammalian K-Hnov potassium channel proteins,
 PT useful for the diagnosis and treatment of episodic ataxia with myokymia,
 PT cardiac arrhythmia, epilepsy and Bartter's syndrome.
 XX
 PS Claim 4; Page 90-91; 112pp; English.
 XX
 CC This sequence represents splice variant 2 of a human potassium channel
 CC K-Hnov44 cDNA. Alternative splicing does not affect the amino acid
 CC sequence of the protein. K-Hnov proteins have a high degree of homology
 CC to known potassium channels and may be alpha subunits, which form the
 CC functional channel, or accessory subunits that act to modulate the
 CC channel activity. K-Hnov44 is a potassium channel beta subunit. The
 CC gene's chromosomal location is 22p13, determined via PCR chromosomal
 CC localisation using primers AAZ11934 and AAZ11936. K-Hnov cDNAs were
 CC isolated by extension of expressed sequence tags (ESTs) which were
 CC related but not identical to known human potassium channels. Potential
 CC polymorphisms detected as sequence variants between multiple independent
 CC clones. Potassium channels have critical roles in various cell types and
 CC biochemical pathways. Defective potassium channels are known to cause
 CC four human diseases: episodic ataxia with myokymia; cardiac arrhythmia
 CC (long QT syndrome); epilepsy; and Bartter's syndrome. As potassium
 CC channels are critical components of virtually all cells, it is likely
 CC that abnormal potassium channels are also implicated in certain renal,
 CC cardiovascular and central nervous system (CNS) disorders. Nucleotides
 CC encoding K-Hnov proteins may be used for identifying homologous or
 CC related proteins and the DNA sequences encoding them. They may be used to
 CC produce compositions that modulate the expression and function of the
 CC K-Hnov protein and in studying the biochemical pathways associated with
 CC it. They may also be used for the recombinant production of K-Hnov
 CC protein in fermentation cultures. Additionally, such nucleotides may be
 CC used in gene therapy protocols for the treatment of diseases associated
 CC with abnormal potassium channels
 XX
 SQ Sequence 1111 BP; 347 A; 237 C; 263 G; 264 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,55e-45 Length: 1111
 Score: 478.00 Matches: 94
 Percent Similarity: 62.73% Conservative: 41
 Best Local Similarity: 43.72% Mismatches: 70
 Query Match: 38.52% Indels: 10
 DB: 2 Gaps: 4
 US-09-914-053A-5 (1-235) x AAZ11913 (1-1111)
 QY 27 AspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAlaGlyAspArg 46
 Db 234 GATGAGACCCACTAGATGTGCACAAAGAGGCTGCCATCC---AGTGTGAGAGGACCGA 290
 QY 47 AlalileuLeuGlyLeuAlaMetMetValCysSerIleMetTyrPheLeuLeuGly 66
 Db 291 GCCGTGATGCTGGGTTTGCATGATGGCTTCTCAGTCCCTAAATGTTCTTCTCTCGGA 350
 QY 67 IleThrLeuLeuArgSerTyrMetGlnSerValThrTrpThrGluGluSerGlnCysThrLeu 86
 Db 351 ACAACCATCTTAAGCCCTTTATGCTCAGCATTCAGAGAGAAGATCGACCTGCACCTGCC 410
 QY 87 LeuAsnAlaSerIleThrGluThrPhe---AsnCysSerPheSerCysGlyProAspCys 105
 Db 411 ATCCACAGATATCATGAGACACTGGCTGGACTGTGCTTCACTGTGGTGTGCACCTGC 470
 QY 106 TrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGlyGlu 125
 Db 471 CACGGTCAGGGAGTAGTACCGGTGTCTCAGGTGTTTGTGAACCTCAGCCATCCAGGTCAG 530
 QY 126 LysLeuLeuLeuTyrHisThrGluGluThrIleLysLeuGlnLysCysSerTyrIle 145

Miller AP, Curran ME, Hu P, Rutter M, Wang J;

CC	peptide therapy. The polypeptides have various cytokine-like activities, e.g. stem cell growth factor activity, haematopoiesis regulating activity, tissue growth factor activity, immunomodulatory activity and activin/inhibin activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the CC sequence listing were missing at the time of publication			
XX	Sequence 1144 BP; 289 A; 296 C; 291 G; 268 T; 0 U; 0 Other;			
Alignment Scores:				
Pred. No.:		1.86e-45	Length:	1144
Score:		477.50	Matches:	97
Percent Similarity:		60.00%	Conservative:	44
Best Local Similarity:		41.28%	Mismatches:	81
Query Match:		38.48%	Indels:	13
DB:		4	Gaps:	5
US-09-914-053A-5 (1-235) x AAK52128 (1-1144)				
QY	7	GlyArgThrSerSerTyrArgHisAspGluLysArgAsnIleTyrGlnLysIleArg	26	
DB	371	GGGAGGACAGCCCTTCTCCCTCAGGGAAGAGAGAGACAGACTACAGT-----	421	
QY	27	AspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAlaGlyGluAspArg	46	
DB	422	GATGGAGACCCACTAGATGTGCACAGAGGCTGCCATCC---AGTACTGGAGAGCCGA	478	
QY	47	AlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeuLeuGly	66	
DB	479	GCGGTGATCTGGGTTTGCCATGATGGCTTCTCAGTCTTAATGTTCTTGTGTCGA	538	
QY	67	IleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGluGluSerGlnCysThrLeu	86	
DB	539	ACAACATCTTAAGCCCTTTATGTCACATTCAGAGAGAGATCGACCTGCATGCC	598	
QY	87	LeuAsnAlaSerIleThrGluThrPhe---AsnCysSerPheSerCysGlyProAspCys	105	
DB	599	ATCCACACAGATATCATGGAGACTGGCTGGAGTGTGCTTCCCTTCCCTGTGTGCACTGC	658	
QY	106	TyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGlyGlu	125	
DB	659	CACGGTCAGGGAAGTACCCTGCTTTCAGGTGTTTGTAACCTCAGCCATCCAGTCCAG	718	
QY	126	LysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyrIle	145	
DB	719	AAAGCTCTCTACATTATATGAGAGGCTGTCCAGATAAATCCCAAGTCTTTTACACA	778	
QY	146	ProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValMetGluAsn	165	
DB	779	CCTAAGTGC-----CACCAAGATAGAAATGATTGTCTCAACAGTCTCTGGACATA	829	
QY	166	PheArgLysTyrGlnHis-----PheSerCysTyrSerAspProGluGly	180	
DB	830	AAAGAATTTCTCGATCACAATAATGGAATCCCTTTTCATGCTTCTACAGTCCAGCCAGC	889	
QY	181	AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu	200	
DB	890	CAATCTGAAGATGTCATCTTATAAAAAAGTATGACCAAAATGGCTATCTTCCACTGTTTA	949	
QY	201	PheTyrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr	220	
DB	950	TTTGGCTTCATGACTCTGCTAGGTGGTGGCTGATTGTTGGCAATGGTGAGATTAAACA	1009	
QY	221	GlnTyrLeuSerLeuLysCysGluArgIleGlnArgIleAsnArg	235	
DB	1010	CAACACCTGCTTACTGTGTGAAAAAATATAGCACTGTATGTCAGA	1054	
RESULT 13				
ABA09214				
ID ABA09214 standard; cDNA; 1251 BP.				
XX				

AAK53112;
06-NOV-2001 (first entry)
Human polynucleotide SEQ ID NO. 2641.
Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorder; arthritis; inflammation; ss.
OS Homo sapiens.
XX WO200157190-A2.
XX 09-AUG-2001.
XX 05-FEB-2001; 2001WO-US004098.
XX 03-FEB-2000; 2000US-00496914.
XX 27-APR-2000; 2000US-00560875.
XX 20-JUN-2000; 2000US-00598075.
XX 19-JUL-2000; 2000US-00620325.
XX 01-SEP-2000; 2000US-00654936.
XX 15-SEP-2000; 2000US-00663561.
XX 20-OCT-2000; 2000US-00693325.
XX 30-NOV-2000; 2000US-00728422.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;
XX Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
XX Xue AJ, Yang Y, Wejhran T, Goodrich R;
XX WPI; 2001-476283/51.
XX P-PSDB; AAM79979.
XX Nucleic acids encoding polypeptides with cytokine-like activities, useful
XX in diagnosis and gene therapy.
XX Claim 1; Page 4899-4900; 5221pp; English.
XX The invention relates to polynucleotides (AAK51456-AAK53435) and the
XX encoded polypeptides (AAM78323-AAK80302) that exhibit activity elating to
XX cytokine, cell proliferation or cell differentiation or which may induce
XX production of other cytokines in other cell populations. The
XX polynucleotides and polypeptides are useful in gene therapy, vaccines or
XX peptide therapy. The polypeptides have various cytokine-like activities,
XX e.g. stem cell growth factor activity, haematopoiesis regulating
XX activity, tissue growth factor activity, immunomodulatory activity and
XX activin/inhibin activity and may be useful in the diagnosis and/or
XX treatment of cancer, leukaemia, nervous system disorders, arthritis and
XX inflammation. Note: Records for SEQ ID NO. 2110 (AAK52581), 2111
XX (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the
XX sequence listing were missing at the time of publication
XX SQ Sequence 1251 BP; 331 A; 304 C; 310 G; 306 T; 0 U; 0 Other;
Alignment Scores:
Pred No.: 2.12e-45 Length: 1251
Score: 477.50 Matches: 97
Percent Similarity: 60.00% Conservative: 44
Best Local Similarity: 41.28% Mismatches: 81
Query Match: 38.48% Indels: 13
DB: 4 Gaps: 5
US-09-914-053A-5 (1-235) x AAK53112 (1-1251)
Qy 7 GlyArgThrSerSerSerTyrArgHisAspGluLysArgAsnIleTyrGlnLysIleArg 26
Db 339 GGGAGGACAGCCCTTCTCGCTCGCTGAGGAGAGAGAGAGACAGCTACAGT----- 389
Qy 27 AspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAlaGlyGluAspArg 46

Db 390 GATGGAGACCCACCTAGATGTGCCAAGAGGCTGCCATCC---AGTACTGGAGAGACCGA 446
Qy 47 AlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeuLeuGly 66
Db 447 GCGGTGATGCTGGGGTTTGCATCATGGGCTTCTCAGTCTCTAAATGTTCTTCTTCGCGA 506
Qy 67 IleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGluGluSerGlnCysThrLeu 86
Db 507 ACAACCATTTCTAAAGCCCTTTTATGCTCAGCAATTCAGAGAGAAGAAATGACCTGCTGCTGCC 566
Qy 87 LeuAsnAlaSerIleThrGluThrPhe---AsnCysSerPheSerCysGlyProAspCys 105
Db 567 ATCCACACAGATATCATGGACGACTGGCTGGACGTGCTTCACTTGTGGTGTGCACATGC 626
Qy 106 TrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGlyGlu 125
Db 627 CACGGTCAGGGGAAGTACCCGCTCTTCAGGTGTTGTGAACCTCAGCCATCCAGGTGCTAG 686
Qy 126 LysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyrIle 145
Db 687 AAGGCTCTCTACATTAATAGAGAGGCTGCCAGATAAATCCAGTGTCTTTTACACA 746
Qy 146 ProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValMetGluAsn 165
Db 747 CTTAAGTGC-----CACCAAGATAGAAATGATTTGCTCAACAGTGTCTGACATA 797
Qy 166 PheArgLysTyrGlnHis-----PheSerCysTyrSerAspProGluGly 180
Db 798 AAGAAATCTTCGATCACAATAATGGAACCCCTTTTCATGCTTCTACAGTCCAGCCAGC 857
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
Db 858 CAATCTGAAGATGTCATTCTTATAAAAAAGTATGACCAAAATGGCTATCTTCCACTGTTTA 917
Qy 201 PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220
Db 918 TTTTCGCTTCACTGACTGCTGCTAGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 977
Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db 978 CAACACCTGCTCTACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1022
RESULT 15
AAA75009
ID AAA75009 standard; DNA; 774 BP.
XX AAA75009;
AC AAA75009;
DT 02-JAN-2001 (first entry)
XX DNA encoding a human BK beta-2 polypeptide.
DE Human; BK beta-2; beta subunit; Slo potassium channel; BK beta-3;
KW BK beta-4; ion flux; migraine; hearing; vision problem; seizure; stroke;
KW asthma; cell proliferation; hormone secretion; cancer; viral infection;
KW ss.
XX Homo sapiens.
OS XX
FH Key Location/Qualifiers
CDS 1..774
FT /+tag= a
FT /product= "BK beta-2"
XX WO200050444-A1.
XX 31-AUG-2000.
PD XX
XX 22-FEB-2000; 2000WO-US004441.
PF XX
XX 23-FEB-1999; 99US-0121224P.
PR XX
XX 03-NOV-1999; 99US-0163367P.
PR

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 6, 2004, 23:31:06 ; Search time 3203 Seconds
(without alignments)
10438.282 Million cell updates/sec

Title: US-09-914-053A-6
Perfect score: 707
Sequence: 1 atctgatattggaccagtgg.....atccacggatcaatagataa 707

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl.*

1: gb_ba.*
2: gb_hg.*
3: gb_in.*
4: gb_om.*
5: gb_ov.*
6: gb_pat.*
7: gb_ph.*
8: gb_pl.*
9: gb_pt.*
10: gb_ro.*
11: gb_sts.*
12: gb_sy.*
13: gb_un.*
14: gb_vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	692	97.9	1075	9 AF099137	AF099137 Homo sapi
2	692	97.9	1285	9 BC017825	BC017825 Homo sapi
3	692	97.9	2574	9 AF209747	AF209747 Homo sapi
4	666	94.2	1062	6 CO714334	CO714334 Sequence
5	567.2	80.2	708	10 AV062429	AV062429 Mus muscu
6	567.2	80.2	2947	10 BC046227	BC046227 Mus muscu
7	567.2	80.2	2947	10 BC058957	BC058957 Mus muscu
8	564.2	79.8	2098	6 BD223084	BD223084 98 human
9	564.2	79.8	2098	6 BD243782	BD243782 Sequence
10	562.4	79.5	708	10 AY191836	AY191836 Rattus no
11	438.4	62.0	1546	5 BX950825	BX950825 Gallus ga
12	438.4	62.0	1546	5 BX950833	BX950833 Gallus ga
13	384.4	54.4	487	10 XN0517198	AL517198 Rattus no
14	274.8	38.9	204899	9 ACL117457	ACL117457 Homo sapi
15	229.8	32.5	191186	2 ACL15077	ACL15077 Mus muscu
16	225	31.8	227094	2 ACL126508	ACL126508 Rattus no
17	225	31.8	297398	2 AC097578	AC097578 Rattus no
18	193.6	27.4	815	5 CCU67865	U67865 Coturnix co
19	193.6	27.4	826	5 AF077369	AF077369 Gallus ga

20	193.6	27.4	1290	5 AF20468	AF20468 Gallus ga
C 21	151.2	21.4	270878	2 AC114433	AC114433 Rattus no
C 22	145.8	20.6	191186	2 AC115077	AC115077 Mus muscu
23	140.6	19.9	622	11 G97798	G97798 S209P6139FA
24	135.4	19.2	1022	6 CO715541	CO715541 Sequence
25	135.4	19.2	1111	6 AR212368	AR212368 Sequence
26	135.4	19.2	1246	6 AR212367	AR212367 Sequence
27	134.4	19.0	952	9 AF214561	AF214561 Homo sapi
28	134.4	19.0	1022	9 AF139471	AF139471 Homo sapi
29	134.4	19.0	1160	9 AF170916	AF170916 Homo sapi
30	134.4	19.0	1225	9 AF204159	AF204159 Homo sapi
31	134.4	19.0	1311	9 AF204162	AF204162 Homo sapi
32	134.4	19.0	1488	9 AF160968	AF160968 Homo sapi
33	134.4	19.0	1620	9 AF204160	AF204160 Homo sapi
34	134.4	19.0	1747	9 AF204161	AF204161 Homo sapi
35	134	19.0	576	9 AF026002	AF026002 Homo sapi
36	134	19.0	576	9 HSU38907	U38907 Human beta-
37	134	19.0	715	9 AY044441	AY044441 Homo sapi
38	134	19.0	835	9 AY515264	AY515264 Homo sapi
39	134	19.0	1041	9 HSU42600	U42600 Human calci
40	134	19.0	1092	9 HSU61536	U61536 Human potas
41	134	19.0	1106	6 AR016453	AR016453 Sequence
42	134	19.0	1106	6 I45572	I45572 Sequence 3
43	134	19.0	1276	6 CO726048	CO726048 Sequence
44	134	19.0	1277	6 AX337509	AX337509 Sequence
45	134	19.0	1277	9 HSU25138	U25138 Human Maxik

ALIGNMENTS

RESULT 1	AF099137	1075 bp	mRNA	linear	PRI 06-APR-1999
LOCUS	Homo sapiens Maxik channel beta 2 subunit (KCNMB2)	mRNA	linear	KCNMB2	mRNA, complete
DEFINITION	cds.				
ACCESSION	AF099137				
VERSION	AF099137.1	GI:4566496			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	1 (bases 1 to 1075)				
AUTHORS	Wallner,M., Meera,P. and Toro,L.				
TITLE	Molecular basis of fast inactivation in voltage and Ca2+-activated K+ channels: a transmembrane beta-subunit homolog				
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 96 (7), 4137-4142 (1999)				
MEDLINE	99199323				
PUBMED	10097176				
REFERENCE	2 (bases 1 to 1075)				
AUTHORS	Wallner,M.				
TITLE	Direct Submission				
JOURNAL	Submitted (16-OCT-1998) Dept. of Anesthesiology, UCLA, BH-612, CHS				
FEATURES	Box 951778, Los Angeles, CA 90095-1778, USA				
source	Location/Qualifiers				
	1..1075				
	/organism="Homo sapiens"				
	/mol_type="mRNA"				
	/db_xref="taxon:9606"				
	/clone="IMAGE Consortium ID 1417217"				
	/tissue_type="neuroendocrine lung carcinoid"				
gene	1..1075				
	/gene="KCNMB2"				
CDS	146..853				
	/gene="KCNMB2"				
	/function="coexpression with the pore forming Maxik channel alpha subunit leads to fast inactivating currents and to an increase in apparent Ca2+ sensitivity"				
	/notes="modulatory subunit of the voltage and Ca2+-activated K+ (Maxik) channel"				
	/codon_start=1				
	/product="Maxik channel beta 2 subunit"				

```
/protein_id="AAD23380.1"
/db_xref="GI:4566497"
/translation="MFITSGTSSSYRHDEKRNLYQKIRHDLDDKRKVTALKAGE
DRAILLGLAMVYCSIMVFLIGITLLRYSQVWTEESQCTLLNASITETFCFSOG
PDCWKLQVPCIQVYVNTSGEKLILYHTEIKINGKSYIPKCGKNFESMSLVN
VYVNFPRKYHFSCYSDPEGNQKSVILTKYSSNVLFHFWPTCMAGGVAIVAMVK
LTOYLSLLCERIQIRN"
misc_feature
146..202
/gene="KCNMB2"
/notes="intracellular inactivating 'ball' domain;
unclassified site"
misc_feature
287..355
/gene="KCNMB2"
/notes="transmembrane-region site"
misc_feature
728..796
/gene="KCNMB2"
/notes="transmembrane-region site"
ORIGIN
Query Match          97.9%; Score 692; DB 9; Length 1075;
Best Local Similarity 99.3%; Pred. No. 2,3e-194;
Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;
QY 1 ATGTGATATGACACAGTGGCGGACCTCTTCATCTTTATAGACATGATGAAGAAAT 60
DB 146 ATGTTTATATGACACAGTGGCGGACCTCTTCATCTTTATAGACATGATGAAGAAAT 205
QY 61 ATTACCAGAAATCAGGACCATCATCTCTCGGACAAAGAAACAGTCACAGCACTG 120
DB 206 ATTTACCAGAAATCAGGACCATCATCTCTCGGACAAAGAAACAGTCACAGCACTG 265
QY 121 AAGCAGGAGAGACCGAGCTATTCCTGGACTGGCTATGATGGTGTCTCCATCATG 180
DB 266 AAGCAGGAGAGACCGAGCTATTCCTGGACTGGCTATGATGGTGTCTCCATCATG 325
QY 181 ATGTATTTCTCTGGGATCATCTCTCGGCTCATACATGCAGAGGCTGTGACCGAA 240
DB 326 ATGTATTTCTCTGGGATCATCTCTCGGCTCATACATGCAGAGGCTGTGACCGAA 385
QY 241 GAGTCTCAATGACCTGTGTAATCGCTCCATCAGGAAACATTTAATGCTCTTCAGC 300
DB 386 GAGTCTCAATGACCTGTGTAATCGCTCCATCAGGAAACATTTAATGCTCTTCAGC 445
QY 301 TGTGTCAGACTGTGAAACTTCTCAGTACCCCTGCTCCAGGCTAGCTTAACTG 360
DB 446 TGTGTCAGACTGTGAAACTTCTCAGTACCCCTGCTCCAGGCTAGCTTAACTG 505
QY 361 ACTTCTCCGGGAAAGCTCTCTCTTACACAGAGAGACAATAAATCAATCAG 420
DB 506 ACTTCTCCGGGAAAGCTCTCTCTTACACAGAGAGACAATAAATCAATCAG 565
QY 421 AAGTCTCTATATACCTTAATGTGGAAAAATTTGAAGAAATCCATGTCCTCGTGAAT 480
DB 566 AAGTCTCTATATACCTTAATGTGGAAAAATTTGAAGAAATCCATGTCCTCGTGAAT 625
QY 481 GTTGTGATGGAACCTTCAGGAAGPATCAACACTTCTCTCTCTGATCTGACCCAGAGGA 540
DB 626 GTTGTGATGGAACCTTCAGGAAGPATCAACACTTCTCTCTGATCTGATCTGACCCAGAGGA 685
QY 541 AACCAAGAGAGTGTATCTTAACMAAATCTACAGTTCACACGCTGTTTCCATTCACCT 600
DB 686 AACCAAGAGAGTGTATCTTAACMAAATCTACAGTTCACACGCTGTTTCCATTCACCT 745
QY 601 TTCTGGCCAACTGATGATGCTGGGGTGTGCAATTTGTCATGTTGGAACCTTACA 660
DB 746 TTCTGGCCAACTGATGATGCTGGGGTGTGCAATTTGTCATGTTGGAACCTTACA 805
QY 661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
DB 806 CAGTACCTCTCCCTACTATGTGAGAGGATCCACCGGATCAATAGATAA 853
```

RESULT 2

```
BC017825
LOCUS
DEFINITION
Homo sapiens potassium large conductance calcium-activated channel,
subfamily 2, beta member 2, transcript variant 1, mRNA (cDNA clone
MGC:22431 IMAGE:4657825), complete cds.
ACCESSION
BC017825
VERSION
BC017825.1 GI:17389593
KEYWORDS
MGC.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1285)
Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner J., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusik K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L.,
Scheetz T.E., Brownstein M.J., Ustin T.B., Tschiyuki S.,
Carninci P., Prange C., Raha S., Loquellano N.A., Peters G.J.,
Abramson R.D., Mullany S.J., Bosak S.A., McEwan P.J.,
McKernan K.J., Malek J.A., Gunaratne P.H., Richards S.W.,
Villalón D.K., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Fahey J., Helton E., Kettman M., Madan A., Rodriguez S.,
Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y.,
Bouffard G., Blakeley R.W., Touchman J.W., Green E.D.,
Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
Butterfield Y.S., Krzywinski M.I., Skalska U., Small D.E.,
Schnerch A., Schein J.E., Jones S.J. and Marra M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
12477932
PUBMED
12477932
REFERENCE
2 (bases 1 to 1285)
Strausberg R.
Direct Submission
Submitted (03-DEC-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabbs-r@mail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: CLONTECH Laboratories, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
cDNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www-shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAL Place: 36 Row: 1 Column: 8
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 19923319.
Location/Qualifiers
1..1285
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:22431 IMAGE:4657825"
/tissue_type="Testis, embryonal carcinoma"
/clone_lib="NIH MGC 61"
/lab_host="DH10B"
/notes="Vector: pDNR-LIB"
1..1285
/gene="KCNMB2"
/notes="synonym: MGC22431"
```

FEATURES
source

gene

/db_xref="LocusID:10242"
/db_xref="MIM:605214"
344..1051
/gene="KCNMB2"
/codon_start=1
/product="calcium-activated potassium channel beta 2 subunit"
/protein_id="AAH:7825.1"
/db_xref="GI:17389594"
/db_xref="LocusID:10242"
/db_xref="MIM:605214"
/translation="MF1WTSRTSSSYRHDEKRNLYOKIRHDLDDKRTVTALKAGE
DRAILLGLAMVCSIMYFLIGITLLRSYVQSWTESSQCTLLNASITETFNCSFSCG
PDCWKLQYPCLOVYVNLTSSEKLLYHTETIKINQKSYIPKCKNFEESMLVN
VVMENFRKYQHPSCYSDPEGNQKSVILTKLYSSNVLFSHPFTCMAGGVAIVAMVK
LTQYLSLLCERIQIRNR"
ORIGIN
Query Match 97.9%; Score 692; DB 9; Length 1285;
Best Local Similarity 99.3%; Pred. No. 2.3e-194;
Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;
QY 1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60
Db ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 403
QY 61 ATTTACAGAAAATCAGGACCATGACCTCTGTCGACAAAAGAAAACAGTCACAGCACTG 120
Db ATTTACAGAAAATCAGGACCATGACCTCTGTCGACAAAAGAAAACAGTCACAGCACTG 463
QY 121 AAGCAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG 180
Db AAGCAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG 523
QY 181 ATGATTTTCTGCTGGGAATCAGCTCTCGCTCATACATGACAGCGGTGTGACCGGAA 240
Db ATGATTTTCTGCTGGGAATCAGCTCTCGCTCATACATGACAGCGGTGTGACCGGAA 583
QY 241 GAGTCTCAATGCACTTCTGTAATGCGTCCATACAGGAAACATTTAAATGCTCTCCAGC 300
Db GAGTCTCAATGCACTTCTGTAATGCGTCCATACAGGAAACATTTAAATGCTCTCCAGC 643
QY 301 TGTGGTCAGACTGCTGGAAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360
Db TGTGGTCAGACTGCTGGAAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 703
QY 361 ACTTCTCCGGGAAAAGCTCTCTCTTACCACAGAGAGACATAAATAAATCAATCAG 420
Db ACTTCTCCGGGAAAAGCTCTCTCTTACCACAGAGAGACATAAATAAATCAATCAG 763
QY 421 AAGTGCTCTATATACCTAAATGTGGAAAAATTTTGAAGAATCCATGTCCTGGTGAAT 480
Db AAGTGCTCTATATACCTAAATGTGGAAAAATTTTGAAGAATCCATGTCCTGGTGAAT 823
QY 481 GTTGTCTAGGAAACTTCAGAGATATCAACATTTCTCTGCTATTCTGACCCAGAGGA 540
Db GTTGTCTAGGAAACTTCAGAGATATCAACATTTCTCTGCTATTCTGACCCAGAGGA 883
QY 541 AACCAGAGAGTGTATCTTAACMAAACTCTACAGTTCACAGTGTGCTGTTCCTACTC 600
Db AACCAGAGAGTGTATCTTAACMAAACTCTACAGTTCACAGTGTGCTGTTCCTACTC 943
QY 601 TTCTGGCCAACTGTATGATGGCTGGGGGTGTGCAATTTGTCATGGTGAACATTACA 660
Db TTCTGGCCAACTGTATGATGGCTGGGGGTGTGCAATTTGTCATGGTGAACATTACA 1003
QY 661 CAGTACCTCTCCCTACTATGTGAGAGGATCC - ACGGATCAATAGATAA 707
Db CAGTACCTCTCCCTACTATGTGAGAGGATCCACCGGATCAATAGATAA 1051

RESULT 3
AF209747

LOCUS AF209747 2574 bp mRNA linear PRI 29-FEB-2000
DEFINITION Homo sapiens large conductance calcium-activated potassium channel
beta2 subunit (KCNMB2) mRNA, complete cds.
ACCESSION AF209747
VERSION AF209747.1 GI:7108972
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2574)
AUTHORS Brenner, R., Jegla, T.J., Wickenden, A., Liu, Y. and Aldrich, R.W.
TITLE Cloning and functional characterization of novel large conductance
calcium-activated potassium channel beta subunits, hKCNMB3 and
hKCNMB4
JOURNAL J. Biol. Chem. 275 (9), 6453-6461 (2000)
MEDLINE 20158960
PUBMED 10692449
REFERENCE 2 (bases 1 to 2574)
AUTHORS Brenner, R., Jegla, T.J., Wickenden, A., Liu, Y. and Aldrich, R.W.
TITLE Direct Submission
JOURNAL Submitted (30-NOV-1999) Molecular and Cell Physiology, Howard
Hughes Medical Institute, Stanford School of Medicine, Beckman
B173, Stanford, CA 94305, USA
FEATURES
source
1..2574
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue_type="ovary"
1..2574
/gene="KCNMB2"
353..1060
/gene="KCNMB2"
/note="hKCNMB2; large conductance (BK) potassium channel
beta2 subunit"
/codon_start=1
/product="large conductance calcium-activated potassium
channel beta2 subunit"
/protein_id="AAF36562.1"
/db_xref="GI:7108973"
/translation="MF1WTSRTSSSYRHDEKRNLYOKIRHDLDDKRTVTALKAGE
DRAILLGLAMVCSIMYFLIGITLLRSYVQSWTESSQCTLLNASITETFNCSFSCG
PDCWKLQYPCLOVYVNLTSSEKLLYHTETIKINQKSYIPKCKNFEESMLVN
VVMENFRKYQHPSCYSDPEGNQKSVILTKLYSSNVLFSHPFTCMAGGVAIVAMVK
LTQYLSLLCERIQIRNR"
ORIGIN
Query Match 97.9%; Score 692; DB 9; Length 2574;
Best Local Similarity 99.3%; Pred. No. 2.4e-194;
Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;
QY 1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60
Db ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 412
QY 61 ATTTACAGAAAATCAGGACCATGACCTCTCTGGGACAAAAGAAAACAGTCACAGCACTG 120
Db ATTTACAGAAAATCAGGACCATGACCTCTCTGGGACAAAAGAAAACAGTCACAGCACTG 472
QY 121 AAGCAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG 180
Db AAGCAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG 532
QY 181 ATGATTTTCTGCTGGGAATCAGCTCTCGCTCATACATGACAGCGGTGTGACCGGAA 240
Db ATGATTTTCTGCTGGGAATCAGCTCTCGCTCATACATGACAGCGGTGTGACCGGAA 592
QY 241 GAGTCTCAATGCACTTCTGTAATGCGTCCATACAGGAAACATTTAAATGCTCTCCAGC 300
Db GAGTCTCAATGCACTTCTGTAATGCGTCCATACAGGAAACATTTAAATGCTCTCCAGC 652
QY 301 TGTGGTCAGACTGCTGGAAAACCTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360

VWENFRRHQHFPCYSDPEGNQKSVILTKLYSSNVLFHSLFWFTCMAGGVAIVAMVK
LTQYLSLLCERIORINP

ORIGIN

Query Match 80.2%; Score 567.2; DB 10; Length 708;
Best Local Similarity 88.3%; Pred. No. 2.9e-157;
Matches 625; Conservative 2; Mismatches 80; Indels 1; Gaps 1;
Qy 1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATATGACATGATGAAAAAGAAAT 60
Db 1 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATGACAGAGGAGAAAAAGAAAT 60
Qy 61 ATTTACAGAAAAATCAGGACCATGACCTCTGTCGACAAAAAGGAAAAAGACGACGACTG 120
Db 61 ATCTACAGAAAAATCAGGACCATGACCTCTGTCGACAAAAAGGAAAAAGTGTGACGCTCTG 120
Qy 121 AAGCAGGAGAGGACCGAGCTATTTCTCTGGGACTGGCTATGATGGTGTCTCCATCATG 180
Db 121 AAGGCTGGGAGGACCGGACCATCTGCTGGCTGGCCATGATGGTGTCTCCATCATG 180
Qy 181 ATGTATTTCTGCTGGGAATCAGACTCTGGCTCTACATGACGAGCGTGTGGACCGAA 240
Db 181 ATGTACTTCTGCTGGGAATCAGACTCTGGCTCTACATGACGAGCGTGTGGACCGAA 240
Qy 241 GAGTCTCAATGCACCTTGTCTGAATGCGTCCATCAGGAAAAATTTAAATGCTCTCTTCAGC 300
Db 241 GAAGCCAGTGTGCCCTGCTGAATGTCTCATCAGAAACGTTTAACTGTCTCTTCAGC 300
Qy 301 TGTGGTCAGACTCTGGAAATCTTCTCAGTACCCCTGCTCAGAGTGTAGCTTAACCTG 360
Db 301 TGTGGCCGACTCTTGAAGCTCTCTCAGTACCCCTTGGCTGACGAGTGTAGCTGAACCTG 360
Qy 361 ACTTCTTCGGGGAAAAAGCTCTCTCTTACCACAGACAGACAAATAAAAAACAATCAG 420
Db 361 ACATCTTCGGGGAGAGCTCTCTCTTACCACAGGAGAGACCATGAGATCAATCAA 420
Qy 421 AAGTGTCTCTATATACCTAAATGTGAAAAAATTTTGAAGATCCATGTCCCTGGTGAAT 480
Db 421 AAGTGTCTCTATATCTTAAAGTGTGAAAAAACAATTTGAGGAGTCCATGTCTCTCGTGAAT 480
Qy 481 GTTCTCATGGAACACTTCAGGAAGTATCAACATCTCTCTGCTATCTTGACCCAGAGGA 540
Db 481 GTCTGTATGGAACACTTCAGGAGACACCACTTCCCTGCTATCTTGACCCAGAGGA 540
Qy 541 AACGAGAGAGTGTATCTTAAACAACTCTACAGTTCACAGTGTGCTTCCATTCACCTC 600
Db 541 AACGAGAGAGTGTATCTTCACTTCACTTCACTTCACTTCACTTCACTTCACTTCTC 600
Qy 601 TTCTGGCCAACTGTATGAGCTTGGGGGTGTGGCAATTTGTCATGTTGGAACCTTACA 660
Db 601 TTCTGGCCAACTGTATGAGCTTGGGGGTGTGGCAATTTGTCATGTTGGAACCTTAACT 660
Qy 661 CAGTACCTCTCTCTTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
Db 661 CAGTACCTCTCTCTTATGTGAGAGGATCCACACGGATCAACAGATCAACAGATTA 708

RESULT 6

BC046227 2947 bp mRNA linear ROD 30-JUN-2004
LOCUS Mus musculus potassium large conductance calcium-activated
DEFINITION subfamily M, beta member 2, mRNA (cDNA clone MGC:57945
IMAGE:5703879), complete cds.

ACCESSION

BC046227

VERSION

1 (bases 1 to 2947)

KEYWORDS

MGC.

SOURCE

Mus musculus (house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 2947)
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,

Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Schetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,
McKernan, R.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hui, Y.K., S.W.,
Villalón, D.C., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Fahy, J., Hellon, E., Kettner, M., Madan, A., Rodriguez, S.,
Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y.,
Bouffard, G.G., Blackley, R.W., Touchman, J.W., Green, E.D.,
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
Butterfield, Y.S., Krzyzanski, M.I., Skalska, U., Smalios, D.E.,
Scherer, A., Schein, J.E., Jones, S.J., and Marra, M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
12477932
2 (bases 1 to 2947)
Strausberg, R.
Direct Submission
Submitted (31-JAN-2003) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgpbbs@mail.nih.gov
Tissue Procurement: Dr. Jim Lin, University of Iowa
cDNA Library Preparation: M. Bento Soares, University of Iowa
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: University of Iowa, Dr. M. Bento Soares and Dr.
Thomas L. Casavant.
Web site: <http://genome.uiowa.edu>
Contact: bento-soares@uiowa.edu; tom-casavant@uiowa.edu
Bonaldo, M.F., Akabogu, I., Bair, T., Bair, J., Crouch, K., Davis, A.,
Fisher, K., Keppel, C., Kucaba, T., Lebeck, M., Melo, A., Schaefer, K.,
Schetz, T., Smith, C., Snir, E., Tack, D., Trout, K., Walters, J.,
Casavant, T., Soares, M.B.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: Plate: Row: Column: 0
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 21312299.

FEATURES

source

1..2947
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6"
/db_xref="taxon:10090"
/clone="MGC:57945 IMAGE:5703879"
/tissue_type="Brain, mouse 15.5 dpc"
/clone_lib="NIH BMAP_EWO"
/lab_host="DH103"
/note="Vector: pYX-ASC"
1..2947
/gene="Kcnmb2"
/note="synonym: MGC57945"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
391..1098
/gene="Kcnmb2"
/codon_start=1
/product="potassium large conductance calcium-activated
channel, subfamily M, beta member 2"
/protein_id="AAH46227.1"
/db_xref="GI:28279340"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
/translation="FVITWTSRTSSSRQDEKRNYYQKIRDHLLDKRVTALKAGE"

gene

CDS


```
/protein_id="AAH58957.1"
/db_xref="GI:37589335"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
/translation="MFTWTSRTSSSYRQDEKNIYKIRHDLKRTVTKRAGE
DRLLLGLAMVQCSIMVYLLGLITLLRSYQSVYVTEAOCALLNVTTFNFGSFGC
PDCKLSQVPLQVYVNLTSGBELLVHTEETMKINOKCSYIPKCGNPFESMSLVS
VYMFNFRHQHFPICSPSPBEGNQSVILTKLYSSNLFHSLFWPTCMWAGGVAIVMK
LTQVLSLLECIQRIQR"

ORIGIN
Query Match      80.2%; Score 567.2; DB 10; Length 2947;
Best Local Similarity 88.3%; Pred. No. 3.3e-157;
Matches 625; Conservative 2; Mismatches 80; Indels 1; Gaps 1;

QY 1 ATGTCGATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60
DB 1 ATGTTTATATGACACAGTGGCGGACCTCTTCATCTTATAGACAGGACGAGAAAGAAAT 450
QY 61 ATTTACAGAAAAATCAGGACCATGACCTCTGTCGACAAAAAGAAAAAGTACAGCACTG 120
DB 451 ATCTACAGAAAAATCAGGACCATGACCTCTGTCGACAAAAAGAAAAAGTACAGCACTG 510
QY 121 AAGCAGAGAGAGACCGAGTATTTCTCTGGGACTGGCTATGATGATGCTTCATCATG 180
DB 511 AAGCTGGGAGGACCGGCGCATCTGCTGGCGCTGCGCATGATGATGCTTCATCATG 570
QY 181 ATGTATTTCTGCTGGGATCACACTCTGCGCTCATACATGACAGAGCGTGTGACCGAA 240
DB 571 ATGTACTTCTGCTGGGATCACACTCTGCGCTCTTACATGACAGCGTGTGACAGAA 630
QY 241 GAGTCTCAATGACCTTCTGTAATCGCTCCATCACGGAACATTTAAATGCTCTTCAGC 300
DB 631 GAAGCCAGTGTGCCCTGCTGAATGTGCAATCACAGAAAGCTTTAACTGTTCCTTCAGC 690
QY 301 TGTGTCAGACTGCTGGAACCTTCACAGTACCCCTGCTCCAGGTGATAGTTAACTG 360
DB 691 TGTGGCCCGACTGTGGAAGCTCTCTCAGTACCCCTGCTCCAGGTGATAGTTAACTG 750
QY 361 ACTTCTCCGGGAAAAAGCTCTCTCTACACAGAGAGACAAATAAATCAATCAG 420
DB 751 ACATCTCCGGGAGAGCTCTCTCTACACAGAGAGACCAATCAATCAATCAA 810
QY 421 AAGTCTCTTATATACCTAAATGTGGAAAAATTTGAAAGATCATGCTCCCTGCTGAAT 480
DB 811 AAGTCTCTTATATCTTAAAGTGTGAAACAACTTTGAGGAGTCCATGCTCTCTGAGT 870
QY 481 GTTGTCAATGAAACTTCAGGAAGTATCAACACTTCTCTCTATTTCTGACCCAGAGGA 540
DB 871 GTCGTCATGAAAAACTTCAGGAGACCAACACTTCCCTCTATTTCTGACCCAGAGGA 930
QY 541 AACCAAGAGTGTATCTTAAACMAACTTACAGTTCACAGTCCAACTGCTGTTCCATCTC 600
DB 931 AACCAAGAGTGTATCTTAAACMAACTTACAGTTCACAGTCCAACTGCTGTTCCATCTC 990
QY 601 TTCTGGCAACTGTATGATGGCTGGGGTGTGCAATTTGTCATGGTGAATCTACA 660
DB 991 TTCTGGCAACTGTATGATGGCTGGGGTGTGCAATTTGTCATGGTGAATCTACA 1050
QY 661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
DB 1051 CAGTACCTCTCCCTCTTTGTGAGAGGATCCACCGATCAACAGATAA 1098

RESULT 8
BD223084
LOCUS          98 human secretory proteins.
DEFINITION    BD223084
ACCESSION     BD223084
VERSION       BD223084.1 GI:33032854
KEYWORDS      JP 2002521055-A/19.
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 2098)
Komatsoulis,G.A., Rosen,C.A., Ruben,S.M., Duan,R., Moore,P.A.,
Shi,Y., Lafleur,D., Wei,Y.F., Ni,Y., Florence,K.A., Young,P.B.,
Brewer,L.A., Soppet,D.R., Endress,G.A., Ebner,R., Olsen,H.S. and
Mucenski,M.
98 human secretory proteins
Patent: JP 2002521055-A 19 16-JUL-2002;
HUMAN GENOME SCIENCES INC
OS Homo sapiens (human)
PN JP 2002521055-A/19
PD 16-JUL-2002
PE 29-JUL-1999 JP 2000562480
PR 30-JUL-1998 US 60/094657,05-AUG-1998 US 60/095486 PR
06-AUG-1998 US 60/095455,06-AUG-1998 US 60/095454 PR
12-AUG-1998 US 60/096319
PI GEORGE A KOMATSOULIS, CRAIG A ROSEN, STEVEN
M RUBEN, ROXANNE DUAN,
PI PAUL A MOORE, YANGGU SHI, DAVID LAFLEUR, YING FEI WEI, JIAN NI, PI
KIMBERLY A FLORENCE, PAUL E YOUNG, LAURIE A BREWER, DANIEL R PI
SOPPET.
PI GREGORY A ENDRESS, REINHARD EBNER, HENRIK S OLSEN, MICHAEL PI
MUCENSKI
PC C12N15/09, A61K31/713, A61K38/00, A61K48/00, C07K14/47, C07K16/18,
PC C12N1/15,
PC C12N1/19, C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/68, G01N33/ PC
15,
PC G01N33/50, G01N33/53//A61P1/18, A61P5/02, A61P5/06, A61P5/14, A61P9/ PC
10,
PC A61P11/06, A61P17/06, A61P19/02, A61P25/02, A61P25/14, A61P25/16,
PC A61P25/24,
PC A61P25/28, A61P27/02, A61P29/00, A61P31/18, A61P35/02, C12N15/00,
PC C12N5/00,
PC A61K37/02
CC 98 human secretory proteins
FH Key Location/Qualifiers
FT source 1..2098
FT /organism='Homo sapiens (human)'
FT Location/Qualifiers
1..2098
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

ORIGIN
Query Match      79.8%; Score 564.2; DB 6; Length 2098;
Best Local Similarity 99.5%; Pred. No. 2.5e-156;
Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

QY 132 GGACCGAGCTATTTCTCTGGGACTGGCTATGATGGTGTCTCATCATGATGATTTTCT 191
DB 9 GGACCGAGCTATTTCTCTGGGACTGGCTATGATGGTGTCTCATCATGATGATTTTCT 68
QY 192 GCTGGGAATCACACTCTCGGCTCATACATGACAGCGGTGACCGAAGAGTCTCAATG 251
DB 69 GCTGGGAATCACACTCTCGGCTCATACATGACAGCGGTGACCGAAGAGTCTCAATG 128
QY 252 CACCTTGTGTAATCGTCCATCACGGAACATTTAAATGCTCTTCCAGTGTGTCAGA 311
DB 129 CACCTTGTGTAATCGTCCATCACGGAACATTTAAATGCTCTTCCAGTGTGTCAGA 188
QY 312 CTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGTACCTTAACCTGCTTCTCCGG 371
DB 189 CTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGTACCTTAACCTGCTTCTCCGG 248
QY 372 GGAAGAGCTCTCTCTTACACACAGAGACAAATAAATAAATCAATCAGAAGTCTCTTA 431
DB 249 GGAAGAGCTCTCTCTTACACACAGAGACAAATAAATAAATCAATCAGAAGTCTCTTA 308
QY 432 TATACCTAAATGTGGAAAAAATTTTGAAGATCCATGTCCTCGTGAATGTGTCATGGA 491
```

```

Db      309  TATACCTAAATGTGGAATAATTTTGAAGAATCCATGTCCTGGTGAATGTTGTCATGGA 368
QY      492  AAACITTCAGGAAGTATCAACACTTCTCCTGCTATTCTGACCCAGAGGAACCAAGAG 551
Db      369  AAACITTCAGGAAGTATCAACACTTCTCCTGCTATTCTGACCCAGAGGAACCAAGAG 428
QY      552  TGTATATCTTAACMAAACTCTACAGTTCACAGTGTCTTCAATTCACCTCTCTGCGCAAC 611
Db      429  TGTATATCTTAACMAAACTCTACAGTTCACAGTGTCTTCAATTCACCTCTCTGCGCAAC 488
QY      612  CTGTATGATGGCTGGGGGTGGCAATTGTTCCCATGTTGGAACCTTACACAGTACCTCTC 671
Db      489  CTGTATGATGGCTGGGGGTGGCAATTGTTCCCATGTTGGAACCTTACACAGTACCTCTC 548
QY      672  CTGTATGATGGCTGGGGGTGGCAATTGTTCCCATGTTGGAACCTTACACAGTACCTCTC 707
Db      489  CTGTATGATGGCTGGGGGTGGCAATTGTTCCCATGTTGGAACCTTACACAGTACCTCTC 548
QY      672  CTGTATGATGGCTGGGGGTGGCAATTGTTCCCATGTTGGAACCTTACACAGTACCTCTC 707
Db      549  CCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 585
QY      672  CCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707

RESULT 9
LOCUS   AR243782          2098 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION   Sequence 20 from patent US 6476195.
ACCESSION   AR243782
VERSION     AR243782.1  GI:27291275
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 2098)
AUTHORS    Komatsoulis,G., Rosen,C.A., Ruben,S.M., Duan,R.D., Moore,P.A.,
            Shi,Y., Lapleur,D.W., Wei,Y.-F., Ni,J., Florence,K.A., Young,P.,
            Brewer,L.A., Soppet,D.R., Endress,G.A., Ebner,R., Olsen,H. and
            Mucenski,M.
            Secreted protein HNF6F20
            Patent: US 6476195-A 20 05-NOV-2002;
            Location/Qualifiers
              1..2098
                /organism="unknown"
                /mol_type="genomic DNA"

ORIGIN
Query Match 79.8%; Score 564.2; DB 6; Length 2098;
Best Local Similarity 99.5%; Pred. No. 2.5e-156;
Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

QY      132  GGACCGAGCTATTCTCCTGGGACTGGCTATGATGGTGGTCCATCATGATGATTTTCT 191
Db      9      GGACCGAGCTATTCTCCTGGGACTGGCTATGATGGTGGTCCATCATGATGATTTTCT 68
QY      192  GCTGGGAATCACTCTCTCGCTCATATCATGACAGCGGTGTGGACCGAAGAGTCTCAATG 251
Db      69     GCTGGGAATCACTCTCTCGCTCATATCATGACAGCGGTGTGGACCGAAGAGTCTCAATG 128
QY      252  CACCTTGTGTGAATGGTTCATCAGGAACAATTAATGTCCTCTTACGCTGTGTGTCAGA 311
Db      129   CACCTTGTGTGAATGGTTCATCAGGAACAATTAATGTCCTCTTACGCTGTGTGTCAGA 188
QY      312  CTGCTGGAACCTTTCTCAGTACCCCTGCTCAGGTGTACGTTAACTGACTCTTCCCGG 371
Db      189   CTGCTGGAACCTTTCTCAGTACCCCTGCTCAGGTGTACGTTAACTGACTCTTCCCGG 248
QY      372  GGAAGAGCTCTCTCTACCAACAGAGAGACAAATAAATCAATCAGAAGTGTCTCCTA 431
Db      249   GGAAGAGCTCTCTCTACCAACAGAGAGACAAATAAATCAATCAGAAGTGTCTCCTA 308
QY      432  TATACCTAAATGTGGAATAATTTTGAAGAATCCATGTCCTGGTGAATGTTGTCATGGA 491
Db      309   TATACCTAAATGTGGAATAATTTTGAAGAATCCATGTCCTGGTGAATGTTGTCATGGA 368
QY      492  AAACITTCAGGAAGTATCAACACTTCTCCTGCTATTCTGACCCAGAGGAACCAAGAG 551

```

```

Db      369  AAACITTCAGGAAGTATCAACACTTCTCCTGCTATTCTGACCCAGAGGAACCAAGAG 428
QY      552  TGTATATCTTAACMAAACTCTACAGTTCACAGTGTCTTCAATTCACCTCTCTGCGCAAC 611
Db      429  TGTATATCTTAACMAAACTCTACAGTTCACAGTGTCTTCAATTCACCTCTCTGCGCAAC 488
QY      612  CTGTATGATGGCTGGGGGTGGCAATTGTTCCCATGTTGGAACCTTACACAGTACCTCTC 671
Db      489  CTGTATGATGGCTGGGGGTGGCAATTGTTCCCATGTTGGAACCTTACACAGTACCTCTC 548
QY      672  CTGTATGATGGAGAGATCC-ACGGATCAATAGATAA 707
Db      549  CCTACTATGTGAGAGATCCACCGATCAATAGATAA 585

RESULT 10
LOCUS   AY191836          708 bp      mRNA      linear      ROD 26-FEB-2003
DEFINITION   Rattus norvegicus inactivating beta 2 subunit of large conductance
            Ca2+-activated K+ channel mRNA, complete cds.
ACCESSION   AY191836
VERSION     AY191836.1  GI:28565441
KEYWORDS    Rattus norvegicus (Norway rat)
SOURCE      Rattus norvegicus
ORGANISM    Rattus norvegicus
REFERENCE   1 (bases 1 to 708)
AUTHORS    Eghbali,M., Foroughi,S., Toro,L. and Stefani,E.
TITLE      Rat inactivating beta 2 subunit of large conductance Ca2+-activated
            K+ channel (KCMB2, rSlo beta 2 subunit)
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 708)
AUTHORS    Eghbali,M., Foroughi,S., Toro,L. and Stefani,E.
TITLE      Direct Submission
JOURNAL     Submitted (06-DEC-2002) Anesthesiology, UCLA, PO Box 957115, Room
            BH-509A CHS, Los Angeles, CA 90095-7115, USA
FEATURES    Location/Qualifiers
              1..708
                /organism="Rattus norvegicus"
                /mol_type="mRNA"
                /strain="Sprague-Dawley"
                /db_xref="taxon:10116"
                /tissue_type="heart; myometrium"
              1..708
                /note="KCMB2; rSlo beta 2 subunit"
                /codon_start=1
                /product="inactivating beta 2 subunit of large conductance
            Ca2+-activated K+ channel"
                /protein_id="AA043501.1"
                /db_xref="GI:28565442"
                /translation="MFIWTSRTSSSYRDEKENIYOKIRDHLLDKRTVTALKAGE
            DPAILLGLAMVVCSTIMYELIGLITLRSYQSVWTEEAQRALLNVSLITETNCSPSCG
            PCWKLSQPCQLQVTVNLITSSGEKLLLYHTBETMKINKCKSYIPKCGNPFESLSLVS
            VVNEFRHQHPFCYSDDEGNQKSVILTKLYSSNVLFSLFWPTCMAGGVAIVAMVK
            LTQYLSLCEIRQIRNR"
            variation
              48
                /replace="t"
            variation
              171
                /replace="t"
            variation
              175
                /replace="g"
            variation
              231
                /replace="g"
            variation
              250
                /replace="t"

ORIGIN
Query Match 79.5%; Score 562.4; DB 10; Length 708;
Best Local Similarity 87.9%; Pred. No. 7.8e-156;
Matches 622; Conservative 2; Mismatches 83; Indels 1; Gaps 1;

```



```

DEFINITION Gallus gallus finished cDNA, clone CHEST43b24.
ACCESSION BX950833
VERSION BX950833.2 GI:46019324
KEYWORDS Gallus gallus (chicken)
SOURCE Gallus gallus
ORGANISM Gallus gallus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
1 (bases 1 to 1546)
Boardman,P.E., Bonfield,J.K., Brown,W.R.A., Carder,C., Chalk,S.E.,
Croning,M.D.R., Davies,R.M., Francis,M.D., Grafham,D.V.,
Hubbard,S.J., Humphray,S.J., Hunt,P.J., Maddison,M., McLaren,S.R.,
Niblett,D., Overton,I.M., Rogers,J., Scott,C.E., Taylor,R.G.,
Tickle,C. and Wilson,S.A.
Direct Submission
JOURNAL Submitted (29-MAR-2004) Sanger Institute, Hinxton, Cambridgeshire,
CB10 1SA, UK. E-mail enquiries: chickst@hms.unist.ac.uk
COMMENT On Apr.1, 2004 this sequence version replaced gi:42600518.
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST Gallus gallus cDNA
sequencing project.
This sequence is from the
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST cDNA collection,
from a library constructed by Elizabeth Bosch. cDNA was prepared
from RNA extracted from whole embryo, normalised, and poly
A-trimmed. EcoRI-NotI cut cDNA was then ligated into the vector.
Vector: pBluescript II KS(+); Site_1: EcoRI; Site_2: NotI Host:
Escherichia coli DH10B.
FEATURES
Location/Qualifiers
1..1546
/mol_type="mRNA"
/organism="Gallus gallus"
/strain="White Leghorn, HiseX"
/db_xref="taxon:9031"
/clone="CHEST43b24"
/dev_stage="stage 10"
ORIGIN
Query Match 62.0%; Score 438.4; DB 5; Length 1546;
Best Local Similarity 78.5%; Pred. No. 6.5e-119;
Matches 556; Conservative 2; Mismatches 128; Indels 22; Gaps 2;
QY 1 ATGTGGATGATGACAGGCGGCGGACCTCTTCATCTTATACACATGATGATGAAGAAGAT 60
DB 144 ATGTTATTGGACAGTGGCGGAGCTTACATCTTACACACAGATGAGAA----- 197
QY 61 ATTTACGAAATACAGGACCATGACCTCTCTGGACAAAGGAAACAGTCACAGCACTG 120
DB 198 -----ACGGATCAGCATCTACTGGACAAAGGAAACAGTCACAGCCCTA 242
QY 121 AAGGACAGAGGACCGAGCTATTCTCTCTGGAGTGGCTATGATGGTCTCTCATCATG 180
DB 243 AAAGCTGAGAGACCGGGCCATCTCTCTGGGTCGATGATGGTCTCTCATCATG 302
QY 181 ATGATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGGTGGACCGAA 240
DB 303 ATGACTTTCTCTGGGAATCACCTCTCTGGCTCTACATGACAGCGCTGGACAGAA 362
QY 241 GAGTCTCAATGACCTTCTGTAATGCGTCCATACGGAACATTTAATGCTCTTCAGC 300
DB 363 GAGGCTCAGTCTGCTCTCTCAACGATCCATCAACGAAACCTTCAACTGCTGTTAGC 422
QY 301 TGTGCTCAGACTGTGGAAACTTTCTCAGTACCCCTCGCTCCAGGTGTAGCTTAACCTG 360
DB 423 TCGGCCCCAGACTGCTGGAATCTCTCAGTACCCCTGCTGAGGTGTAGCTCAATCTC 482
QY 361 ACTTCTCCGGGAAAGCTCTCTCTTACACAGAGAGACAATAAATCAATCAG 420
DB 483 ACTTCTTCTGCGGAGAGCTTCTGCTCTTACACACCGAAGAAACAATGAAATTAATCT 542
QY 421 AAGTGCTCTATATACCTAAATGTGGAAATAATTTGAAGAATCCATGTCCCTGGTGAAT 480

```

```

Db 543 GAGTGTTCGTACATACCCAAAGTGTGGCAAGAAATTACGAGGAATCCATGTCAATGGTGAAC 602
QY 481 GTTGTGATGGAATAACTTCAGGAAGTATCAACACTTCTCTGCTATCTCAACCCAGAGGA 540
Db 603 GTTGTGATGGAATAACTTCGGAAGTATCAACGCTTCTCTGCTATGATCCTGAGGCG 662
QY 541 AACCAAGAAGAGTGTATCTCTAACMAAATCTACAGTTCCAAAGCTGTGTTCATTCACATC 600
Db 663 ACTCAGAAGAAGTGTATTTGACCAAACTGTACAGCTCCCAACGCTGTGTTCACATCGCTC 722
QY 601 TTTCGCCCAACCTGTATGATGGCTGGGGGTGGGCAATTTGTCATGTTGCAACTTACA 660
Db 723 TTTCGCCCAACCTGTATGATGGCTGGGGGTGGGCAATTTGTCATGTTGCAACTTACA 782
QY 661 CAGTACTCTCTCCCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707
Db 783 CAATACCTTCTCTCTCTGCGAGAGATCCAAAGAGATCAACAGATAA 830

```

```

RESULT 13
RNOS17198 487 bp mRNA linear ROD 15-DEC-2002
LOCUS Rattus norvegicus partial mRNA for calcium-activated potassium
DEFINITION channel beta 2 subunit (Kcnmb2 gene).
ACCESSION AJ517198
VERSION AJ517198.1 GI:26801163
KEYWORDS calcium-activated potassium channel beta 2 subunit; Kcnmb2 gene.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Location/Qualifiers
1..487
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Wistar"
/db_xref="taxon:10116"
/tissue_type="brain"
1..487
/gene="Kcnmb2"
<1..>487
/gene="Kcnmb2"
/function="ion channel"
/codon_start=2
/product="calcium-activated potassium channel beta 2
subunit"
/protein_id="CAD56888.1"
/db_xref="GI:26801164"
/db_xref="GOA:Q8CF83"
/db_xref="TREMBL:Q8CF83"
/translation="LKAGEKRAILGLAMVCSIMVFLGILLRSMQSVWTEBAQ
CALLAVSITETFCNSFCGPDCKLSQVPCLOVYVNTSSCKILLVHTETMKINOK
CSYIPKCNPNFEESNLSVSVMENFRHQHPCYSIDPEGNQKSVILKLYSSNVLFHS
LF"
ORIGIN
Query Match 54.4%; Score 384.4; DB 10; Length 487;
Best Local Similarity 86.6%; Pred. No. 6.8e-103;
Matches 421; Conservative 2; Mismatches 63; Indels 0; Gaps 0;

```

```

RNOS17198
LOCUS Rattus norvegicus partial mRNA for calcium-activated potassium
DEFINITION channel beta 2 subunit (Kcnmb2 gene).
ACCESSION AJ517198
VERSION AJ517198.1 GI:26801163
KEYWORDS calcium-activated potassium channel beta 2 subunit; Kcnmb2 gene.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Location/Qualifiers
1..487
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Wistar"
/db_xref="taxon:10116"
/tissue_type="brain"
1..487
/gene="Kcnmb2"
<1..>487
/gene="Kcnmb2"
/function="ion channel"
/codon_start=2
/product="calcium-activated potassium channel beta 2
subunit"
/protein_id="CAD56888.1"
/db_xref="GI:26801164"
/db_xref="GOA:Q8CF83"
/db_xref="TREMBL:Q8CF83"
/translation="LKAGEKRAILGLAMVCSIMVFLGILLRSMQSVWTEBAQ
CALLAVSITETFCNSFCGPDCKLSQVPCLOVYVNTSSCKILLVHTETMKINOK
CSYIPKCNPNFEESNLSVSVMENFRHQHPCYSIDPEGNQKSVILKLYSSNVLFHS
LF"
ORIGIN
Query Match 54.4%; Score 384.4; DB 10; Length 487;
Best Local Similarity 86.6%; Pred. No. 6.8e-103;
Matches 421; Conservative 2; Mismatches 63; Indels 0; Gaps 0;

```

QY	118	CTGAAGCAGGAGAGGACGAGCTATTCTCTGGAGTGGCTATGATGGTGTCTCCATC	177		
Db	2	CTGAAGCCTGGAGAGGACCGGGCCATCTCTGTTGGACTGGCCATGATGGTGTCTCCATC	61		
QY	178	ATGATGATTTTCTGTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACC	237		
Db	62	ATGATGATCTTCTACTGGGAATCACACTCTCTGGCTCGTACATGCAGAGTGTGTGGACA	121		
QY	238	GAGAGCTCAATGACACTTGTGGAATGCTGCATACCGGAACATTTAAATYGTCTCTTC	297		
Db	122	GAGAGAGCCAGTGTGCCCCCTGCTGAATGTGTCAATCACAGAAAACATTTAACTGTCTCTTC	181		
QY	298	AGCTGTGGTCCAGACTGCTGGAACCTTTCTCAGTACCCCTGCTCCAGGAGTGTACGTTAAC	357		
Db	182	AGCTGTGGGCTGACTGCTGTGAGAGCTCTCTCAGTACCCCTGCTCTCAGGATACGTTGAC	241		
QY	358	CTGACTTTTCCGGGGAAAAAGCTCTCTCTCTACACACAGAGAGACAATAAAATCAAT	417		
Db	242	CTGACATCTTCTGGGAGAAAGCTCTCTCTCTACACACAGAGAGACATGAAGATCAAT	301		
QY	418	CAGAAGTCTCTATATACCTAAATGTGGAAAAAATTTTGAAGATCCATGTCCTCGTG	477		
Db	302	CAAAAGTCTCTCTATATCTCTAGTGTGGAAAAAATTTTGAAGATCCATGTCCTCGTG	361		
QY	478	AATGTTGTCTATGAAAACTTTCAGAGATATCAACACTTCTCTCTCTATTTGACCCAGAA	537		
Db	362	AGTGTCTCATGAAAACTTTCAGAGAGACACCAACTTCTCTCTCTATTTGACCCAGAA	421		
QY	538	GGAAACAGAGAGTGTATCTCTAAACAACTCTACAGTTCCTCAAGCTGTCTCCATTC	597		
Db	422	GGGAACCAAAAGAGCGTCACTCTCTGACCAAACTCTATAGCTCCAATGCTGCTTCATCT	481		
QY	598	CTCTTTC 603			
Db	482	CTCTTTC 487			
RESULT 14	AC117457	204899 bp	DNA	linear	PRI 25-FEB-2003
LOCUS	AC117457	3 BAC RP11-385J1 (Roswell Park Cancer Institute Human			
DEFINITION	AC117457	BAC library) complete sequence.			
ACCESSION	AC117457				
VERSION	AC117457.11	GI:28557825			
KEYWORDS	HTG.				
SOURCE	HTG.				
ORGANISM	HTG.				
REFERENCE	HTG.				
AUTHORS	HTG.				
1 (bases 1 to 204899)	HTG.				
2 (bases 1 to 204899)	HTG.				
3 (bases 1 to 204899)	HTG.				
4 (bases 1 to 204899)	HTG.				
5 (bases 1 to 204899)	HTG.				
6 (bases 1 to 204899)	HTG.				
7 (bases 1 to 204899)	HTG.				
8 (bases 1 to 204899)	HTG.				
9 (bases 1 to 204899)	HTG.				
10 (bases 1 to 204899)	HTG.				
11 (bases 1 to 204899)	HTG.				
12 (bases 1 to 204899)	HTG.				
13 (bases 1 to 204899)	HTG.				
14 (bases 1 to 204899)	HTG.				
15 (bases 1 to 204899)	HTG.				
16 (bases 1 to 204899)	HTG.				
17 (bases 1 to 204899)	HTG.				
18 (bases 1 to 204899)	HTG.				
19 (bases 1 to 204899)	HTG.				
20 (bases 1 to 204899)	HTG.				
21 (bases 1 to 204899)	HTG.				
22 (bases 1 to 204899)	HTG.				
23 (bases 1 to 204899)	HTG.				
24 (bases 1 to 204899)	HTG.				
25 (bases 1 to 204899)	HTG.				
26 (bases 1 to 204899)	HTG.				
27 (bases 1 to 204899)	HTG.				
28 (bases 1 to 204899)	HTG.				
29 (bases 1 to 204899)	HTG.				
30 (bases 1 to 204899)	HTG.				
31 (bases 1 to 204899)	HTG.				
32 (bases 1 to 204899)	HTG.				
33 (bases 1 to 204899)	HTG.				
34 (bases 1 to 204899)	HTG.				
35 (bases 1 to 204899)	HTG.				
36 (bases 1 to 204899)	HTG.				
37 (bases 1 to 204899)	HTG.				
38 (bases 1 to 204899)	HTG.				
39 (bases 1 to 204899)	HTG.				
40 (bases 1 to 204899)	HTG.				
41 (bases 1 to 204899)	HTG.				
42 (bases 1 to 204899)	HTG.				
43 (bases 1 to 204899)	HTG.				
44 (bases 1 to 204899)	HTG.				
45 (bases 1 to 204899)	HTG.				
46 (bases 1 to 204899)	HTG.				
47 (bases 1 to 204899)	HTG.				
48 (bases 1 to 204899)	HTG.				
49 (bases 1 to 204899)	HTG.				
50 (bases 1 to 204899)	HTG.				
51 (bases 1 to 204899)	HTG.				
52 (bases 1 to 204899)	HTG.				
53 (bases 1 to 204899)	HTG.				
54 (bases 1 to 204899)	HTG.				
55 (bases 1 to 204899)	HTG.				
56 (bases 1 to 204899)	HTG.				
57 (bases 1 to 204899)	HTG.				
58 (bases 1 to 204899)	HTG.				
59 (bases 1 to 204899)	HTG.				
60 (bases 1 to 204899)	HTG.				
61 (bases 1 to 204899)	HTG.				
62 (bases 1 to 204899)	HTG.				
63 (bases 1 to 204899)	HTG.				
64 (bases 1 to 204899)	HTG.				
65 (bases 1 to 204899)	HTG.				
66 (bases 1 to 204899)	HTG.				
67 (bases 1 to 204899)	HTG.				
68 (bases 1 to 204899)	HTG.				
69 (bases 1 to 204899)	HTG.				
70 (bases 1 to 204899)	HTG.				
71 (bases 1 to 204899)	HTG.				
72 (bases 1 to 204899)	HTG.				
73 (bases 1 to 204899)	HTG.				
74 (bases 1 to 204899)	HTG.				
75 (bases 1 to 204899)	HTG.				
76 (bases 1 to 204899)	HTG.				
77 (bases 1 to 204899)	HTG.				
78 (bases 1 to 204899)	HTG.				
79 (bases 1 to 204899)	HTG.				
80 (bases 1 to 204899)	HTG.				
81 (bases 1 to 204899)	HTG.				
82 (bases 1 to 204899)	HTG.				
83 (bases 1 to 204899)	HTG.				
84 (bases 1 to 204899)	HTG.				
85 (bases 1 to 204899)	HTG.				
86 (bases 1 to 204899)	HTG.				
87 (bases 1 to 204899)	HTG.				
88 (bases 1 to 204899)	HTG.				
89 (bases 1 to 204899)	HTG.				
90 (bases 1 to 204899)	HTG.				
91 (bases 1 to 204899)	HTG.				
92 (bases 1 to 204899)	HTG.				
93 (bases 1 to 204899)	HTG.				
94 (bases 1 to 204899)	HTG.				
95 (bases 1 to 204899)	HTG.				
96 (bases 1 to 204899)	HTG.				
97 (bases 1 to 204899)	HTG.				
98 (bases 1 to 204899)	HTG.				
99 (bases 1 to 204899)	HTG.				
100 (bases 1 to 204899)	HTG.				

Ma, J., Maheshwari, M., Mapua, P., Martin, R., Martindale, A., Martinez, E., Massey, E., Mawhiney, E., McLeod, M.P., Meador, M., Mei, G., Metzger, M., Miner, G., Miner, Z., Mitchell, T., Mohabbat, K., Moore, S., Morgan, M., Moorish, T., Morris, S., Moser, M., Neal, D., Nelson, D., Newton, J., Newton, N., Nguyen, A., Nguyen, N., Nguyen, N., Nickerson, E., Nwokenkwo, S., Oguh, M., Okwuonu, G., Oragunye, N., Oviedo, R., Pace, A., Payton, B., Peery, J., Perez, L., Peters, L., Pickens, R., Primus, E., Pu, L.L., Quiles, M., Ren, Y., Rives, M., Rojas, A., Rojebokan, I., Rolfe, M., Ruiz, S., Savery, G., Scherer, S., Scott, G., Shen, H., Shooshtari, N., Sisson, I., Sodergren, E., Sonaike, T., Sparks, A., Stanley, H., Stone, H., Sutton, A., Svatek, A., Tabor, P., Tancris, A., Tancris, K., Tang, H., Tansley, J., Taylor, C., Taylor, T., Telford, B., Thomas, N., Thomas, S., Umani, K., Vasquez, L., Vera, V., Villalobos, D., Vinson, R., Wang, Q., Wang, S., Ward-Moore, S., Warren, R., Washington, C., Watlington, S., Williams, G., Williamson, A., Wleczek, R., Wooden, S., Worley, K., Wu, C., Wu, Y., Wu, Y., Zhou, J., Zorrilla, S., Naylor, S.L., Weinstein, G. and Gibbs, R.

Direct Submission
Unpublished
2 (bases 1 to 204899)
Worley, K.C.

Direct Submission
Submitted (10-APR-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
3 (bases 1 to 204899)
Worley, K.C.

Direct Submission
Submitted (22-FEB-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
4 (bases 1 to 204899)
Worley, K.C.

Direct Submission
Submitted (25-FEB-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
On Feb 25, 2003 this sequence version replaced gi:28467084.
INFORMATION: <http://www.hgsc.bcm.tmc.edu/> or email: gc-help@bcm.tmc.edu

CLONE LENGTH: This sequence does not necessarily represent the entire insert of this clone. Overlapping regions of clones are only sequenced and submitted once, so the sequence for the remainder of the insert may be found in the record for the adjacent clones. Overlapping clones are noted at the beginning and end of the Features listing.

ANNOTATION OF FEATURES:
STSs are identified using ePCR (Genome Res. 7:541-550) searches of a local database that includes entries from dbSTS, GDB, and local mapping efforts.
Repeats are identified using RepeatMasker (A. Smit and P. Green, unpublished.) for Human and Mouse sequences.
Genes and Region of sequence similarity are identified by BLAST (Nuc. Acids Res. 25:3389-3402) similarity (expect < 1e-34) to the EST and cDNA sequences. Genes demonstrate at least two exons flanked by consensus splice sites that maintained sequence continuity across the splice junctions. Sequences that are not identical matches are annotated as similar.

SEQUENCING READ COVERAGE: Sequencing is completed to a minimum standard of double strand coverage with a minimum of 2 clones and 2 reads with no ambiguities or 2 chemistries with a minimum of 2 clones and 3 reads with no ambiguities. If the sequence quality for a region does not meet this standard, it will be indicated in the annotation as Low Coverage.

QUALITY OF INDIVIDUAL BASES: This sequence meets stringent quality standards - estimated error rate less than 1 per 10,000 bases. Reports of lowest quality individual bases and measures of base quality are listed below. Description of the metrics can be found

at URL:
http://www.hgsc.bcm.tmc.edu:8088/quality.info/genbank.annotation.ht
ml.

FEATURES

Source

Location/Qualifiers

1..204899
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="3"
/clone="RP11-385J1"
/note="overlaps bases 1..2000 of clone AC139661"

misc_feature

complement(1..2000)
/function="clone overlap"

repeat_region

complement(501..659)

repeat_region

/rpt_family="L2"

repeat_region

complement(1481..1546)

repeat_region

/rpt_family="L2"

repeat_region

1611..1689

repeat_region

/rpt_family="MLT1B"

repeat_region

1694..1879

repeat_region

/rpt_family="MER2"

repeat_region

1893..1922

repeat_region

/rpt_family="AT_rich"

repeat_region

1964..2082

repeat_region

/rpt_family="MLT1B"

repeat_region

2083..2421

repeat_region

/rpt_family="MLT1A"

repeat_region

2422..2587

repeat_region

/rpt_family="MLT1B"

repeat_region

complement(2948..3005)

repeat_region

/rpt_family="L2"

repeat_region

complement(4400..4536)

repeat_region

/rpt_family="L2"

repeat_region

complement(5059..5175)

repeat_region

/rpt_family="MER20"

repeat_region

complement(5428..5572)

repeat_region

/rpt_family="MIR"

repeat_region

complement(5578..5707)

repeat_region

/rpt_family="MIR"

repeat_region

complement(7006..7250)

repeat_region

/rpt_family="MIR"

repeat_region

7575..9962

repeat_region

/rpt_family="L2"

repeat_region

complement(10792..10921)

repeat_region

/rpt_family="MIR"

complement(11688..11850)

/rpt_family="MIR"

complement(12469..13201)

/rpt_family="MER49"

13643..13814

/rpt_family="L2"

13815..13840

/rpt_family="(TTG)n"

13841..13878

/rpt_family="L2"

complement(13891..13953)

/rpt_family="L1PA2"

complement(14053..14222)

/rpt_family="PRAX"

15888..15985

/rpt_family="MER5B"

15990..16149

/rpt_family="MIR"

complement(16360..16474)

/rpt_family="MIR"

16570..16676

/rpt_family="L2"

16945..17166

/rpt_family="MIR"

complement(17322..17473)

/rpt_family="MER33"

17474..18315

/rpt_family="L1PA16"

repeat_region

complement(18329..18510)

repeat_region

/rpt_family="MER33"

repeat_region

18610..19373

repeat_region

/rpt_family="L1MA8"

repeat_region

19374..19673

repeat_region

/rpt_family="AluSp"

repeat_region

19674..19760

repeat_region

/rpt_family="L1MA8"

repeat_region

20088..20127

repeat_region

/rpt_family="MER5B"

repeat_region

20874..20893

repeat_region

/rpt_family="(GA)n"

repeat_region

complement(21009..21423)

repeat_region

/rpt_family="MER39"

repeat_region

22482..22503

repeat_region

/rpt_family="AT_rich"

repeat_region

24182..24476

repeat_region

/rpt_family="AluY"

repeat_region

24861..24881

repeat_region

/rpt_family="AT_rich"

Query Match 38.9%; Score 274.8; DB 9; Length 204899;

Best Local Similarity 98.3%; Pred. No. 4.6e-70;

Matches 287; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 417 TCAGAGTCTCTATATACCTAAATGTGGAAAAAATTTTGAAGATCCATGCTCCTGGT 476

Db 177474 TCACAGTCTCTATATACCTAAATGTGGAAAAAATTTTGAAGATCCATGCTCCTGGT 177533

QY 477 GAATGTTGTCAATGGAACCTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGA 536

Db 177534 GAATGTTGTCAATGGAACCTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGA 177593

QY 537 AGAAACACAGAGAGTGTATCTCTAACMAAATCTACAGTTCCAAAGTCTTCCATTC 596

Db 177594 AGAAACACAGAGAGTGTATCTCTAACMAAATCTACAGTTCCAAAGTCTTCCATTC 177653

QY 597 ACTCTTCTGGCCAACTGTATGATGCTGGGGGTGGCAATGTTGCCATGTTGAACT 656

Db 177654 ACTCTTCTGGCCAACTGTATGATGCTGGGGGTGGCAATGTTGCCATGTTGAACT 177713

QY 657 TACACAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707

Db 177714 TACACAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 177765

RESULT 15

AC115077

LOCUS

AC115077 191186 bp DNA linear HTG 10-JUN-2002

DEFINITION

Mus musculus clone RP24-455M3, WORKING DRAFT SEQUENCE, 20 ordered

ACCESSION

AC115077

VERSION

HTG; HTGS_PHASE2; HTGS_DRAFT; HTGS_FULLTOP.

KEYWORDS

Mus musculus

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

AUTHORS

REFERENCE

2 (bases 1 to 191186)

Unpublished

Birren,B., Linton,L., Nusbaum,C. and Lander,E.

Birren,B., Linton,L., Nusbaum,C., Lander,E., Ali,A., Allen,N.,

Anderson,S., Barna,N., Bastien,V., Bloom,T., Boguslavsky,L.,

Boukhgalter,B., Brown,A., Camarata,J., Campopiano,A., Chang,J.,

Chazaro,B., Choepel,Y., Colangelo,M., Collins,S., Collymore,A.,

Cook,A., Cooke,P., DeArelano,K., Dewar,K., Diaz,J.S., Dodges,S.,

Faro,S., Ferreira,P., Fitzhugh,W., Gage,D., Galagan,J., Gardyna,S.,

Ginde,S., Gord,S., Goyette,M., Graham,L., Grand-Pierre,N.,

Hagos,B., Horton,L., Hulme,W., Iliev,I., Johnson,R., Jones,C.,

Kamat,A., Karatas,A., Kells,C., LaRocque,K., Lamazares,R.,

Landers,T., Lehoczy,J., Levine,R., Lindblad-Toh,K., Liu,G.,

Maclean, C., Macdonald, P., Major, J., Marquis, N., Matthews, C., McCarthy, M., McEwan, P., McKernan, K., Meldrum, J., Meneus, L., Mihova, T., Mienga, V., Murphy, T., Naylor, J., Nguyen, C., Nicol, R., Norbu, C., Norman, C.H., O'Connor, T., O'Donnell, P., O'Neill, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V., Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupback, R., Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N., Strause, N., Subramanian, A., Talamas, J., Tesfaye, S., Theodore, J., Toham, K., Travers, M., Travis, N., Trigilio, J., Vassiliev, H., Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.J., Young, G., Zainoun, J., Zemdek, L., Zimmer, A. and Zody, M.

TITLE

JOURNAL

REFERENCE

AUTHORS

Submitted (14-MAR-2002) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA

3 (bases 1 to 191186)

Biren, B., Linton, L., Nusbaum, C., Lander, E., Ali, A., Allen, N., Anderson, S., Barna, N., Bastien, V., Bloom, T., Boguslavsky, L., Boukhgalter, B., Brown, A., Camarata, J., Campopiano, A., Chang, J., Chazaro, B., Choepel, Y., Colangelo, M., Collins, S., Collymore, A., Cook, A., Cooke, P., DeArelano, K., Dewar, K., Diaz, J.S., Dodge, S., Faro, S., Ferreira, P., FitzGerald, M., FitzHugh, W., Gage, D., Galagan, J., Gardyna, S., Ginde, S., Gord, S., Goyette, M., Graham, L., Grand-Pierre, N., Hagos, B., Horton, L., Hulme, W., Iliev, I., Johnson, R., Jones, C., Kamat, A., Karatas, A., Keils, C., LaRoque, K., Lamazares, R., Landers, T., Lehoczy, J., Levine, R., Lindblad-Toh, K., Liu, G., Maclean, C., Macdonald, P., Major, J., Marquis, N., Matthews, C., McCarthy, M., McEwan, P., McKernan, K., Meldrum, J., Meneus, L., Mihova, T., Mienga, V., Murphy, T., Naylor, J., Nguyen, C., Nicol, R., Norbu, C., Norman, C.H., O'Connor, T., O'Donnell, P., O'Neill, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V., Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupback, R., Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N., Strauss, N., Subramanian, A., Talamas, J., Tesfaye, S., Theodore, J., Toham, K., Travers, M., Travis, N., Trigilio, J., Vassiliev, H., Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.J., Young, G., Zainoun, J., Zemdek, L., Zimmer, A. and Zody, M.

TITLE

JOURNAL

COMMENT

Submitted (10-JUN-2002) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA

On Jun 10, 2002 this sequence version replaced gi:19424573.

All repeats were identified using RepeatMasker:

Smit, A.F.A. & Green, P. (1996-1997)

<http://ftp.genome.washington.edu/RM/RepeatMasker.html>

----- Genome Center

Center: Whitehead Institute/ MIT Center for Genome Research

Center code: WIBX

Web site: <http://www-seq.wi.mit.edu>

Contact: sequence.submissions@genome.wi.mit.edu

----- Project Information

Center project name: L24846

Center clone name: 455_M3

----- Summary Statistics

Sequencing vector: Plasmid; n/a; 100% of reads

Chemistry: Dye-terminator Big Dye; 100% of reads

Assembly program: Phrap; version 0.960731

Consensus quality: 184146 bases at least Q40

Consensus quality: 187658 bases at least Q30

Insert size: 183000; agarose-fp

Quality coverage: 6.1 in Q20 bases; agarose-fp

Quality coverage: 5.9 in Q20 bases; sum-of-contigs

----- NOTE: This is a 'working draft' sequence. It currently

* consists of 20 contigs. Gaps between the contigs

* are represented as runs of N. The order of the pieces

* is believed to be correct as given, however the sizes

* of the gaps between them are based on estimates that have

* provided by the submitter.

* This sequence will be replaced

* by the finished sequence as soon as it is available and

* the accession number will be preserved.

1	733:	contig of 733 bp in length
734	833:	gap of 100 bp
834	1739:	contig of 905 bp in length
1740	1839:	gap of 100 bp
1840	3336:	contig of 1697 bp in length
3637	3636:	gap of 100 bp
3637	5172:	contig of 1536 bp in length
5173	5172:	gap of 100 bp
5273	7064:	contig of 1732 bp in length
7065	7164:	gap of 100 bp
7165	9538:	contig of 2374 bp in length
9539	11844:	contig of 2206 bp in length
11845	11944:	gap of 100 bp
11945	13280:	contig of 1336 bp in length
13281	13280:	gap of 100 bp
13381	16275:	contig of 2835 bp in length
16276	16375:	gap of 100 bp
16376	18266:	contig of 2251 bp in length
18267	18726:	gap of 100 bp
18727	23667:	contig of 4941 bp in length
23668	23767:	gap of 100 bp
23768	31948:	contig of 8181 bp in length
31949	32048:	gap of 100 bp
32049	39436:	gap of 100 bp
39437	49369:	contig of 9933 bp in length
49370	49469:	gap of 100 bp
49470	61362:	contig of 11893 bp in length
61363	61462:	gap of 100 bp
61463	77912:	contig of 16450 bp in length
77913	78012:	gap of 100 bp
78013	92810:	contig of 14798 bp in length
92811	92810:	gap of 100 bp
92911	113012:	contig of 20102 bp in length
113013	113112:	gap of 100 bp
113113	137314:	contig of 24202 bp in length
137315	137414:	gap of 100 bp
137415	191186:	contig of 53772 bp in length.

Location/Qualifiers

1..191186

/organism="Mus musculus"

/mol_type="genomic DNA"

/db_xref="taxon:10090"

/clone_lib="RP24-455M3"

/clone_lib="RPC1-24 Male Mouse BAC"

1..733

/note="assembly_fragment"

834..1739

/note="assembly_fragment"

1840..3536

/note="assembly_fragment"

3637..5172

/note="assembly_fragment"

5273..7064

/note="assembly_fragment"

7165..9538

/note="assembly_fragment"

9539..11844

/note="assembly_fragment"

11945..13280

/note="assembly_fragment"

13381..16275

/note="assembly_fragment"

16376..18266

/note="assembly_fragment"

18727..23667

/note="assembly_fragment"

23768..31948

/note="assembly_fragment"

32049..39336

/note="assembly_fragment"

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature 39437. .49369
 /note="assembly_fragment"
 misc_feature 49470. .61362
 /note="assembly_fragment"
 misc_feature 61463. .77912
 /note="assembly_fragment"
 misc_feature 78013. .92810
 /note="assembly_fragment"
 misc_feature 92911. .113012
 /note="assembly_fragment"
 misc_feature 113113. .137314
 /note="assembly_fragment"
 misc_feature 137415. .191186
 /note="assembly_fragment"

ORIGIN

Query Match 32.5%; Score 229.8; DB 2; Length 191186;
 Best Local Similarity 89.5%; Fred. No. 1.1e-56;
 Matches 257; Conservative 1; Mismatches 28; Indels 1; Gaps 1;
 QY 422 AGTGCTCTATATACCTAAATGTGAAAAAATTTTGAAAGATCCATGTCCTGTGAATG 481
 Db |||||
 QY 482 TTGTCATGGAAGAACTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGAGGAA 541
 Db |||||
 QY 542 ACCAGAAGAGTGTATCTTAACMAAATCTACAGTTCACAGTCTGTTCCATTCACTCT 601
 Db |||||
 QY 602 TCTGCCCAACCTGTATGATGCTGGGGGTGTGGGAAATTTGTCATGCTGAACTTACAC 661
 Db |||||
 QY 662 AGTACCTCTCCCTACTATGTGAGAGGATCC-ACGATCAATAGATAA 707
 Db |||||
 QY 154789 AGTGCTCTATATTCCTAAGTGTGGAACAACCTTIGAGAGTCCATGTCCTGTGAGTG 154848
 Db |||||
 QY 154849 TCGTCATGGAAGAACTTCAGGAGACACCAACACTTCCCTGTCTATTCTGACCCAGAGGAA 154908
 Db |||||
 QY 154909 ACCAGAAGAGTGTATCTGACCAACTCTACAGCTCCAATGTGCTGTCCATTCTCT 154968
 Db |||||
 QY 154969 TCTGCCCAACTGTATGATGCTGGGGGTGTGGCAATCGTTGCTATGCTGAACTAACTC 155028
 Db |||||
 QY 155029 AGTACCTCTCCCTGCTTTGTGAGAGGATCCACCGATCAACAGATAA 155075
 Db |||||

Search completed: November 7, 2004, 00:34:42
 Job time : 3210 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 6, 2004, 23:29:46 ; Search time 425 Seconds
(without alignments)

8732.566 Million cell updates/sec

Title: US-09-914-053a-6

Perfect score: 707

Sequence: 1 atgtcgataggaccagtgg.....atccacggatcaatagataa 707

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 8269772

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N Geneseq_23Sep04:*

1: Geneseq1980s:*

2: Geneseq1990s:*

3: Geneseq2000s:*

4: Geneseq2001as:*

5: Geneseq2001bs:*

6: Geneseq2002as:*

7: Geneseq2002bs:*

8: Geneseq2003as:*

9: Geneseq2003bs:*

10: Geneseq2003cs:*

11: Geneseq2003ds:*

12: Geneseq2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	706.2	99.9	707	3	AA75011 DNA encod
2	692	97.9	1184	4	AA75011 Human cal
3	690.4	97.7	1300	3	AA251632 Human mem
4	564.2	79.8	2098	3	AA263355 Human sec
5	564.2	79.8	2098	8	ADA39669 Human sec
6	564.2	79.8	2098	10	ADA55858 Gene enco
7	564.2	79.8	2098	12	ADL71416 Novel hum
8	281	39.7	558	4	ABA09433 Human K c
9	135.4	19.2	1111	2	AAZ11913 Human pot
10	135.4	19.2	1246	2	AAZ11912 Human pot
11	134.4	19.0	774	3	AA75009 DNA encod
12	134.4	19.0	1144	4	AAK52128 Human pol
13	134.4	19.0	1251	4	ABA09214 Human Ca-
14	134.4	19.0	1251	4	AAK53112 Human pol
15	134.4	19.0	1296	4	AA75095 Human cal
16	134.4	19.0	1632	4	AA75093 Human cal
17	134	19.0	1106	2	AA75047 Human cal
18	134	19.0	1277	6	ABL69681 Prostata
19	134	19.0	1277	10	ADD14749 Human src
20	132.8	18.8	1237	4	AA75092 Human cal
21	131.2	18.6	1759	4	AA75094 Human cal

22	114.2	16.2	2238	2	AA75047 Bovine ca
23	102.2	14.5	608	4	AA75047 Human rep
24	80	11.3	110000	12	ADO34927_0
25	75.8	10.7	1228	2	AA75047 Human cal
26	74.8	10.6	188	3	AA75047 Human sec
27	74.2	10.5	633	3	AA75010 DNA encod
28	74.2	10.5	1501	3	AA75010 Human ORF
29	74.2	10.5	1608	3	AA75010 Human sec
30	67	9.5	394	3	AA75010 Human sec
31	60	8.5	60	6	ABN38341 Human spl
32	51.4	7.3	7045	4	ABA07292 Human dig
33	51.4	7.3	7045	4	AA75047 Human gen
34	51.4	7.3	7045	4	AA75047 Human cal
35	51.4	7.3	7045	8	ABX60417 Human mus
36	51.4	7.3	7045	12	ADJ31167 Human mus
37	49.2	7.0	413	12	ADO35047 Human KCh
38	47.2	6.7	285	2	AA75047 Human gen
39	45.4	6.4	48000	4	AA75047 Human cal
40	44.8	6.3	2787	5	AA75047 DNA encod
41	44.8	6.3	2787	5	AA75047 DNA encod
42	44.8	6.3	2787	5	AA75047 DNA encod
43	44.4	6.3	483	12	ADO35049 Human KCh
44	44.2	6.3	2000	8	ADA71938 Rice gene
45	43.2	6.1	898	6	ABQ25377 Oligonuel

ALIGNMENTS

RESULT 1
AAA75011
ID AAA75011 standard; DNA; 707 BP.
XX
AC AAA75011;
XX
DT 02-JAN-2001 (first entry)
XX
DE DNA encoding a human BK beta-4 polypeptide.

XX Human; BK beta-2; beta subunit; Slo potassium channel; BK beta-3;
KW BK beta-4; ion flux; migraine; hearing; vision problem; seizure; stroke;
KW asthma; cell proliferation; hormone secretion; cancer; viral infection;
KW ss.
XX Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS
FT 1..707
FT /product= "BK beta-4"
FT /transl_except= (pos: 691..692, aa: Gln)

WO200050444-A1.

31-AUG-2000.

22-FEB-2000; 2000WO-US004441.

23-FEB-1999; 99US-0121224P.

03-NOV-1999; 99US-0163367P.

(ICAG-) ICAGEN INC.

Jegla TJ, Wickenden A, Liu Y;

WPI; 2000-533179/48.

P-PSDB; AAB08820.

Isolated beta subunit polynucleotides and polypeptides of Slo potassium channels are used to determine the effects of compounds on ion flux through a potassium channel and in computer modelling systems.

Claim 7; Page 79-80; 84pp; English.

XX The present sequence encodes a human BK beta-4 polypeptide. The
 CC polypeptide is a beta subunit of a Slo potassium channel. The
 CC specification also describes BK beta-3 and BK beta-3 polypeptides. BK
 CC beta subunits are auxiliary subunits or monomers of Slo potassium
 CC channels. The polypeptides, when expressed in cells and cell membranes,
 CC are used to determine the effects of compounds on ion flux through a
 CC potassium channel. The compounds identified may be useful as therapeutic
 CC agents e.g. modulators that target specific Slo channels are useful for
 CC treating migraines, hearing and vision problems, seizures, stroke,
 CC asthma, cell proliferation and hormone secretion. The computer generated
 CC 3-dimensional structures of BK beta 2, BK beta 3 or BK beta 4 are used to
 CC identify ligands that bind to the beta subunit. The characterized BK beta
 CC subunits are used to determine how Slo potassium channels function in
 CC different environments and how they respond to different activation
 CC mechanisms. The polynucleotides are used to transfect cells in vivo and
 CC in vitro to mitigate effects of absent, partial inactivation or abnormal
 CC expression of the BK beta subunit gene e.g. to correct genetic defects,
 CC cancer and viral infection
 XX
 SQ Sequence 707 BP; 205 A; 170 C; 153 G; 177 T; 0 U; 2 Other;
 Query Match 99.9%; Score 706.2; DB 3; Length 707;
 Best Local Similarity 100.0%; Pred. No. 5.1e-211; Indels 0; Gaps 0;
 Matches 707; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ATGTCGATGATGACCAAGTGGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 60
 DB |||||
 QY 1 ATGTCGATGATGACCAAGTGGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 60
 DB |||||
 QY 61 ATTTACCGAATCAGGACCATGACCTCTCTGNCANAGAAAGAAACAGTCACAGCACTG 120
 DB |||||
 QY 61 ATTTACCGAATCAGGACCATGACCTCTCTGNCANAGAAAGAAACAGTCACAGCACTG 120
 DB |||||
 QY 121 AAGGACGAGAGACCGAGCTATTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 180
 DB |||||
 QY 121 AAGGACGAGAGACCGAGCTATTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 180
 DB |||||
 QY 181 ATGATTTTCTGCTGGGAATCACACTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 240
 DB |||||
 QY 181 ATGATTTTCTGCTGGGAATCACACTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 240
 DB |||||
 QY 241 GAGTCTCAATGACCTCTGTAATGCGTCCATCAGGAAACATTTAATGCTCTTCAGC 300
 DB |||||
 QY 241 GAGTCTCAATGACCTCTGTAATGCGTCCATCAGGAAACATTTAATGCTCTTCAGC 300
 DB |||||
 QY 301 TGTGTCGAGACTGTGGAAACTTTCTCAGTACCCCTGCCCTCCAGGTGTACGTTAACCTG 360
 DB |||||
 QY 301 TGTGTCGAGACTGTGGAAACTTTCTCAGTACCCCTGCCCTCCAGGTGTACGTTAACCTG 360
 DB |||||
 QY 361 ACTTCTCCGGGAAAGCTCTCTCTTACCACAGAGAGACAATAAAATCAATCAG 420
 DB |||||
 QY 361 ACTTCTCCGGGAAAGCTCTCTCTTACCACAGAGAGACAATAAAATCAATCAG 420
 DB |||||
 QY 421 AAGTCTCTCTATATACCTTAAATGTGGAATAAATTTGAAGAAATCCATGTCCTGGTGAAT 480
 DB |||||
 QY 421 AAGTCTCTCTATATACCTTAAATGTGGAATAAATTTGAAGAAATCCATGTCCTGGTGAAT 480
 DB |||||
 QY 481 GTTGTGATGGAACCTTCAGGAAGTATCAACACTTCTCTCTCTATTTCTGACCCAGAGGA 540
 DB |||||
 QY 481 GTTGTGATGGAACCTTCAGGAAGTATCAACACTTCTCTCTCTATTTCTGACCCAGAGGA 540
 DB |||||
 QY 541 AACCAAGAGAGTGTATCTTAACAAACTCTACAGTTCACAGTGTGCTTCCATTCACTC 600
 DB |||||
 QY 541 AACCAAGAGAGTGTATCTTAACAAACTCTACAGTTCACAGTGTGCTTCCATTCACTC 600
 DB |||||
 QY 601 TTCTGGCAACCTGTATGATGGCTGGGGGTGTGGCAATTTGTCATGCGTGGTGAACCTTACA 660
 DB |||||
 QY 601 TTCTGGCAACCTGTATGATGGCTGGGGGTGTGGCAATTTGTCATGCGTGGTGAACCTTACA 660
 DB |||||
 QY 661 CAGTACCTCTCCCTACTATGTGAGAGGATCCACGGATCAATAGATAA 707
 DB |||||
 QY 661 CAGTACCTCTCCCTACTATGTGAGAGGATCCACGGATCAATAGATAA 707
 DB |||||

RESULT 2
 AAF27991
 ID AAF27991 standard; DNA; 1184 BP.
 XX
 AC AAF27991;
 XX
 DT 08-MAY-2001 (first entry)
 XX
 DE Human calcium sensitive potassium channel beta2 subunit coding sequence.
 XX
 KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;
 KW beta3 subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;
 KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;
 KW irritable bowel syndrome; Alzheimer's disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200105828-A1.
 XX
 PD 25-JAN-2001.
 XX
 PF 18-JUL-2000; 2000WO-US019585.
 XX
 PR 20-JUL-1999; 99US-0144764P.
 XX
 PA (MERI) MERCK & CO INC.
 XX
 PI Uebele V, Swanson R, Liu Y, Lagrutta A;
 XX
 DR WPI; 2001-159514/16.
 XX
 DR P-PSDB; AAB35301.
 XX
 PT Novel human calcium sensitive potassium channel subunits for identifying
 PT inhibitors and agonists of the potassium channel for use in treating
 PT conditions such as asthma, hypertension, memory disorders, depression.
 XX
 PS Claim 3; Fig 1A; 89pp; English.
 XX
 CC The present invention provides the protein and coding sequences of the
 CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c
 CC and beta3d subunits. These can be used to identify inhibitors and
 CC activators of the channels, which can be used in the treatment of
 CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,
 CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,
 CC incontinence, migraine and irritable bowel syndrome. The coding sequences
 CC are found at human chromosome 3q23-ter. The present sequence is the beta2
 CC subunit coding sequence
 XX
 SQ Sequence 1184 BP; 356 A; 260 C; 255 G; 313 T; 0 U; 0 Other;
 Query Match 97.9%; Score 692; DB 4; Length 1184;
 Best Local Similarity 99.3%; Pred. No. 1.5e-206;
 Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;
 QY 1 ATGTCGATATGACCAAGTGGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 60
 DB |||||
 QY 271 ATGTTTATATGACCAAGTGGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 330
 DB |||||
 QY 61 ATTTACCGAATCAGGACCATGACCTCTCTGNCANAGAAAGAAACAGTCACAGCACTG 120
 DB |||||
 QY 331 ATTTACCGAATCAGGACCATGACCTCTCTGNCANAGAAAGAAACAGTCACAGCACTG 390
 DB |||||
 QY 121 AAGGACGAGAGACCGAGCTATTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 180
 DB |||||
 QY 391 AAGGACGAGAGACCGAGCTATTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 450
 DB |||||
 QY 181 ATGATTTTCTGCTGGGAATCACACTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 240
 DB |||||
 QY 451 ATGATTTTCTGCTGGGAATCACACTCTCTGGGACCTGCTATGATGGTGTGCTCCATCATG 510
 DB |||||
 QY 241 GAGTCTCAATGACCACTTGTGTAATGGTCCATCAGGAAACATTTAATGCTCTTCAGC 300

```
Db 511 GAGTCTCAATGCACCTTGTGTAATGCGTCCATCAGCGAACAATTTAACTGCTCCTTCAGC 570
Qy 301 TGTGTCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360
Db 571 TGTGTCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 630
Qy 361 ACTTCTTCGCGGAAAAGCTCCTCTCTACACACAGAGAGACAATAAAAAATCAATCAG 420
Db 631 ACTTCTTCGCGGAAAAGCTCCTCTCTACACACAGAGAGACAATAAAAAATCAATCAG 690
Qy 421 AAGTGTCTCTATATACCTAATGTGGAATAAATTTTGAAGATCCATGTCCTGGTGAAT 480
Db 691 AAGTGTCTCTATATACCTAATGTGGAATAAATTTTGAAGATCCATGTCCTGGTGAAT 750
Qy 481 GTTGTCTATGAAAACTTCAGGAAGTATCAACACTTCTCTCTATTCGACCCAGAGGA 540
Db 751 GTTGTCTATGAAAACTTCAGGAAGTATCAACACTTCTCTCTATTCGACCCAGAGGA 810
Qy 541 AACGAGAAGAGTGTATCTCTAACMAAATCTTACAGTTCCAACTGCTGTTCCATCACTC 600
Db 811 AACGAGAAGAGTGTATCTCTAACMAAATCTTACAGTTCCAACTGCTGTTCCATCACTC 870
Qy 601 TTCTGGCAACCTGTATGATGCTGGGGGTGGCAATTTGTCATGTTGGAATTTACA 660
Db 871 TTCTGGCAACCTGTATGATGCTGGGGGTGGCAATTTGTCATGTTGGAATTTACA 930
Qy 661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
Db 931 CAGTACCTCTCCCTACTATGTGAGAGGATCCACGGATCAATAGATAA 978

RESULT 3
AAZ51632
ID AAZ51632 standard; cDNA; 1300 BP.
XX
AC AAZ51632;
XX
DT 21-JUN-2000 (first entry)
XX
DE Human membrane channel protein-16 (MECHP-16) cDNA.
XX
KW Membrane channel protein-16; MECHP-16; diagnosis; treatment; lymphoma;
KW cell proliferative disorder; bursitis; atherosclerosis; cancer; sarcoma;
KW inflammatory disorder; AIDS; Addison's disease; cystic fibrosis; asthma;
KW diabetes mellitus; osmoregulatory disorder; diarrhoea; renal failure;
KW muscular disorder; myocarditis; Duchenne's muscular dystrophy; nocturnal;
KW cardiovascular disorder; hypertension; bronchitis; vasculitis; cardiac;
KW neurological disease; Alzheimer's disease; Parkinson's disease; human;
KW Huntington's disease; antiarteriosclerotic; hepatotropic; cytostatic;
KW anti-HIV; antianaemic; neuroprotective; immunomodulator; antidiabetic;
KW hypotensive; vasotropic; antiasthmatic; antiinflammatory; antidepressant;
KW anticonvulsant; thrombolytic; antiParkinsonian; immunostimulant; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
CDS 378..1085
FT /*tag= a
FT /product= "MECHP-16"
FT /note= "Shows homology to human beta subunit of Ca+
FT activated K+ channel"
FT 381..425
FT /*tag= b
FT /bound_moiety= "Primer or Probe"
XX
XX WO200012711-A2.
XX
XX 09-MAR-2000.
XX
XX 02-SEP-1999; 99WO-US020468.
XX
XX 02-SEP-1998; 98US-0155226P.
```

```
PR 12-NOV-1998; 98US-00191283.
PR 09-DEC-1998; 98US-0155225P.
PR 26-JAN-1999; 98US-0155211P.
PR 10-FEB-1999; 98US-0155263P.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Au-Young J, Bandman O, Tang YT, Reddy R, Hillman JL, Yue H;
PI Lal P, Corley NC, Guegler KJ, Gorgone G, Baughn MR, Azimzai Y;
XX
DR WPI: 2000-256643/22.
DR P-FSDB; AAY70466.
XX
XX Novel human membrane channel protein and polynucleotide useful for
PT diagnosing and treating cell proliferative, inflammatory, secretory,
PT osmoregulatory, muscular, cardiovascular and neurological disorders.
XX
PS Claim 9; Page 128-129; 140pp; English.
XX
CC The present sequence is a cDNA identified in Incyte clone 2069907 derived
CC from ISLNOT01 cDNA library. It encodes human membrane channel protein-16
CC (MECHP-16), which is expressed in nervous tissues. Anti-MECHP antibodies
CC can be used as therapeutic antagonists and reagents for diagnosis and
CC monitoring diseases. MECHP cDNA can be used for diagnosis of MECHP-
CC related diseases and gene mapping. MECHP can be used for treatment of
CC cell proliferative disorders such as bursitis and atherosclerosis,
CC cancers like lymphoma and sarcoma, inflammatory disorders like AIDS and
CC Addison's disease, transport/secretory disorders like cystic fibrosis and
CC diabetes mellitus, osmoregulatory disorders like diarrhoea and renal
CC failure, muscular disorders like myocarditis and Duchenne's muscular
CC dystrophy, cardiovascular disorders like hypertension and vasculitis,
CC congenital lung anomalies like bronchitis and asthma and neurological
CC disorders like Alzheimer's disease, Parkinson's disease and Huntington's
CC disease
XX
SQ Sequence 1300 BP; 381 A; 288 C; 279 G; 352 T; 0 U; 0 Other;
```

```
Query Match 97.7%; Score 690.4; DB 3; Length 1300;
Best Local Similarity 99.2%; Pred. No. 6.5e-206;
Matches 702; Conservative 2; Mismatches 3; Indels 1; Gaps 1;
QY 1 ATGTCGATATGACCACTGGCGGACCTCTTTCATCTTATAGACATGATGAAAAAGAAAT 60
Db 378 ATGTTATATGACCACTGGCGGACCTCTTTCATCTTATAGACATGATGAAAAAGAAAT 437
QY 61 ATTTACCAAGAAATCAGGACCATGACCTCTCTGGCAAAAAGAAACAGTCACACACTG 120
Db 438 ATTTACCAAGAAATCAGGACCATGACCTCTCTGGCAAAAAGAAACAGTCACACACTG 497
QY 121 AAGGCAGAGAGACCGAGCTATTCTCTGGGACTGGCTATGATGCTGTCTCCATCATG 180
Db 498 AAGGCAGAGAGACCGAGCTATTCTCTGGGACTGGCTATGATGCTGTCTCCATCATG 557
QY 181 ATGTATTTTCTCTGGGAATCACACTCTCTGGGCTCATATGCTCAGAGGTGTGGACCGAA 240
Db 558 ATGTATTTTCTCTGGGAATCACACTCTCTGGGCTCATATGCTCAGAGGTGTGGACCGAA 617
QY 241 GAGTCTCAATGACCTTGTCTGAATGCTCCATCAGGAAACATTTAAVTGCTCTCTCAGC 300
Db 618 GAGTCTCAATGACCTTGTCTGAATGCTCCATCAGGAAACATTTAAVTGCTCTCTCAGC 677
QY 301 TGTGTCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360
Db 678 TGTGTCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 737
QY 361 ACTTCTTCGCGGAAAAGCTCCTCTCTACACACAGAGAGACAATAAAAAATCAATCAG 420
Db 738 ACTTCTTCGCGGAAAAGCTCCTCTCTACACACAGAGAGACAATAAAAAATCAATCAG 797
QY 421 AAGTGTCTCTATATACCTAATGTGGAATAAATTTTGAAGATCCATGTCCTGGTGAAT 480
Db 798 AAGTGTCTCTATATACCTAATGTGGAATAAATTTTGAAGATCCATGTCCTGGTGAAT 857
```

481	QY	GTGTGATGAAACCTTCAGAAAGTATCAACACTTCTCTGCTGCTATTTCTGACCCAGAAGGA	540
858	Db	GTGTGTCATGAAACCTTCAGAAAGTATCAACACTTCTCTGCTGCTATTTCTGACCCAGAAGGA	917
541	QY	AACCAAGAAGTGTATTCCTTAAACAACTCTACAGTTCCAAACGTGCTGTTCATTCACATC	600
918	Db	AACCAAGAAGTGTATTCCTTAAACAACTCTACAGTTCCAAACGTGCTGTTCATTCACATC	977
601	QY	TTCTGGCCACCTGTATGATGGCTGGGGGTGGCAATTGTCGCATGGTGAACATTACA	660
978	Db	TTCTGGCCACCTGTATGATGGCTGGGGGTGGCAATTGTCGCATGGTGAACATTACA	1037
661	QY	CAGTACCTCTCCCTACTATGTGAGAGATCC-ACGGATCAATGATAA	707
1038	Db	CAGTACCTCTCCCTACTATGTGAGAGATCCACGGATCAATGATAA	1085

RESULT 4	
AAA26355	
AAA26355	ID
AAA26355	standard; cDNA; 2098 BP.
XX	
XX	
XX	AAA26355;
XX	
XX	
XX	29-JUN-2000 {first entry}
XX	
XX	Human secreted protein gene 10 SEQ ID NO:20.
XX	
XX	
XX	Human; secreted protein; diagnosis; cytostatic; immunosuppressive;
KW	antiHIV; antiinflammatory; neutropic; neuroprotective; antiallergic;
KW	osteopathic; antiarthritic; antibacterial; antidiabetic; antiasthma;
KW	antipsoriatic; cardiant; gene therapy; cancer; neurological disorder;
KW	immune disease; inflammation; blood disorder; tumor; ss.

	CC	polynucleotides. Specific uses are described for each of the	
CC	polynucleotides, based on which tissues they are most highly expressed		
CC	in, and include developing products for the diagnosis or treatment of		
CC	cancer, tumours, neurodegenerative disorders, developmental abnormalities		
CC	and foetal deficiencies, blood disorders, diseases of the immune system,		
CC	autoimmune diseases, hepatic and renal disease, inflammation, allergies,		
CC	Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,		
CC	arthritis, infections, AIDS, spinal cord injuries, transplant rejection,		
CC	diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders		
CC	reproductive disorders, gastrointestinal disorders, respiratory disorders		
CC	as metabolic disorders. The proteins or polynucleotides can also be used		
CC	as food additives or preservatives. The proteins are also useful for		
CC	identifying their binding partners. AAA26337 to AAA26345 and		
CC	sequences used in the exemplification of the present invention		
XX			
XX	Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;		
SY			
	Query Match	79.8%; Score 564.2; DB 3; Length 2098;	
	Best Local Similarity	99.5%; Pred. No. 3.9e-166;	
	Matches 574; Conservative	2; Mismatches 0; Indels 1; Gaps 1;	
QY	132	GGACCGAGCTATTCTCTCGGAGCTGGCTATGATGGTGTGCTCCATCATGATGATTTTCT	131
DB	9	GGACCGAGCTATTCTCTCGGAGCTGGCTATGATGGTGTGCTCCATCATGATGATTTTCT	68
QY	192	GCTGGGAATCACACTCTCTGGCTCATACATGCAGACGCTGTGGACCGAAGAGTCTCAATG	251
DB	69	GCTGGGAATCACACTCTCTGGCTCATACATGCAGACGCTGTGGACCGAAGAGTCTCAATG	128
QY	252	CACCTTGCTGAATGCGTGCATACGGAACACATTAAATGCTCTCAGCTGTGGTCCAGA	311
DB	129	CACCTTGCTGAATGCGTGCATACGGAACACATTAAATGCTCTCAGCTGTGGTCCAGA	158
QY	312	CTGCTGGAAACTTTCTCAGTACCCCTGCTCAGGTGTAGTTAACTGACITCTTCCGG	371
DB	189	CTGCTGGAAACTTTCTCAGTACCCCTGCTCAGGTGTAGTTAACTGACITCTTCCGG	248
QY	372	GGAAAAGCTCCTCTCTACACACAGAAGAGACAATAAAAAACAATGCAAGTGCCTCTTA	431
DB	249	GGAAAAGCTCCTCTCTACACACAGAAGAGACAATAAAAAACAATGCAAGTGCCTCTTA	308
QY	432	TATACCTAAATGTGGAAAAAATTTTGAAGAATCCATGTCCCTGGTGAATGTTGTCTATGGA	491
DB	309	TATACCTAAATGTGGAAAAAATTTTGAAGAATCCATGTCCCTGGTGAATGTTGTCTATGGA	368
QY	492	AAACTTCAGGAAGTATCACACTTCTCCTGCTATTCTGACCCAGAGAGAAACACAGAAGAG	551
DB	369	AAACTTCAGGAAGTATCACACTTCTCCTGCTATTCTGACCCAGAGAGAAACACAGAAGAG	428
QY	552	TGTTATCTCTAAACMAAACTCTACAGTTTCCAAACGTCGTGTTTCCATTTCACTCTTCTGGGCAAC	611
DB	429	TGTTATCTCTAAACMAAACTCTACAGTTTCCAAACGTCGTGTTTCCATTTCACTCTTCTGGGCAAC	488
QY	612	CTGTATGATGGCTGGGGGTGTGCGCAATTGTCGCAATGGTGAACCTTACACAGTACCTCTC	671
DB	489	CTGTATGATGGCTGGGGGTGTGCGCAATTGTCGCAATGGTGAACCTTACACAGTACCTCTC	548
QY	672	CCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA	707
DB	549	CCTACTATGTGAGAGGATCCACGGATCAATAGATAA	585

RESULT 5
ADA39669
ID ADA39669 standard; cDNA; 2098 BP.
XX
XX ADA39669;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human secreted protein encoding cDNA.
XX
XX Human; secreted protein; cancer; hyperproliferative disorder;
XX
XX

KW	rheumatoid arthritis; autoimmune disorder; haematopoietic disorder; anaemia; allergic reaction; asthma; cardiovascular disorder; wound healing; cytostatic; immunosuppressive; nontropic; neuroprotective; antiviral; anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; vulnary; cardiant; gene therapy; ss.
OS	Homo sapiens.
XX	
XX	WO2002102993-A2.
PN	
XX	
PD	27-DEC-2002.
XX	
XX	
XX	19-MAR-2002; 2002WO-US008123.
PF	
XX	
XX	21-MAR-2001; 2001US-0277340P.
PR	
PR	19-JUL-2001; 2001US-030617P.
PR	13-NOV-2001; 2001US-0331287P.
XX	
XX	(HUMA-) HUMAN GENOME SCI INC.
PA	
PI	
PI	Rosen CA, Ruben SM;
XX	
XX	WPI; 2003-175238/17.
DR	
XX	New human secreted proteins and nucleic acid molecules, useful for preparing a diagnostic or pharmaceutical composition for diagnosing, preventing or treating cancer or other hyperproliferative disorder, asthma, allergies or AIDS.
PT	
PT	
PT	
XX	
XX	Claim 9; SEQ ID NO 51; 3205pp; English.
PS	
XX	
CC	The invention relates to novel genes ADA39629-ADA40565 and proteins ADA40566-ADA41501 for human secreted proteins, useful for preventing, treating or ameliorating medical conditions e.g. by protein or gene therapy. The polypeptides, nucleic acid molecules, antibodies or their fragments, and agonists or antagonists that bind to the polypeptide are useful for preparing a diagnostic or pharmaceutical composition for diagnosing or treating cancer or other hyperproliferative disorder. The polypeptides and nucleic acid molecules are also useful for detecting, preventing, diagnosing, prognosticating, treating or ameliorating cancer or other hyperproliferative disorders including neoplasms, autoimmune disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic anaemia), haematopoietic or haematological disorders (e.g. anaemia, thrombocytopenia), allergic reactions including asthma or eczema, inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory bowel disease or Crohn's disease), neurodegenerative disorders (e.g. Alzheimer's disease or Parkinson's disease), cardiovascular disorders (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial, fungal or viral infections including HIV/AIDS), or wound healing and disorders of epithelial cell proliferation. The nucleic acids are also useful for chromosome identification, radiation hybrid mapping or long-range restriction mapping, as molecular weight markers, or as hybridization or diagnostic probes. The polypeptides and antibodies are useful for providing immunological probes for differential identification of the tissues immunohistochemistry assays. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIFO at ftp.wifo.int/pub/published_pct_sequences.
CC	
XX	
SQ	Sequence 2098 BP; 645 A; 366 G; 719 T; 0 U; 0 Other;
	Query Match 79.8%; Score 564.2; DB 8; Length 2098;
	Best Local Similarity 99.5%; Pred. No. 3.9e-166;
	Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;
QY	132 GGACCGAGCTATTCCTCGGACCTGGCTATCATGCTGTGCTCCATCATGATGATTTTCT 191
Db	9 GGACCGAGCTATTCCTCGGACCTGGCTATGATGCTGTGCTCCATCATGATGATTTTCT 68
QY	192 GTTGGGAATCACATCTTCGCTCATATGACAGAGCGGTGGACCGAAGAGTCTCAATG 251
Db	69 GTTGGGAATCACATCTTCGCTCATATGACAGAGCGGTGGACCGAAGAGTCTCAATG 128

XX New human secreted polypeptides and polynucleotides, useful for
 PT diagnosing, treating or preventing e.g. immune disorders, inflammatory
 PT conditions, respiratory disorders, cancers, CNS disorders, or
 XX neurodegenerative disorders.

PS Claim 21; SEQ ID NO 47; 1754pp; English.

XX The invention relates to 592 new human secreted polypeptides useful for
 CC diagnosing, treating or preventing e.g. immune disorders, inflammatory
 CC conditions, respiratory disorders, cancers, CNS disorders, or
 CC neurodegenerative disorders, or polypeptides comprising an amino acid
 CC sequence at least 95% identical to the new sequences. The polypeptides,
 CC antibodies or antibody fragments that bind to the polypeptides, nucleic
 CC acids encoding the polypeptides, agonists or antagonists that binds to
 CC the polypeptide, are useful in preparing diagnostic or pharmaceutical
 CC compositions for diagnosing, treating or preventing an e.g. immune
 CC disorders, inflammatory conditions (e.g. inflammatory bowel disease,
 CC nephritis or Crohn's disease), respiratory disorders (e.g. asthma and
 CC allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders
 CC (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative
 CC disorders (e.g. Parkinson's disease or Alzheimer's disease), and
 CC cardiovascular disorders (e.g. atherosclerosis or myocarditis). The
 CC polynucleotides are useful for chromosome identification, chromosome
 CC mapping, for controlling gene expression through triple helix formation
 CC or antisense DNA or RNA, in gene therapy, for identifying individuals
 CC from minute biological samples, in forensic biology, and as hybridization
 CC probes. The polypeptides are useful for as molecular weight markers on
 CC sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
 CC gels, to raise antibodies, for testing biological activities, and for
 CC treating or preventing neural disorders, immune system disorders,
 CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
 CC renal, proliferative and/or cancerous diseases. This sequence corresponds
 CC to a gene encoding one of the polypeptide of the invention. Note: The
 CC sequence data for this patent did form part of the invention specification,
 CC but was obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX
 SQ Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

Query Match 79.8%; Score 564.2; DB 10; Length 2098;
 Best Local Similarity 99.5%; Pred. No. 3.9e-166;
 Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

QY 132 GGACCGAGCTATTCCTCGGACGTGGCTATGATGGTGTCTCCATCATGATGATATTTCT 191
 DB 9 GGACCGAGCTATTCCTCGGACGTGGCTATGATGGTGTCTCCATCATGATGATATTTCT 68

QY 192 GCTGGGAATCACACTCTCTGCGCTCATATCATGACAGAGCGTGTGGACCGAAGAGTCTCAATG 251
 DB 69 GCTGGGAATCACACTCTCTGCGCTCATATCATGACAGAGCGTGTGGACCGAAGAGTCTCAATG 128

QY 252 CACCTTGTGTAATGGTGTCCATCAGGAAACATTTAAATGCTCTCTTACGCTGTGTGTCAGA 311
 DB 129 CACCTTGTGTAATGGTGTCCATCAGGAAACATTTAAATGCTCTCTTACGCTGTGTGTCAGA 188

QY 312 CTGCTGGAAATTTCTCAGTACCCCTGCTCAGGTGTACGTTAACTGACTTCTTCCGG 371
 DB 189 CTGCTGGAAATTTCTCAGTACCCCTGCTCAGGTGTACGTTAACTGACTTCTTCCGG 248

QY 372 GGAAAGTCTCTCTCTACCAACAGAGAGACAAATAAATCAATCAGAAAGTGTCTCTTA 431
 DB 249 GGAAAGTCTCTCTCTACCAACAGAGAGACAAATAAATCAATCAGAAAGTGTCTCTTA 308

QY 432 TATACCTAAATGTGAAAAATTTTGAAGATCCATGTCCCTGTGTGAATGTGTGTCATGGA 491
 DB 309 TATACCTAAATGTGAAAAATTTTGAAGATCCATGTCCCTGTGTGAATGTGTGTCATGGA 368

QY 492 AAACCTCAGGAAGTATCAACACTTCTCTGTATTTCTGACCCAGAAAGAACAGAGAG 551
 DB 369 AAACCTCAGGAAGTATCAACACTTCTCTGTATTTCTGACCCAGAAAGAACAGAGAG 428

QY 552 TGTATCTCTACMAAATCTTACAGTTCACAGTCTCCAGCTGTGTTCATTCCTCTTCTGGCCAAC 611

DB 429 TGTATCTCTAACAAAACCTACAGTTCACAGTTCACAGTTCCTCTTCTGGCCAAC 488
 QY 612 CTGTATGATGGCTGGGGTGTGCGCAATTTGTTGCCATGGTGAACCTTACACAGTACTCTTC 671
 DB 489 CTGTATGATGGCTGGGGTGTGCGCAATTTGTTGCCATGGTGAACCTTACACAGTACTCTTC 548

QY 672 CCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707
 DB 549 CCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 585

RESULT 7
 ID ADL71416
 ID ADL71416 standard; cDNA; 2098 BP.
 XX
 AC ADL71416;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Novel human secreted protein cDNA seqid 20.
 XX
 KW antiinflammatory; neuroprotective; neurotropic; antiparkinsonian;
 KW anticonvulsant; antilipemic; CNS; gynaecological; antiarthritic;
 KW antidiabetic; anti-HIV; virucide; endocrine; cytostatic;
 KW immunosuppressive; antiallergic; cardiovascular; respiratory;
 KW dermatological; antimicrobial; gastrointestinal; gene therapy;
 KW neurodegenerative disease; behavioral disorder; inflammatory condition;
 KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; metabolic disorder; Tay-Sach's disease;
 KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;
 KW arthritis; asthma; AIDS; endocrine disorder; immune disorder;
 KW Hodgkin's lymphoma; haematopoietic disorder; muscular disorder;
 KW leukaemia; autoimmune disorder; allergy; cancer; cardiovascular disorder;
 KW respiratory disorder; pulmonary disorder; connective tissue disorder;
 KW skin disorder; CNS disorder; congenital disorder; infectious disorder;
 KW gastrointestinal disorder; human; secreted protein; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004034196-A1.
 XX
 PD 19-FEB-2004.
 XX
 XX 27-JAN-2003; 2003US-00351334.
 XX
 XX 30-JUL-1998; 98US-0094657P.
 PR 05-AUG-1998; 98US-0095486P.
 PR 06-AUG-1998; 98US-0095454P.
 PR 06-AUG-1998; 98US-0095455P.
 PR 12-AUG-1998; 98US-0096319P.
 PR 29-JUL-1999; 99WO-US017130.
 PR 24-JAN-2000; 2000US-00489847.
 PR 25-JAN-2002; 2002US-0350898P.
 XX
 PA (KONA/) KOMATSOUKIS G A.
 PA (ROSE/) ROSEN C A.
 PA (RUBE/) RUBEN S M.
 PA (DUAN/) DUAN D R.
 PA (MOOR/) MOORE P A.
 PA (SHIY/) SHI Y.
 PA (LAFLE/) LAFLEUR D W.
 PA (WEIY/) WEI Y.
 XX
 PI Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;
 PI Lafleur DW, Wei Y;
 XX
 XX WPI; 2004-180094/17.
 DR P-PSDB; ADL71532.
 XX
 PT New human secreted nucleic acid, useful for diagnosing and treating
 PT neurodegenerative, inflammatory, hyperproliferative, metabolic,
 PT reproductive, cardiovascular, respiratory or immunological disorders or

PT diseases.
XX
XX Claim 1; SEQ ID NO 20; 234pp; English.
XX
CC The invention describes an isolated human nucleic acid molecule (I)
CC comprising a polynucleotide having a nucleotide sequence at least 95%
CC identical to: a sequence polynucleotide fragment of SEQ ID NO: X or of
CC the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable
CC to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or
CC epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA
CC sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID
CC NO: X, having a biological activity. The nucleic acids and polypeptides,
CC pharmaceutical formulations and kits are useful in diagnosing and
CC treating neurodegenerative diseases states, behavioral disorders
CC inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's
CC disease, Parkinson's disease or Huntington's disease), metabolic
CC disorders (e.g. Tay-Sachs' disease or Leish-Nyhan syndrome), reproductive
CC disorders, immunological disorders (e.g. arthritis, asthma or AIDS),
CC endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic
CC or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy,
CC cancer, cardiovascular, respiratory or pulmonary disorders, disorders, or
CC conditions afflicting connective tissue, skin disorders, CNS disorders,
CC congenital disorders, infectious disorders and gastrointestinal
CC disorders. This sequence encodes a novel human secreted protein of the
CC invention. Note: This sequence does not appear in the printed
CC specification but is available in electronic format from the US patent
CC office at ftp.seqdata.uspro.gov/seqdata.html?DocID=20040034196.
XX
XX
SQ Sequence 2098 BP; 645 C; 368 G; 719 T; 0 U; 0 Other;

Query Match 79.8%; Score 564.2; DB 12; Length 2098;
Best Local Similarity 99.5%; Pred. No. 3.9e-166;
Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

Qy 132 GGACCGAGCTATCTCTGGAGCTGGCTATGATGGTGTGCTCCATCATGATGATTTTCT 191
Db 9 GGACCGAGCTATCTCTGGAGCTGGCTATGATGGTGTGCTCCATCATGATGATTTTCT 68

Qy 192 GCTGGGAATCACACTCTCGGCTCATACATGCGAGCGGTGGACCGAAGAGTCTCAATG 251
Db 69 GCTGGGAATCACACTCTCGGCTCATACATGCGAGCGGTGGACCGAAGAGTCTCAATG 128

Qy 252 CACCTTCTGAATGCTGCATACGGAACAATTAAATGCTCTTTCAGCTGGTGCAG 311
Db 129 CACCTTCTGAATGCTGCATACGGAACAATTAAATGCTCTTTCAGCTGGTGCAG 188

Qy 312 CTGCTGGAATCTTCTCAGTACCCCTCCCTCCAGGTGATGTTAACTGACTTCTTCGG 371
Db 189 CTGCTGGAATCTTCTCAGTACCCCTCCCTCCAGGTGATGTTAACTGACTTCTTCGG 248

Qy 372 GGAAAGCTCTCTCTTACCACACAGAGACAATAAAAAATCAATCAGAAGTGTCTCTA 431
Db 249 GGAAAGCTCTCTCTTACCACACAGAGACAATAAAAAATCAATCAGAAGTGTCTCTA 308

Qy 432 TATACCTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAATGTTCTCATGA 491
Db 309 TATACCTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAATGTTCTCATGA 368

Qy 492 AAACCTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAAGAAACCAAGAG 551
Db 369 AAACCTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAAGAAACCAAGAG 428

Qy 552 TGTATCTCAACMAACTTACAGTTCACAGTGCCTGTTCCATCTCTTCTGGCCAC 611
Db 429 TGTATCTCAACMAACTTACAGTTCACAGTGCCTGTTCCATCTCTTCTGGCCAC 488

Qy 612 CTGTATGATGCTGGGGTGTGGCAATTTGTCATGCTGTAACACTTACACAGTACCTCTC 671
Db 489 CTGTATGATGCTGGGGTGTGGCAATTTGTCATGCTGTAACACTTACACAGTACCTCTC 548

Qy 672 CCTACTATGTGAGAGGATCC-ACGATCAATAGATAA 707
Db 549 CCTACTATGTGAGAGGATCCACGATCAATAGATAA 585

RESULT 8
ABA09433
ID ABA09433 standard; cDNA; 558 BP.
XX
XX AC ABA09433;
XX
DT 11-JAN-2002 (first entry)
XX
DE Human K channel subunit homologue-encoding cDNA, SEQ ID NO:1209.
XX
XX Human; cytokine; cell proliferation; cell differentiation; growth factor;
XX haematopoiesis regulation; tissue growth; immunomodulator; activin;
XX inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;
XX proliferation; metastasis; cancer; tumour; haematopoietic disorder;
XX myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
XX chronic inflammatory condition; proliferative retinopathy;
XX atherosclerosis; coronary heart disease; arterial ischaemia;
XX bone disorder; osteoporosis; vascular growth disorder;
XX tissue regeneration; wound healing; infection; immune disorder;
XX cell culture; drug screening; gene therapy; antiinflammatory;
XX antiallergic; antiarthritic; haemostatic; antiarteriosclerotic;
XX cystostatic; osteopathic; vasorropic; cardiant; virucide; antibacterial;
XX antifungal; vulnery; antitumor; ss.
XX
OS Homo sapiens.
XX
XX WO200157188-A2.
XX
XX 09-AUG-2001.
XX
XX 05-FEB-2001; 2001WO-US003800.
XX
XX 03-FEB-2000; 2000US-00496914.
XX 27-APR-2000; 2000US-00560875.
XX
XX (HYSE-) HYSEQ INC.
XX
XX Tang YT, Liu C, Drmanac RT;
XX
XX WPI: 2001-457740/49.
XX P-PSDB; ABB12189.
XX
XX Human proteins and DNA encoding sequences useful for preventing, treating
XX or ameliorating a medical condition in a mammalian subject e.g. arthritis
XX and cancer.
XX
XX Claim 1; Page 945; 1963pp; English.
XX
XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
XX sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
XX invention also relates to vectors and recombinant host cells comprising a
XX nucleotide of the invention, methods of producing the novel polypeptides,
XX antibodies against the polypeptides, methods of detecting the nucleotides
XX or polypeptides in a sample, and methods of identifying compounds which
XX bind to polypeptides of the invention. Although novel, many of the
XX polypeptides of the invention have homology to known proteins, thereby
XX giving an insight into their probable biological activities, and hence
XX potential therapeutic applications. The polypeptides of the invention may
XX have various activities, including cytokine, cell proliferation or cell
XX differentiation activities; stem cell growth factor activity;
XX haematopoiesis regulatory activity; tissue growth activity;
XX immunomodulatory activity; activin- or inhibin-related activities;
XX chemotactic or chemokinetic activities; haemostatic, thrombotic or
XX thrombolytic activities; receptor or ligand activities; or may be
XX involved in oncogenesis, cancer cell proliferation or metastasis.
XX Depending on their biological activities, polypeptides and nucleotides of
XX the invention are useful for preventing, treating or ameliorating medical
XX conditions, e.g., by protein or gene therapy. Such conditions include
XX cancers, haematopoietic disorders (e.g. myeloid or lymphoid cell
XX disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
XX proliferative retinopathy, atherosclerosis, coronary heart disease,

CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
CC vascular growth. Polypeptides involved with tissue regeneration and
CC repair (or nucleic acids encoding them) may be used to promote wound
CC healing (e.g., of burns, incisions and ulcers), while those with
CC immunomodulatory activities may be used in the treatment of viral,
CC bacterial and fungal infections in addition to immune disorders.
CC Polypeptides with growth factor activity may be used in cell cultures to
CC promote cell growth. For example, such polypeptides may be used to
CC manipulate stem cells in culture to give rise to neuroepithelial cells
CC that can be used to augment or replace cells damaged by illness,
CC autoimmune disease or accidental damage. The polypeptides and nucleotides
CC may also be used in the diagnosis of the above conditions, and in drug
CC screening techniques. The present sequence represents a cDNA encoding a
CC novel human polypeptide of the invention

XX Sequence 558 BP; 165 A; 128 C; 144 G; 121 T; 0 U; 0 Other;

Query Match 39.7%; Score 281; DB 4; Length 558;
Best Local Similarity 97.6%; Pred. No. 2e-77;
Matches 284; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 ATGTCCATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAGAAT 60
DB 268 ATGTCCATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAGAAT 327
QY 61 ATTACCAAGAAATCAGGGACCATGACCTCTCTGACAAAAGAAACAGTCACAGCACTG 120
DB 328 ATTACCAAGAAATCAGGGACCATGACCTCTCTGACAAAAGAAACAGTCACAGCACTG 387
QY 121 AAGCAGAGAGACCGAGCTATCTCTCTGGACTGGCTATGATGGTGTGCTCATCATG 180
DB 388 AAGCAGAGAGACCGAGCTATCTCTCTGGACTGGCTATGATGGTGTGCTCATCATG 447
QY 181 ATGATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGACCGAA 240
DB 448 ATGATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGACCGAA 507
QY 241 GAGTCTCAATGACCTTGTGAAATCGCTTCATACCGGAAACATTTAATGTC 291
DB 508 GAGTCTCAATGACCTTGTGAAATCGCTTCATACCGGAAACATTTAATGTC 558

RESULT 9
AAZ11913
ID AAZ11913 standard; cDNA; 1111 BP.

AC AAZ11913;

DT 30-NOV-1999 (first entry)

XX Human potassium channel K-Hnov44 cDNA (splice variant 2).

DE Potassium channel; ataxia; arrhythmia; epilepsy; Barter's syndrome;
KW cardiovascular disorder; CNS disorder; renal disorder; ds.
XX Homo sapiens.

XX Key Location/Qualifiers
FH 297..959
FT CDS /*tag= a
FT /product= "Human K-Hnov44 potassium channel"

XX WO9943696-A1.

XX 02-SEP-1999.

XX 22-FEB-1999; 99WO-US003826.

XX 25-FEB-1998; 98US-0076687P.

XX 07-AUG-1998; 98US-0095836P.

XX 19-JAN-1999; 99US-011648P.

XX (AXIS-) AXIS PHARM INC.

XX Miller AP, Curran ME, Hu P, Rutter M, Wang J;
XX WFI; 1999-527591/44.
XX P-PSDB; AAY34131.

XX New nucleic acids encoding mammalian K-Hnov potassium channel proteins,
XX useful for the diagnosis and treatment of episodic ataxia with myokymia,
XX cardiac arrhythmia, epilepsy and Barter's syndrome.

XX Claim 4; Page 90-91; 112pp; English.

XX This sequence represents splice variant 2 of a human potassium channel
XX K-Hnov44 cDNA. Alternative splicing does not affect the amino acid
XX sequence of the protein. K-Hnov proteins have a high degree of homology
XX to known potassium channels and may be alpha subunits that act to modulate the
XX functional channel, or accessory subunits that act to modulate the
XX channel activity. K-Hnov44 is a potassium channel beta subunit. The
XX gene's chromosomal location is 22p13, determined via PCR chromosomal
XX localisation using primers AAZ11934 and AAZ11936. K-Hnov cDNAs were
XX isolated by extension of expressed sequence tags (ESTs) which were
XX related but not identical to known human potassium channels. Potential
XX polymorphisms detected as sequence variants between multiple independent
XX clones. Potassium channels have critical roles in various cell types and
XX biochemical pathways. Defective potassium channels are known to cause
XX four human diseases: episodic ataxia with myokymia; cardiac arrhythmia
XX (long QT syndrome); epilepsy; and Barter's syndrome. As potassium
XX channels are critical components of virtually all cells, it is likely
XX that abnormal potassium channels are also implicated in certain renal,
XX cardiovascular and central nervous system (CNS) disorders. Nucleotides
XX encoding K-Hnov proteins may be used for identifying homologous or
XX related proteins and the DNA sequences encoding them. They may be used to
XX produce compositions that modulate the expression and function of the
XX K-Hnov protein and in studying the biochemical pathways associated with
XX it. They may also be used for the recombinant production of K-Hnov
XX protein in fermentation cultures. Additionally, such nucleotides may be
XX used in gene therapy protocols for the treatment of diseases associated
XX with abnormal potassium channels

XX Sequence 1111 BP; 347 A; 237 C; 263 G; 264 T; 0 U; 0 Other;

Query Match 19.2%; Score 135.4; DB 2; Length 1111;
Best Local Similarity 54.6%; Pred. No. 1.7e-31;

Matches 312; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

QY 124 GCAGGAGGACCGAGCTATTCTCTGGAGCTGGCTATGATGGTGTCTCATCATGATG 183

DB 276 GCTGAGAGGACCGAGCGCTGATGCTGGGTTTGCATGATGGGCTTCTCAGTCTAATG 335

QY 184 TATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGACGAGAG 243

DB 336 TTCTTTCTGCTGGGAACCAACCTTCTAAAGCTTTTATGCTCAGATTTCAGAGAGAGAA 395

QY 244 TCTCAATGACACCTTCTGTAATCGCTCCATCAGGAAACAT---TTAATGCTCTCTCAGC 300

DB 396 TCGACCTGCACCTGCCATCCACACAGATATCATGACGACTGGCTGGCTTCCACC 455

QY 301 TGTGTCAGACTGCTGGAACCTTTCTCAGTACCCCTCCCTCCAGGTGACGTAAACCTG 360

DB 456 TGTGCTGCTGCACTGCCACGGTCAGGGGAAGTACCCTGCTCTCTCAGGTGTTTGTGAACCTC 515

QY 361 ACTTCTTCCGGGAAAGCTCCTCTCTACACACAGAGAGACAATAAATCAATCAG 420

DB 516 AGCCATCCAGGTCAGAAAGCTCTCTCATATATGAGAGGCTGCCAGATATATCCC 575

QY 421 AAGTCTCTCTATATACCTTAATGTGGAAAAAATTTTGAAGATCCATGCTCCCTGGTGAAT 480

DB 576 AAGTCTCTTTTACACACCTTAAGTGGCCACCAAGATAGAAATGATTTTCTCAACAGTCTG 635

QY 481 GTTGTGTCATGGAAACCTT-----CAGGAAGTATCAACACTTCTCTGCTATCTGACCCA 534

DB 636 GACATAAAGAAATTTCTTCATCAAAAATGGAATCCCTTTTCTATGCTTCTACAGTCCA 695

QY 535 GAAGGAACACAGAGAGTGTATCTTAAACAACTCTACAGTCCACAGTGTGTCCAT 594
Db 696 GCCAGCAATCTGAAGATGATCTTATATAAAGATGACCAATGGTATCTCCAC 755
QY 595 TCACTCTTCTGGCAACTGTATGATGGCTGGGGTGTGCAATGTGTGCAATGGTGA 654
Db 756 TGTATTATTTGGCTTCACTGACTCTGCTAGTGTGGCTGATTTGTGCAATGGTGA 815
QY 655 CTTACACAGTACCTCTCCCTACTATGTGAGA 685
Db 816 TTAACACACACCTGTCTTACTGTGTGAAA 846

RESULT 10

AAZ11912
ID AAZ11912 standard; cDNA; 1246 BP.

XX AAZ11912;

DT 30-NOV-1999 (first entry)

XX Human potassium channel K-Hnov44 cDNA (splice variant 1).

XX Potassium channel; ataxia; arrhythmia; epilepsy; Bartter's syndrome;
KW cardiovascular disorder; CNS disorder; renal disorder; ds.

XX Homo sapiens.

EH Key Location/Qualifiers

FT CDS 432..1094

FT /*tag= a

FT /product= "Human K-Hnov44 potassium channel."

XX WO9943696-A1.

XX 02-SEP-1999.

XX 22-FEB-1999; 99WO-US003826.

XX 25-FEB-1998; 98US-0076687P.

XX 07-AUG-1998; 98US-0095836P.

XX 19-JAN-1999; 99US-0116448P.

XX (AXYS-) AXYS PHARM INC.

XX Miller AP, Curran ME, Hu P, Rutter M, Wang J;

XX P-PSDB; AAY34131.

XX WPI; 1999-527591/44.

XX New nucleic acids encoding mammalian K-Hnov potassium channel proteins,

XX useful for the diagnosis and treatment of episodic ataxia with myokymia,

XX cardiac arrhythmia, epilepsy and Bartter's syndrome.

XX Claim 4; Page 89-90; 112pp; English.

XX This sequence represents splice variant 1 of a human potassium channel

XX K-Hnov44 cDNA. Alternative splicing does not affect the amino acid

XX sequence of the protein. K-Hnov proteins have a high degree of homology

XX to known potassium channels and may be alpha subunits, which form the

XX functional channel, or accessory subunits that act to modulate the

XX channel activity. K-Hnov44 is a potassium channel beta subunit. The

XX gene's chromosomal location is 2p13, determined via PCR chromosomal

XX localisation using primers AAZ11934 and AAZ11936. K-Hnov cDNAs were

XX isolated by extension of expressed sequence tags (ESTs) which were

XX related but not identical to known human potassium channels. Potential

XX polymorphisms detected as sequence variants between multiple independent

XX clones. Potassium channels have critical roles in various cell types and

XX biochemical pathways. Defective potassium channels are known to cause

XX four human diseases: episodic ataxia with myokymia; cardiac arrhythmia

XX (long QT syndrome); epilepsy; and Bartter's syndrome. As potassium

XX channels are critical components of virtually all cells, it is likely

XX that abnormal potassium channels are also implicated in certain renal,

CC cardiovascular and central nervous system (CNS) disorders. Nucleotides
CC encoding K-Hnov proteins may be used for identifying homologous or
CC related proteins and the DNA sequences encoding them. They may be used to
CC produce compositions that modulate the expression and function of the
CC K-Hnov protein and in studying the biochemical pathways associated with
CC it. They may also be used for the recombinant production of K-Hnov
CC protein in fermentation cultures. Additionally, such nucleotides may be
CC used in gene therapy protocols for the treatment of diseases associated
CC with abnormal potassium channels

XX Sequence 1246 BP; 345 A; 299 C; 302 G; 300 T; 0 U; 0 Other;

Query Match

Best Local Similarity 19.2%; Score 135.4; DB 2; Length 1246;

Matches 312; Conservative 54.6%; Pred. No. 1.8e-31;

Mismatches 248; Indels 9; Gaps 2;

QY 124 GCAGAGAGGACCGAGCTATTCTCTGGAGCTGGCTATGATGGTGTGCTCATCATGATG 183

Db 411 GCTGGAGAGCGCCGAGCCGCTGATGCTGGGTTTGCATGATGGGCTTCTCAGTCTTAATG 470

QY 184 TATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGCAGAGCTGTGGACCGAAGAG 243

Db 471 TTCTTCTGCTGGACACCACTTCTAAAGCTTTTATGCTCAGCATTCAGAGAGAGAA 530

QY 244 TCTCAATGACCTTGTGTAATGCGTCCATCAGGAAACAT---TTAATGTCTCTTTCAGC 300

Db 531 TCGACCTGCACTGCCATCCACACAGATATCATGGACGACTGGCTGGCTGCTTCCACC 590

QY 301 TGTGTTCCAGACTGTGGAACTTTTCTCAGTACCCCTGCTCCAGTGTGTACGTTAACCTG 360

Db 591 TGTGTTGCTCACTGCCAGCTCAGGGAAGTACCCGCTGTCTTCAGGTGTTGTGACCTC 650

QY 361 ACTTCTTCGGGGAAAAGCTCTCTCTACCAACAGAGAGACAAATAAATCAATCAG 420

Db 651 AGCCATCCAGGTCAAGAAAGCTCTCTACATTAATGAAGGCTGTCCAGATAAATCCC 710

QY 421 AAGTGTCTCTATATACCTAAATGTGGAAATTTTGAAGATCCATGTCCCTGGTGAAT 480

Db 711 AAGTGTCTTTTACACACCTTAAGTGCACCAAGATAGAAATGATTTGCTCAACAGTCTCTG 770

QY 481 GTTGTTCATGGAAAAGCTT-----CAGGAAGTATCAACACTTCTCTGTGTATTCTGACCCA 534

Db 771 GACATATAAGAAATTTCTCGATCACAATAAGAACTCCCTTTTCATGCTCTTACAGTCCA 830

QY 535 GAAGGAACACAGAGAGTGTATCTTAAACAACTCTACAGTCCACAGTGTGTCCAT 594

Db 831 GCCAGCAATCTGAAGATGTCATTTCTTATAAAGATATGACCAATGGCTATCTTCCAC 890

QY 595 TCACTCTTCTGGCCCACTGTATGATGGCTGGGGTGTGGCAATTTTGCCATGGTGA 654

Db 891 TGTATTATTTGGCTTCACTGACTCTGCTAGTGTGGCTGCTGCTGCTGCTGCTGCTGCTG 950

QY 655 CTTACACAGTACCTCTCCCTACTATGTGAGA 685

Db 951 TTAACACACACCTGTCTTACTGTGTGAAA 981

RESULT 11

AAAY5009

ID AAAY5009 standard; DNA; 774 BP.

XX AAAY5009;

XX AAAY5009;

DT 02-JAN-2001 (first entry)

XX DNA encoding a human BK beta-2 polypeptide.

XX Human; BK beta-2; beta subunit; Sio potassium channel; BK beta-3;

XX BK beta-4; ion flux; migraine; hearing; vision problem; seizure; stroke;

XX asthma; cell proliferation; hormone secretion; cancer; viral infection;

XX ss.

XX Homo sapiens.

XX Key Location/Qualifiers
 XX FT 1..774
 XX FT /*tag= a
 XX FT /product= "BK beta-2"
 XX PN WO200050444-A1.

XX PD 31-AUG-2000.

XX PF 22-FEB-2000; 2000WO-US004441.

XX PR 23-FEB-1999; 99US-0121224P.

XX PR 03-NOV-1999; 99US-0163367P.

XX PA (ICAG-) ICAGEN INC.

XX PI Jegla TJ, Wickenden A, Liu Y;

XX DR WPI: 2000-533179/48.

XX DR P-PSDB; AAB08918.

XX Isolated beta subunit polynucleotides and polypeptides of Slo potassium

XX channels are used to determine the effects of compounds on ion flux

XX through a potassium channel and in computer modelling systems.

XX Claim 7; Page 79; 84pp; English.

XX The present sequence encodes a human BK beta-2 polypeptide. The

XX polypeptide is a beta subunit of a Slo potassium channel. The

XX specification also describes BK beta-3 and BK beta-4 polypeptides. BK

XX beta subunits are auxiliary subunits or monomers of Slo potassium

XX channels. The polypeptides, when expressed in cells and cell membranes,

XX are used to determine the effects of compounds on ion flux through a

XX potassium channel. The compounds identified may be useful as therapeutic

XX agents e.g. modulators that target specific Slo channels are useful for

XX treating migraines, hearing and vision problems, seizures, stroke,

XX asthma, cell proliferation and hormone secretion. The computer generated

XX 3-dimensional structures of BK beta 2, BK beta 3 or BK beta 4 are used to

XX identify ligands that bind to the beta subunit. The characterized BK beta

XX subunits are used to determine how Slo potassium channels function in

XX different environments and how they respond to different activation

XX mechanisms. The polynucleotides are used to transfect cells in vivo and

XX in vitro to mitigate effects of absent, partial inactivation or abnormal

XX expression of the BK beta subunit gene e.g. to correct genetic defects,

XX cancer and viral infection

XX Sequence 774 BP; 223 A; 177 C; 179 G; 195 T; 0 U; 0 Other;

XX Query Match 19.0%; Score 134.4; DB 3; Length 774;

XX Best Local Similarity 54.6%; Pred. No. 2.8e-31;

XX Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

XX 125 CAGGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCATCATGATGT 184

XX 92 CTGGAGAGACCGAGCCGCTGATGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 151

XX 185 ATTTTCTCTGGGAATCACACTCTCTGGCTCATACATGAGAGCGTGTGGACGGAAGT 244

XX 152 TCTTCTTCTCGGAACACCACTTCTAAGCCCTTTTATGCTCAGCATTCAGAGAGAAGAT 211

XX 245 CTCATGACCTTGTGTAATGCTTCATTCACGGAACAT---TTAATGCTCTTCACT 301

XX 212 CGAAGTCACTGCAATCCACACATATCATGAGAGAGTGGCTGGCTGGCTGGCTACCT 271

XX 302 GTGGTCCAGACTGTGGGAACATTTCTCAGTACCCCTGCTCCAGTGTAGCTTAACCTGA 361

XX 272 GTGGTGTGCACTGCCAGCGTCAGGGGAAGTACCGGTGCTTCAGTGTGTTGTAACCTCA 331

XX 362 CTTCTTCCGGGGAAGAGCTCTCTCTTACCCACAGAGAGACAAATAAATCAATCAGA 421

XX 332 GCCATCCAGGTTCAGAAAGCTCTCTTACATTATATGAAGAGGCTGTCCAGATAAATCCCA 391

QY 422 AGTGCTCTTATATACCTAAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAATG 481
 DB 392 AGTGCTTTTACACACCTAAGTCCCAAGATAGAAATGATTGTCTCAACAGTGTCTGG 451
 QY 482 TTGTGATGGAACACTT-----CAGGAAGTATCAACACATTCCTCTGCTATTCTGACCCAG 535
 DB 452 ACATTAAGAATCTTCGATCAAAAATGGAACCCCTTTTCATGCTTACACATCCAG 511
 QY 536 AAGGAAACCAAGAGAGTGTATCTTAACMAAACTCTACAGTTCACAGTGTCTTCCATT 595
 DB 512 CCAGCCATCTGAAGATGCAATCTTATAAAAAAGTATGACCAAAATGGCTATCTTCCACT 571
 QY 596 CACTCTTCTGGCAACCTGTATGATGGCTGGGGGTGGCAATTTGCCATTTGCTGGTGAAC 655
 DB 572 GTTTATTTTGGCTTCACTGACTCTGCTAGGTGGTGCCTGATTGTGGCATGGTGAGAT 631
 QY 656 TTACACAGTACCTCTCCCTACTATGTGAGA 685
 DB 632 TAACACACACCTGCTTACTGTGTGAAA 661

RESULT 12

AAK52128

ID AAK52128 standard; cDNA; 1144 BP.

XX AAK52128;

XX DT 06-NOV-2001 (first entry)

XX DE Human polynucleotide SEQ ID NO 673.

XX KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;

XX KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;

XX KW tissue growth factor; immunomodulatory; cancer; leukaemia;

XX KW nervous system disorder; arthritis; inflammation; ss.

XX OS Homo sapiens.

XX PN WO200157190-A2.

XX PD 09-AUG-2001.

XX PF 05-FEB-2001; 2001WO-US004098.

XX PR 03-FEB-2000; 2000US-00496914.

XX PR 27-APR-2000; 2000US-00560875.

XX PR 20-JUN-2000; 2000US-00598075.

XX PR 19-JUL-2000; 2000US-00620325.

XX PR 01-SEP-2000; 2000US-00654936.

XX PR 15-SEP-2000; 2000US-00663561.

XX PR 20-OCT-2000; 2000US-00693325.

XX PR 30-NOV-2000; 2000US-00728422.

XX (HYSE-) HYSEQ INC.

XX PA Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;

XX PI Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;

XX PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;

XX WPI: 2001-476283/51.

XX P-PSDB; AAK78995.

XX Nucleic acids encoding polypeptides with cytokine-like activities, useful

XX in diagnosis and gene therapy.

XX Claim 1; Page 2356-2357; 6221pp; English.

XX The invention relates to polynucleotides (AAK51456-AAK53435) and the

XX encoded polypeptides (AAK78323-AAK80302) that exhibit activity elating to

XX cytokine, cell proliferation or cell differentiation or which may induce

XX production of other cytokines in other cell populations. The

XX polynucleotides and polypeptides are useful in gene therapy, vaccines or

XX peptide therapy. The polypeptides have various cytokine-like activities,

XX

CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation. Note: Records for SEQ ID NO.2110 (AAK52581), 2111
CC (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the
CC sequence listing were missing at the time of publication
XX
XX
SQ Sequence 1144 BP; 289 A; 296 C; 291 G; 268 T; 0 U; 0 Other;

Query Match 19.0%; Score 134.4; DB 4; Length 1144;
Best Local Similarity 54.6%; Pred. No. 3.5e-31;
Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

Qy 125 CAGGAGAGCCGAGCTATTCTCTGGAGCTGGCTATGATGTTGCTCCATCATGATGT 184
Db |||||
465 CTGGAGAGGACCGAGCGTGATGCTGGGGTTTGGCATGATGGGCTTCTCAGTCTTAATGT 524

Qy 185 ATTTCTGCTGGGAATCACACTCTCTGCTCATACATGACAGAGCTGTGGACCGAGAGT 244
Db |||||
525 TCCTCTGCTGGGAACCAACATTTAAAGCCTTTATGCTCAGCATTCAGAGAGAGAT 584

Qy 245 CTCAATGACCTTCTGCTGAATGCTCCATCAGCGAAACAT---TTAATGCTCTTCAGCT 301
Db |||||
585 CGACCTGACCTGCCATCCACAGATATCATGGACGACTGGCTGGACTGTGCCTTCACCT 644

Qy 302 GTGCTCAGACTGTGGAACTTTCTCAGTACCTCTGCTCCAGTGTCGTTAACTGA 361
Db |||||
645 GTGGTGTGCACTGCCACGGTCAGGGAAGTACCACCTGTCTTCAGGTGTTTGTGAACCTCA 704

Qy 362 CTCTCTCGGGGAAAGCTCTCTCTTACCACAGAGAGACATAAATAATCAATCAGA 421
Db |||||
705 GCCATCAGGTCAGAAAGCTCTCTCATATATATGAGAGGCTGTCAGATAATCCCA 764

Qy 422 AGTGCTCTATATACCTAAATGTGGAAATTTTGAAGATCCATGCTCCGTGGTGAATG 481
Db |||||
765 AGTGCTTTTACACACCTAAAGTCCACCAAGATAGAAATGATTTTCTCAACAGTGTCTGG 824

Qy 482 TTGTCATGGAAACTT-----CAGGAAGTATCAACTTCTCTGCTATTCTGACCCAG 535
Db |||||
825 ACATAAAGAATTTCTGATCACAAATAGTGAATCCCTTTTCAAGTCTTACAGTCCAG 884

Qy 536 AAGGAACCCAGAGAGTGTATTCTCTAACMAAATCTACAGTCCAACTGCTGTTCATT 595
Db |||||
895 CCAGCAATCTGAAGATGTCATTCTTATAAAGATATGACCAATGGCTATCTTCCACT 944

Qy 596 CACTCTTCTGCCACCTGTATGCTGGGCTGGGCTGGCAATTTGTCATGCTGCGTGAAC 655
Db |||||
945 GTTATTTTGGCTTCACTGACTCTGCTAGGTGGTGGCCCTGATTGTTGGCATGTGAGAT 1004

656 TTACACAGTACTCTCCCTACTATGTGAGA 685
1005 TAACACACACTGTCTTACTGTGTGAA 1034

RESULT 13
ABA09214

ID ABA09214 standard; cDNA; 1251 BP.

XX ABA09214;

XX 11-JAN-2002 (first entry)

XX Human Ca-activated K channel homologue-encoding cDNA, SEQ ID NO:990.

XX Human; cytokine; cell proliferation; cell differentiation; growth factor;
XX haematopoiesis regulation; tissue growth; immunomodulator; activin;
XX inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;
XX proliferation; metastasis; cancer; tumour; haematopoietic disorder;
XX myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
XX chronic inflammatory condition; proliferative retinopathy;
XX atherosclerosis; coronary heart disease; arterial ischaemia;
XX bone disorder; osteoporosis; vascular growth disorder;

XX tissue regeneration; wound healing; infection; immune disorder;
XX cell culture; drug screening; gene therapy; antiinflammatory;
XX antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;
XX cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;
XX antifungal; vulnery; antiulcer; ss.
OS Homo sapiens.
XX WO200157188-A2.
XX 09-AUG-2001.
XX 05-FEB-2001; 2001WO-US003800.
XX 03-FEB-2000; 2000US-00496914.
XX 27-APR-2000; 2000US-00560875.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Drmanac RT;
XX WPI; 2001-457740/49.
XX P-PSDE; ABB11970.

XX Human proteins and DNA encoding sequences useful for preventing, treating
XX or ameliorating a medical condition in a mammalian subject e.g. arthritis
XX and cancer.

XX Claim 1; Page 843-844; 1963pp; English.

XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
XX sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
XX invention also relates to vectors and recombinant host cells comprising a
XX nucleotide of the invention, methods of producing the novel polypeptides,
XX antibodies against the polypeptides, methods of detecting the nucleotides
XX or polypeptides in a sample, and methods of identifying compounds which
XX bind to polypeptides of the invention. Although novel, many of the
XX polypeptides of the invention have homology to known proteins, and hence
XX giving an insight into their probable biological activities, and hence
XX potential therapeutic applications. The polypeptides of the invention may
XX have various activities, including cytokine, cell proliferation or cell
XX differentiation activities; stem cell growth factor activity;
XX haematopoiesis regulatory activity; tissue growth activity;
XX immunomodulatory activity; activin- or inhibin-related activities;
XX chemotactic or chemokinetic activities; haemostatic, thrombotic or
XX thrombolytic activities; receptor or ligand activities; or may be
XX involved in oncogenesis, cancer cell proliferation or metastasis.
XX Depending on their biological activities, polypeptides and nucleotides of
XX the invention are useful for preventing, treating or ameliorating medical
XX conditions, e.g., by protein or gene therapy. Such conditions include
XX cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell
XX disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
XX proliferative retinopathy, atherosclerosis, coronary heart disease,
XX arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
XX vascular growth. Polypeptides involved with tissue regeneration and
XX repair (or nucleic acids encoding them) may be used to promote wound
XX healing (e.g., of burns, incisions and ulcers), while those with
XX immunomodulatory activities may be used in the treatment of viral,
XX bacterial and fungal infections in addition to immune disorders.
XX Polypeptides with growth factor activity may be used in cell cultures to
XX promote cell growth. For example, such polypeptides may be used to
XX manipulate stem cells in culture to give rise to neuroepithelial cells
XX that can be used to augment or replace cells damaged by illness,
XX autoimmune disease or accidental damage. The polypeptides and nucleotides
XX may also be used in the diagnosis of the above conditions, and in drug
XX screening techniques. The present sequence represents a cDNA encoding a
XX novel human polypeptide of the invention

XX Sequence 1251 BP; 331 A; 304 C; 310 G; 306 T; 0 U; 0 Other;

XX Query Match 19.0%; Score 134.4; DB 4; Length 1251;

XX Best Local Similarity 54.6%; Pred. No. 3.7e-31;
XX Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

QY 125 CAGGAGGACCGAGCTATTCTCTGGAGCTGGCTATGATGGTGGCTCCATCATGATGT 184
 Db 433 CTGGAGAGGACCGAGCGGTGATGCTGGGTTTGGCATGATGGCTTCTCAGTCCCTAAATGT 492
 QY 185 ATTTCTGTGGGAATCACACTCTCTGGCTATACATGACAGACGCTGTGGACCGAAGAGT 244
 Db 493 TCTTCTGTGGGAACCACTCTTAAGCCCTTTATGCTCAGCATTACAGAGAGAAT 552
 QY 245 CTCATGACACTTGTGATGGTCCATCACGGAACAT---TTAATGCTCTTCACT 301
 Db 553 CGACCTGACCTGCCATCCACAGATATCATGGACGACTGGTGGACTGTGCTTCACT 612
 QY 302 GTGGTCCAGACTGCTGGAACCTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTGA 361
 Db 613 GTGGTGTGCACTGCCACGCTCAGGGGAGTACCCGTGCTTCAGTGTTTGTGAACCTCA 672
 QY 362 CTTCTTCGGGGAAGCTCTCTCTACACAGAGAGACAAATAAAATCAATCAGA 421
 Db 673 GCATCCAGGTGAGAAAGCTCTCTACATTAATAATGAAGAGCTGTCCAGATAAAATCCA 732
 QY 422 AGTGCTCTCTATACCTAAATGTGGAATAATTTTGAAGAATCCATGTCCTGTGTAATG 481
 Db 733 AGTGCTTTTACACCTAAGTGCACCAAGATAGAAATGTTTGTCTCAACAGTGTCTGG 792
 QY 482 TTGTCATGGAACCTT-----CAGGAAGTATCAACACTTCTCTGCTTATCTGACCCAG 535
 Db 793 ACATAAAAGATTTCTTCGATACAAAATGGAACCCCTTTTCATGCTTCTACAGTCCAG 852
 QY 536 AAGGAACACGAGAGAGTGTATCTTAACVAACTCTACAGTCCAGTGTGTTCCATT 595
 Db 853 CCAGCAATCTGAAGTGTATCTTATAAAAGTATGACCAATGCTATCTTCCACT 912
 QY 596 CACTCTTCTGGCCAACTGTATGATGGTGGGGGTGGCAATTTGTCCTATGTTGCAATG 655
 Db 913 GTTTATTTTGGCCTTCACTGACTCTGCTAGTGGTGGTGGCTGATTTGGCATGTGAGAT 972
 QY 656 TTACACAGTACTCTCCCTACTATGTGAGA 685
 Db 973 TAACACACACTGTCTTACTGTGTGAAA 1002

RESULT 14

AAK53112

ID AAK53112 standard, cDNA, 1251 BP.

XX AAK53112;

AC AAK53112;

XX 06-NOV-2001 (first entry)

XX Human polynucleotide SEQ ID NO 2641.

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorder; arthritis; inflammation; ss.

XX Homo sapiens.

XX WO200157190-A2.

XX 09-AUG-2001.

XX 05-FEB-2001; 2001WO-US004098.

XX 03-FEB-2000; 2000US-00496914.

XX 27-APR-2000; 2000US-00560875.

XX 20-JUN-2000; 2000US-00598075.

XX 19-JUL-2000; 2000US-00620325.

XX 01-SEP-2000; 2000US-00654936.

XX 15-SEP-2000; 2000US-00663561.

XX 20-OCT-2000; 2000US-00693325.

XX 30-NOV-2000; 2000US-00728422.

XX (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;
 PI Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
 PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
 XX WPI: 2001-476283/51.
 DR P-PSDE; AAM79979.

Nucleic acids encoding polypeptides with cytokine-like activities, useful in diagnosis and gene therapy.

Claim 1; Page 4899-4900; 6221pp; English.

The invention relates to polynucleotides (AAK51456-AAK53435) and the encoded polypeptides (AAM78323-AAM80302) that exhibit activity relating to cytokine, cell proliferation or cell differentiation or which may induce production of other cytokines in other cell populations. The polynucleotides and polypeptides are useful in gene therapy, vaccines or peptide therapy. The polypeptides have various cytokine-like activities, e.g. stem cell growth factor activity, haematopoiesis regulating activity, tissue growth factor activity, immunomodulatory activity and activin/inhibin activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3656 (AAM80020) are omitted as the relevant pages from the sequence listing were missing at the time of publication

Sequence 1251 BP; 331 A; 304 C; 310 G; 306 T; 0 U; 0 Other;

Query Match

Best Local Similarity 19.0%; Score 134.4; DB 4; Length 1251;

Matches 311; Conservative 54.6%; 2; Mismatches 248; Indels 9; Gaps 2;

QY 125 CAGGAGAGACCGAGCTATTCTCTGGAGCTGGCTATGATGGTGGCTCCATCATGATGT 184
 Db 433 CTGGAGAGACCGAGCGGTGATGCTGGGGTTTGGCATGATGGCTTCTCAGTCCCTAAATGT 492
 QY 185 ATTTCTGTGGGAATCACACTCTCTGCGCTCATATCAGAGAGCTGTGGACCGAAGAGT 244
 Db 493 TCTTCTGTGGGAACCACTTCTTAAGCCCTTTTANGCTCAGCATTACAGAGAGAAT 552
 QY 245 CTCATGACCTTGTGATGGTCCATCAGCAACGAAACAT---TTAATGCTCTTCACT 301
 Db 553 CGACCTGCACTGCCATCCACAGATATCATGGACGACTGGCTGGCTGTGCTTCACT 612
 QY 302 GTGGTCCAGACTGCTGGAACCTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTGA 361
 Db 613 GTGGTGTGCACTGCCACGCTCAGGGGAGTACCCGTGCTTCAGTGTTTGTGAACCTCA 672
 QY 362 CTTCTTCGGGGAAGCTCTCTCTACACAGAGAGACAAATAAAATCAATCAGA 421
 Db 673 GCATCCAGGTGAGAAAGCTCTCTACATTAATAATGAAGAGCTGTCCAGATAAAATCCA 732
 QY 422 AGTGCTCTCTATACCTAAATGTGGAATAATTTTGAAGAATCCATGTCCTGTGTAATG 481
 Db 733 AGTGCTTTTACACCTAAGTGCACCAAGATAGAAATGTTTGTCTCAACAGTGTCTGG 792
 QY 482 TTGTCATGGAACCTT-----CAGGAAGTATCAACACTTCTCTGCTTATCTGACCCAG 535
 Db 793 ACATAAAAGATTTCTTCGATACAAAATGGAACCCCTTTTTCATGCTTCTACAGTCCAG 852
 QY 536 AAGGAACACGAGAGTGTATCTTAACVAACTCTACAGTCCAGTGTGTTCCATT 595
 Db 853 CCAGCAATCTGAAGTGTATCTTATAAAAGTATGACCAATGCTATCTTCCACT 912
 QY 596 CACTCTTCTGGCCAACTGTATGATGGTGGGGGTGGCAATTTGTCCTATGTTGCAATG 655
 Db 913 GTTTATTTTGGCCTTCACTGACTCTGCTAGTGGTGGTGGCTGATTTGGCATGTGAGAT 972
 QY 656 TTACACAGTACTCTCCCTACTATGTGAGA 685

Db 973 TAACACAACACCTGCTCCTTACTGTGTGAAA 1002

RESULT 15
AAAF27995
ID AAF27995 standard; DNA; 1296 BP.
XX
XX
AC AAF27995;
XX
XX 08-MAY-2001 (first entry)
XX
XX Human calcium sensitive potassium channel beta3d subunit coding sequence.
XX
XX Human; calcium sensitive potassium channel; beta2 subunit; asthma;
KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;
KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;
KW irritable bowel syndrome; Alzheimer's disease; ds.
XX
XX Homo sapiens.
XX
XX WO200105828-A1.
XX
XX 25-JAN-2001.
XX
XX 18-JUL-2000; 2000WO-US019585.
XX
XX 20-JUL-1999; 99US-0144764P.
XX
XX (MERI) MERCK & CO INC.
XX
XX Uebele V, Swanson R, Liu Y, Lagrutta A;
XX
XX WPI; 2001-159514/16.
XX
XX P-PSDB; AAB35305.
XX
XX Novel human calcium sensitive potassium channel subunits for identifying
PT inhibitors and agonists of the potassium channel for use in treating
PT conditions such as asthma, hypertension, memory disorders, depression.
XX
XX Claim 3; Fig 5A; 89pp; English.
XX
XX The present invention provides the protein and coding sequences of the
CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c
CC and beta3d subunits. These can be used to identify inhibitors and
CC activators of the channels, which can be used in the treatment of
CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,
CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,
CC incontinence, migraine and irritable bowel syndrome. The coding sequences
CC are found at human chromosome 3q23-ter. The present sequence is the
CC beta3d subunit coding sequence
XX
XX

QY 362 CTTCTTCGGGGAAAGCTCCTCTACACACAGAGAGACAATAAAATCAATCAGA 421
Db 854 GCCATCCAGGTCAGAAAGCTCTCTTACATTATATGAAGGCTGTCCAGATAATCCCA 913
QY 422 AGTGCTCCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCCTGGGAATG 481
Db 914 AGTGCTTTTACACACCTTAAGTCCACCAAGATAGAATGATTGTCTCAACAGTGTCTGG 973
QY 482 TTGTCATGAAAACTT-----CAGGAGTATCAACACTTCTCTCTTATTTGACCCAG 535
Db 974 ACATAAAAAAGATTCTTCGATCACAAAAATGGAACCCCTTTTCATGCTTCTACAGTCCAG 1033
QY 536 AAGGAAACACAGAGAGTGTATTCTTAACMAAACTCTACAGTCCAACTGTGTTCATT 595
Db 1034 CCAGCCAATCTGAAGATGTCAATCTTTATAAAAAAGTATGACCAAAATGGCTATCTTCCACT 1093
QY 596 CACTCTTCTGGCCAACCTGTATGATGGCTGGGGGTGGCAATTTGTCCTGATGTAAC 655
Db 1094 GTTATTTTGGCTTCACTGACTCTGTAGTGGTGGCCCTGATTGTTGGCAATGGTGAAT 1153
QY 656 TTACACAGTACCTCTCCCTACTATGTGAGA 685
Db 1154 TAACACAACACCTGTCTTACTGTGAAA 1183

Search completed: November 6, 2004, 23:41:06
Job time : 431 secs

QY 125 CAGAGAGAGCCGAGCTATTCCTCGGACTGGCTATGATGGTGTGCTCCATCATGATGT 184
Db 614 CTGGAGAGGACCGAGCGCTGATGTGGGGTTTGGCATGATGGGCTTCTCAGTCTTAATGT 673
QY 185 ATTTTCTGCTGGGATCACACTCTCGCTCATACATGACAGCGTGTGGACCGAAGAGT 244
Db 674 TCTTCTTGTCTGGAAACCAACCTTTAAAGCCCTTTTATGCTCAGCATTCAGAGAGAGAT 733
QY 245 CTCATGACACCTTGTGAATGCGTCCATCAGGAAACAT---TTAAVTGCTCTTCAGCT 301
Db 734 CGACCTGCATGCGCATCCACACAGATATCATGGACGACTGGCTGGACTGTGCCCTCACCT 793
QY 302 GTGCTCCAGACTGTGAAAACCTTTCTCAGTACCCCTGCCCTCCAGGTGTAGTTAACTGA 361
Db 794 GTGGTGTGCACTGCCACGGTCAGGGGAAGTACCCGTGTCTTCTCAGGTGTTTGTGAACCTCA 853

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 6, 2004, 23:32:22 ; Search time 2961 Seconds
(without alignments)
8700.740 Million cell updates/sec

Title: US-09-914-053a-6

Perfect score: 707
Sequence: 1 atgcgatagggaccagtg.....atccacggatcaatagataa 707

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST.*

- 1: gb_est1.*
- 2: gb_est2.*
- 3: gb_hic.*
- 4: gb_est3.*
- 5: gb_est4.*
- 6: gb_est5.*
- 7: gb_est6.*
- 8: gb_est1.*
- 9: gb_est2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	692	97.9	801	4	BG188850 RST7884 A
2	649.6	91.9	803	4	BG198614 RST17879
3	642.4	90.9	816	4	BG195580 RST14773
4	636.6	88.6	795	4	BG218411 RST38279
5	604.2	85.5	817	4	BG214809 RST34463
6	584.8	82.7	694	7	CK945448 4069809 B
7	567.2	80.2	2356	3	AK012400 Mus muscu
8	563	79.6	949	5	BQ942589 AGENCOURT
9	556.8	78.8	1597	3	AK014106 Mus muscu
10	427.4	60.5	855	5	BU216989 603107309
c 11	382	54.0	598	7	CK903430 1e57a02.x
c 12	362.8	51.3	622	5	BU950136 1e77a08.x
13	349.4	49.4	778	4	BG502844 602550401
14	343.2	48.5	939	5	BU222329 603105389
15	338.6	47.9	562	2	BF433029 7a23h12.x
c 16	327.2	46.3	709	7	CK476300 AGENCOURT
17	311.4	44.0	852	5	EX723097 BX729097
18	305.4	43.2	870	4	BG701449 602682671
19	300.4	42.5	598	6	CB297668 12822017
20	298.8	42.3	835	7	CK601161 AGENCOURT
21	296.8	41.9	567	2	BF445488 7q99h09.x
22	291.6	41.2	756	5	BQ179892 UI-M-EW0-
23	281	39.7	558	1	AA904191 0e72h09.s
24	280	39.6	769	7	CN064012 Ag2_p46_A

25	260	36.8	608	7	CK903431	CK903431	1e57a02.y
26	256.4	35.3	591	4	BT964810	BT964810	1e57a02.y
27	233.4	33.0	294	6	CA780337	CA780337	MPL384.6
c 28	226.6	32.1	446	1	AT299145	AT299145	GM98f01.x
29	222.4	31.5	992	6	BY713099	BY713099	BY713099
30	215.2	30.4	495	2	BF477842	BF477842	7r01h09.x
31	184.4	26.1	824	5	BU355397	BU355397	603473149
c 32	171.6	24.3	796	5	BU205207	BU205207	603949389
33	170.6	24.1	386	1	AI301175	AI301175	gn04b11.x
34	168.4	23.8	446	7	CK898372	CK898372	SGP161943
35	163.6	23.1	856	7	CH331278	CH331278	AGENCOURT
36	156.8	22.2	459	5	BU950418	BU950418	1c77a08.y
37	141.4	20.0	884	7	CF548250	CF548250	AGENCOURT
38	141.4	20.0	1253	3	BC075236	BC075236	Xenopus 1
39	134	19.0	885	6	CD516242	CD516242	AGENCOURT
c 40	132.8	18.8	847	7	CN232966	CN232966	WLB054C10
41	132.6	18.8	686	5	BU445726	BU445726	603214459
42	132.4	18.7	784	5	BU483866	BU483866	603847676
43	131	18.5	666	2	BB632101	BB632101	BB632101
44	131	18.5	1552	3	AK038987	AK038987	Mus muscu
45	127.6	18.0	509	7	CN237073	CN237073	RJB129C03

ALIGNMENTS

RESULT 1
BG188850
LOCUS RST7884 Atherysys RAGE Library Homo sapiens cDNA, mRNA sequence.
DEFINITION RST7884 Atherysys RAGE Library Homo sapiens cDNA, mRNA sequence.
ACCESSION BG188850
VERSION BG188850.1 GI:13710537
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 801)
AUTHORS Harrington,J.O., Sharf,B., Rundlett,S., Jackson,P.D., Perry,R.,
Call,S., Leventhal,C., Thornton,M., Ramachandran,R.,
Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S.,
Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K.,
Offenbacher,J., Danzig,J. and Ducar,M.
Creation of genome-wide protein expression libraries using random
activation of gene expression
Nat. Biotechnol. 19 (5), 440-445 (2001)

JOURNAL MEDLINE
PUBMED
COMMENT Contact: Scott J. Cain
Athersys, Inc.
3201 Carnegie Ave, Cleveland, OH 44115, USA
Tel: 216 431 9900
Fax: 216 361 9596
Email: scain@atersys.com
High quality sequence stop: 554.
Location/Qualifiers
1. - 801
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="Htt1080"
/clone_lib="Athersys RAGE Library"
/note="See 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is Htt1080, since a random activation method was used, these sequence tags are not necessarily expressed in Htt1080 under normal circumstances."

ORIGIN
Query Match 97.9%; Score 692; DB 4; Length 801;
Best Local Similarity 99.3%; Pred. No. 1e-192;
Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;

QY 1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAGAAAT 60
DB 72 ATGTTTATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAGAAAT 131
QY 61 ATTACCAAGAAATCAGGACCATGACCTCTCTGGACAAAGAAAGAAAGAGTGCATG 120
DB 132 ATTACCAAGAAATCAGGACCATGACCTCTCTGGACAAAGAAAGAAAGAGTGCATG 191
QY 121 AAGGACAGAGGACCGAGCTATTCTCTGGACATGCTGCTATGATGGTGTCTCATG 180
DB 132 AAGGACAGAGGACCGAGCTATTCTCTGGACATGCTGCTATGATGGTGTCTCATG 251
QY 181 ATGATTTTCTGCTGGAAATCAGACTCTCTGGCTCATACATGACAGAGGCTGTGGACGAA 240
DB 252 ATGATTTTCTGCTGGAAATCAGACTCTCTGGCTCATACATGACAGAGGCTGTGGACGAA 311
QY 241 GAGTCTCAATGACCTTCTGCTGAATGCTGCTCATACAGGAAACATTTAATGCTCTCAGC 300
DB 312 GAGTCTCAATGACCTTCTGCTGAATGCTGCTCATACAGGAAACATTTAATGCTCTCAGC 371
QY 301 TGTGTCAGAGCTGCTGAAACTTTCTCAGTACCCCTGCTCCAGGCTGATGTTAACTG 360
DB 372 TGTGTCAGAGCTGCTGAAACTTTCTCAGTACCCCTGCTCCAGGCTGATGTTAACTG 431
QY 361 ACTTCTCCGGGAAAGCTCTCTCTTACACAGAGAGACAATAAATAATCAATCAG 420
DB 432 ACTTCTCCGGGAAAGCTCTCTCTTACACAGAGAGACAATAAATAATCAATCAG 491
QY 421 AAGTCTCTTATACCTTAATGTTGAAATAATTTGAAGATCCATGCTCCGTGTAAT 480
DB 492 AAGTCTCTTATACCTTAATGTTGAAATAATTTGAAGATCCATGCTCCGTGTAAT 551
QY 481 GTTGTCTAGGAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGGA 540
DB 552 GTTGTCTAGGAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGGA 611
QY 541 AACCAAGAGTGTATCTTACAAACTCTACAGTTCACAGCTGCTGCTTCACTC 600
DB 612 AACCAAGAGTGTATCTTACAAACTCTACAGTTCACAGCTGCTGCTTCACTC 671
QY 601 TTCTGCCAACCTGATGATGCTGGGGTGTGGCAATTTGTGCAATGTTGCAATGTTGCAAT 660
DB 672 TTCTGCCAACCTGATGATGCTGGGGTGTGGCAATTTGTGCAATGTTGCAATGTTGCAAT 731
QY 661 CAGTACCTCTCCCTACTATGTGAGAGATCC-ACGGATCAATGATTA 707
DB 732 CAGTACCTCTCCCTACTATGTGAGAGATCCACGGATCAATGATTA 779

RESULT 2
BG198614
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT

803 bp mRNA linear EST 21-APR-2001
R517879 Athersys RAGE Library Homo sapiens cdna, mRNA sequence.
BG198614
BG198614.1 GI:13720301
EST
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 803)
Harrington, J.J., Sherf, B., Rundlett, S., Jackson, P.D., Perry, R.,
Cain, S., Leventhal, C., Thornton, M., Ramachandran, R.,
Whittington, J., Lerner, L., Costanzo, D., McElligott, K., Booser, S.,
Mays, R., Smith, E., Veloso, N., Klika, A., Hess, J., Cochran, K., Lo, K.,
Offenbacher, J., Danzig, J., and Ducar, M.
Creation of genome-wide protein expression libraries using random
activation of gene expression
Nat. Biotechnol. 19 (5), 440-445 (2001)
21227151
11329013
Contact: Scott J. Cain

Athersys, Inc.
3201 Carnegie Ave., Cleveland, OH 44115, USA
Tel: 216 431 9900
Fax: 216 361 9596
Email: scain@athersys.com
High quality sequence stop: 553.
Location/Qualifiers
1..803
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="HT1080"
/clone_lib="Athersys RAGE Library"
/note="Gee 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

FEATURES
source

ORIGIN
Query Match 91.9%; Score 649.6; DB 4; Length 803;
Best Local Similarity 96.6%; Pred. No. 3.3e-180;
Matches 672; Conservative 2; Mismatches 21; Indels 1; Gaps 1;

QY 1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAGAAAT 60
DB 73 ATGTTTATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAGAAAT 132
QY 61 ATTACCAAGAAATCAGGACCATGACCTCTCTGGACAAAGAAAGAAAGAGTGCATG 120
DB 133 ATTACCAAGAAATCAGGACCATGACCTCTCTGGACAAAGAAAGAGTGCATG 192
QY 121 AAGGACAGAGGACCGAGCTATTCTCTGGACATGCTGCTATGATGGTGTCTCATG 180
DB 193 AAGGACAGAGGACCGAGCTATTCTCTGGACATGCTGCTATGATGGTGTCTCATG 252
QY 181 ATGATTTTCTGCTGGAAATCAGACTCTCTGGCTCATACATGACAGAGGCTGTGGACGAA 240
DB 253 ATGATTTTCTGCTGGAAATCAGACTCTCTGGCTCATACATGACAGAGGCTGTGGACGAA 312
QY 241 GAGTCTCAATGACCTTCTGCTGAATGCTGCTCATACAGGAAACATTTAATGCTCTCAGC 300
DB 313 GAGTCTCAATGACCTTCTGCTGAATGCTGCTCATACAGGAAACATTTAATGCTCTCAGC 372
QY 301 TGTGTCAGAGCTGCTGAAACTTTCTCAGTACCCCTGCTCCAGGCTGATGTTAACTG 360
DB 373 TGTGTCAGAGCTGCTGAAACTTTCTCAGTACCCCTGCTCCAGGCTGATGTTAACTG 432
QY 361 ACTTCTCCGGGAAAGCTCTCTCTTACACAGAGAGACAATAAATAATCAATCAG 420
DB 433 ACTTCTCCGGGAAAGCTCTCTCTTACACAGAGAGACAATAAATAATCAATCAG 492
QY 421 AAGTCTCTTATACCTTAATGTTGAAATAATTTGAAGATCCATGCTCCGTGTAAT 480
DB 493 AAGTCTCTTATACCTTAATGTTGAAATAATTTGAAGATCCATGCTCCGTGTAAT 552
QY 481 GTTGTCTAGGAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGGA 540
DB 553 GTTGTCTAGGAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGGA 612
QY 541 AACCAAGAGTGTATCTTACAAACTCTACAGTTCACAGCTGCTGCTTCACTC 600
DB 613 AACCAAGAGTGTATCTTACAAACTCTACAGTTCACAGCTGCTGCTTCACTC 672
QY 601 TTCTGCCAACCTGATGATGCTGGGGTGTGGCAATTTGTGCAATGTTGCAATGTTGCAAT 659
DB 673 TTCTGCCAACCTGATGATGCTGGGGTGTGGCAATTTGTGCAATGTTGCAATGTTGCAAT 732
QY 660 ACAGTACCTCTCCCTACTATGTGAGAGATCCACGG 695
DB 733 CCAGTCTCTTTCCCTACTATGTGAGAGATCCACGG 768

QY	361	ACTCTTCGCGGGAAAGCTCCTCTCTACCCACAGAAGAGACAATAAATCAATCAG	420
DB	432	ACTTCTTTGCGGGAAGAGCTCCTCTCTACCCACAGAAGAGACAATAAATCAATCAG	491
QY	421	AAGTGCTCCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCCATGCCCGGTGAAT	480
DB	492	AAGTGCTCCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCCATGCCCGGTGAAT	551
QY	481	GTTGTCATGGAAAACHTTCAGGAAGTATCAACACTTCTCTGCTATTCTGCACCAGGA	540
DB	552	GTTGTCATGGAAAACHTTCAGGAAGTATCAACACTTCTCTGCTATTCTGCACCAGGA	611
QY	541	AACCAAGAAGAGTGTATCCTTAACMAAACHTCTACAGTTCCAA-CGTGCTGTTCATTCACT	599
DB	612	AACCAAGAAGAGTGTATNCTTAACMAAACHTCTACAGTTCCAA-CGTGCTGTTCATTCACT	671
QY	600	CTTCTGGCCAACTGTATGAT-GGCTGGGGGTGGCAATTTGTCATGGTGAACCTTA	658
DB	672	TCFCTGGCAAACTGTATGATGGGCTGGGGGGTGCAATTTGTCATGGTGAACCTTA	731
QY	659	CACAGTACCTCTCCCCTACTATGTGAGAGGATCCA	692
DB	732	CACAGGACCTCINCCCTACTATGGAGAGGATCCA	765
RESULT 4			
EG218411			
LOCUS	RST38279	Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.	EST 21-APR-2001
DEFINITION	EG218411		
ACCESSION	EG218411.1	GI:13744560	
VERSION			
KEYWORDS	Est.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.		
AUTHORS	Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Coscanzo,D., McElligott,K., Boozer,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.		
TITLE	Creation of genome-wide protein expression libraries using random activation of gene expression		
JOURNAL	Nat Biotechnol. 19 (5), 440-445 (2001)		
MEDLINE	21227151		
PUBMED	11329013		
COMMENT	Contact: Scott J. Cain Athersys, Inc. 3201 Carnegie Ave, Cleveland, OH 44115, USA Tel: 216 431 9900 Fax: 216 361 9596 Email: scain@atersys.com High quality sequence stop: 483. Location/Qualifiers 1..795 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /cell_line="HT1080" /clone_lib="Athersys RAGE Library" /note="See 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."		
FEATURES	source		
ORIGIN			
Query Match		88.6%; Score 626.6; DB 4; Length 795;	
Best Local Similarity		96.8%; Pred. No. 2.1e-173;	
Matches 669; Conservative		2; Mismatches 16; Indels 4; Gaps 3;	

QY 2 TGTGATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAATA 61
Db 73 TGTATTATGACACAGCGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAATA 132
QY 62 TTATACAGAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTGA 121
Db 133 TTATACAGAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTGA 192
QY 122 AGGAGGAGAGACCGACATATCTCTGGACCTGGCTATGATGGTGTCTCCATCATGA 181
Db 193 AGGAGGAGAGACCGACATATCTCTGGACCTGGCTATGATGGTGTCTCCATCATGA 252
QY 182 TGATTTTCTGCTGGAAATCACACTCTCTGGCTCATATACATGACAGAGCGGTGGACCGAAG 241
Db 253 TGATTTTCTGCTGGAAAT--TCITCTGCTGGCTCATATGACAGAGCGGTGGACCGAAG 310
QY 242 AGTCTCAATGACACCTGTGTAATGGCTCCATCAGGAAACATTTAAATGCTCTCTCACT 301
Db 311 AGTCTCAATGACACCTGTGTAATGGCTCCATCAGGAAACATTTAAATGCTCTCTCACT 370
QY 302 GTGGTCCAGACTGTGGAAATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTCTGA 361
Db 371 GTGGTCCAGACTGTGGAAATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTCTGA 430
QY 362 CTTCTTCGGGGAAGAGTCTCTCTTACCAACAGAGACAAATAAAATCAATCAGA 421
Db 431 CTTCTTCGGGGAAGAGTCTCTTACCAACAGAGACAAATAAAATCAATCAGA 489
QY 422 AGTCTCTATATACCTAAATGTGGAAATTTTGAAGATCCATGTCCTGTGTGAATG 481
Db 490 AGTCTCTATATACCTAAATGTGGAAATTTTGAAGATCCATGTCCTGTGTGAATG 549
QY 482 TTGTCTGGAAGATTCAGGAAGTATCAACATCTCTCTGCTATTTGACACCAAGGAA 541
Db 550 TTGTCTGGAAGATTCAGGAAGTATCAACATCTCTCTGCTATTTGACACCAAGGAA 609
QY 542 ACCAGAGAGTGTATCTCAACAACTCTACAGTTCAGAGTCTGTTCCATTCACCTCT 601
Db 610 ACCAGAGAGTGTATCTCAACAACTCTACAGTTCAGAGTCTGTTCCATTCACCTCT 669
QY 602 TCTGCCCAACCTGTATGATGGCTGGGGGTGGCAATTTGTCATGTTGCAATGTTACAC 661
Db 670 TCTGCCCAACCTGTATGATGGCTGGGGGTGGCAATTTGTCATGTTGCAATGTTACAC 728
QY 662 AGTACCTCTCCCTACTATGTAGAGAGATCCA 692
Db 729 AGTACCTTTCCCTACTATGTAGAGAGATCCA 759

RESULT 5
LOCUS BG214809 817 bp mRNA linear EST 21-APR-2001
DEFINITION RST34463 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.
ACCESSION BG214809
VERSION BG214809.1 GI:13740830
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 817)
Harrington, J.J., Sherf, B., Rundlett, S., Jackson, P.D., Perry, R.,
Cain, S., Leventhal, C., Thornton, M., Ramachandran, R.,
Whittington, J., Lerner, L., Costanzo, D., McElligott, K., Booser, S.,
Mays, R., Smith, E., Veloso, N., Klika, A., Hess, J., Cothren, K., Lo, K.,
Offenbacher, J., Danzig, J., and Ducar, M.
Creation of genome-wide protein expression libraries using random
activation of gene expression
Nat. Biotechnol. 19 (5), 440-445 (2001)
JOURNAL
MEDLINE 2127151
PUBMED 11329013
COMMENT Contact: Scott J. Cain
Athersys, Inc.

3201 Carnegie Ave, Cleveland, OH 44115, USA
Tel: 216 431 9900
Fax: 216 361 9596
Email: scain@atersys.com
High quality sequence stop: 364.
Location/Qualifiers
1. 817
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="HT1080"
/clone_lib="Athersys RAGE Library"
/note="See 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

ORIGIN

Query Match 85.5%; Score 604.2; DB 4; Length 817;
Best Local Similarity 95.6%; Pred. No. 8.5e-167;
Matches 681; Conservative 2; Mismatches 23; Indels 6; Gaps 6;
QY 1 ATGTGATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60
Db 72 ATGTTTATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 131
QY 61 ATTATACAGAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTG 120
Db 132 ATTATACAGAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTG 191
QY 121 AAGGAGAGAGAGACCGACATTTCTCTGGACCTGGCTATGATGGTGTCTCCATCATG 180
Db 192 AAGGAGAGAGAGACCGACATTTCTCTGGACCTGGCTATGATGGTGTCTCCATCATG 251
QY 181 ATGTATTTCTCTGGAAATCACATCTCTGCGCTCATATACATGACAGAGCGGTGGACCGAA 240
Db 252 ATGTATTTCTCTGGAAATCACATCTCTGCGCTCATATACATGACAGAGCGGTGGACCGAA 311
QY 241 GAGTCTCAATGACACCTGTGTAATGGTCCATCAGGAAACATTTAATGTCTCTCTCAGC 300
Db 312 GAGTCTCAATGACACCTGTGTAATGGTCCATCAGGAAACATTTAATGTCTCTCTCAGC 371
QY 301 TGTGTCAGAGTGTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTCTG 360
Db 372 TGTGTCAGAGTGTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTCTG 431
QY 361 ACTTCTTCCGGGAAAGCTCTCTCTACACACAGAGAGACAAATAAAATCAATCAG 420
Db 432 ACTTCTTCCGGGAAAGCTCTCTCTACACACAGAGAGACAAATAAAATCAATCAG 491
QY 421 AAGTCTCTATATACCTAAATGTGGAAATTTTGAAGATCCATGT-CCCTGGTGA 479
Db 492 AAGTCTCTATATACCTAAATGTGGAAATTTTGAAGATCCATGTCCCTGGTGA 551
QY 480 TGTGTGCA-TGGAAACTTTCAGGAAGTATCAACAC-TTCTCTGCTATTTTCACCCAGAA 537
Db 552 TGTGTGCA-TGGAAACTTTCAGGAAGTATCAACAC-TTCTCTGCTATTTTCACCCAGAA 611
QY 538 GGAACACAGAGAGTGTATCTTAACAACTCTACAGTTCACAGTGTGTTCCATTC 597
Db 612 GGAACACAGAGAGTGTATCTTAACAACTCTACAGTTCACAGTGTGTTCCATTC 670
QY 598 CTCTCTGCGCAACCTGTATGATGGTGGGGGTGGCAATTTGTTCCATGTTG-AACT 656
Db 671 CTCTCTGCGCAACCTGTATGATGGTGGGGGTGGCAATTTGTTCCATGTTG-AACT 730
QY 657 TACACAGTACCTCTCTCTACTATGTAGAGAGATCCA-CGGATCAATAGATA 707
Db 731 AACACAGTACCTCTCTCTACTATGTAGAGAGATCCA-CGGATCAATAGATA 782


```
RESULT 6
CK945448      694 bp      mRNA      linear      EST 15-MAR-2004
LOCUS         4069809 BARC 10BOV Bos taurus cDNA clone 10BOV17_N10 5', mRNA
DEFINITION    sequence.
ACCESSION     CK945448
VERSION       CK945448.1 GI:45459828
KEYWORDS      EST.
SOURCE        Bos taurus (cow)
ORGANISM      Bos taurus
REFERENCE     1 (bases 1 to 694)
AUTHORS       Sonstegard, T.S., Van Tassel, C.P., Matukumalli, L.K., Harhay,
              G.P., Bosa, S., Rubinfeld, M. and Gasbarre, L.C.
TITLE         Production of EST from cDNA libraries derived from immunologically
              activated bovine gut
JOURNAL       Unpublished (2004)
COMMENT       Contact: Tad S. Sonstegard
              Bovine Functional Genomics Laboratory
              Animal and Natural Resources Institute
              Bldg. 200 Rm2A BARC-East, Beltsville, MD 20705, USA
              Tel: 3015048416
              Fax: 3015048414
              Email: tads@nri.barc.usda.gov
              Single pass sequencing. Bases called and trimmed with phred
              0.000925 using options -trim_alt "-trim_fasta. Vector identified
              by cross_match using options -minmatch 12 -minscore 12
              Plate: 17 row: N column: 10
              Seq primer: CCCAGTCACGACGTTGTAACG
              High quality sequence stop: 694.
FEATURES      Location/Qualifiers
              1..694
                /organism="Bos taurus"
                /mol_type="mRNA"
                /strain="Holstein"
                /db_xref="taxon:9913"
                /clone="10BOV17_N10"
                /sex="Male"
                /tissue_type="Pooled"
                /dev_stage="Multiple"
                /lab_host="DH10B T1 phage resistant"
                /clone_lib="BARC 10BOV"
                /note="Organ: Small Intestine; Vector: pAGEN-1; Site 1:
              EcoRV; Site 2: NotI; Equimolar amounts of mRNA extracted
              from proximal jejunums of 18 and 21 wk old steers, and
              distal ileums of 14 day old calves. proximal jejunum
              exposed to C. oncophora for 3 and 6 weeks, and distal
              ileum exposed to C. parvum for 7 days"
ORIGIN
Query Match      82.7%; Score 584.8; DB 7; Length 694;
Best Local Similarity 93.6%; Pred. No. 4.3e-161;
Matches 629; Conservative 2; Mismatches 39; Indels 2; Gaps 2;
Qy 1 ATGTCGATATGGACAGTCGGCCGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60
Db 1 ATGTTTATATGACAGTCGGCCGACCTCTTCATCTTACAGACATGATGAAAAGAAAT 76
Qy 61 ATTTACAGAAAATCAGGACCATGACCTCTGCGACAAAAGAAAAGAACAGTCAGCTG 120
Db 77 ATTTACAGAAAATCAGGACCATGACCTCTGCGACAAAAGAAAAGAACAGTCAGCTG 136
Qy 121 AAGCAGAGAGAGGACCGAGCTATTCCTCTGGGACTGCTATGATGGTCTCATCATG 180
Db 137 AAACAGAGAGAGGACCGGACCTATTCCTGGGACTGCGCATGATGGTCTCATCATG 196
Qy 181 ATGTAATTTCTGTTGGGAATACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAA 240
Db 197 ATGTAATTTCTGTTGGGAATACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAG 256
Qy 241 GAGTCTCAATGCACCTTGTGTAATGCGTCCATCAGGGAACATTTAAATGCTCTTCAGC 300
```

```
257 GAGGCTCAGTCGACCTTGTCTGAATGCATCCATCAGAGAAACATTTAACTGCTCTTCAGC 316
301 TGTGTCCTCAGACTGCTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTACCTG 360
317 TGTGTCCTCAGACTGCTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTATGTTAACCTG 376
361 ACTTCTTCCGGGAAAAGCTCTCTTACACAGAGAGAGACAAATAAAATCAATCAG 420
377 ACTTCTTCCGGTGAAGAGCTCTTCTTACACAGAGAGAGACAAATAAAATCAATCAG 436
421 AGTGTCTCTATATACCTTAAATGTGGAAAAATTTTGAAGAATCCATGTCCTCGTGAAT 480
437 AAGTGTCTCTATATACCTTAAATGTGGAAAAATTTTGAAGAATCCATGTCCTCGTGAAT 496
481 GTTGTCTATGAAAACTTTCAGGAAGTATCAACTTCTCTCTGCTATTCTGACCCAGAGGA 540
497 GTTGTCTATGAAAACTTTCAGGAAGTATCAACTTCTCTCTGCTATTCTGACCCAGAGGA 556
541 AACGAGAGAGTGTATCTCTAACTTCACTACAGTTCACAGTTCACAGTGTTCCTCATTC 600
557 AACGAGAGAGTGTATCTCTAACTTCACTACAGTTCACAGTTCACAGTGTTCCTCATTC 616
601 TTCTGCGCAACCTGTATGATGCTGGGGTGTGGCAATTTGTTGCCATGTTGAACTTACA 660
617 TTTTGGCCCAACTGATGATGCTGGGGTGTGGCAATTTGTTGCCATGTTGAACTTACA 674
661 CAGTACCTCTCC 672
675 CAGTATCTTTC 686

RESULT 7
AK012400
LOCUS         2356 bp      mRNA      linear      HTC 03-APR-2004
DEFINITION    Mus musculus 11 days embryo whole body cDNA, RIKEN full-length
              cDNA library, clone:2700049B16 product:LARGE CONDUCTANCE
              CALCIUM-ACTIVATED K CHANNEL BETA2 SUBUNIT, full insert sequence.
ACCESSION     AK012400
VERSION       AK012400.1 GI:12849119
KEYWORDS      HTC; CAP trapper.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE     1
AUTHORS       Carninci, P. and Hayashizaki, Y.
TITLE         High-efficiency full-length cDNA cloning
              Meth. Enzymol. 303, 19-44 (1999)
JOURNAL       99279253
MEDLINE       99279253
PUBMED        10349636
REFERENCE     2
AUTHORS       Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K.,
              Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
              Normalization and subtraction of cap-trapper-selected cDNAs to
              prepare full-length cDNA libraries for rapid discovery of new genes
              Genome Res. 10 (10), 1617-1630 (2000)
JOURNAL       20499374
MEDLINE       20499374
PUBMED        11042159
REFERENCE     3
AUTHORS       Shibata, K., Itoh, M., Aizawa, K., Nagao, S., Sasaki, N., Carninci, P.,
              Konno, H., Akiyama, J., Nishi, K., Katsunai, T., Tashiro, H., Itoh, M.,
              Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A.,
              Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K.,
              Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Wachi, M.,
              Yoneda, Y., Iehikawa, T., Ozawa, K., Tanaka, T., Matsura, S., Kawai, J.,
              Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A. and Hayashizaki, Y.
              RIKEN integrated sequence analysis (RISA) system--384-format
              sequencing pipeline with 384 multipipillary sequencer
              Genome Res. 10 (11), 1757-1771 (2000)
JOURNAL       20530913
MEDLINE       20530913
PUBMED        11076851
REFERENCE     4
```


Tissue Procurement: Susan L. Sullivan, PhD.
cDNA Library Preparation: ResGen, Invitrogen Corp
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Plate: LLAM13735 row: n column: 08
High quality sequence start: 36
High quality sequence stop: 564.
Location/Qualifiers
1..949
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="IMAGE:6311623"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH_MGC_129"
/note="Organ: olfactory epithelium; Vector: pCMV-SPORT6.1; Site 1: EcoRV; Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 2.2 kb. Constructed by ResGen, Invitrogen Corp. Note: this is a NIH_MGC Library."
ORIGIN
Query Match 79.6%; Score 563; DB 5; Length 949;
Best Local Similarity 87.3%; Pred. No. 1.3e-154;
Matches 614; Conservative 2; Mismatches 87; Indels 0; Gaps 0;
QY 5 CGATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAGAAAGAAATATTT 64
Db 13 CGGATGACACAGTGGCGGACCTCTTCATCTTATAGACAGGACGAGAAAGAAATATCT 72
QY 65 ACCAGAAATACAGGACCATGACCTCTCTGGACAAAGAAACAGTCCAGCACTGAAGG 124
Db 73 ACCAGAAATACAGGACCATGACCTCTCTGGACAAAGAAACAGTCCAGCACTGAAGG 132
QY 125 CAGGAGGACCGAGCTATTTCTCTGGAGCTGCTATGATGGTGTCTCCATCATGATGT 184
Db 133 CTGGGAGGACCGGACCATCTCTCTGGCCCTGGCCATGATGGTGTCTCCATCATGATGT 192
QY 185 ATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGAGGTGTGGACCGAAGT 244
Db 193 ACTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGAGGTGTGGACCGAAGT 252
QY 245 CTCATGACCTTCTGTAAGTCCATCAGGAAACATTTAATGCTCTCTTACGCTGTG 304
Db 253 CCCAGTGTGCTCTGTAATGTCAATCAGAAACGTTTAACTGTTCTCTTACGCTGTG 312
QY 305 GTCCAGACTGCTGAAACTTTCTCAGTACCCCTCCAGGTGTAGCTTAACCTGACTT 364
Db 313 GGCCGACTGTGGAAGCTCTCTCAGTACCTCTCAGTACCTCTGCTGAGTGTGACAT 372
QY 365 CTCCGGGAAAGCTCTCTCTACACAGAGAGACAAATAAATCAATCAGAGT 424
Db 373 CTTCGGGAGAGGCTCTCTCTACACAGGAGAGACCATGAAGATCAATCAAAAGT 432
QY 425 GCTCCTATATACCTAAATGTGGAAATTTTGAAGATCCATCTCCCTGGTGAATCTTG 484
Db 433 GCTCCTATTTCTTAAGTGTGAAACAACTTTGAGGAGTCCATGCTCTCTGAGTGTG 492
QY 485 TCATGGAAACTCTCAGGAAGTATCAACACTTCTCTCTCTCTCTCTCTCTCTCTCTCT 544
Db 493 TCATGGAAACTCTCAGGAGACACCAACTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 552
QY 545 AGAAGAGTGTATCTTACMAAATCTTACAGTTCACAGTTCACAGTTCACATCTCTCT 604
Db 553 AGAAGAGTGTATCTGACCAAACTTACAGCTTCAAGTTCATGCTGCTCTCTCTCTCT 612
QY 605 GGCACACTGTATGATGCTGGGGTGTGGCAATTTGTCATGCTGCTGCTGCTGCTGCTG 664
Db 613 GGCACACTGTATGATGCTGGGGTGTGGCAATCGTGTGCTGCTGCTGCTGCTGCTGCT 672

QY 665 ACCTCTCCCTACTATGTGAGAGATCCACGGATCAATAGATAA 707
Db 673 ACCTCTCCCTGCTTGTGAGATCCACGGATCAATAGATAA 715
RESULT 9
AK014106
LOCUS
DEFINITION
Mus musculus 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110031N04 product: LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL BETA2 SUBUNIT, full insert sequence.
AK014106
AK014106.1 GI:12851769
VERSION
HTC; CAP trapper.
KEYWORDS
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 Carrinci, P. and Hayashizaki, Y.
TITLE
High-efficiency full-length cDNA cloning
JOURNAL
Meth. Enzymol. 303, 19-44 (1999)
MEDLINE
99279253
PUBMED
10349636
REFERENCE
2 Carrinci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
TITLE
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
JOURNAL
Genome Res. 10 (10), 1617-1630 (2000)
MEDLINE
20499374
PUBMED
11042159
REFERENCE
3 Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P., Konno, H., Akiyama, J., Nishi, K., Kitsuai, T., Tashiro, H., Itoh, M., Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watahiki, M., Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A. and Hayashizaki, Y.
TITLE
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer
JOURNAL
Genome Res. 10 (11), 1757-1771 (2000)
MEDLINE
20530913
PUBMED
11076861
REFERENCE
4 The RIKEN Genome Exploration Research Group Phase II Team and the FANTOM Consortium.
TITLE
Functional annotation of a full-length mouse cDNA collection
JOURNAL
Nature 409, 685-690 (2001)
MEDLINE
11076861
REFERENCE
5 The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team.
TITLE
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
JOURNAL
Nature 420, 563-573 (2002)
MEDLINE
11076861
REFERENCE
6 (bases 1 to 1597)
ADACHI, J., AIZAWA, K., AKAHIRA, S., AKIMURA, T., ARAI, A., ANONO, H., ARAKAWA, T., BONO, H., CARNINCI, P., FUKUDA, S., FUKUNISHI, Y., FURUKO, M., HANAGAKI, T., HARA, A., HAYATSU, N., HIRAMOTO, K., HIRAKAWA, T., HORII, F., IMOTANI, K., ISHII, Y., ITOH, M., IZAWA, M., KASUKAWA, T., KATO, H., KAWAI, J., KOJIMA, Y., KONNO, H., KOUDE, M., Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Nishi, K., Nomura, K., Numazaki, R., Ohno, M., Okazaki, Y., Okido, T., Owa, C., Saito, H., Saito, R., Sakai, C., Sakai, K., Sano, H., Sasaki, D., Shibata, K., Shibata, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Suzuki, H., Tagami, T., Tagawa, A., Takahashi, F., Tanaka, T., Tejima, Y., Toya, T., Yamamura, T., Yasunishi, A., Yoshida, K., Yoshino, M., Muramatsu, M. and Hayashizaki, Y.
TITLE
Direct Submission
JOURNAL
Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC),

RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail: genome-res@gsc.riken.jp, URL: <http://genome.gsc.riken.jp/>, Tel: 81-45-503-9222, Fax: 81-45-503-9216)
Please visit our web site (<http://genome.gsc.riken.jp/>) for further details.

cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. First strand cDNA was primed with a primer [5'-GAGAGAGAGATCCAGAGCTCTTTTCTTTTCTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by cap-trapper. Second strand cDNA was prepared with the primer adapter of sequence [5'-GAGAGAGATTCCTCGAGTTAATTAATTCCTCCCTCCCTCC 3']. cDNA was cleaved with XhoI and SstI. Cloning sites, 5' end: XhoI; 3' end: SstI.

Host: SOLR.

Location/Qualifiers

1..1597
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="PANTOM DB:3110031N04"
/db_xref="taxon:10090"
/clone="3110031N04"
/tissue_type="head"
/clone_lib="RIKEN full-length enriched mouse cDNA library"
/dev_stage="13 days embryo"
488..1194

misc_feature

/note="LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL BETA2 SUBUNIT (SPR1AAL38982, evidence: FASTY, 100%ID, 100%length, match=705) putative"

ORIGIN

Query Match 78.8%; Score 556.8; DB 3; Length 1597;
Best Local Similarity 88.3%; Pred. No. 1.1e-152;
Matches 625; Conservative 2; Mismatches 79; Indels 2; Gaps 2;
QY 1 ATGTGATATGACACGATGGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 60
DB 488 ATGTTTATATGACACGATGGCGGACCTCTTCATCTTACACAGGACGAAAAAGAAAT 547
QY 61 ATTTACCAAAATCAGGACATGACCTCTGTCGACGAAAGGAAACAGTCACAGCACTG 120
DB 548 ATCTACCAAAATCAGGACATGACCTCTGTCGACGAAAGGAAACAGTCACAGCACTG 607
QY 121 AAGGCAGAGAGACCGAGCTATTCTCTGGGACTGCTATGATGCTGTGCTCCATCATG 180
DB 608 AAGGCTGGGAGGACCGGACATCTCTGCGCTGGCCATGATGGTGTGCTCCATCATG 667
QY 181 ATGTATTTTCTGCTGGAAATACACTCTGCGCTCATACATGACAGGCTGTGACCGAA 240
DB 668 ATGTACTTCTGCTGGAAATCAGCTGTGCGCTCTACATGACAGCGTGTGACAGAA 727
QY 241 GAGTCTCAATGACCTGTGTAATCGCTCCATCAGGAAACATTAATGCTCTCTCAGC 300
DB 728 GAG-CCAGTGTGCTGCTGTAATGCTCAATCAGAGAAAGTTTAACTGTTCTTTCAGC 786
QY 301 TGTGTTCAGACTGTGAAACTTTCTCAGTACCGCTCCCTCCAGGTGTAGTTAACTG 360
DB 787 TGTGGGCGGAGTGTGGAAGCTCTCTCAGTACCTCTGCTGCGAGTGTAGTGAACCTG 846
QY 361 ACTTCTTCGGGAAAGCTCTCTCTTACACACAGAGAGACAATAAATCAATCAG 420
DB 847 ACATCTTCGGGAGAGCTCTCTCTTACACACGGAAGAGACATGAGATCAATCAA 906
QY 421 AAGTCTCTCTATATACCTTAAATGTGAAAAAATTTTGAAGAAATCCATGTCCCTGTGAAT 480
DB 907 AAGTCTCTCTATATCTTAAAGTGTGAAAAAATTTTGAAGAAATCCATGTCTCTGTGAGT 966
QY 481 GTTGTGATGGAACCTTCAGGAGTATCAACACTCTCTCTCTCTCTCTCTGACCCAGAGGA 540

DB 967 GTGCTCATGAAAACTTCAGGAGACACCAACACTTCCCTGCTGCTATTCGACCCAGAGGA 1026
QY 541 ACCAGAGAGGTATCTCTACMAAATCTACAGTTCACAGTCTGTTCCATTCACCTC 600
DB 1027 ACCAGAGAGGTATCTCTGACCAAACTCTACAGTTCATGCTGTTCCATTCCTC 1086
QY 601 TTCTGCCCAACCTGTATGATGCTGGGGTGTGGCAATTGTTGCCATGTTGAAACTTACA 660
DB 1087 TTCTGCCCAACCTGTATGATGCTGGGGTGTGGCAATCGTTGCTATGTTGAAACTAAT 1146
QY 661 CAGTACTCTCTCTACTATGTCAGAGGATCC-ACGATCNAATAGATAA 707
DB 1147 CAGTACTCTCTCTGTTGTGAGAGGATCCAAACGATCAACAGATAA 1194

RESULT 10

BU216989

LOCUS

DEFINITION

603107309F1 CSEQCHN04 Gallus gallus cDNA clone CHEST48b4 5', mRNA

sequence.

ACCESSION

BU216989

VERSION

BU216989.1

KEYWORDS

EST

SOURCE

ORGANISM

Gallus gallus (chicken)

Gallus gallus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Archosauria; Aves; Neognathae; Galliformes; Phasianidae;

Phasianinae; Gallus

1 (bases 1 to 855)

REFERENCE

AUTHORS

Boardman, P.E., Sanz-Ezquerro, J., Overton, I.M., Burt, D.W., Bosch, E.,

Pong, W.T., Tickle, C., Brown, W.R.A., Wilson, S.A. and Hubbard, S.J.

A Comprehensive Collection of Chicken cDNAs

Curr. Biol. 12 (22), 1985-1969 (2002)

22335534

PUBMED

12445392

COMMENT

Contact: Simon Hubbard

Department of Biomolecular Sciences

University of Manchester Institute of Science and Technology

(UMIST)

PO Box 88, Manchester, M60 1QD, UK

Tel: 01612008930

Fax: 01612360409

Email: Simon.Hubbard@umist.ac.uk.

Location/Qualifiers

1..855

/organism="Gallus gallus"

/mol_type="mRNA"

/strain="White Leghorn, Hise"

/db_xref="taxon:9031"

/clone="CHEST48b4"

/tissue_type="whole embryo"

/dev_stage="20-21"

/lab_host="DH10B"

/clone_lib="CSEQCHN04"

/note="Organ: whole embryo; Vector: pBluescript II KS(+);

Site 1: EcoRI; Site 2: NotI; This normalized library was

constructed from 1 million independent clones. cDNA

synthesis was initiated using an oligo(dT) primer, using

methylated C in the first strand synthesis reaction.

Following this first strand reaction, double-stranded cDNA

was blunted, ligated to NotI adapters, digested with

EcoRI, size-selected, and cloned into the NotI and EcoRI

compatible sites of a custom modified MCS of the

pBluescript (KS+) vector. The library was normalized in 2

rounds using conditions adapted from Soares et al., PNAS

(1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6

(1996): 791, except that a significantly longer

reannealing hybridization was used."

ORIGIN

Query Match 60.5%; Score 427.4; DB 5; Length 855;
Best Local Similarity 78.4%; Pred. No. 1.4e-114;

Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@biohp.harvard.edu
This read is a 3' RESEQUENCE of a previously sequenced pancreas
clone

This resequenced clone has not previously been sequenced on this
end, resequencing from this end represents new data
Seq primer: -40UP from Gibco
High quality sequence stop: 584.
Location/Qualifiers
1..598
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5670818"
/sex="Both"
/tissue_type="Islets of Langerhans"
/dev_stage="Adult"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pSPORT1; Site 1: Not 1;
Site 2: Sal 1; Starting library constructed using
SuperScript Plasmid Library kit (Life Technologies). cDNA
made by oligo-dT priming. Size-selected by column
fractionation; average insert size 1.08 kb. Library was
amplified once on solid support and plasmid DNA from
library was prepared. The library DNA was normalized by
method #4 from Bonaldo, Lennon, and Soares 1996 Genome
Research 6:791-806; 0.5 microgram single-stranded library
plasmid DNA was mixed with 5 micrograms PCR product
representing library inserts and hybridized to an Ecot of
20. Single-stranded (unhybridized) plasmids were isolated
by hydroxyapatite chromatography and used to make this
library."

FEATURES
source

Query Match 54.0%; Score 382; DB 7; Length 598;
Best Local Similarity 99.2%; Pred. No. 3.2e-101;
Matches 393; Conservative 1; Mismatches 1; Indels 1; Gaps 1;
QY 313 TGCTGAAAATTCTTCAGTACCCCTCCAGGTGAGTAACTGACTGCTTCTCCGGG 372
DB 598 TGCTGAAAATTCTTCAGTACCCCTCCAGGTGAGTAACTGACTGCTTCTCCGGG 539
QY 373 GAAAAGCTCCTCTCTACCAAGAGAGACAATAAATAATCAATCAGAAGTGTCTCTAT 432
DB 538 GAAAAGCTCCTCTCTACCAAGAGAGACAATAAATAATCAATCAGAAGTGTCTCTAT 479
QY 433 ATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCTGCTGAATTTCTCATGAA 492
DB 478 ATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCTGCTGAATTTCTCATGAA 419
QY 493 AACTTCAGGAAGTATCAACACTTCCTGCTATTTCTGACCCAGAGAGAAACAGAGAGT 552
DB 418 AACTTCAGGAAGTATCAACACTTCCTGCTATTTCTGACCCAGAGAGAAACAGAGAGT 359
QY 553 GTTATCTTAACAACTCTACAGTTCACAGTCCACAGTGTCTTCCATCTCTCTTGGGCAACC 612
DB 358 GTTATCTTAACAACTCTACAGTTCACAGTTCACAGTGTCTTCCATCTCTCTTGGGCAACC 299
QY 613 TGTATGATGGCTGGGGGTGTGGCAATTTGTTCCTGCTGTTGCTGTTGAACTTACACAGTACCTCTCC 672
DB 298 TGTATGATGGCTGGGGGTGTGGCAATTTGTTCCTGCTGTTGCTGTTGAACTTACACAGTACCTCTCC 239
QY 673 CTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
DB 238 CTACTATGTGAGAGGATCCACACGGATCAATAGATAA 203

ORIGIN

Query Match 54.0%; Score 382; DB 7; Length 598;
Best Local Similarity 99.2%; Pred. No. 3.2e-101;
Matches 393; Conservative 1; Mismatches 1; Indels 1; Gaps 1;
QY 313 TGCTGAAAATTCTTCAGTACCCCTCCAGGTGAGTAACTGACTGCTTCTCCGGG 372
DB 598 TGCTGAAAATTCTTCAGTACCCCTCCAGGTGAGTAACTGACTGCTTCTCCGGG 539
QY 373 GAAAAGCTCCTCTCTACCAAGAGAGACAATAAATAATCAATCAGAAGTGTCTCTAT 432
DB 538 GAAAAGCTCCTCTCTACCAAGAGAGACAATAAATAATCAATCAGAAGTGTCTCTAT 479
QY 433 ATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCTGCTGAATTTCTCATGAA 492
DB 478 ATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCTGCTGAATTTCTCATGAA 419
QY 493 AACTTCAGGAAGTATCAACACTTCCTGCTATTTCTGACCCAGAGAGAAACAGAGAGT 552
DB 418 AACTTCAGGAAGTATCAACACTTCCTGCTATTTCTGACCCAGAGAGAAACAGAGAGT 359
QY 553 GTTATCTTAACAACTCTACAGTTCACAGTTCACAGTGTCTTCCATCTCTCTTGGGCAACC 612
DB 358 GTTATCTTAACAACTCTACAGTTCACAGTTCACAGTGTCTTCCATCTCTCTTGGGCAACC 299
QY 613 TGTATGATGGCTGGGGGTGTGGCAATTTGTTCCTGCTGTTGCTGTTGAACTTACACAGTACCTCTCC 672
DB 298 TGTATGATGGCTGGGGGTGTGGCAATTTGTTCCTGCTGTTGCTGTTGAACTTACACAGTACCTCTCC 239
QY 673 CTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
DB 238 CTACTATGTGAGAGGATCCACACGGATCAATAGATAA 203

Matches 556; Conservative 2; Mismatches 128; Indels 23; Gaps 3;
QY 1 ATGTCGATATGACACAGTGGCGGAGCTCTTTCATCTTATAGACATGATGAAAAAGAAAT 60
DB 152 ATGTTTATTTGACACAGTGGCGGAGCTCTTACATCTTACAGACATGAGAAA----- 205
QY 61 ATTTACAGAAAATCAGGACCATGACCTCTGCAAAAAGGAAAAACAGTCACAGCACTG 120
DB 206 -----AGGATCAGCATCTACTGCAAAAAGGAAAAACAGTCACAGCACTG 250
QY 121 AAGCAGGAGAGGACCGAGCTATTTCTCTGGGACTGCTATGATGATGCTGCTCATCATG 180
DB 251 AAAGCTGAGAGACCGGCGCATACTCTCGGGCTGGCCATGATGATGCTGCTCATCATG 310
QY 181 ATGATTTTCTGCTGGGAATCACACTCTGCGGCTATACATGAGAGCGGTGTGACCGAA 240
DB 311 ATGATACTTTCTCTGGGAATCACACTCTGCGGCTATACATGAGAGCGGTGTGACAGAA 370
QY 241 GAGTCTCAATGCATCTGCTGAATCGGTCATACAGGAAACATTAATTAATGCTCTTCAGC 300
DB 371 GAGGCTAGTCTGCTTCTCAAGCATCCATACAGGAAACATTAATTAATGCTCTTCAGC 430
QY 301 TGTGTCAGACTCTGGAATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360
DB 431 TGGGCGCCAGACTCTGGAATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 490
QY 361 ACTTCTTCGGGGAAGTCTCTCTTACACAGAGAGACAATAAATAATCAATCAG 420
DB 491 ACTTCTTCGGGGAAGTCTCTTACACAGAGAGACAATAAATAATCAATCAG 550
QY 421 AAGTCTCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCATGCTCCCTGGTGAAT 480
DB 551 GAGTCTCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCATGCTCCCTGGTGAAT 610
QY 481 GTTGTATGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGGA 540
DB 611 GTTGTATGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGGA 670
QY 541 AACAGAGAGTGTATCTCTAACMAAATCTACAGTTCACAGTTCACAGTTCACATCTACTC 600
DB 671 ACTCAGAGAGACGTGATATGACCAACACTGTACAGTTCACAGTTCACATCTACTC 730
QY 601 TTCTGGGCAACTGTATGATG- GTTGGGGGTGTGGCAATTTGTCCTGCTGAGTAACTTAC 659
DB 731 TTCTGGGCAACTGTATGATG- GTTGGGGGTGTGGCAATTTGTCCTGCTGAGTAACTGAC 790
QY 660 ACAGTACTCTCCCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707
DB 791 TCAATACCTTCTCTCTCTGGGAGAAATCCAAAGGATCAACAGATAA 839

RESULT 11
CK903430/c
LOCUS
DEFINITION
ie57a02.x5 Melton Normalized Human Islet 4 N4-HIS 1 Homo sapiens
CDNA clone IMAGE:5670818 3' similar to TR:Q91691 Q91691 MAXIK
CHANNEL BETA 2 SUBUNIT. ; mRNA sequence.
CK903430
CK903430.1 GI:45364961
EST.
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 598)
REFERENCE
Wyllie, T., Martin, J., Blistain, A., Schmitt, A., Theising, B.,
Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M.,
McCann, R., Cole, R., Tsagarishvili, R., Williams, T., Jackson, Y. and
Bowers, Y.
WashU-Harvard Pancreas EST Project
Unpublished (2000)
Other_ESTs: ie57a02.y1

```

RESULT 12
BU950136/c
LOCUS
DEFINITION
  BU950136 622 bp mRNA linear EST 21-OCT-2002
  i077a08.xl HR85 islet Homo sapiens cDNA IMAGE:6132374 3'
  similar to TR:Q9Y691 Q9Y691 MAXIK CHANNEL BETA 2 SUBUNIT. , mRNA
  sequence.
ACCESSION
  BU950136
VERSION
  BU950136.1 GI:24201487
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 622)
  Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
  Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
  Hillier,L., Marr,M., Pape,D., Wylie,T., Martin,J., Blistain,A.,
  Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J.,
  Cardenas,M., Gibbons,M., McCann,R., Cole,R., Tsagareishvili,R.,
  Williams,T., Jackson,Y. and Bowers,Y.
  Endocrine Pancreas Consortium
  Unpublished (2000)
  Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
  Endocrine Pancreas Consortium
  Harvard University, Howard Hughes Medical Institute
  Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
  MA 02138
  Tel: 617-495-1812
  Fax: 617-495-8557
  Email: dmelton@bcbp.harvard.edu
  Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
  Washington University Genome Sequencing Center For information on
  obtaining a clone please contact: Dr. Hiroshi Inoue
  (hinoue@im.wustl.edu)
  Seq primer: -40UP from Gibco
  High quality sequence stop: 293.
  Location/Qualifiers
    1..622
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="IMAGE:6132374"
      /tissue_type="Purified pancreatic islet"
      /lab_host="DH10B"
      /clone_lib="HR85 islet"
      /note="Organ: Pancreas; Vector: pBluescript SK(-); Site 1:
      NotI; Site 2: XhoI; cDNA made by oligo-dT priming.
      Size: selected on agarose gel. Average insert size ~1kb. 5'
      XhoI site was destroyed after directional cloning.
      Amplified once. Contact information: Hiroshi Inoue, MD,
      Metabolism Div. (Alan Permutt Lab), Washington University
      School of Medicine, Box 8127, 660 South Euclid Ave., St.
      Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
      314-362-1916, Fax: 314-747-2692."
ORIGIN
  Query Match 51.3%; Score 362.8; DB 5; Length 622;
  Best Local Similarity 92.9%; Pred. No. 1.5e-95;
  Matches 390; Conservative 1; Mismatches 28; Indels 1; Gaps 1;

QY 289 TGCTCTTCAGTGTGGTCCAGACTGCTGGAACTTCTCAGTACCCCTGCTCCAGGTG 348
Db 622 TGCTCTTCAGTGTGGTCCAGACTGCTGGAACTTCTCAGTACCCCTGCTCCAGGTG 563

QY 349 TACGTTAACCTGACCTTCTTCGGGGGAAAGCTCTCTCTACACACAGAGAGACAATA 408
Db 562 TCGGTTAACCTGCTCTTTTCGGGGGAAAGGCTCTCTTTTACCACCCAGAGAGACAATA 503
QY 409 AAAATCAATCAGAGTGTCTCTATACCTAAATGTGGAAAAATTTTGAAGATCCATG 468
Db 502 TAAATCAATCAGAGTGTCTCTATACCTAAATGTGGAAAAATTTTGAAGATCCATG 443

```

```

QY 469 TCCTCGTGAATGTTGTGTCATGGAACTTCAGAAAGTATCAACACTTCTCCTGCTATTCT 528
Db 442 TCCTCGTGAATGTTGTGTCATGGAACTTCAGAAAGTATCAACACTTCTCCTGCTATTCT 383
QY 529 GACCCAGAAGAAACAGAAAGAGTGTATCTCTTAACMAAACTCTACAGTTCCAACGTGTG 588
Db 382 GACCCAGAAGAAACAGAAAGAGTGTATCTCTTAACMAAACTCTACAGTTCCAACGTGTG 323
QY 589 TTCCATTCACTCTTCTGGCCAACTGTATGATGGCTGGGGGTGGCAATCTTCCCATG 648
Db 322 TTCCATTCACTGTCTGGCCAACTGTATGATGGCTGGGGGTGGCAATCTTCCCATG 263
QY 649 GTGAAACTTACAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
Db 262 GTGAAACTTACAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 203

RESULT 13
BU9502844
LOCUS
DEFINITION
  BU9502844 778 bp mRNA linear EST 27-MAR-2001
  602550401F1 NIH_MGC_61 Homo sapiens cDNA clone IMAGE:4657825 5',
  mRNA sequence.
ACCESSION
  BU9502844
VERSION
  BU9502844.1 GI:13464361
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  1 (bases 1 to 778)
  NIH-MGC http://mgi.nci.nih.gov/.
  National Institutes of Health, Mammalian Gene Collection (MGC)
  Unpublished (1999)
  Contact: Robert Strausberg, Ph.D.
  Email: cgabbs-r@mail.nih.gov
  Tissue Procurement: ATCC
  cDNA Library Preparation: CLONETECH Laboratories, Inc.
  cDNA Library Arrayed by: the I.M.A.G.E. Consortium (LLNL)
  DNA Sequencing by: Incyte Genomics, Inc.
  Clone Distribution: MGC clone distribution information can be
  found through the I.M.A.G.E. Consortium/LLNL at:
  http://image.llnl.gov
  Plate: LCM1451 row: b column: 02
  High quality sequence stop: 759.
  Location/Qualifiers
    1..778
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="IMAGE:4657825"
      /tissue_type="embryonal carcinoma"
      /lab_host="DH10B (T1 phage-resistant)"
      /clone_lib="NIH MGC_61"
      /note="Organ: Testis; Vector: pDNR-LIB (Clontech); Site 1:
      SfiI (ggccgctcgcc); Site 2: SfiI (ggccattagggc);
      Double-stranded cDNA was prepared from cell line RNA. 5'
      and 3' adaptors were used in cloning as follows: 5'
      adaptor sequence: 5'-ATTCTAGAGCGGCGGCGGCATG-dt(30)BN-3'
      (where B = A, C, or G and N = A, C, G, or T). Average
      insert size 1.75 kb (range 0.9-4.0 kb). 15/15 colonies
      contained inserts by PCR. This library was enriched for
      full-length clones and was constructed by Clontech
      Laboratories (Palo Alto, CA). Note: this is a NIH_MGC
      Library."
ORIGIN
  Query Match 49.4%; Score 349.4; DB 4; Length 778;
  Best Local Similarity 94.9%; Pred. No. 1.5e-91;
  Matches 392; Conservative 1; Mismatches 17; Indels 3; Gaps 3;

QY 1 ATGTCGATATGACCAAGTGGCGGACCTCTTCATCTTATAGCATGATGAAAAAGAAAT 60

```

Db 344 ATGTTTATATGACCGAGCGGACCTCTTTCATCTTATAGACATGATGAAAAAGAAAT 403
Qy 61 ATTACACAGAAAATCAGGACACATGACCTCTGACAAAAGAAAAGACAGTCACAGCACTG 120
Db 404 ATTTACAGAAAATCAGGACACATGACCTCTGACAAAAGAAAAGACAGTCACAGCACTG 463
Qy 121 AAGCAGAGAGGACCGAGCTATTTCTCTGGAGCTGGCTATGATGGTGTGCTCCATCATG 180
Db 464 AAGCAGAGAGGACCGAGCTATTTCTCTGGAGCTGGCTATGATGGTGTGCTCCATCATG 523
Qy 181 ATGATATTTCTCTGGAGTACACATCTCTGGCTCATACATGACAGAGGT-GTGGACCGA 239
Db 524 ATGATATTTCTCTGGAGTACACATCTCTGGCTCATACATGACAGAGGTGATGGTGTGCTCCATCATG 583
Qy 240 AGAGTCTCAATGACCTCTGTAATGCTCCATCAGGAAAACATTTAATGCTCTCTTCAG 299
Db 584 AGAGTCTCAATGACCTCTGTAATGCTCCATCAGGAAAACATTTAATGCTCTCTTCAG 643
Qy 300 CTGTGGTCCAGACTGCTGGAAC-TTTTCTCAGTACCTCTGCTCCAGGTGACGTTAAC 358
Db 644 CTGTGGTCCAGACTGCTGGAAC-TTTTCTCAGTACCTCTGCTCCAGGTGACGTTAAC 703
Qy 359 TGACTTCTTCGGGGAAAAGCTCTCTCTTACCACACAGAGACATATAAA 411
Db 704 TGACTTCTTCGGGGAAAAGCTCTCTCTTACCACACAGAGACATATAAA 755

BU222329 939 bp mRNA linear EST 25-NOV-2002
LOCUS 603105389F1 CSEQCHN04 Gallus gallus cDNA clone CHEST43b24 5', mRNA
DEFINITION sequence.
ACCESSION BU222329.1 GI:25411618
VERSION Gallus gallus (chicken)
KEYWORDS Gallus gallus
SOURCE EST.
ORGANISM Gallus gallus
REFERENCE Boardman, P.E., Sanz-Ezquerro, J., Overton, I.M., Burt, D.W., Bosch, E.,
Fong, W.T., Tickle, C., Brown, W.R.A., Wilson, S.A. and Hubbard, S.J.
A Comprehensive Collection of Chicken cDNAs
JOURNAL Curr. Biol. 12 (22), 1965-1969 (2002)
MEDLINE 22335534
PUBMED 12445392
COMMENT Contact: Simon Hubbard
Department of Biomolecular Sciences
University of Manchester Institute of Science and Technology
(UMIST)
PO Box 88, Manchester, M60 1QD, UK
Tel: 01612008930
Fax: 01612360409
Email: Simon.Hubbard@umist.ac.uk.

FEATURES
source Location/Qualifiers
1..939
/organism="Gallus gallus"
/mol_type="mRNA"
/strain="White Leghorn, Hisex"
/db_xref="taxon:9031"
/clone="CHEST43b24"
/tissue_type="whole embryo"
/dev_stage="20-21"
/lab_host="DH10B"
/clone_lib="CSPQCHN04"
/note="Organ: whole embryo; Vector: pBluescript II KS(+);
Site_1: EcoRI; Site_2: NotI; This normalized library was
constructed from 1 million independent clones. cDNA
synthesis was initiated using an oligo(dT) primer, using
methylated C in the first strand synthesis reaction.
Following this first strand reaction, double-stranded cDNA
was blunted, ligated to NotI adapters, digested with

EcORI, size-selected, and cloned into the NotI and EcoRI
compatible sites of a custom modified MCS of the
pBluescript (KS+) vector. The library was normalized in 2
rounds using conditions adapted from Soares et al., PNAS
(1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6
(1996): 791, except that a significantly longer
reamnealing hybridization was used."

ORIGIN
Query Match 48.5%; Score 343.2; DB 5; Length 939;
Best Local Similarity 78.2%; Pred. No. 1.1e-89;
Matches 444; Conservative 2; Mismatches 100; Indels 22; Gaps 2;
Qy 1 ATGTCATATGACCGAGCTCTTTCATCTTATAGACATGATGAAAAAGAAAT 60
Db 152 ATGTTTATTTGGACAGTGGCGGAGCTTACATCTTACAGACCATGAGAAA----- 205
Qy 61 ATTACCAGAAAATCAGGAGACCATGACCTCTCGGACAAAAGAAAAGACAGTCACAGCACTG 120
Db 206 -----AGGGATCAGATCTTACGGACAAAAGAAAAGACAGTCACAGCCCTA 250
Qy 121 AAGCAGAGAGGACCGAGCTATTTCTCTGGAGCTGGCTATGATGGTGTGCTCCATCATG 180
Db 251 AAAGCTGGAGAGACCGGGCCATCTCTCGGGCTGGCCATGATGGTGTGCTCTATCATG 310
Qy 181 ATGATATTTCTCTGGAGTACACATCTCTGGCTCATACATGACAGAGCTGTGGACCGAA 240
Db 311 ATGATATTTCTCTGGAGTACACATCTCTGGCTCATACATGACAGAGCTGTGGACCGAA 370
Qy 241 GAGTCTCAATGACCTTGTGTAATGCTCCATCAGGAAAACATTTAATGCTCTCTTCAGC 300
Db 371 GAGGCTCAGTGCTCGTCTTCTCAACGCATCCATCAGGAAAACCTTCACTGCTCGTTTAGC 430
Qy 301 TGTGTTCCAGACTGCTGGAAAACCTTCTCAGTACCTCGCTCCAGGTGACGTTACCTG 360
Db 431 TGCAGGACAGACTGCTGGAAAACCTTCTCAGTACCTCGCTCCAGGTGACGTTACCTG 490
Qy 361 ACTTCTTCCGGGAAAAGCTCTCTCTTACCACACAGAGAGACAAAT-AAAAATCAATCA 419
Db 491 ACTTCTTCCGGGAAAAGCTCTCTCTTACCACACAGAGAGACAAAT-AAAAATCAATCA 550
Qy 420 GAGTGTCTCTATATACCTTAATGTCGAAAAAATTTTGAAGATTCATGCTCCCTGTGAA 479
Db 551 TGAGTGTCTCTATACATCCCAAGTGTGGCAAGAAATACAGAGAAATCCATGTCATGTGAA 610
Qy 480 TGTGTCATGAAAACCTTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGG 539
Db 611 CGTTGTGATGAAAACCTTTCGAAAGTATCAACGCTTCTCTGCTTCTATGATCCTGAGG 670
Qy 540 AAACCCAGAGAGTGTATTCCTAACMAAA 567
Db 671 CACTCAGAGACGTGATATTGACCAAA 698

RESULT 15
BF433029/c
LOCUS 7n23h12.x1 NCI CGAP Lu24 Homo sapiens cDNA clone IMAGE3565679 3,
DEFINITION similar to TR:Q9Y691 Q9Y691 MAXIK CHANNEL BETA 2 SUBUNIT. i, mRNA
sequence.
ACCESSION BF433029
VERSION BF433029.1 GI:11445192
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 562)
REFERENCE NCI-CCAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
AUTHORS National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
TITLE Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.

Email: cgapbs@mail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL, send email to:
info@image.llnl.gov

Seq primer: -40UP from Gibco
High quality sequence stop: 498.

FEATURES

source
1..562
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:3565679"
/tissue_type="carcinoid"
/lab_host="DH10B"
/clone_lib="NCI CGAP Lu24"
/note="Organ: lung; Vector: pTVT3D-Pac (Pharmacia) with a
modified polylinker; Plasmid DNA from the normalized
library NCI CGAP Lu5 was prepared, and ss circles were
made in vitro. Following HAP purification, this DNA was
used as tracer in a subtractive hybridization reaction.
The driver was PCR-amplified cDNAs from a pool of 5,000
clones made from the same library (clones
1414920-1417991 and 1520904-1522439). Subtraction by Bento
Soares and M. Fatima Bonaldo."

ORIGIN

Query Match 47.9%; Score 338.6; DB 2; Length 562;
Best Local Similarity 99.4%; Pred. No. 2e-88;
Matches 349; Conservative 1; Mismatches 0; Indels 1; Gaps 1;
QY 358 CTGACTTCTTCGGGAAAGCTCTCTCTACACAGAGACAAATAAATCAAT 417
DB |||||||
DB 562 CTGACTTCTTCGGGAAAGCTCTCTCTACACAGAGACAAATAAATCAAT 503
QY 418 CAGAAAGTCTCTATATACCTAAATGTGAAAAATTTTGAAGATCCATGTCCTGGTG 477
DB |||||||
DB 502 CAGAAAGTCTCTATATACCTAAATGTGAAAAATTTTGAAGATCCATGTCCTGGTG 443
QY 478 AATGTTGTCATGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTCTGACCCGAA 537
DB |||||||
DB 442 AATGTTGTCATGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTCTGACCCGAA 383
QY 538 GGAACACAGAGAGTGTATCTCTAAACAACTCTACAGTCCACGCTGCTGTCATTCA 597
DB |||||||
DB 382 GGAACACAGAGAGTGTATCTCTAAACAACTCTACAGTCCACGCTGCTGTCATTCA 323
QY 598 CTCCTCTGCCAACCTGTATGATGCTGGGGGTGGCAATTTGTCATGCTGAACTT 657
DB |||||||
DB 322 CTCCTCTGCCAACCTGTATGATGCTGGGGGTGGCAATTTGTCATGCTGAACTT 263
QY 658 ACACAGTACTCTCTCTCTATGATGAGAGGATCC-ACGGATCAATAGATAA 707
DB |||||||
DB 262 ACACAGTACTCTCTCTCTATGATGAGAGGATCCACCGATCAATAGATAA 212

Search completed: November 7, 2004, 01:24:17
Job time : 2971 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 23:27:01 ; Search time 16 Seconds
(without alignments)
1413.184 Million cell updates/sec

Title: US-09-914-053a-5
Perfect score: 1241
Sequence: 1 MSITWSTGRTSSSYRHDEKN.....MVKLTQYLSLCLERQINR 235
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues 283416
Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 200000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79.*
1: Pirl.*
2: Pirl.*
3: Pirl.*
4: Pirl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	421	33.9	191	2 S68842	calcium-regulated
2	382	30.8	191	2 A54165	charybdotoxin rece
3	93.5	7.5	255	2 T25853	hypothetical prote
4	89	7.2	286	1 C42053	gap junction prote
5	89	7.2	359	1 HLHUB4	MHC class I histoc
6	89	7.2	362	2 I37519	MHC class I histoc
7	88	7.1	362	2 I61851	MHC HLA-B*44.2 chai
8	87.5	7.1	1880	2 T18531	tractin - medicina
9	87	7.0	398	2 F90206	histidinol dehydro
10	87	7.0	497	2 G87793	protein C27A12.7 [
11	86	6.9	238	2 B36284	prolactin-like pro
12	85.5	6.9	491	2 F87793	protein C27A12.6 [
13	84.5	6.8	422	2 C34597	hypothetical prote
14	84	6.8	362	2 G35997	MHC class I histoc
15	83	6.7	362	2 T38421	gene HLA B-1519 pr
16	83	6.7	1562	2 T07323	DNA-directed RNA p
17	83	6.7	1589	1 RBYC5	cell division cont
18	82.5	6.6	247	2 A86809	hypothetical prote
19	82	6.6	336	2 T21531	hypothetical prote
20	82	6.6	350	2 I54308	MHC HLA B*71 - huma
21	82	6.6	354	2 S24433	class I histocompa
22	82	6.6	362	2 I84866	transmembrane gly
23	82	6.6	362	2 I62042	MHC HLA-B cell sur
24	82	6.6	362	2 G01230	MHC class I histoc
25	82	6.6	362	2 G01230	major histocompati
26	82	6.6	362	2 I59654	gene HLA B-1517 pr
27	82	6.6	362	2 I62045	MHC HLA-B*46 - hum
28	82	6.6	362	2 I61863	MHC class I histoc
29	82	6.6	362	2 S77966	MHC class I histoc
30	82	6.6	362	2 I37520	MHC class I histoc

ALIGNMENTS

RESULT 1

S68842
calcium-regulated potassium channel beta chain - human
C:Species: Homo sapiens (man)
C:Date: 04-Dec-1997 #sequence_revision 12-Dec-1997 #text_change 09-Jul-2004
C:Accession: S68842; S62905
R:Meera, P.; Wallner, M.; Jiang, Z.; Toro, L.
FEBS Lett. 385, 124-131, 1996
A:Title: Corrigendum to: a calcium switch for the functional coupling between alpha (hslo
A:Reference number: S62904; MUID:96196569; PMID:8612769
A:Accession: S68842
A:Molecule type: mRNA
A:Residues: 1-191 <ME3>
A:Cross-references: UNIPROT:Q16558
R:Meera, P.; Wallner, M.; Jiang, Z.; Toro, L.
FEBS Lett. 382, 84-88, 1996
A:Title: A calcium switch for the functional coupling between alpha (hslo) and beta subu
A:Reference number: S62904; MUID:96196569; PMID:8612769
A:Accession: S62905
A>Status: nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-165, 'L', 167-191 <MEW>
A:Cross-references: EMBL:U25138

Query Match	33.9%	Score	421;	DB	2;	Length	191;
Best Local Similarity	43.0%	Pred. No.	8.5e-31;				
Matches	83;	Conservative	40;	Mismatches	62;	Indels	8;
Gaps	2;						
QY	34	RTVTALKAGEDRAILLGLAMVCSIMMYFLIGLILRSYMSQSVWTERSQCTLLNASITE	93				
DB	3	KKLNVAKRGKTRALCLGVTWVCAVITYILVTTLPLYQKSVWTQESKCHLIETNIRD	62				
QY	94	TFNCSFSGPCDCKLSQYPCLOVYVNLTSGBKLLYHTEETIKINQKCSYIPKCGKNFE	153				
DB	63	QBELKKGK-----KVPQYFCL--WNVNAGRWAVLYHTEFTRDQNCQSYIPGSDVNVQ	114				
QY	154	ESMSLVNVMNFRKYQHFSCYSDPEGKQSVILTKYLSNVLFHSLWPTCMAGGVAI	213				
DB	115	TARADVEKRAKFEQCFYCFPSAPRGNETSVLFQRLYQPALLFSLFWPTFLTGGLLI	174				
QY	214	VAMVKLTQYLSLL	226				
DB	175	IAWVSNQYLSIL	187				

RESULT 2

A54165
charybdotoxin receptor beta chain - bovine
C:Species: Bos primigenius taurus (cattle)
C:Date: 02-Aug-1994 #sequence_revision 02-Aug-1994 #text_change 09-Jul-2004
C:Accession: A54165
R:Knaus, H.G.; Folander, K.; Garcia-Calvo, M.; Garcia, M.L.; Kaczorowski, G.J.; Smith, M


```

F;217-282/Domain: immunoglobulin homology <IMM>
F;305-328/Domain: Transmembrane #status predicted <TM>
F;329-359/Domain: Intracellular #status predicted <INT>
F;107/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match      7.2%; Score 89; DB 1; Length 359;
Best Local Similarity 21.3%; Pred. No. 2.2;
Matches 50; Conservative 37; Mismatches 88; Indels 60; Gaps 10;

QY 1 MSITSGRTSSSYRHEKRNIIYQKIRDHDLDDKRTVTKAGEDRAILLGLAMVCSIM 60
DB 151 LSWTAADTAQ-----ITQKWEAARVAEOADRAYLEGLC----- 185
QY 61 MYFLLGITLRSYMQSVWTEESQOTLLNASITETNCFSCGPD-----CWKLSQYPCQL 115
DB 186 -----VESLRYL-----ENKQETLQRADPPKTHVTHHPISDHEATLRCSLGFYPA-E 233
QY 116 VYVNLTSSEKLLLYHTETIKINQKCSYIPKCGKPEESMSLVNVMENFRKYQHFSY 175
DB 234 ITLTWQRDGD---QTDTELVETR---PAGDRTFKWAAVVVPSGEE---QRYTCH 281
QY 176 SDPEGNQKSVILTKLYSSNLFHSLFWPTCMAGGVAIVAMVKLTQYL-SLLCER 229
DB 282 VQHEGLPKPLTRWEPSSQSTV-----PIVGIVAGLAVLVAVVIGAVVAVMCCR 331

RESULT 6
I37519
MHC class I histocompatibility antigen HLA-B45 alpha chain precursor - human
C;Species: Homo sapiens (man)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C;Accession: I37519; S16772
E;Madrigal, J.A.; Belich, M.P.; Hildebrand, W.H.; Benjamin, R.J.; Little, A.M.; Zemmour,
J.; Immunol. 149, 3411-3415, 1992
A;Title: Distinctive HLA-A,B antigens of black populations formed by interallelic conver-
A;Reference number: I37476; MUID:93056508; PMID:11431115
A;Accession: I37519
A;Status: preliminary; translated from GB/EMBL/DBDJB
A;Molecule type: mRNA
A;Residues: 1-362 <RES>
A;Cross-references: UNIPROT:P30483; EMBL:X61710; NID:G32182; PIDN:CAA43879.1; PID:G32182
A;Note: this allele is designated B*4501
C;Genetics:
A;Gene: GDB:HLA-B
A;Cross-references: GDB:120048; OMIM:142830
A;Map position: 6p21.3-6p21.3
C;Superfamily: class I histocompatibility antigen; immunoglobulin homology
C;Keywords: glycoprotein; heterodimer; transmembrane protein
F;1-24/Domain: signal sequence #status predicted <SIG>
F;220-285/Domain: immunoglobulin homology <IMM>
F;110/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match      7.2%; Score 89; DB 2; Length 362;
Best Local Similarity 21.3%; Pred. No. 2.2;
Matches 50; Conservative 37; Mismatches 88; Indels 60; Gaps 10;

QY 1 MSITSGRTSSSYRHEKRNIIYQKIRDHDLDDKRTVTKAGEDRAILLGLAMVCSIM 60
DB 154 LSWTAADTAQ-----ITQKWEAARVAEOADRAYLEGLC----- 188
QY 61 MYFLLGITLRSYMQSVWTEESQOTLLNASITETNCFSCGPD-----CWKLSQYPCQL 115
DB 189 -----VESLRYL-----ENKQETLQRADPPKTHVTHHPISDHEATLRCSLGFYPA-E 236
QY 116 VYVNLTSSEKLLLYHTETIKINQKCSYIPKCGKPEESMSLVNVMENFRKYQHFSY 175
DB 237 ITLTWQRDGD---QTDTELVETR---PAGDRTFKWAAVVVPSGEE---QRYTCH 284
QY 176 SDPEGNQKSVILTKLYSSNLFHSLFWPTCMAGGVAIVAMVKLTQYL-SLLCER 229
DB 285 VQHEGLPKPLTRWEPSSQSTI-----PIVGIVAGLAVLVAVVIGAVVAVMCCR 334

```

```

RESULT 7
161861
MHC HLA-B44.2 chain - human
C:Species: Homo sapiens (man)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Accession: I61861
R:Parham, P.; Lawlor, D.A.; Lomen, C.E.; Ennis, P.D.
J. Immunol. 142, 3937-3950, 1989
A:Title: Diversity and diversification of HLA-A,B,C alleles.
A:Reference number: I36956; MUID:89235215; PMID:2715640
A:Accession: I61861
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-362 <RES>
A:Cross-references: UNIPROT:P30481; GB:M24038; NID:gi87811; PID:AAAS9663.1; PID:g386900
C:Superfamily: class I histocompatibility antigen; immunoglobulin homology
P:220-285/Domain: immunoglobulin homology <IM>

Query Match 7.1%; Score 88; DB 2; Length 362;
Best Local Similarity 21.3%; Pred. No. 2.7;
Matches 50; Conservative 37; Mismatches 88; Indels 60; Gaps 10;

Qy 1 MSWITSGTSSSYRHXDEKRNIIQKIRHDLDDKRTVTALKAGEDRAILLGLAMMVCSIM 60
Db 154 LSSWTAADTAQ-----IQRKEAARVAEQDRAYLEGLC----- 188

Qy 61 MYFLLGITLLRSYQSWTESQCTLLNASITETNCSFGPD-----CWKLSQYPCLO 115
Db 189 -----VESLRYL-----ENGKETLQRADPPKTHVTHPISDHEVTLRCWALGFYPA-E 236

Qy 116 VYVNLTSSEKLLAVHTETTKINQKSYIPCKGNFEESMSLVNVVMENFRKYQHFSCY 175
Db 237 IITLWQRDGED-----QTQDTLVEYR-----PAGDRTFQKWAAVVPSGEB---QRYTCH 284

Qy 176 SDPEGNQKSVILTKDYSNVLFHSFLFWFTCMAGGVAIVAMVKLTQYL-SLLCER 229
Db 285 VQHEGLPKFLRLWEPFSQSTV-----PIVGIVAGLAVLAVVIGAVVAAMCRR 334

RESULT 8
Ti8531
tractin - medicinal leech
C:Species: Hirudo medicinalis (medicinal leech)
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004
C:Accession: Ti8531
R:Huang, Y.; Jellies, J.; Johansen, K.M.; Johansen, J.
J. Cell Biol. 138, 143-157, 1997
A:Title: Differential glycosylation of Tractin and LeechCAM, two novel Ig-superfamily members
A:Reference number: Zi8951; MUID:97362067; PMID:9214388
A:Accession: Ti8531
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-1880 <HUA>
A:Cross-references: UNIPROT:O18465; EMBL:U92813; NID:g2275259; PID:g2275260; PIDN:AAAC476;

Query Match 7.1%; Score 87.5; DB 2; Length 1880;
Best Local Similarity 22.0%; Pred. No. 19;
Matches 42; Conservative 24; Mismatches 64; Indels 61; Gaps 8;

Qy 21 IVQKIRHDLDDKRTVTALKAGEDRAILLGLAMMVCSIMYFLLGITLLRS-----YM 74
Db 64 VFQWFKDESPLEKSAERPPK-DEOQGT-----ITLYNNELKDEGY 104

Qy 75 QSV-----WTESQCTLLNASITETP-----NCSFSGPCDCWKLSQYPCFL 114
Db 105 QCIIVKNKYGTAAVKRTLKQAVQESFPTVKPEQIVNVRVGDNLTLRCNPP-----KSYPTP 160

Qy 115 QVYVNLTSSEKLLVHTETTKINQKSYIPCKGNFEESMSLVNVVMENFRKYQHFSC 174
Db 161 DVIWGTVKGAKLL--PLENTWYN-----LDYEGNTHFANWVEDHREGAYVLC 208

Qy 175 YSDPEGNQKSV 185

```

Db 209 ISHNNAMRSSV 219

RESULT 9

F90206

Histidinol dehydrogenase (HDH) (hisD) [imported] - Sulfolobus solfataricus

C:Species: Sulfolobus solfataricus

C>Date: 24-May-2001 #sequence_revision 24-May-2001 #text_change 16-Aug-2004

C:Accession: F90206

R:She, Q.; Singh, R.K.; Confalonieri, F.; Zivanovic, Y.; Allard, G.; Awayez, M.J.; Chan-aret, R.A.; Jeffries, A.C.; Kozera, C.J.; Medina, N.; Peng, X.; Thi-Ngoc, H.P.; Redder, H. submitted to GenBank, April 2001

A:Description: Sulfolobus solfataricus complete genome.

A:Reference number: A99139

A:Accession: F90206

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-398 <KUR>

A:Cross-references: UNIPROT:O33775; GB:AE006641; NID:gi31813763; PIDN:AAK40909.1; GSPDB:G90206

C:Genetics:

C:Superfamily: Histidinol dehydrogenase; histidinol dehydrogenase homology

Query Match 7.0%; Score 87; DB 2; Length 398;

Best Local Similarity 22.8%; Pred. No. 3.7;

Matches 34; Conservative 25; Mismatches 50; Indels 40; Gaps 7;

QY 102 GPCDWKLSQYPCLOVYVNLTSSEKLLYHTEETIKNQKSFESMSLVV 161

DB 248 GPD-----TYVLLSNDSB-LIRRVEEKIKNDKIYIYIKT-KNLDEAIEIANK 294

QY 162 VVENFRKYCHFSYSDPE-----GNQKSVILTKLYSSNVLFHSLFWPTCM 206

DB 295 IAP-----EHLVSVKDAYTMDKIVAGALSNGTTPPAIDYVAGNHLPINGW--AK 347

QY 207 MAGGVAIVAMVKLTQYLSLLCERIQINR 235

DB 348 IRGGITVYDFIKPTMYAN-----VRDINK 371

RESULT 10

G87793

protein C27A12.7 [imported] - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C>Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 09-Jul-2004

C:Accession: G87793

R:Anonymous, The C. elegans Sequencing Consortium.

Science 282, 2012-2018, 1998

A:Title: Genome sequence of the nematode C. elegans: a platform for investigating biology

A:Reference number: A75000; MUID:99069613; PMID:9851916

A>Note: see websites genome.wustl.edu/gsc/C_elegans/ and www.sanger.ac.uk/Projects/C_elegans

A:Accession: G87793

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-497 <STO>

A:Cross-references: UNIPROT:O01964; GB:chr_I; PIDN:AA9393644.1; PID:g2105479; GSPDB:GN000

C:Genetics:

A:Gene: C27A12.7

A:Map position: 1

Query Match 7.0%; Score 87; DB 2; Length 497;

Best Local Similarity 19.4%; Pred. No. 4.7;

Matches 43; Conservative 36; Mismatches 87; Indels 56; Gaps 8;

QY 5 TSGRTSSSYRHDERNYVQKIRDHLLDKRKTVTALKAGEDRAILLGLAMWCSIMMY-- 62

DB 37 TSDNDTSYAKEDKSE--NEVLNDLLAEWNNTI-----ADVQAVLQVDPGVCRILLHKY 90

QY 63 -----FLGHTLLRSYQSVWTEESQCTLLNASITET--FNCSFSC 101

DB 91 KWNKESLLERLYEHPTDTIAFLIDAQVTPROQEVIPAGDAECDIC-CSDMBSLGLSCNHRA 149

QY 102 GPCDWKL-----SQYPCLOVYVNLTSSEKLLYHTEET-----IK 137

DB 150 CAECWQAYLTNKTIVSDAQSEIECMAPNCKLLIEDEKVLAYIKDPTIIAKYKRWVASYIE 209

QY 138 INQKCSYIP--KCGKNFESMSLVVNVNMFNFRKYQHFSYSD 177

DB 210 INALLKWCFGVDCGRVTYKVSHGEPRLVWCTGSRFCFCGQD 251

RESULT 11

B36284

Prolactin-like protein II, placental - bovine

C:Species: Bos primigenius taurus (cattle)

C>Date: 18-Jan-1991 #sequence_revision 18-Jan-1991 #text_change 09-Jul-2004

C:Accession: B36284

R:Yamakawa, M.; Tanaka, M.; Koyama, M.; Kagesato, Y.; Watahiki, M.; Yamamoto, M.; Nakashima, J. Biol. Chem. 265, 8915-8920, 1990

A:Title: Expression of new members of the prolactin growth hormone gene family in bovine

A:Reference number: A36284; MUID:90256825; PMID:2341410

A:Accession: B36284

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-238 <YAM>

A:Cross-references: UNIPROT:PI9159; GB:M33269; GB:J05458; NID:gi163630; PIDN:AAA30740.1; I

C:Superfamily: prolactin

Query Match 6.9%; Score 86; DB 2; Length 238;

Best Local Similarity 24.3%; Pred. No. 2.5;

Matches 36; Conservative 19; Mismatches 59; Indels 34; Gaps 7;

QY 72 SYMQSVWT---EESQCTLL-----NASITFNCSFGPCDWKLSQYPCLOVYVNLTS 123

DB 6 SFRGHQWTVNVRGSCLLLLVSNLLICQGISCP-SCGPDMFVLSQKSLIDVFNAAASL 64

QY 124 GKLLLYHTEETIKNQKSYIPKCGKNFESMSLVVNVNMFNFRKYQHFSYSDPEGNQK 183

DB 65 SHD---FHNLSITMFNE-----FDEKYAQGLYINATKSCHTNSFHTPEERDK 110

QY 184 SV-----ILTKLYS-SNVLFHSL 200

DB 111 AQOMNEDLSKWTLLVLYSWNPLIYLL 138

RESULT 12

F87793

protein C27A12.6 [imported] - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C>Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 09-Jul-2004

C:Accession: F87793

R:Anonymous, The C. elegans Sequencing Consortium.

Science 282, 2012-2018, 1998

A:Title: Genome sequence of the nematode C. elegans: a platform for investigating biology

A:Reference number: A75000; MUID:99069613; PMID:9851916

A>Note: see websites genome.wustl.edu/gsc/C_elegans/ and www.sanger.ac.uk/Projects/C_elegans

A:Accession: F87793

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-491 <STO>

A:Cross-references: UNIPROT:O01963; GB:chr_I; PIDN:AA9393643.1; PID:g2105478; GSPDB:GN000

C:Genetics:

A:Gene: C27A12.6

A:Map position: 1

Query Match 6.9%; Score 85.5; DB 2; Length 491;

Best Local Similarity 18.5%; Pred. No. 6.3;

Matches 36; Conservative 37; Mismatches 57; Indels 65; Gaps 9;

QY 14 RHDEKRNYY-----QKIRDHLL--DKRKTVTALKAGEDRAILLGLAMWCSIMMY-- 62

DB 32 RHDSQASDYLNNKDKNEVLNHDLSLEAMKKAISEVA-----VLQVKTGVCRILLHKY 85

Qy 63 -----FLGILTLRSYMQSVWTEESQCTLLNASITET--FNCSPSC 101
Db 86 KWNKESLLERYEHPDTIAFLDAQVIPROCEVIPAAGDAEDIC-CSDMDELSGLSCNHR 144
Qy 102 GPDCWKL-----SQVPCLVVYVNLTSGEKLLYHTBET-----IK 137
Db 145 CAECQWYLTNKKVSDQSIQECWAPNCKLLIEDKVLVSIQFTWYKRYKRLWVASYVE 204
Qy 138 INQKCSYIP--KCK 150
Db 205 INCLLRWCPGDCGK 219
RESULT 13
S24451
hypothetical protein - phage SPPI
C:Species: phage SPPI
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
C:Accession: S24451; T42263
R:Chai, S.; Bravo, A.; Lueder, G.; Nedlin, A.; Trautner, T.A.; Alonso, J.C.
J. Mol. Biol. 224, 87-102, 1992
A:Title: Molecular analysis of the Bacillus subtilis bacteriophage SPPI region encompass
A:Reference number: S24450; MUID:92194332; PMID:1548711
A:Accession: S24451
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-422 <CHA>
A:Cross-references: UNIPROT:P54308; EMBL:X56064; NID:gl5464; PIDN:CAA39537.1; PID:gl5466
R:Alonso, J.C.; Luder, G.; Stiege, A.C.; Chai, S.; Weise, F.; Trautner, T.A.
Gene 204, 201-212, 1997
A:Title: The complete nucleotide sequence and functional organization of Bacillus subtil
A:Reference number: T22137; MUID:98094274; PMID:9434185
A:Accession: T42263
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-422 <ALO>
A:Cross-references: EMBL:X97918; PIDN:CAA66573.1
Query Match 6.8%; Score 84.5; DB 2; Length 422;
Best Local Similarity 23.1%; Pred. No. 6.6;
Matches 48; Conservative 29; Mismatches 90; Indels 41; Gaps 9;
Qy 17 EKRNHYKIRHDLKRVKIVTA-----LKAGEDRAILLGLAMVCSIMYFLGIL 69
Db 2 KKVLSKFTPH-FLEVNRITVKAQHLKYVLKGRGSAKSTHAMWTLILMMWPIIFLV 60
Qy 70 LRSYMQSVWTEESQCTLLNASITETFCSPSCGPDCKWLSQYPCLVVYVNLTSGEKLL 129
Db 61 IRRVYNTV--EQSVPEQLKEAID-----MLEVG-HLWKVSKSPRLTYI---PRGNSIIP 109
Qy 130 YHTEETKINQ-KCSYIPKCKNFER-----SMGLVNVVWVNFPRKYQHFSY 175
Db 110 RGGDDVQKIKSAKSPVAGMWTEELAEFKTEBEVSIVIEKSVLRALPFCRCYIPFYSY 169
Qy 176 SDPEGNOKSVILTKLYSSNVLFHSLFWP 203
Db 170 NPPRKQSWV-----NKVFNSSFLP 189
RESULT 14
C35997
MHC class I histocompatibility antigen HLA-B*37 alpha chain precursor - human
C:Species: Homo sapiens (man)
C:Date: 16-Nov-1990 #sequence_revision 13-Jan-1993 #text_change 09-Jul-2004
C:Accession: C35997
R:Ennis, P.D.; Zemmour, J.; Salter, R.D.; Parham, P.
Proc. Natl. Acad. Sci. U.S.A. 87, 2833-2837, 1990
A:Title: Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency
A:Reference number: A35997; MUID:90207291; PMID:2320591
A:Accession: C35997
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-362 <ENN>

A:Cross-references: UNIPROT:P18463; GB:M32320; NID:gl87792; PIDN:AAA36233.1; PID:g307224
C:Genetics:
A:Gene: GDB:HLA-B
A:Cross-references: GDB:120048; OMIM:142830
A:Map position: 6p21.3-6p21.3
C:Superfamily: class I histocompatibility antigen; immunoglobulin homology
C:Keywords: transmembrane protein
F:220-285/Domain: immunoglobulin homology <IMV>
Query Match 6.8%; Score 84; DB 2; Length 362;
Best Local Similarity 21.3%; Pred. No. 6.2;
Matches 50; Conservative 37; Mismatches 89; Indels 60; Gaps 11;
Qy 1 MSITSGRTSSSYRHDEKRNIVQKIRHDLKRVKIVTALKAGEDRAILLGLAMVCSIM 60
Db 154 LSSWTAADTAQ-----ITQRWEAREAEQRAYLEG-----TC--- 188
Qy 61 MYFLIGITLRSYMQSVWTEESQCTLLNASITETFCSPSCGPD-----CWKLSYPCLO 115
Db 189 -----VEWLRRL-----ENGETLQRADPPKTHVTHHPISDHEATLRCWALGFYPA-E 236
Qy 116 VYVNLTSSEKLLYHTETIKINOKSVIPKCGNFEESMLNVVWVNFPRKYQHFSY 175
Db 237 IILTWRDGED-----QTQTELVETR-----PAGDTRFKWAAVVVPSGEE-----QRYTCH 284
Qy 176 SDPEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLYOYL-SLICER 229
Db 285 VQHEGLPKPLTLRWEPSSQSTI-----PIVGIVAGLAVLVVIGAVVATVCMCR 334
RESULT 15
I38421
gene HLA B-1519 protein - human
C:Species: Homo sapiens (man)
C:Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 09-Jul-2004
C:Accession: I38421
R:Hildebrand, W.H.; Domene, J.D.; Shen, S.Y.; Lau, M.; Terasaki, P.I.; Bunce, M.; Marsh,
Tissue Antigens 43, 209-218, 1994
A:Title: HLA-B*15: a widespread and diverse family of HLA-B alleles.
A:Reference number: I38421; MUID:94367483; PMID:7521976
A:Accession: I38421
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-362 <RES>
A:Cross-references: UNIPROT:P30464; EMBL:U03027; NID:g413769; PIDN:AAA18902.1; PID:g4137
C:Genetics:
A:Gene: HLA-B-1519
C:Superfamily: class I histocompatibility antigen; immunoglobulin homology
F:220-285/Domain: immunoglobulin homology <IMV>

Query Match 6.7%; Score 83; DB 2; Length 362;
Best Local Similarity 20.9%; Pred. No. 7.6;
Matches 49; Conservative 39; Mismatches 87; Indels 60; Gaps 10;
Qy 1 MSITSGRTSSSYRHDEKRNIVQKIRHDLKRVKIVTALKAGEDRAILLGLAMVCSIM 60
Db 154 LSSWTAADTAQ-----ITQRWEAREAEQRAYLEG----- 188
Qy 61 MYFLIGITLRSYMQSVWTEESQCTLLNASITETFCSPSCGPD-----CWKLSYPCLO 115
Db 189 -----VDGLRRL-----ENGETLQRADPPKTHVTHHPISDHEATLRCWALGFYPA-E 236
Qy 116 VYVNLTSSEKLLYHTETIKINOKSVIPKCGNFEESMLNVVWVNFPRKYQHFSY 175
Db 237 IILTWRDGED-----QTQTELVETR-----PAGDTRFKWAAVVVLSGEE-----QRYTCH 284
Qy 176 SDPEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLYOYL-SLICER 229
Db 285 VQHEGLPKPLTLRWEPSSQSTI-----PIVGIVAGLAVLVVIGAVVATVCMCR 334

Search completed: November 6, 2004, 23:32:42
Job time : 20 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 23:22:16 ; Search time 65 Seconds
(without alignments)
1296.944 Million cell updates/sec

Title: US-09-914-053A-5
Perfect score: 1241
Sequence: 1 MSINSGRTSSSYRDEKKN.....MVKLTQYLSLLCERIQINR 235

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_23Sep04:.*
1: Genesecp1980s:.*
2: Genesecp1990s:.*
3: Genesecp2000s:.*
4: Genesecp2001s:.*
5: Genesecp2002s:.*
6: Genesecp2003as:.*
7: Genesecp2003bs:.*
8: Genesecp2004s:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1241	100.0	235	3	AAB08820 Amino aci
2	1235	99.5	235	4	AAB35301 Human cal
3	1228	99.0	235	3	AAY70466 Human mem
4	971	78.2	182	6	ADA56755 Human sec
5	971	78.2	182	6	ADA40606 Human sec
6	971	78.2	183	3	AAY91460 Human sec
7	971	78.2	183	8	ADL71532 Novel hum
8	886	71.4	165	3	AAY91601 Human sec
9	886	71.4	165	8	ADL71677 Novel hum
10	484	39.0	137	4	ABBI2189 Human K c
11	478.5	38.6	277	4	AAB35302 Human cal
12	477.5	38.5	277	4	AAM78995 Human Ca-
13	477.5	38.5	301	4	ABB11970 Human pro
14	477.5	38.5	301	4	AAM79979 Human pro
15	475	38.3	275	4	AAB35304 Human cal
16	474	38.2	257	3	AAB08818 Amino aci
17	474	38.2	257	4	AAB35303 Human cal
18	474	38.2	279	4	AAB35305 Human cal
19	435.5	35.1	220	2	AAY34131 Human pot
20	421	33.9	190	7	ADE54752 Human pro
21	421	33.9	191	2	AAR85305 Human cal
22	421	33.9	191	5	ABP33982 Human Max
23	421	33.9	191	5	ABJ10903 K-beta M6
24	421	33.9	191	5	ABP51818 Human Max
25	421	33.9	191	5	ADJ33391 Human Max

26	421	33.9	191	7	ADD14147	Ad14147 Human src
27	418	33.7	191	7	ADE54750	Ad54750 Rat Prote
28	382	30.8	191	2	AAR85305	Aar85305 Bovine ca
29	352	28.4	202	4	AAM96297	Aam96297 Human rep
30	318	25.6	218	3	AAB41606	Aab41606 Human ORF
31	317	25.5	210	7	ADJ69109	Adj69109 Human hea
32	316	25.5	210	2	AAY21839	Aay21839 Human cal
33	316	25.5	210	3	AAY77561	Aay77561 Human pot
34	316	25.5	210	3	AAB08819	Aab08819 Amino aci
35	177	14.3	85	3	AAG03607	Aag03607 Human sec
36	125	10.1	928	4	ABG13226	Abg13226 Novel hum
37	125	10.1	928	4	ABG13406	Abg13406 Novel hum
38	125	10.1	928	4	ABG18125	Abg18125 Novel hum
39	120.5	9.7	185	2	AAY07968	Aay07968 Human sec
40	93.5	7.5	495	8	ADQ08798	Adq08798 Ciona int
41	92	7.4	897	6	ABU40481	Abu40481 Protein e
42	92	7.4	897	7	ADF03964	Adf03964 Bacterial
43	91.5	7.4	448	4	ABB67183	Abb67183 Drosophil
44	91	7.3	347	4	AAM41242	Aam41242 Human pol
45	91	7.3	807	8	ADJ66497	Adj66497 KIAA0792

ALIGNMENTS

RESULT 1
AAB08820
ID AAB08820 standard; protein; 235 AA.
XX
AC AAB08820;
XX
XX 02-JAN-2001 (first entry)
DT
DE Amino acid sequence of a human BK beta-4 polypeptide.
XX
KW Human; BK beta-2; beta subunit; Slo potassium channel; BK beta-3;
KW BK beta-4; ion flux; migraine; hearing; vision problem; seizure; stroke;
KW asthma; cell proliferation; hormone secretion; cancer; viral infection.
XX
OS Homo sapiens.
XX
EH Key Location/Qualifiers
FT Misc-difference 230
FT /note= "encoded by CA"
XX
PN WO200050444-A1.
XX
XX 31-AUG-2000.
XX
XX 22-FEB-2000; 200CWO-US004441.
XX
XX 23-FEB-1999; 99US-0121224P.
PR 03-NOV-1999; 99US-0163367P.
XX
XX (ICAG-) ICAGEN INC.
XX
XX Jegla TJ, Wickenden A, Liu Y;
PI WPI; 2000-533179/48.
XX
XX N-PSDB; AAA75011.
XX
XX Isolated beta subunit polynucleotides and polypeptides of Slo potassium channels are used to determine the effects of compounds on ion flux through a potassium channel and in computer modelling systems.
PT
PT Claim 17; Page 79; 84pp; English.
XX
XX The present sequence represents a human BK beta-4 polypeptide. The polypeptide is a beta subunit of a Slo potassium channel. The specification also describes BK beta-3 and BK beta-2 polypeptides. BK beta subunits are auxiliary subunits or monomers of Slo potassium channels. The polypeptides, when expressed in cells and cell membranes, are used to determine the effects of compounds on ion flux through a

CC potassium channel. The compounds identified may be useful as therapeutic
 CC agents e.g. modulators that target specific S10 channels are useful for
 CC treating migraines, hearing and vision problems, seizures, stroke,
 CC asthma, cell proliferation and hormone secretion. The computer generated
 CC 3-dimensional structures of BK beta 2, BK beta 3 or BK beta 4 are used to
 CC identify ligands that bind to the beta subunit. The characterized BK beta
 CC subunits are used to determine how S10 potassium channels function in
 CC different environments and how they respond to different activation
 CC mechanisms. The polynucleotides are used to transfect cells in vivo and
 CC in vitro to mitigate effects of absent, partial inactivation or abnormal
 CC expression of the BK beta subunit gene e.g. to correct genetic defects,
 CC cancer and viral infection
 XX
 SQ

Sequence 235 AA;

Query Match 100.0%; Score 1241; DB 3; Length 235;
 Best Local Similarity 100.0%; Pred. No. 3.9e-129;
 Matches 235; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 60
 DB 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 60
 QY 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120
 DB 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120
 QY 121 TSSGEKLLLYHTEETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDEP 180
 DB 121 TSSGEKLLLYHTEETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDEP 180
 QY 181 NOKSVILTKLYSSNVLFHSLFWPTCMWAGGVAIVAMVKLTQYLSLLCERIQINR 235
 DB 181 NOKSVILTKLYSSNVLFHSLFWPTCMWAGGVAIVAMVKLTQYLSLLCERIQINR 235

RESULT 2

AAB35301
 ID AAB35301 standard; protein; 235 AA.

AC AAB35301;

XX 08-MAY-2001 (first entry)

DE Human calcium sensitive potassium channel beta2 subunit.

XX Human; calcium sensitive potassium channel; beta2 subunit; asthma;

KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;
 KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;
 KW irritable bowel syndrome; Alzheimer's disease.

XX Homo sapiens.

XX WO200105828-A1.

PN 25-JAN-2001.

XX 18-JUL-2000; 2000WO-US019585.

XX 20-JUL-1999; 99US-0144764P.

XX (MERI) MERCK & CO INC.

XX Uebele V, Swanson R, Liu Y, Lagrutta A;

XX WPI; 2001-159514/16.

XX N-PSDB; AAF27991.

XX Novel human calcium sensitive potassium channel subunits for identifying
 PT inhibitors and agonists of the potassium channel for use in treating
 PT conditions such as asthma, hypertension, memory disorders, depression.
 XX
 PS Claim 9; Fig 1B; 89pp; English.

XX The present invention provides the protein and coding sequences of the
 CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c
 CC and beta3d subunits. These can be used to identify inhibitors and
 CC activators of the channels, which can be used in the treatment of
 CC conditions including asthma, diabetes, glaucoma, cerebral ischemia,
 CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,
 CC incontinence, migraine and irritable bowel syndrome. The coding sequences
 CC are found at human chromosome 3q23-ter. The present sequence is the beta2
 CC subunit
 XX
 SQ

Sequence 235 AA;

Query Match 99.5%; Score 1235; DB 4; Length 235;
 Best Local Similarity 99.6%; Pred. No. 1.8e-128;
 Matches 234; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 60
 DB 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 60
 QY 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120
 DB 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120
 QY 121 TSSGEKLLLYHTEETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDEP 180
 DB 121 TSSGEKLLLYHTEETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDEP 180
 QY 181 NOKSVILTKLYSSNVLFHSLFWPTCMWAGGVAIVAMVKLTQYLSLLCERIQINR 235
 DB 181 NOKSVILTKLYSSNVLFHSLFWPTCMWAGGVAIVAMVKLTQYLSLLCERIQINR 235

RESULT 3

AAY70466
 ID AAY70466 standard; protein; 235 AA.

XX AAY70466;

XX 21-JUN-2000 (first entry)

DE Human membrane channel protein-16 (MECHP-16).

XX Membrane channel protein-16; MECHP-16; diagnosis; treatment; lymphoma;
 KW cell proliferative disorder; bursitis; atherosclerosis; cancer; sarcoma;
 KW inflammatory disorder; AIDS; Addison's disease; cystic fibrosis; asthma;
 KW diabetes mellitus; osmoregulatory disorder; diarrhoea; renal failure;
 KW muscular disorder; myocarditis; Duchenne's muscular dystrophy; nontropic;
 KW cardiovascular disorder; hypertension; bronchitis; vasculitis; cardiac;
 KW neurological disorder; Alzheimer's disease; Parkinson's disease; human;
 KW Huntington's disease; antiarteriosclerotic; hepatotropic; cytostatic;
 KW anti-HIV; antianaemic; neuroprotective; immunomodulator; antidiabetic;
 KW hypotensive; vasotropic; antiasthmatic; antiinflammatory; antidepressant;
 KW anticonvulsant; thrombolytic; antiParkinsonian; immunostimulant.

XX Homo sapiens.

XX Location/Qualifiers

FT Modified-site 6 /note= "Phosphorylation site"

FT Modified-site 12 /note= "Phosphorylation site"

FT Modified-site 36 /note= "Phosphorylation site"

FT Domain 48..68 /label= Transmembrane_domain

FT Modified-site 88 /note= "Glycosylation site"

FT Modified-site 90 /note= "Phosphorylation site"

FT Modified-site 96 /note= "Glycosylation site"

FT Modified-site 119 /note= "Glycosylation site"
FT Modified-site 122 /note= "Phosphorylation site"
FT Modified-site 135 /note= "Phosphorylation site"
FT Modified-site 176 /note= "Phosphorylation site"
FT Modified-site 176 /note= "Phosphorylation site"

XX WO200012711-A2.

XX 09-MAR-2000.

XX 02-SEP-1999; 99WO-US020468.

XX 02-SEP-1998; 98US-0155226P.

XX 13-NOV-1998; 98US-00191283.

XX 09-DEC-1998; 98US-0155225P.

XX 26-JAN-1999; 99US-0155211P.

XX 10-FEB-1999; 99US-0155263P.

XX (INCY-) INCYTE PHARM INC.

XX Au-Young J, Bandman O, Tang YT, Reddy R, Hillman JL, Yue H;
PI Lal P, Corley NC, Guegler KJ, Gorgone G, Baughn MR, Azimzai Y;

XX WPI; 2000-256643/22.

XX N-PSDB; AAZ51632.

XX Novel human membrane channel protein and polynucleotide useful for
PT diagnosing and treating cell proliferative, inflammatory, secretory,
PT osmoregulatory, muscular, cardiovascular and neurological disorders.

XX Claim 1; Page 115; 140pp; English.

XX The present sequence is the human membrane channel protein-16 (MECHP-16),
CC which is expressed in nervous tissues. Anti-MECHP antibodies can be used
CC as therapeutic antagonists and reagents for diagnosis and monitoring
CC diseases. MECHP cDNA can be used for diagnosis of MECHP-related diseases
CC and gene mapping. MECHP can be used for treatment of cell proliferative
CC disorders such as bursitis and atherosclerosis, cancers like lymphoma and
CC sarcoma, inflammatory disorders like AIDS and Addison's disease,
CC osmoregulatory disorders like cystic fibrosis and diabetes mellitus,
CC transport/secretory disorders like diarrhoea and renal failure, muscular
CC disorders like myocarditis and Duchenne's muscular dystrophy,
CC cardiovascular disorders like hypertension and vasculitis, congenital
CC lung anomalies like bronchitis and asthma and neurological disorders like
CC Alzheimer's disease, Parkinson's disease and Huntington's disease

XX SQ Sequence 235 AA;

Query Match 99.0%; Score 1228; DB 3; Length 235;
Best Local Similarity 99.1%; Pred. No. 1.1e-127;
Matches 233; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 MSIIWTSRTSSVYHDEKRNIIQKIRHDLDDKRTVTKAGEDRAILLGLAMVCSIM 60

Db 1 MFIWTSRTSSVYHDEKRNIIQKIRHDLDDKRTVTKAGEDRAILLGLAMVCSIM 60

Qy 61 MYFLGLITLLRSYMQSVWTEESQCTLLNASITETFNCSFGCGPDCWKLSQYPCQVYVNL 120

Db 61 MYFLGLITLLRSYMQSVWTEESQCTLLNASITETFNCSFGCGPDCWKLSQYPCQVYVNL 120

Qy 121 TSSGEKLLVHTETIKINQKCSYIPKCGKNFEESMLNVNMFNPKYQHFSCYSDPEG 180

Db 121 TSSGEKLLVHTETIKINQKCSYIPKCGKNFEESMLNVNMFNPKYQHFSCYSDPEG 180

Qy 181 NQKSVILTKLYSSNVLFHSLFPWPCMMAGGVAIVAVWKLQYLSLLCERIQINR 235

Db 181 NQKSVILTKLYSSNVLFHSLFPWPCMMAGGVAIVAVWKLQYLSLLCERIQINR 235

RESULT 4

ADA56755
ID ADA56755 standard; protein; 182 AA.
XX
AC ADA56755;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted protein #37.
XX
KW immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;
KW cytosolic; cerebroprotective; neuroprotective; neurotropic;
KW cardiovascular; antiarteriosclerotic; gene therapy;
KW human secreted protein; immune disorder; inflammation;
KW respiratory disorder; cancer; CNS disorder; neurodegenerative disorders;
KW inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;
KW multiple sclerosis; ischaemic brain injury; Parkinson's disease;
KW Alzheimer's disease; atherosclerosis; myocarditis; chromosome mapping;
KW triple helix formation; antisense gene therapy; forensic biology.
OS Homo sapiens.
XX
FN WO2002102994-A2.
XX
PD 27-DEC-2002.
XX
PF 19-MAR-2002; 2002WO-US008278.
XX
PR 21-MAR-2001; 2001US-0277340P.
PR 19-JUL-2001; 2001US-0306171P.
PR 13-NOV-2001; 2001US-0331287P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PI Rosen CA, Ruben SM;
XX
XX WPI; 2003-167512/16.
DR N-PSDB; ADA55858.
XX
PT New human secreted polypeptides and polynucleotides, useful for
PT diagnosing, treating or preventing e.g. immune disorders, inflammatory
PT conditions, respiratory disorders, cancers, CNS disorders, or
PT neurodegenerative disorders.
XX
PS Claim 13; SEQ ID NO 944; 1754pp; English.
XX
CC The invention relates to 592 new human secreted polypeptides useful for
CC diagnosing, treating or preventing e.g. immune disorders, inflammatory
CC conditions, respiratory disorders, cancers, CNS disorders, or
CC neurodegenerative disorders, or polypeptides comprising an amino acid
CC sequence at least 95% identical to the new sequences. The polypeptides,
CC antibodies or antibody fragments that bind to the polypeptides, nucleic
CC acids encoding the polypeptides, agonists or antagonists that binds to
CC the polypeptide, are useful in preparing diagnostic or pharmaceutical
CC compositions for diagnosing, treating or preventing an e.g. immune
CC disorders, inflammatory conditions (e.g. inflammatory bowel disease,
CC nephritis or Crohn's disease), respiratory disorders (e.g. asthma and
CC allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders
CC (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative
CC disorders (e.g. Parkinson's disease or Alzheimer's disease), and
CC cardiovascular disorders (e.g. atherosclerosis or myocarditis). The
CC polynucleotides are useful for chromosome identification, chromosome
CC mapping, for controlling gene expression through triple helix formation
CC or antisense DNA or RNA, in gene therapy, for identifying individuals
CC from minute biological samples, in forensic biology, and as hybridization
CC probes. The polypeptides are useful for as molecular weight markers on
CC sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
CC gels, to raise antibodies, for testing biological activities, and for
CC treating or preventing neural disorders, immune system disorders,
CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
CC renal, proliferative and/or cancerous diseases. This sequence data for
CC to one of the polypeptide of the invention. Note: The sequence data for
CC this patent did form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 182 AA;
 SQ

Query Match 78.2%; Score 971; DB 6; Length 182;
 Best Local Similarity 100.0%; Pred. No. 2.9e-99;
 Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 MMVCSIMMYFLGILITLLRSYQSWVTEESQCTLLNASITETFNCSFGCPDCWKLSQYPC 113
 DB 1 MMVCSIMMYFLGILITLLRSYQSWVTEESQCTLLNASITETFNCSFGCPDCWKLSQYPC 60
 QY 114 LOVYVNLTSSEKLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHFS 173
 DB 61 LOVYVNLTSSEKLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHFS 120
 QY 174 CYSDEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 233
 DB 121 CYSDEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 180
 QY 234 NR 235
 DB 181 NR 182

RESULT 5
 ADA40606
 ID ADA40606 standard; protein; 182 AA.
 AC ADA40606;
 XX
 XX 20-NOV-2003 (first entry)
 XX Human secreted protein.
 DE
 DE Human; secreted protein; cancer; hyperproliferative disorder;
 KW rheumatoid arthritis; autoimmune disease; haematopoietic disorder;
 KW anaemia; allergic reaction; asthma; cardiovascular disease;
 KW wound healing; cytostatic; immunosuppressive; neutropenic; antidiabetic;
 KW antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory;
 KW vulnary; cardiant; gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX WO2002102993-A2.
 XX
 XX 27-DEC-2002.
 XX
 XX 19-MAR-2002; 2002WO-US008123.
 XX
 XX 21-MAR-2001; 2001US-0277340P.
 XX
 XX 19-JUL-2001; 2001US-0306171P.
 XX
 XX 13-NOV-2001; 2001US-0331287P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Rosen CA, Ruben SM;
 XX
 XX WPI; 2003-175238/17.
 XX
 XX New human secreted proteins and nucleic acid molecules, useful for
 PT preparing a diagnostic or pharmaceutical composition for diagnosing,
 PT preventing or treating cancer or other hyperproliferative disorder,
 PT asthma, allergies or AIDS.
 XX
 XX Claim 1; SEQ ID NO 988; 3205pp; English.
 XX
 XX The invention relates to novel genes ADA39629-ADA40565 and proteins
 CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,
 CC treating or ameliorating medical conditions e.g. by protein or gene
 CC therapy. The polypeptides, nucleic acid molecules, antibodies or their
 CC fragments, and agonists or antagonists that bind to the polypeptide are
 CC useful for preparing a diagnostic or pharmaceutical composition for

CC diagnosing or treating cancer or other hyperproliferative disorder. The
 CC polypeptides and nucleic acid molecules are also useful for detecting,
 CC preventing, diagnosing, prognosticating, treating or ameliorating cancer
 CC or other hyperproliferative disorders including neoplasms, autoimmune
 CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus
 CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haematolytic
 CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,
 CC thrombocytopenia), allergic reactions including asthma or eczema,
 CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory
 CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.
 CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders
 CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,
 CC fungal or viral infections including HIV/AIDS), or wound healing and
 CC disorders of epithelial cell proliferation. The nucleic acids are also
 CC useful for chromosome identification, radiation hybrid mapping or long-
 CC range restriction mapping, as molecular weight markers, or as
 CC hybridization or diagnostic probes. The polypeptides and antibodies are
 CC useful for providing immunological probes for differential identification
 CC of the tissues immunohistochemistry assays. Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 XX Sequence 182 AA;
 SQ

Query Match 78.2%; Score 971; DB 6; Length 182;
 Best Local Similarity 100.0%; Pred. No. 2.9e-99;
 Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 MMVCSIMMYFLGILITLLRSYQSWVTEESQCTLLNASITETFNCSFGCPDCWKLSQYPC 113
 DB 1 MMVCSIMMYFLGILITLLRSYQSWVTEESQCTLLNASITETFNCSFGCPDCWKLSQYPC 60
 QY 114 LOVYVNLTSSEKLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHFS 173
 DB 61 LOVYVNLTSSEKLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHFS 120
 QY 174 CYSDEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 233
 DB 121 CYSDEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 180
 QY 234 NR 235
 DB 181 NR 182

RESULT 6
 AAY91460
 ID AAY91460 standard; protein; 183 AA.
 XX
 XX AAY91460;
 XX
 XX 29-JUN-2000 (first entry)
 XX Human secreted protein sequence encoded by gene 10 SEQ ID NO:133.
 XX
 XX Human; secreted protein; diagnosis; cytostatic; immunosuppressive;
 KW antiHIV; antiinflammatory; neutropenic; neuroprotective; antiallergic;
 KW osteopathic; antiallergic; antibacterial; antidiabetic; antiasthma;
 KW antipsoriatic; cardiant; gene therapy; cancer; neurological disorder;
 KW immune disease; inflammation; blood disorder; tumour.
 XX
 OS Homo sapiens.
 XX
 XX WO200006598-A1.
 XX
 XX 10-FEB-2000.
 XX
 XX 29-JUL-1999; 99WO-US017130.
 XX
 XX 30-JUL-1998; 98US-0094657P.
 XX
 XX 05-AUG-1998; 98US-0095486P.
 XX
 XX 06-AUG-1998; 98US-0095454P.

PR 06-AUG-1998; 98US-0095455P.
PR 12-AUG-1998; 98US-0096319P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Komatsoulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y;
PI Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA;
PI Soppet DR, Endress GA, Ebner R, Olsen HS, Mucenski M;
XX WPI; 2000-195282/17.
DR N-PSDB; AAA26355.
XX New isolated human genes and the secreted polypeptides they encode,
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX Claim 11; Page 463; 634pp; English.
XX The polynucleotide sequences given in AAA26346 to AAA26458 encode the
CC human secreted proteins given in AAY91451 to AAY91691. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic;
CC immunosuppressive; antiHIV; antiinflammatory; neurotropic; neuroprotective;
CC antiasthmatic; osteopathic; antiarthritic; antibacterial; antidiabetic;
CC antiallergic; antipsoriatic; and cardiant. The polynucleotides and their
CC corresponding secreted proteins are useful for preventing, treating or
CC ameliorating medical conditions, e.g. by protein or gene therapy. Also
CC pathological conditions can be diagnosed by determining the amount of the
CC proteins in a sample or by determining the presence of mutations in the
CC polynucleotides. Specific uses are described for each of the
CC polynucleotides, based on which tissues they are most highly expressed
CC in, and include developing products for the diagnosis or treatment of
CC cancer, tumours, neurodegenerative disorders, developmental abnormalities
CC and foetal deficiencies, blood disorders, diseases of the immune system,
CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,
CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,
CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,
CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,
CC reproductive disorders, gastrointestinal disorders, respiratory disorders
CC and metabolic disorders. The proteins or polynucleotides can also be used
CC as food additives or preservatives. The proteins are also useful for
CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are
CC sequences used in the exemplification of the present invention
XX Sequence 183 AA;
QY Query Match 75.2%; Score 971; DB 3; Length 183;
Best Local Similarity 100.0%; Pred. No. 2.9e-99;
Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
54 MMVCSIMMYFLGTLILRSYQSVWTEESQTLINASITETFCSCGPDCKWLSQYPC 113
1 MMVCSIMMYFLGTLILRSYQSVWTEESQTLINASITETFCSCGPDCKWLSQYPC 60
114 LQVYVNLTSSEKLLLYHTETIKINQCSYIPKCGKNFESMSLVNVMNFRKYQHS 173
61 LQVYVNLTSSEKLLLYHTETIKINQCSYIPKCGKNFESMSLVNVMNFRKYQHS 120
174 CYSPEGNQKSVILTKYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLCERTQRI 233
121 CYSPEGNQKSVILTKYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLCERTQRI 180
234 NR 235
181 NR 182
RESULT 7
ADL71532
ID ADL71532 standard; protein; 183 AA.
XX AC ADL71532;
XX

DT 20-MAY-2004 (first entry)
XX Novel human secreted protein seqid 136.
DE
XX
KW antinflammatory; neuroprotective; neurotropic; antiparkinsonian;
KW anticonvulsant; antilipemic; CNS; gynaecological; antiarthritic;
KW antiasthmatic; anti-HIV; virucide; endocrine; cytostatic;
KW immunosuppressive; antiasthmatic; cardiovascular; respiratory;
KW dermatological; antimicrobial; gastrointestinal; gene therapy;
KW neurodegenerative disease; behavioral disorder; inflammatory condition;
KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;
KW Huntington's disease; metabolic disorder; Tay-Sach's disease;
KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;
KW arthritis; asthma; AIDS; endocrine disorder; immune disorder;
KW Hodgkin's lymphoma; haematopoietic disorder; muscular disorder;
KW leukaemia; autoimmune disorder; allergy; cancer; cardiovascular disorder;
KW respiratory disorder; pulmonary disorder; connective tissue disorder;
KW skin disorder; CNS disorder; congenital disorder; infectious disorder;
KW gastrointestinal disorder; human; secreted protein.
XX Homo sapiens.
XX US2004034196-A1.
XX 19-FEB-2004.
XX 27-JAN-2003; 2003US-00351334.
XX 30-JUL-1998; 98US-0094657P.
PR 05-AUG-1998; 98US-0095486P.
PR 06-AUG-1998; 98US-0095454P.
PR 06-AUG-1998; 98US-0095455P.
PR 12-AUG-1998; 98US-0096319P.
PR 29-JUL-1999; 99WO-05017130.
PR 24-JAN-2000; 2000US-00489847.
PR 25-JAN-2002; 2002US-0350898P.
XX (KOMA/) KOMATSOUKIS G A.
PA (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (DUAN/) DUAN D R.
PA (MOOR/) MOORE P A.
PA (SHI/) SHI Y.
PA (LAFLE/) LAFLEUR D W.
PA (WEI/) WEI Y.
XX Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;
PI Lafleur DW, Wei Y;
XX WPI; 2004-180094/17.
DR N-PSDB; ADL71416.
XX New human secreted nucleic acid, useful for diagnosing and treating
PT neurodegenerative, inflammatory, hyperproliferative, metabolic, or
PT reproductive, cardiovascular, respiratory or immunological disorders or
XX diseases.
PS Claim 11; SEQ ID NO 136; 234pp; English.
XX The invention describes an isolated human nucleic acid molecule (I)
CC comprising a polynucleotide having a nucleotide sequence at least 95%
CC identical to: a sequence polynucleotide fragment of SEQ ID NO: X or of
CC the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable
CC to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or
CC epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA
CC sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID
CC NO: X, having a biological activity. The nucleic acids and polypeptides,
CC pharmaceutical formulations and kits are useful in diagnosing and
CC treating neurodegenerative diseases states, behavioral disorders,
CC inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's
CC disease, Parkinson's disease or Huntington's disease), metabolic
CC disorders (e.g. Tay-Sach's disease or Leash-Nyhan syndrome), reproductive
CC disorders, immunological disorders (e.g. arthritis, asthma or AIDS),

CC endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic
 CC or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy,
 CC cancer, cardiovascular, respiratory or pulmonary disorders, disorders or
 CC conditions affecting connective tissue, skin disorders, CNS disorders,
 CC congenital disorders, infectious disorders and gastrointestinal
 CC disorders. This is the amino acid sequence of a novel human secreted
 CC protein of the invention. Note: This sequence does not appear in the
 CC printed specification but is available in electronic format from the US
 CC patent office at ftp.segdata.uspto.gov/segdata.html?docID=20040034196.
 XX
 SQ Sequence 183 AA;

Query Match 78.2%; Score 971; DB 8; Length 183;
 Best Local Similarity 100.0%; Pred. No. 2.9e-99;
 Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 54 MMVCSIMYFLLIGITLLRSYMQSVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPC 113
 Db 1 MMVCSIMYFLLIGITLLRSYMQSVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPC 60
 QY 114 LOVYNLTSSGKLLYHTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 173
 Db 61 LOVYNLTSSGKLLYHTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 120
 QY 174 CYSDEPGNQKSVILTKLYSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORI 233
 Db 121 CYSDEPGNQKSVILTKLYSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORI 180
 QY 234 NR 235
 Db 181 NR 182

RESULT 8
 ID AAY91601
 AC AAY91601;
 DT 29-JUN-2000 (first entry)
 DE Human secreted protein sequence encoded by gene 10 SEQ ID NO:274.
 DE Human; secreted protein; diagnosis; cytostatic; immunosuppressive;
 KW antiHIV; antiinflammatory; nontropic; neuroprotective; antiarthritic;
 KW osteopathic; antiarthritic; antibacterial; antidiabetic; antiasthma;
 KW antipsoriatic; cardians; gene therapy; cancer; neurological disorder;
 KW immune disease; inflammation; blood disorder; tumour.
 OS Homo sapiens.
 XX WO200006698-A1.
 XX 10-FEB-2000.
 XX 29-JUL-1999; 99WO-US017130.
 XX 30-JUL-1998; 98US-0094657P.
 PR 05-AUG-1998; 98US-0095486P.
 PR 06-AUG-1998; 98US-0095454P.
 PR 06-AUG-1998; 98US-0095455P.
 PR 12-AUG-1998; 98US-0096319P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX Komatsulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y;
 PI Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA;
 PI Soppet DR, Endress GA, Ebner R, Olsen HS, Mucenski M;
 DR WFI; 2000-195282/17.
 XX New isolated human genes and the secreted polypeptides they encode,
 PT useful for diagnosis and treatment of e.g. cancers, neurological

PT disorders, immune diseases, inflammation or blood disorders.
 XX Disclosure; Page 29; 634pp; English.
 CC The polynucleotide sequences given in AA26346 to AAA26458 encode the
 CC human secreted proteins given in AAY91451 to AAY91691. The human secreted
 CC proteins can have activities based on the tissues and cells they are
 CC expressed in. Examples of the activities are: cytostatic;
 CC immunosuppressive; antiHIV; antiinflammatory; nontropic; neuroprotective;
 CC antiarthritic; osteopathic; antiasthma; antiarthritic; antibacterial; antidiabetic;
 CC antiasthma; antipsoriatic; and cardiant. The polynucleotides and their
 CC corresponding secreted proteins are useful for preventing, treating or
 CC ameliorating medical conditions, e.g. by protein or gene therapy. Also
 CC pathological conditions can be diagnosed by determining the amount of the
 CC proteins in a sample or by determining the presence of mutations in the
 CC polynucleotides. Specific uses are described for each of the
 CC polynucleotides, based on which tissues they are most highly expressed
 CC in, and include developing products for the diagnosis or treatment of
 CC cancer, tumour, neurodegenerative disorders, developmental abnormalities
 CC and foetal deficiencies, blood disorders, diseases of the immune system,
 CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,
 CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,
 CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,
 CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,
 CC reproductive disorders, gastrointestinal disorders, respiratory disorders
 CC and metabolic disorders. The proteins or polynucleotides can also be used
 CC as food additives or preservatives. The proteins are also useful for
 CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are
 CC sequences used in the exemplification of the present invention
 XX
 SQ Sequence 165 AA;

Query Match 71.4%; Score 886; DB 3; Length 165;
 Best Local Similarity 100.0%; Pred. No. 7.1e-90;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 71 RSYMQSVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPCLOVYNLTSSGKLLY 130
 Db 1 RSYMQSVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPCLOVYNLTSSGKLLY 60
 QY 131 HTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHSYDSEGNQKSVILTKL 190
 Db 61 HTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHSYDSEGNQKSVILTKL 120
 QY 191 YSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORINR 235
 Db 121 YSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORINR 165

RESULT 9
 ADL71677
 ID ADL71677 standard; protein; 165 AA.
 XX ADL71677;
 AC ADL71677;
 DT 20-MAY-2004 (first entry)
 DE Novel human secreted protein fragment seqid 281.
 DE antiinflammatory; neuroprotective; nontropic; antiparkinsonian;
 KW anticonvulsant; antilipemic; CNS; gynaecological; antiarthritic;
 KW antithrombotic; anti-HIV; virucide; endocrine; cytostatic;
 KW immunosuppressive; antiarthritic; cardiovascular; respiratory;
 KW dermatological; antimicrobial; gastrointestinal; gene therapy;
 KW neurodegenerative disease; behavioral disorder; inflammatory condition;
 KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; metabolic disorder; Tay-Sach's disease;
 KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;
 KW arthritis; asthma; AIDS; endocrine disorder; muscular disorder;
 KW Hodgkin's lymphoma; haematopoietic disorder; cancer; cardiovascular disorder;
 KW leukaemia; autoimmune disorder; allergy; cancer; connective tissue disorder;
 KW respiratory disorder; pulmonary disorder; congenital disorder; infectious disorder;
 KW skin disorder; CNS disorder; congenital disorder; infectious disorder;

KW gastrointestinal disorder; human; secreted protein.

OS Homo sapiens.

XX US2004034196-A1.

FN 19-FEB-2004.

XX 27-JAN-2003; 2003US-00351334.

XX 30-JUL-1998; 98US-0094657P.

PR 06-AUG-1998; 98US-0095486P.

PR 06-AUG-1998; 98US-0095454P.

PR 06-AUG-1998; 98US-0095455P.

PR 12-AUG-1998; 98US-0096319P.

PR 29-JUL-1999; 99WO-US017130.

PR 24-JAN-2000; 2000US-00489847.

PR 25-JAN-2002; 2002US-0350898P.

XX (KOMA/) KOMATSOULIS G A.

PA (ROSE/) ROSEN C A.

PA (ROBE/) RUBEN S M.

PA (DUAN/) DUAN D R.

PA (MOOR/) MOORE P A.

PA (SHIY/) SHI Y.

PA (LAFU/) LAFLEUR D W.

PA (WEIY/) WEI Y.

XX Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y; Lafleur DW, Wei Y; WPI; 2004-180094/17.

XX New human secreted nucleic acid, useful for diagnosing and treating neurodegenerative, inflammatory, hyperproliferative, metabolic, reproductive, cardiovascular, respiratory or immunological disorders or diseases.

PT Disclosure; SEQ ID NO 281; 234pp; English.

PS The invention describes an isolated human nucleic acid molecule (I) comprising a polynucleotide having a nucleotide sequence at least 95% identical to: a sequence polynucleotide fragment of SEQ ID NO: X or of the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID NO: X, having a biological activity. The nucleic acids and polypeptides, pharmaceutical formulations and kits are useful in diagnosing and treating neurodegenerative diseases states, behavioral disorders, inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's disease, Parkinson's disease or Huntington's disease), metabolic disorders (e.g. Tay-Sach's disease or Leash-Nyhan syndrome), reproductive disorders, immunological disorders (e.g. arthritis, asthma or AIDS), endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy, cancer, cardiovascular, respiratory or pulmonary disorders, disorders or conditions affecting connective tissue, skin disorders, CNS disorders, congenital disorders, infectious disorders and gastrointestinal disorders. This is the amino acid sequence of a novel human secreted protein fragment of the invention. Note: This sequence does not appear in the printed specification but is available in electronic format from the US patent office at ftp.segdata.uspto.gov/segdata.html?DocID=20040034196.

XX Sequence 165 AA;

SQ

Query Match 71.4%; Score 886; DB 8; Length 165;

Best Local Similarity 100.0%; Pred. No. 7.1e-90;

Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 RSYMQSVWTEBSQCTLLNASITETFNCSFGPCGDKWLSQVPCIQVYVNLTSSEKLLY 130

DB 1 RSYMQSVWTEBSQCTLLNASITETFNCSFGPCGDKWLSQVPCIQVYVNLTSSEKLLY 60

QY 131 HTEETIKINQKCSYIPKCGKNFEESMLVNVVNMENFRKYQHFCYSDEGKQSVILTKL 190

DB 61 HTEETIKINQKCSYIPKCGKNFEESMLVNVVNMENFRKYQHFCYSDEGKQSVILTKL 120

QY 131 YSSNVLPHSLFWPTCMAGGVAIVAMVKLTOYLSLLCERIQINR 235

DB 121 YSSNVLPHSLFWPTCMAGGVAIVAMVKLTOYLSLLCERIQINR 165

RESULT 10

ABB12189

ID ABB12189 standard; peptide; 137 AA.

XX ABB12189;

AC ABB12189;

XX 11-JAN-2002 (first entry)

DT Human K channel subunit homologue, SEQ ID NO:2559.

DE Human; cytokine; cell proliferation; cell differentiation; growth factor; haematopoiesis regulation; tissue growth; immunomodulator; activin; inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis; proliferation; metastasis; cancer; tumour; haematopoietic disorder; myeloid cell disorder; lymphoid cell disorder; asthma; arthritis; chronic inflammatory condition; proliferative retinopathy; atherosclerosis; coronary heart disease; arterial ischaemia; bone disorder; osteoporosis; vascular growth disorder; tissue regeneration; wound healing; infection; immune disorder; cell culture; drug screening; gene therapy; antiinflammatory; cell asthma; antiarthritic; haemostatic; antiinflammatory; cytostatic; osteopathic; vasotropic; cardiac; virucide; antibacterial; antifungal; vulnery; antiulcer.

XX Homo sapiens.

OS WO200157188-A2.

XX 09-AUG-2001.

PD 05-FEB-2001; 2001WO-US003800.

PF 03-FEB-2000; 2000US-00496914.

PR 27-APR-2000; 2000US-00560875.

XX (HYSE-) HYSEQ INC.

PA Tang YT, Liu C, Drmanac RT; WPI; 2001-457740/49.

PI N-PSDS; ABA09433.

XX Human proteins and DNA encoding sequences useful for preventing, treating or ameliorating a medical condition in a mammalian subject e.g. arthritis and cancer.

PT Claim 20; Page 314; 1963pp; English.

PS Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and sequences ABA08225-ABA09574 represent nucleic acids encoding them. The invention also relates to vectors and recombinant host cells comprising a nucleotide of the invention, methods of producing the novel polypeptides, antibodies against the polypeptides, methods of detecting the nucleotides or polypeptides in a sample, and methods of identifying compounds which bind to polypeptides of the invention. Although novel, many of the polypeptides of the invention have homology to known proteins, thereby giving an insight into their probable biological activities, and hence potential therapeutic applications. The polypeptides of the invention may have various activities including cytokine, cell proliferation or cell differentiation activities; stem cell growth factor activity; haematopoiesis regulatory activity; tissue growth activity; immunomodulatory activity; activin- or inhibin-related activities; chemotactic or chemokinetic activities; haemostatic, thrombotic or

CC thrombolytic activities; receptor or ligand activities; or may be
 CC involved in oncogenesis, cancer cell proliferation or metastasis.
 CC Depending on their biological activities, polypeptides and nucleotides of
 CC the invention are useful for preventing, treating or ameliorating medical
 CC conditions, e.g., by protein or gene therapy. Such conditions include
 CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell
 CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
 CC proliferative retinopathy, atherosclerosis, coronary heart disease,
 CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
 CC vascular growth. Polypeptides involved with tissue regeneration and
 CC repair (or nucleic acids encoding them) may be used to promote wound
 CC healing (e.g., of burns, incisions and ulcers), while those with
 CC immunomodulatory activities may be used in the treatment of viral,
 CC bacterial and fungal infections in addition to immune disorders.
 CC Polypeptides with growth factor activity may be used in cell cultures to
 CC promote cell growth. For example, such polypeptides may be used to
 CC manipulate stem cells in culture to give rise to neuroepithelial cells
 CC that can be used to augment or replace cells damaged by illness,
 CC autoimmune disease or accidental damage. The polypeptides and nucleotides
 CC may also be used in the diagnosis of the above conditions, and in drug
 CC screening techniques. The present sequence represents a novel human
 CC polypeptide of the invention
 XX
 SQ Sequence 137 AA;

Query Match 39.0%; Score 484; DB 4; Length 137;
 Best Local Similarity 96.9%; Pred. No. 2.8e-45;
 Matches 94; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1 MSIWTSSTSSYRDEKRNLYQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 60
 DB 41 MSIWTSSTSSYRDEKRNLYQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 100
 QY 61 MYFLIGITLLRSYMQSVWTESSQCTLLNASITETFC 97
 DB 101 MXFLIGITLLRSYMQSVWTESSQCTLLNASITETFC 137

RESULT 11
 AAB35302
 ID AAB35302 standard; protein; 277 AA.
 AC AAB35302;
 DT 08-MAY-2001 (first entry)
 DE Human calcium sensitive potassium channel beta3a subunit.
 KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;
 KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;
 KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;
 KW irritable bowel syndrome; Alzheimer's disease.
 XX
 OS Homo sapiens.
 XX WO200105828-A1.
 XX
 XX 25-JAN-2001.
 XX
 XX 18-JUL-2000; 2000WO-US019585.
 XX
 XX 20-JUL-1999; 99US-0144764P.
 XX
 XX (MERI) MERCK & CO INC.
 XX
 XX Uebele V, Swanson R, Liu Y, Lagrutta A;
 XX WFI; 2001-159514/16.
 XX N-PSDE; AAF27592.
 XX
 XX Novel human calcium sensitive potassium channel subunits for identifying
 PT inhibitors and agonists of the potassium channel for use in treating
 PT conditions such as asthma, hypertension, memory disorders, depression.

XX
 PS Claim 9; Fig 2B; 89pp; English.
 XX
 CC The present invention provides the protein and coding sequences of the
 CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c
 CC and beta3d subunits. These can be used to identify inhibitors and
 CC activators of the channels, which can be used in the treatment of
 CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,
 CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,
 CC incontinence, migraine and irritable bowel syndrome. The coding sequences
 CC are found at human chromosome 3q23-ter. The present sequence is the
 CC beta3a subunit
 XX
 SQ Sequence 277 AA;
 Query Match 38.6%; Score 478.5; DB 4; Length 277;
 Best Local Similarity 41.3%; Pred. No. 3.3e-44;
 Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;
 QY 7 GRTSSSYRDEKRNLYQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIMMYFLIG 66
 DB 20 GRTAPASGKKRETDYS---DGDPLDVHKRLPS-STGEDRAVLMGFAMNGSVLMFFLIG 75
 QY 67 ITLLRSYMQSVWTESSQCTLLNASITETFC-NQSPSCGPDCKLSQYPCLOVYVNLTSSE 125
 DB 76 TTILKPFMLSIQREESTCTAIHTDMDMLDCAFTCGVHCHGQKYPCLQVFNLSHFQ 135
 QY 126 KLLLYHTETIKINOKSVIPKCGKNFESMSLVNVMENFRKYOH----FSCYSDPEG 180
 DB 136 KALLHNEAVQINPCYTPKC---HQDSLLNSALDIKEFPDKNKGTFFSCFYSPAS 192
 QY 181 NOKSVILTKLSSNLYPHSLFWPTCMAGGVAIVAMVKLTQVLSLLCBRIQRINR 235
 DB 193 QSEDEVILIKKYDQMAIFHCFLEWPSLTLGGALIVGWLTLQHLISLCEKYSTVVR 247
 RESULT 12
 AAM78995
 ID AAM78995 standard; protein; 277 AA.
 AC AAM78995;
 DT 06-NOV-2001 (first entry)
 DE Human protein SEQ ID NO 1657.
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorder; arthritis; inflammation.
 XX
 OS Homo sapiens.
 XX WO200157190-A2.
 XX
 XX 09-AUG-2001.
 XX
 XX 05-FEB-2001; 2001WO-US004098.
 XX
 XX 03-FEB-2000; 2000US-00496914.
 XX 27-APR-2000; 2000US-00560875.
 XX 20-JUN-2000; 2000US-00598075.
 XX 19-JUL-2000; 2000US-00620325.
 XX 01-SEP-2000; 2000US-00654936.
 XX 15-SEP-2000; 2000US-00863561.
 XX 20-OCT-2000; 2000US-00893325.
 XX 30-NOV-2000; 2000US-00728422.
 XX (HYSE-) HYSEQ INC.
 XX
 XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;
 PI Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
 PI Xue AJ, Yang Y, Wejhran T, Goodrich R;

```
XX DR WPI; 2001-476283/51.
XX DR N-PSDB; AAK52128.
XX PT Nucleic acids encoding polypeptides with cytokine-like activities, useful
XX PT in diagnosis and gene therapy.
XX PS Claim 20; Page 4002-4003; 6221pp; English.
XX CC The invention relates to polynucleotides (AAK51456-AAK53435) and the
XX CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity relating to
XX CC cytokine, cell proliferation or cell differentiation or which may induce
XX CC production of other cytokines in other cell populations. The
XX CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
XX CC peptide therapy. The polypeptides have various cytokine-like activities,
XX CC e.g. stem cell growth factor activity, haematopoiesis regulating
XX CC activity, tissue growth factor activity, immunomodulatory activity and
XX CC activin/inhibin activity and may be useful in the diagnosis and/or
XX CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
XX CC inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111
XX CC (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the
XX CC sequence listing were missing at the time of publication
XX SQ Sequence 277 AA;
Query Match 38.5%; Score 477.5; DB 4; Length 277;
Best Local Similarity 41.3%; Pred. No. 4.2e-44;
Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;
QY 7 GRTSSYRDEKRNIIYQKIRDHLDLDRKRTVTALKAGEDRAILLGLAMMVCIMMYFLILG 66
DB 20 GRTAFPSGKKRETDYS---DGDPLDVHKRLPS-STGEDRAVLMGFAMGFSVLMPLILG 75
QY 67 ITLLRSYMQSVWTEESQCTLLNASITETTF-NCSPSCGPDCKWLSQYPCLOVYVNLTSQGE 125
DB 76 TTILKPFMLSIQREESTCTAIHTDMDLDCAFTGCHGQKYPCLQVFNVLSPHGQ 135
QY 126 KLLLYHTETTKIKQKSYTPCKGNFEESMLVNVNENFRKYQH-----FSCYSPEG 180
DB 136 KALLHYNEEAQINPKCFYTPKC---HQDRNLLNSALDIKEFDHKNQGFPSCFYSPAS 192
QY 181 NQKSVILTKLYSSNVLFSLFWPTCMAGGVAIVANVKLYQLYSLLCERTQINR 235
DB 193 QSEDVILIKKYDQMAIFHCLFWPSLTLGGALIVGMVRLTQHLSCERKSTVVR 247
RESULT 13
ABBI1970
XX AC ABBI1970;
XX DT 11-JAN-2002 (first entry)
XX XX Human Ca-activated K channel homologue, SEQ ID NO:2340.
XX KW Human; cytokine; cell proliferation; cell differentiation; growth factor;
XX KW haematopoiesis regulation; tissue growth; immunomodulator; activin;
XX KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;
XX KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;
XX KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
XX KW chronic inflammatory condition; proliferative retinopathy;
XX KW atherosclerosis; coronary heart disease; arterial ischaemia;
XX KW bone disorder; osteoporosis; vascular growth disorder;
XX KW tissue regeneration; wound healing; infection; immune disorder;
XX KW cell culture; drug screening; gene therapy; antiinflammatory;
XX KW antiasthmatic; antiarthritis; haemostatic; antiarteriosclerotic;
XX KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;
XX KW antifungal; vulnery; antiulcer.
XX OS Homo sapiens.
XX XX WO200157188-A2.
XX PD 09-AUG-2001.
XX PF 05-FEB-2001; 2001WO-US003800.
XX PR 03-FEB-2000; 2000US-00496914.
XX PR 27-APR-2000; 2000US-00560875.
XX PA (HYSE-) HYSEQ INC.
XX PI Tang YT, Liu C, Drmanac RT;
XX DR WPI; 2001-457740/49.
XX DR N-PSDB; ABA09214.
XX CC Human proteins and DNA encoding sequences useful for preventing, treating
XX CC or ameliorating a medical condition in a mammalian subject e.g. arthritis
XX CC and cancer.
XX PS Claim 20; Page 288-289; 1963pp; English.
XX CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
XX CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
XX CC invention also relates to vectors and recombinant host cells comprising a
XX CC nucleotide of the invention, methods of producing the novel polypeptides,
XX CC antibodies against the polypeptides, methods of detecting the nucleotides
XX CC or polypeptides in a sample, and methods of identifying compounds which
XX CC bind to polypeptides of the invention. Although novel, many of the
XX CC polypeptides of the invention have homology to known proteins, thereby
XX CC giving an insight into their probable biological activities, and hence
XX CC potential therapeutic applications. The polypeptides of the invention may
XX CC have various activities, including cytokine, cell proliferation or cell
XX CC differentiation activities; stem cell growth factor activity;
XX CC haematopoiesis regulatory activity; tissue growth activity;
XX CC immunomodulatory activity; activin- or inhibin-related activities;
XX CC chemotactic or chemokinetic activities; haemostatic, thrombotic or
XX CC thrombolytic activities; receptor or ligand activities; or may be
XX CC involved in oncogenesis, cancer cell proliferation or metastasis.
XX CC Depending on their biological activities, polypeptides and nucleotides of
XX CC the invention are useful for preventing, treating or ameliorating medical
XX CC conditions, e.g. by protein or gene therapy. Such conditions include
XX CC cancers, haematopoietic disorders (e.g. myeloid or lymphoid cell
XX CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
XX CC proliferative retinopathy, atherosclerosis, coronary heart disease,
XX CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
XX CC vascular growth. Polypeptides involved with tissue regeneration and
XX CC repair (for nucleic acids encoding them) may be used to promote wound
XX CC healing (e.g., of burns, incisions and ulcers), while those with
XX CC immunomodulatory activities may be used in the treatment of viral,
XX CC bacterial and fungal infections in addition to immune disorders.
XX CC Polypeptides with growth factor activity may be used in cell cultures to
XX CC promote cell growth. For example, such polypeptides may be used to
XX CC manipulate stem cells in culture to give rise to neuroepithelial cells
XX CC that can be used to augment or replace cells damaged by illness,
XX CC autoimmune disease or accidental damage. The polypeptides and nucleotides
XX CC may also be used in the diagnosis of the above conditions, and in drug
XX CC screening techniques. The present sequence represents a novel human
XX CC polypeptide of the invention
XX SQ Sequence 301 AA;
Query Match 38.5%; Score 477.5; DB 4; Length 301;
Best Local Similarity 41.3%; Pred. No. 4.7e-44;
Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;
QY 7 GRTSSYRDEKRNIIYQKIRDHLDLDRKRTVTALKAGEDRAILLGLAMMVCIMMYFLILG 66
DB 44 GRTAFPSGKKRETDYS---DGDPLDVHKRLPS-STGEDRAVLMGFAMGFSVLMPLILG 99
QY 67 ITLLRSYMQSVWTEESQCTLLNASITETTF-NCSPSCGPDCKWLSQYPCLOVYVNLTSQGE 125
DB 100 TTILKPFMLSIQREESTCTAIHTDMDLDCAFTGCHGQKYPCLQVFNVLSPHGQ 159
```

QY 126 KLLVHTETIKINOKCSYIPKCGKNFESMLVNVMMENFRKYQH-----FSCYSDPEG 180
 Db 160 KALLHYNBAVQINPKCFYTPKC---HQDRNDLLNSALDIKEFFDHKNGTFFSCFYSPAS 216
 QY 181 NOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQVLSLCCERIQIRNR 235
 Db 217 QSEDEVILIKKYDQMAIFHCLFWPSLTLGGALIVGMVRLTQHLSSLCEKYSTVVR 271

RESULT 14
 AAM79979
 ID AAM79979 standard; protein; 301 AA.
 AC AAM79979;
 XX
 DT 06-NOV-2001 (first entry)
 XX
 DE Human protein SEQ ID NO 3625.
 XX
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorder; arthritis; inflammation.
 XX
 OS Homo sapiens.
 XX
 PN WO200157190-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 05-FEB-2001; 2001WO-US004098.
 XX
 PR 03-FEB-2000; 2000US-00496914.
 PR 27-APR-2000; 2000US-00560875.
 PR 20-JUN-2000; 2000US-00598075.
 PR 19-JUL-2000; 2000US-00620325.
 PR 01-SEP-2000; 2000US-00654936.
 PR 15-SEP-2000; 2000US-00683561.
 PR 20-OCT-2000; 2000US-00693325.
 PR 30-NOV-2000; 2000US-00728422.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;
 PI Ma Y, Zhao QP, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZH;
 PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
 XX
 WPI; 2001-476283/51.
 DR N-PSDB; AAK53112.
 XX
 PT Nucleic acids encoding polypeptides with cytokine-like activities, useful
 PT in diagnosis and gene therapy.
 XX
 PS Claim 20; Page 401; 6221pp; English.
 XX
 CC The invention relates to polynucleotides (AAK51456-AAK53435) and the
 CC encoded polypeptides (AAM78323-AAK80302) that exhibit activity relating to
 CC cytokine, cell proliferation or cell differentiation or which may induce
 CC production of other cytokines in other cell populations. The
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
 CC peptide therapy. The polypeptides have various cytokine-like activities,
 CC e.g. stem cell growth factor activity, haematopoiesis regulating
 CC activity, tissue growth factor activity, immunomodulatory activity and
 CC activin/inhibin activity and may be useful in the diagnosis and/or
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
 CC inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111
 CC (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the
 CC sequence listing were missing at the time of publication
 XX
 SQ Sequence 301 AA;
 Query Match 38.5%; Score 477.5; DB 4; Length 301;
 Best Local Similarity 41.3%; Pred. No. 4.7e-44;
 Matches 93; Conservative 41; Mismatches 71; Indels 10; Gaps 4;

Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;
 QY 7 GRTSSSYRDEKKNYQKIRDHLLDKRKTVTALKAGEDRAILLGLAMVCSIMMYFLIG 66
 Db 44 GRTAFPASGKKRETDYS--DGPDLVHKRLPS-STGEDRAVNLGFMAMGFVSLMFFLIG 99
 QY 67 ITLLRSVMSQVWTEESQCTLLNASITETP-NCFSFGCPDCKLSQVPCLOVYVNLTSCE 125
 Db 100 TTILKPFMLSIQREESTCTAIHTDINDWDDCAFTCGVCHGCGKYPCLQVFNLSHPGQ 159
 QY 126 KLLVHTETIKINOKCSYIPKCGKNFESMLVNVMMENFRKYQH-----FSCYSDPEG 180
 Db 160 KALLHYNBAVQINPKCFYTPKC---HQDRNDLLNSALDIKEFFDHKNGTFFSCFYSPAS 216
 QY 181 NOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQVLSLCCERIQIRNR 235
 Db 217 QSEDEVILIKKYDQMAIFHCLFWPSLTLGGALIVGMVRLTQHLSSLCEKYSTVVR 271

RESULT 15
 AAB35304
 ID AAB35304 standard; protein; 275 AA.
 XX
 AC AAB35304;
 XX
 DT 08-MAY-2001 (first entry)
 XX
 DE Human calcium sensitive potassium channel beta3c subunit.
 XX
 KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;
 KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;
 KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;
 KW irritable bowel syndrome; Alzheimer's disease.
 XX
 OS Homo sapiens.
 XX
 PN WO200105828-A1.
 XX
 PD 25-JAN-2001.
 XX
 PF 18-JUL-2000; 2000WO-US019585.
 XX
 PR 20-JUL-1999; 99US-0144764P.
 XX
 PA (MERI) MERCK & CO INC.
 XX
 PI Uebele V, Swanson R, Liu Y, Lagrutta A;
 DR WPI; 2001-159514/16.
 DR N-PSDB; AAF27994.
 XX
 PT Novel human calcium sensitive potassium channel subunits for identifying
 PT inhibitors and agonists of the potassium channel for use in treating
 PT conditions such as asthma, hypertension, memory disorders, depression.
 XX
 PS Claim 9; Fig 4B; 89pp; English.
 XX
 CC The present invention provides the protein and coding sequences of the
 CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c
 CC and beta3d subunits. These can be used to identify inhibitors and
 CC activators of the channels, which can be used in the treatment of
 CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,
 CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,
 CC incontinence, migraine and irritable bowel syndrome. The coding sequences
 CC are found at human chromosome 3q23-ter. The present sequence is the
 CC beta3c subunit
 XX
 SQ Sequence 275 AA;
 Query Match 38.3%; Score 475; DB 4; Length 275;
 Best Local Similarity 43.3%; Pred. No. 7.9e-44;
 Matches 93; Conservative 41; Mismatches 71; Indels 10; Gaps 4;

Qy	27	DHLLDKRKIVTALKAGEDRAILGLAMVCSIMMYFLLGITLLIRSYMOSVWTEESQCTL	86
Db	35	DGDFLDVHKRLPS-STGEDRAVMLGFAMGFSVLMFLLGTITLKPMLSIQREESTCTA	93
Qy	87	LNASITETP-NCSPSCGPDCKLSQYPCLOVYNLTSSGKLLYHTEETIKINQCSYI	145
Db	94	IHTDIMDDWLDCAFTCGVHCHGQKYPCLOVFNLSHPGQKALLHYNEEAVQINPKCFYT	153
Qy	146	PKCGKNFEESMLNVVNMENFRKYOH-----FSCYSDPEGNQKSVILTKLYSSNVLFHSL	200
Db	154	PKC---HQDRSDDLNSALDIKEFPDHKNGTFFSCFYSPASQSEDVILIKKYDQMAIFHCL	210
Qy	201	FWPTCMAGGVAIVAMVKLTQYLSLLCERIQRINR	235
Db	211	FWPSLTLLGGALIVGMVELTQHLSSLCEKYSTVVR	245

Search completed: November 6, 2004, 23:31:01
Job time : 71 secs

This Page Blank (usp10)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 23:26:11 ; Search time 64 Seconds
(without alignments)
2112.704 Million cell updates/sec

Title: US-09-914-053A-5
Perfect score: 1241
Sequence: 1 MSITSGRTSSRYHDEKRN.....MKLTQYLSLCLERIORINR 235

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_02:*

1: uniprot_sprot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1235	99.5	235	1	Q9Y691 h calcium-a
2	1186	95.6	235	1	Q9CXM9 m calcium-a
3	1185	95.5	235	1	Q811Q0 r calcium-a
4	507	40.9	200	1	Q98855 coturnix co
5	490	39.5	200	2	Q93393 gallus gall
6	474	38.2	279	1	Q9N9A1 h calcium-a
7	421	33.3	190	1	Q16358 h calcium-a
8	421	33.9	191	2	AAS20193 homo sapi
9	418	33.7	190	1	P97678 r calcium-a
10	415	33.4	190	1	Q8CAE3 m calcium-a
11	406	32.7	190	1	O46372 o calcium-a
12	396	31.9	190	1	Q28266 c calcium-a
13	382	30.8	190	1	Q28067 b calcium-a
14	316	25.5	210	1	Q86W47 h calcium-a
15	312	25.1	210	1	Q86XK8 r calcium-a
16	309	24.9	210	2	Q6QXK8 c meriones un
17	309	24.9	210	2	AAS55654 meriones
18	308	24.8	210	1	Q9JINE m calcium-a
19	94.5	7.6	482	2	Q8GWP7 arabidopsis
20	93.5	7.5	526	2	Q9NJP1 caenorhabdi
21	92	7.4	897	2	Q85661 proteus mir
22	91.5	7.4	448	2	Q9VZG8 drosophila
23	91	7.3	828	2	Q94886 homo sapien
24	90.5	7.3	895	2	Q6FUM7 candida gla
25	90.5	7.3	895	2	Q9CIS1 candida gla
26	89	7.2	285	1	P28333 rattus norv
27	89	7.2	362	1	P30483 homo sapien
28	89	7.2	550	2	Q6BWF2 debaryomyce
29	89	7.2	949	2	Q7RRD8 plasmodium
30	88	7.1	362	1	P30481 homo sapien
31	88	7.1	362	2	Q29849 homo sapien

RESULT 1

ID	CKB2_HUMAN	STANDARD;	PRT;	235 AA.
AC	Q9Y691;			
DT	05-JUL-2004 (Rel. 44, Created)			
DT	05-JUL-2004 (Rel. 44, Last sequence update)			
DT	01-OCT-2004 (Rel. 45, Last annotation update)			
DE	Calcium-activated potassium channel beta subunit 2 (Calcium-activated			
DE	potassium channel, subfamily M, beta subunit 2) (Maxi K channel beta			
DE	subunit 2) (BK channel beta subunit 2) (Slo-beta 2) (K(VCA)beta 2)			
DE	(Charybdotoxin receptor beta subunit 2) (BKbeta2) (Hbeta2) (Hbeta3).			
GN	Name=KCNMB2;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A., FUNCTION, DOMAIN, TISSUE SPECIFICITY, AND			
RP	INTERACTION WITH KCNMB1.			
RC	TISSUE=Neuroepithelium;			
RX	MEDLINE=99199323; PubMed=10097176;			
RA	Wallner M., Meera P., Toro L.;			
RT	"Molecular basis of fast inactivation in voltage and Ca2+-activated K+			
RT	channels: a transmembrane beta-subunit homolog."			
RL	Proc. Natl. Acad. Sci. U.S.A. 96:4137-4142(1999).			
RN	[2]			
RP	SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.			
RC	TISSUE=Ovary;			
RX	MEDLINE=20158960; PubMed=10692449;			
RA	Brenner R., Jegla T.J., Wickenden A., Liu Y., Aldrich R.W.;			
RT	"Cloning and functional characterization of novel large conductance			
RT	calcium-activated potassium channel subunits, hKCNMB3 and hKCNMB4."			
RL	J. Biol. Chem. 275:6453-6461(2000).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Embryonic testis;			
RX	MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			
RA	Strausberg R.D., Feingold E.A., Grouse L.H., Derge J.G.,			
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,			
RA	Ahtschul S.F., Zeeb B., Buetow K.H., Schaefer C.F., Bhat N.K.,			
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,			
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,			
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,			
RA	Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,			
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,			
RA	Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			
RA	Blakesley R., Touchman J.W., Green E.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzyzinski M.I., Skalska U., Smailus D.E.,			
RA	Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;			

32	88	7.1	563	2	Q8IL46
33	88	7.1	591	2	Q9LL51
34	87.5	7.1	548	2	Q8WQ1
35	87.5	7.1	592	2	Q9HB37
36	87.5	7.1	592	2	Q8WQ2
37	87.5	7.1	592	2	Q7KK3
38	87.5	7.1	1880	2	O18465
39	87	7.0	398	1	HISX_SULSO
40	87	7.0	497	2	O01964
41	87	7.0	500	2	Q96CS4
42	87	7.0	500	2	Q99PJ7
43	86.5	7.0	438	2	Q91VC4
44	86	6.9	238	1	CSH2_BOVIN
45	86	6.9	494	2	O01965

ALIGNMENTS

RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [4]
RP FUNCTION, DOMAIN, AND TISSUE SPECIFICITY.
RX PubMed=10377337;
RA Xia X.-M., Ding J.-P., Lingle C.J.;
RT "Molecular basis for the inactivation of Ca2+- and voltage-dependent
RT BK channels in adrenal chromaffin cells and rat insulinoma tumor
RT cells.";
RT J. Neurosci. 19:5255-5264(1999).
RN [5]
RP GLYCOSYLATION.
RX MEDLINE=20266405; PubMed=10792059; DOI=10.1073/pnas.100118597;
RA Meera P., Wallner M., Toro L.;
RT "A neuronal beta subunit (KCNMB4) makes the large conductance,
RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and
RT iberiotoxin.";
RT Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567(2000).
RN [6]
RP MUTAGENESIS OF 2-PHB--TRP-4.
RX PubMed=12566540;
RA Xia X.-M., Ding J.-P., Lingle C.J.;
RT "Inactivation of BK channels by the NH2 terminus of the beta2
RT auxiliary subunit: an essential role of a terminal peptide segment of
RT three hydrophobic residues.";
RT J. Gen. Physiol. 121:125-148(2003).
RN [7]
RP REVIEW.
RX PubMed=12136044;
RA Orio P., Rojas P., Ferreira G., Latorre R.;
RT "New disguises for an old channel: MaxiK channel beta-subunits.";
RT News Physiol. Sci. 17:156-161(2002).
RN [8]
RP STRUCTURE BY NMR OF 1-45.
RX PubMed=11517332; DOI=10.1074/jbc.M107118200;
RA Bentrup D., Beyersmann M., Wisemann R., Fakler B.;
RT "NMR structure of the 'ball-and-chain' domain of KCNNB2, the beta 2-
RT subunit of large conductance Ca2+- and voltage-activated potassium
RT channels";
RL J. Biol. Chem. 276:42116-42121(2001).
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
CC KCNNM1 (maxiK) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNNM1, thereby contributing to KCNNM1 channel
CC diversity. Acts as a negative regulator that confers rapid and
CC complete inactivation of KCNNM1 channel complex. May participate
CC in KCNNM1 inactivation in chromaffin cells of the adrenal gland or
CC in hippocampal CA1 neurons.
CC -!- SUBUNIT: Interacts with KCNNM1 tetramer. There are probably 4
CC molecules of KCNNB2 per KCNNM1 tetramer.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- TISSUE SPECIFICITY: Expressed in kidney, heart and brain. Highly
CC expressed in ovary. Expressed at low level in other tissues.
CC -!- DOMAIN: The ball and chain domain mediates the inactivation of
CC KCNNM1. It occludes the conduction pathway of KCNNM1 channels, and
CC comprises the pore-blocking ball domain (residues 1-17) and the
CC chain domain (residues 20-45) linking it to the transmembrane
CC segment. The ball domain is made up of a flexible N-terminus
CC anchored at a well ordered loop-helix motif. The chain domain
CC consists of a 4-turn helix with an unfolded linker at its C-
CC terminus.
CC -!- PTM: N-glycosylated.
CC -!- SIMILARITY: Belongs to the KCNNB family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.ebi.ac.uk/announcements/>
CC or send an email to license@ebi.ac.uk).
CC
CC EMBL; AF099137; AAD23380.1; -

DR EMBL; AF209747; AAF36562.1; -;
DR EMBL; BC017825; AAH17825.1; -;
DR PDB; 1QAK; X-ray; A=1-5.
DR PDB; 1J06; NMR; A=1-44.
DR Genew; HGNC:6286; KCNNB2.
DR MIM; 605214; -;
DR GO; GO:0008075; C:voltage-gated potassium channel complex; IDA.
DR GO; GO:0015265; P:calcium-activated potassium channel activity; IDA.
DR GO; GO:0008200; F:ion channel inhibitor activity; TAS.
DR GO; GO:0015459; F:potassium channel regulator activity; TAS.
DR GO; GO:0005113; P:calcium ion sensing; IDA.
DR GO; GO:0019228; P:generation of action potential; IDA.
DR GO; GO:0006813; P:potassium ion transport; IDA.
DR GO; GO:001508; P:regulation of action potential; IDA.
DR GO; GO:0019229; P:regulation of vasoconstriction; TAS.
DR InterPro; IPR003930; BK_channel_beta.
DR Pfam; PF03185; CASK; 1.
KW 3D-structure; Glycoprotein; Ionic channel; Transmembrane.
FT DOMAIN 1 46
FT TRANSMEM 47 67
FT DOMAIN 68 194
FT TRANSMEM 195 215
FT DOMAIN 216 235
FT DOMAIN 1 45
FT CARBOHYD 88 96
FT CARBOHYD 96 96
FT CARBOHYD 119 119
FT MUTAGEN 2 4
FT KCNNM1 channel.
SQ SEQUENCE 235 AA; 27129 MW; 5752021DF27B8CF5 CRC64;
Query Match 99.5%; Score 1235; DB 1; Length 235;
Best Local Similarity 99.6%; Pred. No. 4.1e-101;
Matches 234; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MSINTSGTSSSYRDEKNIYQKIRDDHLLDKRVTALKAGEDRAILLGLAMVCSIM 60
DB 1 MFINTSGTSSSYRDEKNIYQKIRDDHLLDKRVTALKAGEDRAILLGLAMVCSIM 60
QY 61 MYFLLGITLLRSYMQSVMTESQCTLLNASITETFNCSFSGPCDCKLQYVYVNL 120
DB 61 MYFLLGITLLRSYMQSVMTESQCTLLNASITETFNCSFSGPCDCKLQYVYVNL 120
QY 121 TSSGKLLLYHTEETIKNQCSYIPKCGKPFESMSLVNVMENFRKYQHFSYSDPEG 180
DB 121 TSSGKLLLYHTEETIKNQCSYIPKCGKPFESMSLVNVMENFRKYQHFSYSDPEG 180
QY 181 NOKSVILTKLYSSNVLFHSLFPTCMAGGVAIVAVVAVVAVVAVVAVVAVVAVVAVV 235
DB 181 NOKSVILTKLYSSNVLFHSLFPTCMAGGVAIVAVVAVVAVVAVVAVVAVVAVVAVV 235
RESULT 2
CKB2_MOUSE STANDARD; PRT; 235-AA.
ID_CKB2_MOUSE
AC Q9CZ9;
DT 05-JUL-2004 (Rel. 44, Created)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Calcium-activated potassium channel beta subunit 2 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 2) (Maxi K channel beta
DE subunit 2) (BK channel beta subunit 2) (SLO-beta 2) (K(VCA)beta 2)
DE (Charybdotoxin receptor beta subunit 2) (BKbeta2).
GN Name-Kcnnb2;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6; TISSUE=Kidney;
RA Garcia-Valdes J., Eghbali M., Stefani E., Toro L.;
RT "Mouse kcnnb2 subunit of the large conductance calcium-activated K


```
RT channel (Maxik, BK).";
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Embryo;
RA MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA Nikaide I., Oeato Y., Saiko R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA Baldarelli R., Hilli D.P., Bult C., Hume D.A., Quackenbush J.,
RA Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA Blake J.A., Bradt D., Brusci V., Chothia C., Corbani L.E., Cousins S.,
RA Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA Gaasterland T., Gariboldi M., Glessi C., Godzik A., Gough J.,
RA Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA Mgolott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA Nagashima T., Numata K., Okido T., Pavan W.J., Perte G., Pesole G.,
RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA Sandelin A., Schneider C., Sempke C.A., Setou M., Shimada K.,
RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang L., Yang L.,
RA Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA Birney E., Hayashizaki Y.;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs";
RL Nature 420:563-573(2002).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6; TISSUE=Brain;
RA MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
RA Diatchenko L., Narusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Lequellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Pahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Gramwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,
RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -1- FUNCTION: Regulatory subunit of the calcium activated potassium
CC KCNMA1 (maxik) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel
CC diversity. Acts as a negative regulator that confers rapid and
CC complete inactivation of KCNMA1 channel complex (By similarity).
CC -1- SUBUNIT: Interacts with KCNMA1 tetramer. There are probably 4
CC molecules of KCNB2 per KCNMA1 tetramer (By similarity).
CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC -1- DOMAIN: The ball and chain domain mediates the inactivation of
CC KCNMA1. It occludes the conduction pathway of KCNMA1 channels, and
CC comprises the pore-blocking ball domain (residues 1-17) and the
CC chain domain (residues 20-45) linking it to the transmembrane
CC segment. The ball domain is made up of a flexible N-terminus
CC anchored at a well ordered loop-helix motif. The chain domain
```


QY 94 TFNCSFGPCDCKWLSOYPCLOVYVNLTSSEKLLVHTETIKINOKSVIPKCGKNFE 153
DB 64 KTHCTNBSGSEDEDFHYPCQVWVNLTSASQGVNLVHTEDTLERNPKCSYVPGNSNSK 123
QY 154 ESMGLVNVYVMEFRKYQHFSCYSPGEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213
DB 124 EVKARIEFIASFKKYQTFPCYDPGGQNTVILSRVPPKGLLFTFLWPTLMFTGGLI 183
QY 214 VAMVKLTQYLSLCLER 229
DB 184 IVLVKISQYFVSLSAR 199
RESULT 5
Q93393 PRELIMINARY; PRT; 200 AA.
AC O93393;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Putative calcium-activated potassium channel regulatory subunit
DE (Calcium-activated potassium channel beta subunit).
GN Name=C06; gallus (Chicken).
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 1); AND TISSUE SPECIFICITY.
RX MEDLINE=97224079; PubMed=90708660;
RA Oberst C., Weiskirchen R., Hartl M., Bister K.;
RT "Suppression in transformed avian fibroblasts of a gene (C06) encoding
RT a membrane protein related to mammalian potassium channel regulatory
RT subunits";
EL onco gene 14:1109-1116 (1997).
RN [2]
RP SEQUENCE FROM N.A.
RA Oberst C., Bister K.;
RL Submitted (JUL-1998) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RA Bait S.L., Hudspeth A.J.;
RL Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF077369; AAC27490.1; -;
DR EMBL; AF420468; AAL16898.1; -;
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0015269; F:calcium-activated potassium channel activity; IEA.
DR GO; GO:0005216; F:ion channel activity; IEA.
DR GO; GO:0006813; P:potassium ion transport; IEA.
DR InterPro; IPR003930; BK_channel_beta.
DR Pfam; PF03185; CaKB; 1.
DR PRINTS; PR01450; BKCHANNELB.
KW Ionic channel.
SQ SEQUENCE 200 AA; 22663 MW; CFPD676158CSB0535 CRC64;
Query Match 39.5%; Score 490; DB 2; Length 200;
Best Local Similarity 46.4%; Pred. No. 2.9e-35;
Matches 91; Conservative 41; Mismatches 64; Indels 0; Gaps 0;
QY 34 RKTVTALAGDRAILLGLAMVCSIMYFLLGILLTLRSYMQSVMTESQCTLLNASITE 93
DB 4 KKLVTAKRGEGTRALCLGLGVACSMYFPIGIVFPYTKSVWTTETICKLVKNKD 63
QY 94 TFNCSFGPCDCKWLSOYPCLOVYVNLTSSEKLLVHTETIKINOKSVIPKCGKNFE 153
DB 64 KALCSNBSGSEDEDFHYPCQVWVNLTSASQGVNLVHTEDTLERNPKCSYVPGNSNAK 123
QY 154 ESMGLVNVYVMEFRKYQHFSCYSPGEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213
DB 124 EVKARIEFIASFKKYQTFPCYDPGGQNTVILSRVPPKGLLFTFLWPTLMFTGGLI 183

QY 214 VAMVKLTQYLSLCLER 229
DB 184 IVLVKISQYFVSLSAR 199
RESULT 6
CKB3_HUMAN STANDARD; PRT; 279 AA.
ID CKB3_HUMAN
AC Q9NP1; Q9NPG7; Q9NRM9; Q9UHN3;
DT 05-JUL-2004 (Rel. 44, Created)
DT 05-JUL-2004 (Rel. 44, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Calcium-activated potassium channel beta subunit 3 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 3) (Maxi K channel beta
DE subunit 3) (BK channel beta subunit 3) (Slo-beta 3) (K(VCA)beta 3)
DE (Charybdotoxin receptor beta subunit 3) (BKbeta3) (Hbeta3).
GN Name=KCNMB3; (Human).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Theria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 3); AND TISSUE SPECIFICITY.
RX MEDLINE=20054359; PubMed=10585773; DOI=10.1006/geno.1999.5975;
RA Riaz M.A., Brinkman-Mills F., Johnson A., Naylor S.L., Minoshima S.,
RA Shimizu N., Baldini A., McDermid H.E.;
RT "Identification of a putative regulatory subunit of a calcium-
RT activated potassium channel in the dup(3q) syndrome region and a
RT related sequence on 22q11.2";
RL Genomics 62:90-94 (1999).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM 4); TISSUE SPECIFICITY, AND INTERACTION
RP WITH KCNB1.
RX TISSUE=Brain;
RC MEDLINE=20158960; PubMed=10692449;
RA Brenner R., Jegla T.J., Wickenden A., Liu Y., Aldrich R.W.;
RT "Cloning and functional characterization of novel large conductance
RT calcium-activated potassium channel subunits, hKCNMB3 and hKCNMB4";
RL J. Biol. Chem. 275:6453-6461 (2000).
RN [3]
RP SEQUENCE FROM N.A. (ISOFORMS 1; 2; 3 AND 4); FUNCTION, ALTERNATIVE
RP SPLICING, TISSUE SPECIFICITY, AND VARIANT SER-165.
RC TISSUE=Spleen;
RX MEDLINE=20390083; PubMed=10766764; DOI=10.1074/jbc.M910187199;
RA Uebele V.N., Lagrutta A.A., Wade T., Figueroa D.J., Liu Y.,
RA McKenna E., Austin C.P., Bennett P.B., Swanson R.;
RT "Cloning and functional expression of two families of Beta-subunits of
RT the large conductance calcium-activated potassium channel";
RL J. Biol. Chem. 275:23211-23218 (2000).
RN [4]
RP SEQUENCE FROM N.A. (ISOFORM 1); AND GLYCOSYLATION.
RX MEDLINE=20266405; PubMed=10792058; DOI=10.1073/pnas.100118597;
RA Meera P., Wallner M., Toro L.;
RT "A neuronal beta subunit (KCNMB4) makes the large conductance,
RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and
RT iberictoxin";
RL Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567 (2000).
RN [5]
RP SEQUENCE FROM N.A. (ISOFORM 4).
RX PubMed=10828459;
RA Behrens R., Nolting A., Reimann F., Schwarz M., Waldschuetz R.,
RA Pongs O.;
RT "hKCNMB3 and hKCNMB4, cloning and characterization of two members of
RT the large-conductance calcium-activated potassium channel beta subunit
RT family";
RL FEBS Lett. 474:99-106 (2000).
RN [6]
RP FUNCTION.
RX PubMed=10864947;
RA Xia X.-M., Ding J.-P., Zeng X.-H., Duan X.-L., Lingle C.J.;
RT "Rectification and rapid activation at low Ca2+ of Ca2+-activated,
RT voltage-dependent BK currents: consequences of rapid inactivation by a
RT novel beta subunit";

RL J. Neurosci. 20:4890-4903 (2000).
 RN [7]
 RN DOMAIN.
 RP PubMed=11382808;
 RX Lingle C.J., Zeng X.-H., Ding J.-P., Xia X.-M.,
 RA "Inactivation of BK channels mediated by the NH(2) terminus of the
 RT beta3b auxiliary subunit involves a two-step mechanism: possible
 RT separation of binding and blockade.";
 RL J. Gen. Physiol. 117:583-606 (2001).
 RN [8]
 RN DOMAIN.
 RP PubMed=11382809;
 RX Zeng X.-H., Ding J.-P., Xia X.-M., Lingle C.J.;
 RA "Gating properties conferred on BK channels by the beta3b auxiliary
 RT subunit in the absence of its NH(2)- and COOH termini.";
 RL J. Gen. Physiol. 117:607-628 (2001).
 RN [9]
 RN VARIANTS VAL-75; SER-165 AND THR-230.
 RP PubMed=14612589; DOI=10.1152/physiolgenomics.00110.2003;
 RX Hu S., Labuda M.Z., Pandolfo M., Goss G.G., Mcdermid H.E., Ali D.W.;
 RA "Variants of the KCNB3 regulatory subunit of maxi BK channels affect
 RT channel inactivation.";
 RL Physiol. Genomics 15:191-198 (2003).
 RN [10]
 RN DISULFIDE BONDS, AND DOMAIN.
 RP PubMed=12740608; DOI=10.1038/nsb932;
 RX Zeng X.-H., Xia X.-M., Lingle C.J.;
 RA "Redox-sensitive extracellular gates formed by auxiliary beta subunits
 RT of calcium-activated potassium channels.";
 RL Nat. Struct. Biol. 10:448-454 (2003).
 RN [11]
 RN REVIEW.
 RP PubMed=12136044;
 RX Orio P., Rojas P., Ferreira G., Latorre R.;
 RA "New disguises for an old channel: MaxiK channel beta-subunits.";
 RL News Physiol. Sci. 17:156-161 (2002).
 CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
 CC KCNA1 (maxiK) channel. Modulates the calcium sensitivity and
 CC gating kinetics of KCNA1. Modulates the calcium sensitivity and
 CC diversity. Alters the functional properties of the current
 CC expressed by the KCNA1 channel. Isoform 2, isoform 3 and isoform
 CC 4 partially inactivate the current of KCNEA. Isoform 4 induces a
 CC fast and incomplete inactivation of KCNA1 channel that is
 CC detectable only at large depolarizations. In contrast, isoform 1
 CC does not induce detectable inactivation of KCNA1. Two or more
 CC subunits of KCNEB3 are required to block the KCNA1 tetramer.
 CC -!- SUBUNIT: Interacts with KCNA1 tetramer. There are probably 4
 CC molecules of KCNEB3 per KCNA1 tetramer.
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event-Alternative splicing; Named isoforms=4;
 CC Name=1; Synonyms=3d;
 CC IsoId=Q3NPAL-1; Sequence=Displayed;
 CC Name=2; Synonyms=3a;
 CC IsoId=Q3NPAL-2; Sequence=VSP_009827;
 CC Name=3; Synonyms=3c;
 CC IsoId=Q3NPAL-3; Sequence=VSP_009828;
 CC Name=4; Synonyms=3b;
 CC IsoId=Q3NPAL-4; Sequence=VSP_009830;
 CC -!- TISSUE SPECIFICITY: Isoform 1, isoform 3 and isoform 4 are widely
 CC expressed. Isoform 2 is expressed in placenta, pancreas, kidney and
 CC heart. Isoform 1 and isoform 3 are highly expressed in pancreas
 CC and testis.
 CC -!- DOMAIN: The cytoplasmic N-terminus domain of isoform 4
 CC participates to the partial inactivation of KCNA1, possibly by
 CC binding of to a receptor site.
 CC -!- DOMAIN: The extracellular domain forms gates to block ion
 CC permeation, providing a mechanism by which current can be rapidly
 CC diminished upon cellular repolarization.
 CC -!- PTM: N-Glycosylated.
 CC -!- PTM: The extracellular domain contains disulfide bond essential
 CC for the gating mechanism.
 CC -!- SIMILARITY: Belongs to the KCNB family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 DR EMBL; AF139471; AAD54771.1; -
 DR EMBL; AF214561; AAF36598.1; -
 DR EMBL; AF204159; AAF97031.1; -
 DR EMBL; AF204160; AAF97032.1; -
 DR EMBL; AF204161; AAF97033.1; -
 DR EMBL; AF204162; AAF97034.1; -
 DR EMBL; AF160968; AAF67811.1; -
 DR EMBL; AF170916; AAF89698.1; -
 DR GenBank; HGNC:6287; KCNB3.
 DR MIM; 603222; -
 DR GO; GO:0016020; C:membrane; NAS.
 DR GO; GO:0015459; P:potassium channel regulator activity; NAS.
 DR GO; GO:0006813; P:potassium ion transport; NAS.
 DR InterPro; IPR003930; BK_channel_beta.
 DR Pfam; PF03185; CakB; 1.
 KW Alternative splicing; Glycoprotein; Ionic channel; Polymorphism;
 KW Transmembrane.
 FT DOMAIN 1 60 Cytoplasmic (Potential).
 FT TRANSMEM 61 81 1 (Potential).
 FT DOMAIN 82 207 Extracellular (Potential).
 FT TRANSMEM 208 228 2 (Potential).
 FT DOMAIN 229 279 Cytoplasmic (Potential).
 FT CARBOHYD 131 131 N-linked (GlcNAc...) (Potential).
 FT VARSPPLIC 1 22 MDPSPSELGPHFVAFILLTRH -> MQPSPFVQITLQGS
 FT RRRQG (in isoform 2).
 FT FTID=VSP_009827.
 FT VARSPPLIC 1 22 MDPSPSELGPHFVAFILLTRH -> MPFLLYELTAVSPSP
 FT FPQ (in isoform 3).
 FT FTID=VSP_009828.
 FT Missing (in isoform 4).
 FT VARSPPLIC 1 22 /FTID=VSP_009829.
 FT VARSPPLIC 23 23 R -> M (in isoform 4).
 FT VARSPPLIC 44 44 /FTID=VSP_009830.
 FT VARIANT 53 53 D -> G (in dbSNP:1170672).
 FT VARIANT 53 53 /FTID=VAR_018173.
 FT VARIANT 53 53 T -> A (in dbSNP:7645550).
 FT VARIANT 75 75 /FTID=VAR_018174.
 FT VARIANT 165 165 L -> V (in dbSNP:2276802).
 FT VARIANT 165 165 /FTID=VAR_018175.
 FT VARIANT 230 230 N -> S.
 FT VARIANT 230 230 /FTID=VAR_018176.
 FT VARIANT 230 230 M -> T.
 FT SEQUENCE 279 AA; 31633 MW; A6F5A0F64E19AB86 CRC64;
 SQ
 Query Match 38.2%; Score 474; DB 1; Length 279;
 Best Local Similarity 43.3%; Pred. No. 1.1e-33;
 Matches 93; Conservative 41; Mismatches 71; Indels 10; Gaps 4;
 QY 27 DHDLDKRTVTALKAGEDRALLLGLAMVVCSSIMVYFLLGITLLRSYMQSVWTEESQCTL 86
 DB 39 DGDPLDVHKLPS-STGEDRAVLMGFAMWGFVLMFFLLGITLLRPFMLSLQRESECTA 97
 QY 87 LNASITETP-NCSPFCGPDCKWLKSOYCLQVYVNYLTSSEKLLLYHTTETIKNKCSYI 145
 DB 98 IHTDIMDDLDCAFTCGVHCCHQKYPCLQVFNLSHPGQKALLHYNEAVQINPKCYT 157
 QY 145 PKCGKNFESMSLVNVMENFKYOH-----PSCYSDPEGNCKSVILTKLYSSNVLEHSL 200
 DB 158 PKC---HQNRDNLNSALDIKEFFPHKNGTFFPCFYSPASQSEVILLIKKYDQVAIFHCL 214
 QY 201 FWPTCMAGGVAIVAMVKLTQVLSLLCERIQINR 235
 DB 215 FWPSUTLLGGALIVGNVRLTQHLSLCEKYSTVVR 249

RESULT 7
 CKB1_HUMAN
 ID CKB1_HUMAN STANDARD; PRT: 190 RA
 AC Q16558; O00707; O00708; P78475; Q8TAX3; Q93005;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last annotation update)
 DT 01-OCT-2004 (Rel. 45, Last sequence update)
 DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated
 DE potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta
 DE subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1)
 DE (Charybdotoxin receptor beta subunit 1) (BKbeta1) (Hbeta1) (Calcium-
 DE activated potassium channel beta subunit) (BKbeta) (Slo-beta).
 GN Name=KCNMB1;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Uterus;
 RX MEDLINE=96196569; PubMed=8612769;
 RA Meera P., Wallner M., Jiang Z., Toro L.;
 RT "A calcium switch for the functional coupling between alpha (halo) and
 RT beta subunits (KV,Ca beta) of maxi K channels.";
 RL FEBS Lett. 382:84-88(1996).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Uterus;
 RX MEDLINE=96335638; PubMed=8764643;
 RA Dworetzky S.I., Boissard C.G., Lum-Ragan J.T., McKay M.C.,
 RA Post-Munson D.J., Trojnecki J.T., Chang C.P., Gribkoff V.K.;
 RT "Phenotypic alteration of a human BK (hSlo) channel by hSlobeta
 RT subunit coexpression: changes in blocker sensitivity,
 RT activation/relaxation and inactivation kinetics, and protein kinase A
 RT modulation.";
 RL J. Neurosci. 16:4543-4550(1996).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Brain;
 RX MEDLINE=96392390; PubMed=8799178;
 RA Tseng-Crank J., Godnot N., Johansen T.E., Ahning P.K., Strobaek D.,
 RA Metzger R., Foster C.D., Olesen S.P., Reihardt P.H.;
 RT "Cloning, expression, and distribution of a Ca(2+)-activated K+
 RT channel beta-subunit from human brain.";
 RL Proc. Natl. Acad. Sci. U.S.A. 93:9200-9205(1996).
 RN [4]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Aortic smooth muscle;
 RA Folander K., Biazio D., Swanson R.;
 RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
 RN [5]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Myometrium;
 RX PubMed=12434576;
 RA Mazonne J.N., Kaiser R.A., Buxton I.L.;
 RT "Calcium-activated potassium channel expression in human myometrium:
 RT effect of pregnancy";
 RL Proc. West. Pharmacol. Soc. 45:184-186(2002).
 RN [6]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Pancreas;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 Fahey J., Helton E., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,
 RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.L., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [7]
 RP GLYCOSYLATION
 RX MEDLINE=20286405; PubMed=10792058; DOI=10.1073/pnas.100118597;
 RA Meera P., Wallner M., Toro L.;
 RT "A neuronal beta subunit (KCNMB4) makes the large conductance,
 RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and
 RT iberiotoxin.";
 RL Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567(2000).
 RN [8]
 RP E2-BINDING.
 RX PubMed=10489376;
 RA Valverde M.A., Rojas P., Amigo J., Cosmelli D., Orio P.,
 RA Bahamonde M.I., Mann G.E., Vergara C., Latorre R.;
 RT "Acute activation of Maxi-K channels (hSlo) by estradiol binding to
 RT the beta subunit.";
 RL Science 285:1929-1931(1999).
 RN [9]
 RP REVIEW.
 RX PubMed=12136044;
 RA Orio P., Rojas P., Ferreira G., Latorre R.;
 RT "New disguises for an old channel: MaxiK channel beta-subunits.";
 RL News Physiol. Sci. 17:156-161(2002).
 RN [10]
 RP VARIANT LYS-64.
 RX PubMed=15057310; DOI=10.1172/JCI200420347;
 RA Fernandez-Fernandez J.M., Tomas M., Vazquez E., Orio P., Latorre R.,
 RA Senti M., Marrugat J., Valverde M.A.;
 RT "Gain-of-function mutation in the KCNMB1 potassium channel subunit is
 RT associated with low prevalence of diastolic hypertension.";
 RL J. Clin. Invest. 113:1032-1039(2004).
 CC -1- FUNCTION: Regulatory subunit of the calcium activated potassium
 CC KCNMB1 (maxiK) channel. Modulates the calcium sensitivity and
 CC gating kinetics of KCNMB1, thereby contributing to KCNMB1 channel
 CC diversity. Increases the apparent Ca(2+)/voltage sensitivity of
 CC the KCNMB1 channel. It also modifies KCNMB1 channel kinetics and
 CC alters its pharmacological properties. It slows down the
 CC activation and the deactivation kinetics of the channel. Acts as a
 CC negative regulator of smooth muscle contraction by enhancing the
 CC calcium sensitivity to KCNMB1. Its presence is also a requirement
 CC for internal binding of the KCNMB1 channel opener
 CC dehydroscaponein I (DHS-1) triterpene glycoside and for external
 CC binding of the agonist hormone 17-beta-estradiol (E2). Increases
 CC the binding activity of charybdotoxin (CTX) toxin to KCNMB1
 CC peptide blocker by increasing the CTX association rate and
 CC decreasing the dissociation rate.
 CC -1- SUBUNIT: Interacts with KCNMB1 tetramer. There are probably 4
 CC molecules of KCNMB1 per KCNMB1 tetramer.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein.
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event-Alternative splicing; Named isoforms=2;
 CC Name=1;
 CC IsoId=Q16558-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=Q16558-2; Sequence=VSP_009822, VSP_009823;
 CC Note=No experimental confirmation available;
 CC -1- TISSUE SPECIFICITY: Abundantly expressed in smooth muscle. Low
 CC levels of expression in most other tissues. Within the brain,
 CC relatively high levels found in hippocampus and corpus callosum.
 CC -1- FTM: N-glycosylated.
 CC -1- POLYMORPHISM: Genetic variation in KCNMB1 can influence the
 CC severity of diastolic hypertension.
 CC -1- SIMILARITY: Belongs to the KCNMB family.

RT characterizations.":
FL Genomics 55:57-67(1999).
RN [3]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC STRAIN-Sprague-Dawley; TISSUE=Vascular smooth muscle;
RL Large A.R., Gebremedhin D., Aebly M., Harder D.R.;
RA Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC STRAIN-Sprague-Dawley; TISSUE=Uterus;
RA Reimann F.;
RL Submitted (NOV-1995) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE FROM N.A. (ISOFORMS 2 AND 3).
RC TISSUE=Aorta;
RA Ohya S., Watanabe M., Imaizumi Y.;
RT "Molecular cloning of a novel spliced variant of calcium activated
RL potassium channel beta subunit in rat smooth muscle.";
RL Submitted (FEB-1998) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
CC KCNMA1 (maxik) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel
CC diversity. Increases the apparent Ca(2+)/voltage sensitivity of
CC the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and
CC alters its pharmacological properties. It slows down the
CC activation and the deactivation kinetics of the channel. Acts as a
CC negative regulator of smooth muscle contraction by enhancing the
CC calcium sensitivity to KCNMA1. Its presence is also a requirement
CC for internal binding of the KCNMA1 channel opener
CC dehydroisoquinoline I (DHS-1) triterpene glycoside and for external
CC binding of the agonist hormone 17-beta-estradiol (E2). Increases
CC the binding activity of charybdotoxin (CTX) toxin to KCNMA1
CC peptide blocker by increasing the CTX association rate and
CC decreasing the dissociation rate (By similarity).
CC -!- SUBUNIT: Interacts with KCNMA1 tetramer. There are probably 4
CC molecules of KCNMB1 per KCNMA1 tetramer (By similarity).
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- ALTERNATIVE PRODUCTS:
CC Event-Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=p97678-1; Sequence=Displayed;
CC Name=2; Synonyms=1b;
CC IsoId=p97678-2; Sequence=VSP_009825, VSP_009826;
CC Name=3; Synonyms=1c;
CC IsoId=p97678-3; Sequence=VSP_009824, VSP_009825, VSP_009826;
CC -!- TISSUE SPECIFICITY: Weakly expressed. In brain, it is expressed in
CC a few discrete populations of neurons that also express KCNMA1.
CC -!- PTM: N-glycosylated (By similarity).
CC -!- SIMILARITY: Belongs to the KCNMB family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.ebi.ac.uk/ebis-sib.ch>)
CC or send an email to license@ebi-sib.ch.
CC
CC EMBL; U54498; AAD11548.1; -;
CC EMBL; AF020712; AAD11855.1; -;
CC EMBL; U79661; AAB38413.1; -;
CC EMBL; U40602; AAB96355.1; -;
CC EMBL; AB010963; BAA33448.1; -;
CC EMBL; AB050745; BAB17678.1; -;
CC RGD; 2961; Kcnmb1.
CC InterPro; IPR003930; BK_channel_beta.
CC Pfam; PF03185; CaKb; 1.
KW Alternative splicing; Glycoprotein; Ionic channel; Transmembrane.
FT INIT MET 0 0 By similarity.
FT DOMAIN 1 17 Cytoplasmic (Potential).
FT TRANSMEM 18 38 1 (Potential).
FT DOMAIN 39 154 Extracellular (Potential).
FT TRANSMEM 155 175 2 (Potential).

FT DOMAIN 176 190 Cytoplasmic (Potential).
FT CARBOHYD 79 79 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 141 141 N-linked (GlcNAc...) (Potential).
FT VARSPLIC 102 121 Missing (in isoform 3).
FT VARSPLIC 122 145 /FTId=VSP_009824.
FT VARSPLIC 146 190 VTRNGKGPQA (in isoform 2 and isoform 3).
FT VARSPLIC 146 190 Missing (in isoform 2 and isoform 3).
FT VARSPLIC 146 190 /FTId=VSP_009825.
FT VARSPLIC 146 190 /FTId=VSP_009826.
FT CONFLICT 13 13 T -> A (in Ref. 2).
FT CONFLICT 27 29 AIT -> VVA (in Ref. 2).
FT CONFLICT 37 37 V -> M (in Ref. 2).
FT CONFLICT 55 60 VETNIK -> IESNIR (in Ref. 2).
FT CONFLICT 68 68 R -> K (in Ref. 2).
FT CONFLICT 88 88 M -> V (in Ref. 2).
FT CONFLICT 104 104 Y -> H (in Ref. 1).
FT CONFLICT 108 104 NLD -> SLE (in Ref. 2).
FT CONFLICT 114 120 TALVDVK -> VARADVE (in Ref. 2).
FT CONFLICT 124 124 A -> T (in Ref. 2).
FT CONFLICT 127 131 YKHNN -> HEHRI (in Ref. 2).
FT CONFLICT 137 140 APQV -> TTR (in Ref. 2).
FT CONFLICT 144 148 SVVQ -> TVLYR (in Ref. 2).
FT CONFLICT 155 155 I -> T (in Ref. 2).
FT CONFLICT 160 160 F -> L (in Ref. 2).
FT CONFLICT 176 176 M -> I (in Ref. 1).
FT CONFLICT 179 181 LNR -> INQ (in Ref. 2).
FT CONFLICT 185 186 VL -> IP (in Ref. 1).
FT CONFLICT 185 185 V -> I (in Ref. 2).
FT CONFLICT 190 190 K -> R (in Ref. 1 and 2).
SQ SEQUENCE 190 AA; 21777 MW; EA092F4B26FBADDF CRC64;
Query Match 33.7%; Score 418; DB 1; Length 190;
Best Local Similarity 43.0%; Pred. No. 6.5e-29;
Matches 83; Conservative 42; Mismatches 60; Indels 8; Gaps 2;
QY 34 RKTVTALKAGEDRAILLGLAMVCSIMMYFLGILTLRSYMQSVMTESQCTLLNASITE 93
DB 2 KKLWMAQRGETRALCLGVAMVCAITIIYIGTLVLPYQKSVMTQESTCHLVETNIKD 61
QY 94 TFCSPSCGPDCKWKLQSOYPCLOVYVNLTSSEKLLIYHTTEIKINQKCSYIPKCKNFE 153
DB 62 QBEL-----EGKVPQYFCL--WNVSAVGRWAMLYHTEDTRDQNCQSYIPRLNDNQ 113
QY 154 EMSLVNVVMEPRKYQHFSCYSDPEGNQKSVILTKLYSNVFLPSLFWPTCMAGGVAI 213
DB 114 TALVDVKVRANFYKHNFYCFSAPOVNETSVVYQRLYGPQLLFFSFFWPTTLTGGLLI 173
QY 214 VAMVKLTQVLSLL 226
DB 174 IAWKLNRLSLVL 186
RESULT 10
CKB1_MOUSE STANDARD; PRT; 190 AA.
AC QSCA3; Q35336; Q35645;
DT 05-JUL-2004 (Rel. 44, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta
DE subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1)
DE (Charybdotoxin receptor beta subunit 1) (BKbeta1) (Calcium-activated
DE potassium channel beta-subunit) (BKbeta) (Slo-beta).
GN Name:Kcnmb1;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6; TISSUE=Intestinal smooth muscle;

Db 174 IANVKLNRLSL 186

RESULT 11

CKB1_RABIT STANDARD; PRT; 190 AA.

AC 046372;

DT 05-JUL-2004 (Rel. 44, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1) (Charybdotoxin receptor beta subunit 1) (BKbeta) (Calcium-activated potassium channel beta-subunit) (BKbeta) (Slo-beta).

GN Name=KCNMB1;

OS Oryctolagus cuniculus (Rabbit);

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.

OX NCBI_TaxID=9986;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=New Zealand white; TISSUE=Brain;

EX PubMed=10821684; DOI=10.1021/bi92865z;

RA Giangiacomo K.M., Fremont V., Mullmann T.J., Hanmer M., Cox R.H., Garcia M.L.;

RT "Interaction of charybdotoxin S10A with single maxi-K channels: kinetics of blockade depend on the presence of the beta 1 subunit.";

RL Biochemistry 39:6115-6122(2000).

RN [2]

RP SEQUENCE FROM N.A.

RX PubMed=11294242;

RA Ohya S., Yamamura H., Muraki K., Watanabe M., Imaizumi Y.;

RT "Comparative study of the molecular and functional expression of L-type Ca2+ channels and large-conductance, Ca2+-activated K+ channels in rabbit aorta and vas deferens smooth muscle.";

RL Pflogers Arch. 441:611-620(2001).

RN [3]

RP SEQUENCE FROM N.A.

RC TISSUE=Skeletal muscle;

RA Sakamoto H., Ide T., Kasai M.;

RL Submitted (NOV-1997) to the EMBL/GenBank/DBJ databases.

CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium channel (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydroxyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate (By similarity).

CC -!- SUBUNIT: Interacts with KCNMA1 tetramer. There are probably 4 molecules of KCNMB1 per KCNMA1 tetramer (By similarity).

CC -!- SUBCELLULAR LOCATION: Integral membrane protein.

CC -!- SIMILARITY: Belongs to the KCNB family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.ebi.ac.uk/announcements/> or send an email to license@ebi.ac.uk).

CC -----

DB EMBL; AF107300; AAD17994.1; -

DR EMBL; AB001934; BAA25630.1; -

DR EMBL; AB009313; BAA23748.1; -

DR InterPro; IPR003930; BK_channel_beta.

DR Pfam; PF03185; CakB; 1.

KN Glycoprotein; Ionic channel; Transmembrane.

FT INIL_MET 0 0 By similarity.

FT DOMAIN 1 14 Cytoplasmic (Potential).

FT TRANSMEM 15 35 1 (Potential).

FT DOMAIN 36 156 Extracellular (Potential).

FT TRANSMEM 157 177 2 (Potential).

FT DOMAIN 178 190 Cytoplasmic (Potential).

FT CARBOHYD 79 79 N-linked (GlcNAc...) (Potential).

FT CARBOHYD 141 141 N-linked (GlcNAc...) (Potential).

SQ SEQUENCE 190 AA; 21697 MW; 687C2F40E5A4FC9 CRC64;

Query Match 32.7%; Score 406; DB 1; Length 190;

Best Local Similarity 42.0%; Pred. No. 7.5e-28;

Matches 81; Conservative 42; Mismatches 62; Indels 8; Gaps 2;

QY 34 RKTIVTALKAGEDRAILLGLAMVCSIMVYFLGILITLLSYMQSVMTESQCTLLNASITE 93

DB 2 KKLVMQAQKRGETALCLGVAMVCAVITYIIGTLMPLVYQKSVMTQSLCLRIETNRD 61

QY 94 TFNCSPSCGPDCKWLSQYPCLOVYVNLITSSGKLLYHTEETIKNQKSYIPKCGKNPE 153

DB 62 QEELECK-----KVPQYFCL--WNVSAVGKAWLYHTEETDRNQCSYIPGSLDNYQ 113

QY 154 EMSLVNVVNMFRKQHSYCSDEGKQSKVILKLYSSNVLFHSLFWPTCMAGGVAI 213

DB 114 MALADYEVKRAKFERQVFCFTQENETSVLYQRLYQPQALLASFLFWPTFLTGLLI 173

QY 214 VAMVKLTQYLSLL 226

DB 174 IANVKLNRLSL 186

RESULT 12

CKB1_CANFA STANDARD; PRT; 190 AA.

AC Q282Z6;

DT 01-NOV-1997 (Rel. 35, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1) (Charybdotoxin receptor beta subunit 1) (BKbeta) (Calcium-activated potassium channel beta-subunit) (BKbeta) (Slo-beta).

GN Name=KCNMB1;

OS Canis familiaris (Dog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.

OX NCBI_TaxID=9615;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=97053370; PubMed=897882;

RA Vogalis F., Vincent T., Qureshi I., Schmalz F.M., Ward M.W., Sanders K.M., Horowitz B.;

RT "Cloning and expression of the large-conductance Ca(2+)-activated K+ channel from colonic smooth muscle.";

RL Am. J. Physiol. 271:G629-G639(1996).

CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium channel (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydroxyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases

CC the binding activity of charybdotoxin (CTX) toxin to KCNNM1
CC peptide blocker by increasing the CTX association rate and
CC decreasing the dissociation rate (By similarity).
CC
CC -!- SUBUNIT: Interacts with KCNNM1 tetramer. There are probably 4
CC molecules of KCNNM1 per KCNNM1 tetramer (By similarity).
CC -!- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC -!- PTM: N-glycosylated (By similarity).
CC -!- SIMILARITY: Belongs to the KCNB family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

CC
CC EMBL; U41002; AAA84001.1; -.
CC InterPro; IPR003930; BK_channel_beta.
CC Pfam; PF03185; CakB; 1.
CC Glycoprotein; Ionic channel; Transmembrane.
CC INIT MET 0
CC DOMAIN 1 14 Cytoplasmic (Potential).
CC TRANSMEM 15 35 1 (Potential).
CC DOMAIN 36 156 Extracellular (Potential).
CC TRANSMEM 157 177 2 (Potential).
CC DOMAIN 178 190 Cytoplasmic (Potential).
CC TRANSMEM 179 79 N-linked (GlcNAc...) (Potential).
CC CARBOHYD 79 79 N-linked (GlcNAc...) (Potential).
CC CARBOHYD 141 141 N-linked (GlcNAc...) (Potential).
CC SEQUENCE 190 AA; 21803 MW; 087715070A35D3C8 CRC64;

Query Match 31.9%; Score 396; DB 1; Length 190;
Best Local Similarity 40.9%; Pred. No. 5.8e-27;
Matches 79; Conservative 41; Mismatches 65; Indels 8; Gaps 2;

QY 34 RKTVTALKAGEDRAILLGLAMVCSIMVYFLIGITLLRSYMQSVWTERSQCTLLNASITE 93
DB 2 KKLVAQRGETRALCLGVAMVCAIYIYLLGTMLLYOKSVWTKSTCHLETIRE 61
QY 94 TFCNSFCGPDCKLQYPCLOVYVNLTSFGSKLLYHTEETIKINOKCSYIPKCGKFE 153
DB 62 QBELECK-----KVPQVPCLL--WNVSAVGKRWAVLXHTEDTRDQNHQCSYIPGSLNYQ 113
QY 154 ESMISLVNVMENFRKYQHFSCYSDPEGKQSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213
DB 114 VARADVEKVRARFENQDFCFSTTRENETTTLVRLYGPQTLFLFLFWPTFLTLTGGLI 173
QY 214 VAMVKLTQVLSLL 226
DB 174 IAWVKINQSLSL 186

RESULT 13
CKB1_BOVIN STANDARD; PRT; 190 AA.
AC Q28067;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta
DE subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1)
DE (Charybdotoxin receptor beta subunit 1) (BKbeta) (Calcium-activated
DE potassium channel beta-subunit) (BKbeta) (Slo-beta).
GN Name=KCNMB1.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A., AND SEQUENCE OF 1-28.
RC TISSUE=Aorta, and Trachea;

RX MEDLINE-94274724; PubMed=8006036;
RA Knaus H.-G., Follander K., Garcia-Calvo M., Garcia M.L.,
RA Kaczorowski G.J., Smith M., Swanson R.;
RT "Primary sequence and immunological characterization of beta-subunit
RT of high conductance Ca(2+)-activated K+ channel from smooth muscle.";
RL J. Biol. Chem. 269:17274-17278(1994).
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
CC KCNNM1 (maxiK) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNNM1, thereby contributing to KCNNM1 channel
CC diversity. Increases the apparent Ca(2+)/voltage sensitivity of
CC the KCNNM1 channel. It also modifies KCNNM1 channel kinetics and
CC alters its pharmacological properties. It slows down the
CC activation and the deactivation kinetics of the channel. Acts as a
CC negative regulator of smooth muscle contraction by enhancing the
CC calcium sensitivity to KCNNM1. Its presence is also a requirement
CC for internal binding of the KCNNM1 channel opener
CC denodroxyasaponin 1 (DHS-1) triterpene glycoside and for external
CC binding of the agonist hormone 17-beta-estradiol (E2). Increases
CC the binding activity of charybdotoxin (CTX) toxin to KCNNM1
CC peptide blocker by increasing the CTX association rate and
CC decreasing the dissociation rate (By similarity).
CC -!- SUBUNIT: Interacts with KCNNM1 tetramer. There are probably 4
CC molecules of KCNNM1 per KCNNM1 tetramer (By similarity).
CC -!- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC -!- PTM: N-glycosylated (By similarity).
CC -!- SIMILARITY: Belongs to the KCNB family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

CC
CC EMBL; L26101; AAA21741.1; -.
CC PIR; A54165; A54165. BK_channel_beta.
CC InterPro; IPR003930; BK_channel_beta.
CC Pfam; PF03185; CakB; 1.
CC Direct protein sequencing; Glycoprotein; Ionic channel; Transmembrane.
CC INIT MET 0 0
CC DOMAIN 1 17 Cytoplasmic (Potential).
CC TRANSMEM 18 38 1 (Potential).
CC DOMAIN 39 156 Extracellular (Potential).
CC TRANSMEM 157 177 2 (Potential).
CC DOMAIN 178 190 Cytoplasmic (Potential).
CC CARBOHYD 79 79 N-linked (GlcNAc...) (Potential).
CC CARBOHYD 141 141 N-linked (GlcNAc...) (Potential).
CC SEQUENCE 190 AA; 21826 MW; 289A154B52D06EF8 CRC64;

Query Match 30.8%; Score 382; DB 1; Length 190;
Best Local Similarity 40.4%; Pred. No. 1e-25;
Matches 78; Conservative 39; Mismatches 66; Indels 8; Gaps 2;

QY 34 RKTVTALKAGEDRAILLGLAMVCSIMVYFLIGITLLRSYMQSVWTERSQCTLLNASITE 93
DB 2 KKLVAQRGETRALCLGVAMVCAIYIYLLGTMLLYOKSVWTKSTCHLETIRE 61
QY 94 TFCNSFCGPDCKLQYPCLOVYVNLTSFGSKLLYHTEETIKINOKCSYIPKCGKFE 153
DB 62 QBELECK-----RVQVPCLL--WNVSAVGKRWAVLXHTEDTRDQNHQCSYIPGSLNYQ 113
QY 154 ESMISLVNVMENFRKYQHFSCYSDPEGKQSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213
DB 114 VARADVEKVRARFENQDFCFSTTRENETTTLVRLYGPQTLFLFLFWPTFLTLTGGLI 173
QY 214 VAMVKLTQVLSLL 226
DB 174 IAWVKINQSLSL 186

RESULT 14
CKB34_HUMAN

ID AC CK64 HUMAN STANDARD; PRT; 210 AA.
DT 05-JUL-2004 (Rel. 44, Q9P0G5;
DT 05-JUL-2004 (Rel. 44, last sequence update)
DT 05-JUL-2004 (Rel. 44, last sequence update)
DE DE Calcium-activated potassium channel beta subunit 4 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 4) (Maxi K channel beta
DE subunit 4) (BK channel beta subunit 4) (Slc-beta 4) (K(VCA)beta 4)
DE (Charybdotoxin receptor beta subunit 4) (BKbeta4) (Hbeta44).
GN Name=KCNMB4;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A., FUNCTION, GLYCOSYLATION, AND VARIANT ILE-199.
RX MEDLINE=20266405; PubMed=10792058; DOI=10.1073/pnas.100118597;
RA Meera P., Wallner M., Toro L.;
RT "A neuronal beta subunit (KCNMB4) makes the large conductance,
RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and
RT iberiotoxin";
RL Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567(2000).
RN [2]
RP SEQUENCE FROM N.A., FUNCTION, GLYCOSYLATION, AND TISSUE SPECIFICITY.
RX PubMed=10828459;
RA Behrens R., Nolting A., Reimann F., Schwarz M., Waldschuetz R.,
RA Pongs O.;
RT "hKCNMB3 and hKCNMB4, cloning and characterization of two members of
RT the large-conductance calcium-activated potassium channel beta subunit
RT family";
RL FEBS Lett. 474:99-106(2000).
RN [3]
RP SEQUENCE FROM N.A., FUNCTION, INTERACTION WITH KCNMAL, AND TISSUE
RP SPECIFICITY.
RX MEDLINE=20159960; PubMed=10692449;
RA Brenner R., Jegla T.J., Wickenden A., Liu Y., Aldrich R.W.;
RT "Cloning and functional characterization of novel large conductance
RT calcium-activated potassium channel beta subunits, hKCNMB3 and
RT hKCNMB4";
RL J. Biol. Chem. 275:6453-6461(2000).
RN [4]
RP SEQUENCE FROM N.A., AND INTERACTION WITH KCNMAL.
RN [5]
RP SEQUENCE FROM N.A.
RC TISSUE=Eye, and Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Frange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettunen M., Madan A.C., Rodriguez S., Sanchez A.,
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield J.S.N., Krzywinski M.I., Skalska U., Smalley D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";

Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[6]
RP PHOSPHORYLATION, AND MUTAGENESIS OF THR-11; SER-17 AND SER-210.
RX PubMed=11790768; DOI=10.1074/jbc.M10768200;
RA Jin P., Weiger T.M., Wu Y., Levitan I.B.;
RT "Phosphorylation-dependent functional coupling of hSlo calcium-
RT dependent potassium channel and its beta 4 subunit";
RL J. Biol. Chem. 277:10014-10020(2002).
RN [7]
RP GLYCOSYLATION, AND MUTAGENESIS OF ASN-53 AND ASN-90.
RX PubMed=12223479; DOI=10.1074/jbc.M205795200;
RA Jin P., Weiger T.M., Levitan I.B.;
RT "Reciprocal modulation between the alpha and beta 4 subunits of hSlo
RT calcium-dependent potassium channels";
RL J. Biol. Chem. 277:43724-43729(2002).
RN [8]
RP REVIEW.
RX PubMed=12136044;
RA Orio P., Rojas P., Ferreira G., Latorre R.;
RT "New disguises for an old channel: MaxiK channel beta-subunits";
RL News Physiol. Sci. 17:156-161(2002).
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
CC KCNMAL (maxik) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNMAL, thereby contributing to KCNMAL channel
CC diversity. Decreases the gating kinetics and calcium sensitivity
CC of the KCNMAL channel, but with fast deactivation kinetics. May
CC decrease KCNMAL channel openings at low calcium concentrations but
CC increases channel openings at high calcium concentrations. Makes
CC KCNMAL channel resistant to 100 nM charybdotoxin (CTX) toxin
CC concentrations.
CC -!- SUBUNIT: Interacts with KCNMAL tetramer. There are probably 4
CC molecules of KCNMAL per KCNMAL tetramer.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- TISSUE SPECIFICITY: Predominantly expressed in brain. In brain, it
CC is expressed in the cerebellum, cerebral cortex, medulla, spinal
CC cord, occipital pole, frontal lobe, temporal lobe, putamen,
CC amygdala, caudate nucleus, corpus callosum, hippocampus,
CC substantia nigra and thalamus. Weakly or not expressed in other
CC tissues.
CC -!- DOMAIN: Resistance to charybdotoxin (CTX) toxin is mediated by the
CC extracellular domain.
CC -!- PTM: Phosphorylated. Phosphorylation modulates its effect on
CC KCNMAL activation kinetics.
CC -!- PTM: N-glycosylated. A highly glycosylated form is promoted by
CC KCNMAL Glycosylation, which is not required for the interaction
CC with KCNMAL and subcellular location, increases protection against
CC charybdotoxin.
CC -!- MISCELLANEOUS: Treatment with okadaic acid reduces its effect on
CC KCNMAL.
CC -!- SIMILARITY: Belongs to the KCNM family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AF160967; AAF69805.1; --
CC EMBL; AF170917; AAF89699.1; --
CC EMBL; AF207992; AAF28333.1; --
CC EMBL; AF215891; AAF75596.1; --
CC EMBL; BC042446; AAF42446.2; --
CC EMBL; BC050621; AAF50621.2; --
CC Genbank; F06289; KCNM4.
CC MIM; 603223; --
CC GO; GO:0008076; C:voltage-gated potassium channel complex; IDA.
CC GO; GO:0015269; F:calcium-activated potassium channel activity; IDA.
CC GO; GO:0005515; P:protein binding; IDA.
CC GO; GO:0005513; P:calcium ion sensing; IDA.
CC GO; GO:0019228; P:generation of action potential; IDA.
CC GO; GO:0006813; P:potassium ion transport; IDA.

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: November 7, 2004, 00:34:47 ; Search time 2961 Seconds
(without alignments)

2892.042 Million cell updates/sec

Title: US-09-914-053A-5

Perfect score: 1241

Sequence: 1 MSITSGRTSSSYRHDEKRN.....MVKLTQYLLCERIORINR 235

Scoring table: BLOSUM62

Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-Q=/cgn2 1/USPTO.spool_p/US09914053/runat 04112004 183922 18233/app_query.fasta_1.391
-DB=EST -OPMT=fastap -SUFFIX=rst -MINMATCH=0.1 -LOPCP=0 -LOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFM=ptc -NOR=ext -HEA=SIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09914053 @CGN 1.1 5180 @runat 04112004 183922 18233 -NCFU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

EST:
1: gb_est1.*
2: gb_est2.*
3: gb_hic.*
4: gb_est3.*
5: gb_est4.*
6: gb_est5.*
7: gb_est6.*
8: gb_est1.*
9: gb_est2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	1235	99.5	801	4	RG188850
2	1186	95.6	2356	3	AK012400 Mus muscu
3	1174	94.6	949	5	BQ942589 AGENCOURT
4	1156	93.2	1597	3	AK014106 Mus muscu
5	1131.5	91.2	694	7	CK945448 4069809 B
6	1123	90.5	803	4	RG198614 RST17879
7	1122	90.4	816	4	RG195580 RST14773
8	1100.5	88.7	795	4	BG218411 RST38279
9	1093.5	88.1	855	5	BG216989 603107309

10	1089	87.8	817	4	BG214809
11	972.5	78.4	939	5	BU222329
12	695	56.0	598	7	CK903430
13	695	56.0	709	7	CK476300
14	688	55.4	852	5	BX729097
15	656	52.9	835	7	CK601161
16	650	52.4	769	7	CK604012
17	648	52.2	622	5	BU950136
18	624.5	50.3	778	4	BG502844
19	608	49.0	562	2	BF433029
20	608	49.0	756	5	BQ179892
21	527	42.5	870	4	BG701449
22	513	41.3	598	6	CB297668
23	508	40.9	567	2	BF446488
24	488.5	39.4	608	7	CK903431
25	481	38.8	558	1	AA904191
26	474	38.2	591	4	BI964810
27	471	38.0	992	6	BY713099
28	466.5	37.6	884	7	CF548250
29	466.5	37.6	1253	3	BC075236
30	464	37.4	796	5	BU205207
31	461	37.1	824	5	BU355397
32	451.5	36.4	446	7	CK898372
33	451	36.3	294	6	CA780337
34	443	35.7	856	7	CK331278
35	421	33.9	885	6	CD516242
36	415	33.4	666	2	BB632101
37	415	33.4	1552	3	AK038987
38	408	32.9	446	1	AI299145
39	403.5	32.5	807	5	BU750277
40	388.5	31.3	547	1	AL641479
41	388.5	31.3	686	5	BU445726
42	387	31.2	829	5	BF17468
43	369	29.7	495	2	BF477842
44	349	28.1	784	5	BU483866
45	344.5	27.8	788	5	BX716835

ALIGNMENTS

RESULT 1	BG188850	801 bp	linear	EST 21-APR-2001
LOCUS	RG188850	Athersys RAGE Library Homo sapiens	cdna, mRNA sequence.	
DEFINITION	RG188850			
ACCESSION	RG188850.1	GI:13710537		
VERSION	EST.			
KEYWORDS	Homo sapiens (human)			
SOURCE	Homo sapiens			
ORGANISM	Homo sapiens			
REFERENCE	1 (bases 1 to 801)			
AUTHORS	Harrington,J.J., Sharf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar M.			
TITLE	Creation of genome-wide protein expression libraries using random activation of gene expression			
JOURNAL	Nat. Biotechnol. 19 (5), 440-445 (2001)			
MEDLINE	21227151			
PUBMED	11329013			
COMMENT	Contact: Scott J. Cain Athersys, Inc. 3201 Carnegie Ave, Cleveland, OH 44115, USA Tel: 216 431 9900 Fax: 216 361 9596 Email: scain@atersys.com High quality sequence stop: 554. Location/Qualifiers 1. 801 /organism="Homo sapiens" /mol_type="mRNA"			

/db_xref="taxon:9606"
 /cell_line="HT1080"
 /clone_lib="Athersys RAGE Library"
 /note="See 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

ORIGIN

Alignment Scores:

Pred. No.: 5.08e-131 Length: 801
 Score: 1235.00 Matches: 234
 Percent Similarity: 99.57% Conservative: 0
 Best Local Similarity: 99.57% Mismatches: 1
 Query Match: 99.52% Indels: 0
 DB: 4 Gaps: 0

US-09-914-053A-5 (1-235) x BG188850 (1-801)

Qy 1 MetSerIleTrrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 21 IleTyrGlnLysIleA:GAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 132 ATTTACAGAAATCAGGACCATGCTCTCTGGACAAAAGGAAACAGTCACGACACTG 191
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMet 60
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 192 AAGCAGAGAGAGGACCATGCTCTCTGGACATGATGATGATGATGATGATGATGATG 251
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGlu 80
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 252 ATGTATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACGATGATGACGAA 311
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 312 GAGTCTCAATGACCTGCTGGAATGCTGATCATCAGGAAACATTTAATGCTCTCTCAGC 371
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 101 CysGlyProAspCysTrrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 372 TGTGTCAGACTGCTGGAATCTTCTCAGTACCTGCTCCAGGTGACGTAACTG 431
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 432 ACTTCTTCCGGGAAAAGCTCTCTCTACACAGAGAGACATATAAATCAATCAG 491
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 141 LysCysSerTrrLysProLysGlyLeuAsnGluSerMetSerLeuValAsn 160
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 492 AAGTCTCTCTATATACCTAATGATGGAATAATTTTGAAGATCCATGCTCTGCTGAT 551
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 552 GTTCTCATGAAAACCTTCAGGAAGTATCAACTCTCTCTGCTATTCTGACCCAGGAAGA 611
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 612 AACCAAGAGAGTATTCCTAACAAAACCTCTACAGTTCACAGTCTGCTGCTTCCATCTC 671
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 201 PheTrrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 672 TTCTGGCAACCTGATGATGCTGGGGTGTGGCAATTTGCTGATGCTGGGAACTTACA 731
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Qy 732 CAGTACCTCTCTCTACATGATGAGAGGATCCAAACGGATCAATAGA 776
 Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 2

AK012400 2356 bp mRNA linear HTC 03-APR-2004
 LOCUS Mus musculus 11 days embryo whole body cDNA, RIKEN full-length
 DEFINITION

ACCESSION
 VERSION
 KEYWORDS
 ORGANISM

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

REFERENCE
 AUTHORS

TITLE
 JOURNAL
 MEDLINE
 PUBMED

enriched library, clone:2700049B16 product:LARGE CONDUCTANCE
 CALCIUM-ACTIVATED K CHANNEL BETA2 SUBUNIT, full insert sequence.
 AK012400
 AK012400.1 GI:12849119
 HTC; CAP trapper.
 Mus musculus (house mouse)
 Mus musculus
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1
 Carninci, P. and Hayashizaki, Y.
 High-efficiency full-length cDNA cloning
 Meth. Enzymol. 303, 19-44 (1999)
 99279253
 10349636
 2
 Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K.,
 Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
 Normalization and subtraction of cap-trapper-selected cDNAs to
 prepare full-length cDNA libraries for rapid discovery of new genes
 Genome Res. 10 (10), 1617-1630 (2000)
 20499374
 11042159
 3
 Shibata, K., Itoh, M., Aizawa, K., Nagaoaka, S., Sasaki, N., Carninci, P.,
 Konno, H., Akiyama, J., Nishi, K., Kitsuai, T., Tashiro, H., Itoh, M.,
 Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A.,
 Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K.,
 Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watahiki, M.,
 Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsuura, S., Kawai, J.,
 Okazaki, Y., Muramatsu, M., Inoue, Y., Kita, A. and Hayashizaki, Y.
 RIKEN integrated sequence analysis (RISA) system--384-format
 sequencing pipeline with 384 multiplexed capillary sequencer
 Genome Res. 10 (11), 1757-1771 (2000)
 20530913
 11076861
 4
 The RIKEN Genome Exploration Research Group Phase II Team and the
 FANTOM Consortium.
 Functional annotation of a full-length mouse cDNA collection
 Nature 409, 685-690 (2001)
 5
 The FANTOM Consortium and the RIKEN Genome Exploration Research
 Group Phase I & II Team.
 Analysis of the mouse transcriptome based on functional annotation
 of 60,770 full-length cDNAs
 Nature 420, 563-573 (2002)
 6 (bases 1 to 2356)
 Adachi, J., Aizawa, K., Akahira, S., Akimura, T., Arai, A., Aono, H.,
 Arakawa, T., Bono, H., Carninci, P., Fukuda, S., Fukunishi, Y.,
 Furuno, M., Hanagaki, T., Hara, A., Hayatsu, N., Hiramoto, K.,
 Hiraoka, T., Hori, F., Imotani, K., Ishii, Y., Itoh, M., Izawa, M.,
 Kasukawa, T., Kato, H., Kawai, J., Kojima, Y., Konno, H., Kouda, M.,
 Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Nishii, K.,
 Nomura, K., Numazaki, R., Ohno, M., Okazaki, Y., Okido, T., Owa, C.,
 Saito, H., Saito, R., Sakai, C., Sano, H., Sano, H., Sasaki, D.,
 Shibata, K., Shibata, Y., Shinagawa, A., Shiraki, T., Sogabe, Y.,
 Suzuki, H., Tagami, M., Tagawa, A., Takahashi, F., Tanaka, T.,
 Tejima, Y., Toya, T., Yamamura, T., Yasunishi, A., Yoshida, K.,
 Yoshino, M., Muramatsu, M. and Hayashizaki, Y.
 Direct Submission
 Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of
 Physical and Chemical Research (RIKEN), Laboratory for Genome
 Exploration Research Group, RIKEN Genomic Sciences Center (GSC),
 RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,
 Kanagawa 230-0045, Japan (E-mail: genome-res@gs.c.riken.jp,
 URL: http://genome.gsc.riken.jp/, Tel: 81-45-503-9222,
 Fax: 81-45-503-9216)
 Please visit our web site (http://genome.gsc.riken.jp/) for further
 details.
 cDNA library was prepared and sequenced in Mouse Genome
 Encyclopedia Project of Genome Exploration Research Group in Riken
 Genomic Sciences Center and Genome Science Laboratory in RIKEN.


```
/tissue type="head"
/clone_lib="RIKEN full-length enriched mouse cDNA library"
/dev_stage="13 days embryo"
488..1194
/note="LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL BETA2
SUBUNIT (SPTR)AAL38982, evidence: FASTY, 100%ID,
100%length, match=705)
putative"
```

misc_feature

ORIGIN

Alignment Scores:

```
Pred. No.: 1.73e-121 Length: 1597
Score: 1156.00 Matches: 222
Percent Similarity: 96.60% Conservative: 5
Best Local Similarity: 94.47% Mismatches: 8
Query Match: 93.15% Indels: 1
DB: 3 Gaps: 0
```

US-09-914-053A-5 (1-235) x AK014106 (1-1597)

```
Qy 1 MetSerIleTrrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
Db 488 ATGTTTATATGACGACGAGCGGACCTCTTCATCTTACAGACGAGGAGAAAGAAAT 547
Qy 21 IletYrGlnLysIleAgaSpHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db 548 ATCTACAGAAATACAGGACCATGACCTCTGACAAAGGAAACTGTGACAGCTCTG 607
Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMet 60
Db 608 AAGCTGGGAGGACCGGACATCTGCTGGCCCTGGCCATGATGGTGTCTCCATCATG 667
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrpGlu 80
Db 668 ATGTACTTCTCTGGGATACACTGCTGGCTCTCTCATGACGACGCTGGACAGAA 727
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 728 GAGCC-CAGTGTGCGCTGCTGAATGTGTCAATCACAGAAAGCTTAACTGTCTCTCAGC 786
Qy 101 CysGlyProAspCysTrrpLysLeuSerGlnTyrProCysLeuGlnValTrrpValAsnLeu 120
Db 787 TGTGGCCCGACTGTGTGAACCTCTCAGTACCCCTTGCCTGAGGCTGACGTAACCTG 846
Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
Db 847 ACATCTTCGGGAGAGGCTCTCTCTTACACAGGAGACCATGAAGATCAATCAA 906
Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluSerMetSerLeuValAsn 160
Db 907 AAGTGCTCTATATCTTAACTGTGAACAACTTTGAGGAGTCCATGCTCTCGTGAGT 966
Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
Db 967 GTCTGTCATGGAACCTTCAGAGACCAACACTTCCCTGCTATTCTGACCCAGAGGA 1026
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
Db 1027 AACCAAGAGAGTGTATCTGACCAAACTCTACAGCTCCCATGTGCTGTTCCTCTC 1086
Qy 201 PheTrrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220
Db 1087 TTCTGGCCAACTTGTATGATGGCTGGGGGTGGCAATCGTTGCTATGTTGGTAACACT 1146
Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db 1147 CAGTACCTCTCCCTGCTTTGTGAGAGGATCCAAAGGATCAACAGA 1191
```

RESULT 5

```
CK945448 594 bp mRNA linear EST 15-MAR-2004
LOCUS 4069809 BARC 10BOV Bos taurus cDNA clone 10BOV17_N10 5', mRNA
DEFINITION sequence.
```

```
ACCESSION CK945448
VERSION CK945448.1 GI:45459828
KEYWORDS EST.
SOURCE Bos taurus (cow)
ORGANISM Bos taurus
```

```
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovinae; Bos.
1 (bases 1 to 694)
Sonstegard, T.S., Van Tassel, C.P., Matukumalli, L.K., Harhay,
G.P., Bosak, S., Rubenfield, M. and Gasbarre, L.C.
Production of EST from cDNA libraries derived from immunologically
activated bovine gut
Unpublished (2004)
Contact: Tad S. Sonstegard
Bovine Functional Genomics Laboratory
Animal and Natural Resources Institute
Bldg. 200 Rm2A BARC-East, Beltsville, MD 20705, USA
Tel: 3015048416
Fax: 3015048414
Email: tad@ari.barc.usda.gov
Single pass sequencing. Bases called and trimmed with phred
0.000925 using options -trim alt - -trim fasta. Vector identified
by cross_match using options -minmatch 12 -minscore 12
Plate: 17 row: N column: 10
Seq primer: CCCAGTCACGACGTTGTAAACG
High quality sequence stop: 694.
```

```
REFERENCE
AUTHORS Location/Qualifiers
TITLE
JOURNAL
COMMENT
```

```
FEATURES
source
1..694
/organism="Bos taurus"
/mol_type="mRNA"
/strain="Holstein"
/db_xref="taxon:9913"
/clone="10BOV17_N10"
/sex="Male"
/tissue_type="Pooled"
/dev_stage="Multiple"
/lab_host="DH10B fl phage resistant"
/clone_lib="BARC 10BOV"
Note="Organ: Small Intestine; Vector: pagen-1; Site 1:
ECRV; Site 2: NotI; Equimolar amounts of mRNA extracted
from proximal jejunum of 18 and 21 wk old steers, and
distal ileums of 14 day old calves; proximal jejunum
exposed to C. oncophora for 3 and 6 weeks, and distal
ileum exposed to C. parvum for 7 days"
```

```
Alignment Scores:
Pred. No.: 3.21e-119 Length: 694
Score: 1131.50 Matches: 220
Percent Similarity: 98.66% Conservative: 1
Best Local Similarity: 98.21% Mismatches: 3
Query Match: 91.18% Indels: 2
DB: 7 Gaps: 0
```

US-09-914-053A-5 (1-235) x CK945448 (1-694)

```
Qy 1 MetSerIleTrrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
Db 17 ATGTTTATATGACGACGAGCGGACCTCTTCATCTTACAGACATGATGAGAAAGAAAT 76
Qy 21 IletYrGlnLysIleAgaSpHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db 77 ATTACCAAAAATCAGGACCCACGACCTCTCTGGACCTGGCAAAAGGAAACTGTACAGCAGCTG 136
Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMet 60
Db 137 AAAGCAGGAGAGACCGGGCCATCTCTCTGGACTGGCCATGATGTGTGTCTCCATCATG 196
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrpThrGlu 80
Db 197 ATGTACTTCTCTGGGAATCACTCTCTGCGCTCATACATGACAGAGTGTATGGACCGAG 256
```

ORIGIN

```
Alignment Scores:
Pred. No.: 1.73e-121 Length: 1597
Score: 1156.00 Matches: 222
Percent Similarity: 96.60% Conservative: 5
Best Local Similarity: 94.47% Mismatches: 8
Query Match: 93.15% Indels: 1
DB: 3 Gaps: 0
```

US-09-914-053A-5 (1-235) x AK014106 (1-1597)

```
Qy 1 MetSerIleTrrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
Db 488 ATGTTTATATGACGACGAGCGGACCTCTTCATCTTACAGACGAGGAGAAAGAAAT 547
Qy 21 IletYrGlnLysIleAgaSpHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db 548 ATCTACAGAAATACAGGACCATGACCTCTGACAAAGGAAACTGTGACAGCTCTG 607
Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMet 60
Db 608 AAGCTGGGAGGACCGGACATCTGCTGGCCCTGGCCATGATGGTGTCTCCATCATG 667
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrpGlu 80
Db 668 ATGTACTTCTCTGGGATACACTGCTGGCTCTCTCATGACGACGCTGGACAGAA 727
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 728 GAGCC-CAGTGTGCGCTGCTGAATGTGTCAATCACAGAAAGCTTAACTGTCTCTCAGC 786
Qy 101 CysGlyProAspCysTrrpLysLeuSerGlnTyrProCysLeuGlnValTrrpValAsnLeu 120
Db 787 TGTGGCCCGACTGTGTGAACCTCTCAGTACCCCTTGCCTGAGGCTGACGTAACCTG 846
Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
Db 847 ACATCTTCGGGAGAGGCTCTCTCTTACACAGGAGACCATGAAGATCAATCAA 906
Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluSerMetSerLeuValAsn 160
Db 907 AAGTGCTCTATATCTTAACTGTGAACAACTTTGAGGAGTCCATGCTCTCGTGAGT 966
Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
Db 967 GTCTGTCATGGAACCTTCAGAGACCAACACTTCCCTGCTATTCTGACCCAGAGGA 1026
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
Db 1027 AACCAAGAGAGTGTATCTGACCAAACTCTACAGCTCCCATGTGCTGTTCCTCTC 1086
Qy 201 PheTrrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220
Db 1087 TTCTGGCCAACTTGTATGATGGCTGGGGGTGGCAATCGTTGCTATGTTGGTAACACT 1146
Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db 1147 CAGTACCTCTCCCTGCTTTGTGAGAGGATCCAAAGGATCAACAGA 1191
```

RESULT 5

```
CK945448 594 bp mRNA linear EST 15-MAR-2004
LOCUS 4069809 BARC 10BOV Bos taurus cDNA clone 10BOV17_N10 5', mRNA
DEFINITION sequence.
```

QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
 DB 257 GAGGCTCAGTCACCTGCTGAATGCATCCATCAGAGAAACATTAATGCTCTTCAGC 316

QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
 DB 317 TGTGCTCCGGACTGCGAACTCTCTCAGTATCCCTGCTACAGGTGATGTTAACTG 376

QY 121 ThrSerSerGlyGluLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
 DB 377 ACTTCTCCGGTGAAGAGCTCTCTCTACACAGAGAGAGCAATAAATAATCAATCAG 436

QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
 DB 437 AAGTCTCTATATACCTAAGTGTGGAATAATTTTGAAGATCCATGCTCCCTGTAAT 496

QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
 DB 497 GTTGTCATGGAAAACCTTCAGGAAGTACCAACACTCTCTCTGCTACTCTGACCCGAAAGGA 556

QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
 DB 557 AACCCAGAGAGTGTCTCTTACCAAACTCTACAGTTCACACGCTGCTTCCATTCACCT 616

QY 201 PheTrpProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
 DB 617 TTTTGCCCAACATGATGCTGGGGCGTGGCAATTGT-GCCATGTTGAA-CTCACA 674

QY 221 GlnTyrLeuSer 224
 DB 675 CAGTATCTTTC 686

RESULT 6
 BG198614
 LOCUS RST17879 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.
 DEFINITION BG198614
 ACCESSION BG198614.1 GI:13720301
 VERSION EST.
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 803)
 Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R.,
 Cain,S., Leventhal,C., Thornton,M., Ramachandran,R.,
 Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S.,
 Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K.,
 Offenbacher,J., Danzig,J. and Ducar M.
 Creation of genome-wide protein expression libraries using random
 activation of gene expression
 Nat. Biotechnol. 19 (5), 440-445 (2001)
 21227151
 11329013
 Contact: Scott J. Cain
 Athersys, Inc.
 3201 Carnegie Ave, Cleveland, OH 44115, USA
 Tel: 216 431 9900
 Fax: 216 361 9596
 Email: scain@atersys.com
 High quality sequence stop: 553.
 Location/Qualifiers
 1. 803
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /cell_line="HT1080"
 /clone_lib="Athersys RAGE Library"
 /note="See 'Creation of Genome-wide Protein Expression'
 Libraries using Random Activation of Gene Expression',
 Nature Biotechnology, in press. Note that even though the
 cell type indicated is HT1080, since a random activation
 method was used, these sequence tags are not necessarily

expressed in HT1080 under normal circumstances."

ORIGIN
 Alignment Scores: 3.8e-118 Length: 803
 Pred. No.: 1123.00 Matches: 217
 Score: 1123.00 Conservative: 3
 Percent Similarity: 94.02% Mismatches: 13
 Best Local Similarity: 92.74% Indels: 1
 Query Match: 90.49% Gaps: 0
 DB: 4

US-09-914-053A-5 (1-235) x BG198614 (1-803)

QY 1 MetSerIleTyrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
 DB 73 ATGTTTATATGACACAGTGGCGGACCTCTTCATCTTATAGACATCATGAAAAAGAAAT 132

QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
 DB 133 ATTTCACAGAAAATCAGGACCATGACCTCTCTGGACAAAAGGAAACAGTCACAGCACTG 192

QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
 DB 193 AAGGACGAGGAGAGAGAGCTATTCTCCGGACCTGGCTATGTTGGTCTCCATCATG 252

QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80
 DB 253 ATGTAATTTCTCTGGGAATCACATCTCTCGCTCATACATGACAGGGTGTGGACCGAA 312

QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
 DB 313 GAGTCTCAATGACCTTGTGTAATGCTCCATCAGGAAACATCTAATTCCTCTTCAGC 372

QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
 DB 373 TGTGCTCCAGACTGCTGGAACTTTCTCAGTACCTCCCTCCAGGTGACGTTAACTG 432

QY 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
 DB 433 ACTTCTTCCGGGAAAAGCTCTCTCTACACAGAGAGACAAATAAATCAATCAG 492

QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerSerLeuValAsn 160
 DB 493 AAGTCTCTCTATATACCTAAATGTGGAATAATTTTGAAGATCCATGCCCTGCTGAAT 552

QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
 DB 553 GTTGTATGAGAAAATTCAGGAAGCATCAACACTCTCTCTGCTATTCTGACCCAGAACGA 612

QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
 DB 613 AACCCAGAGAGTGTATCTTAAACAACTTACAGTTTCAACGGGCTGTTCCATTCATC 672

QY 201 PheTrpProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetVal-LysLeuTh 220
 DB 673 TTTCTGCCCAACCTGTATGATGCTGGGGTGGGGAATTTGTTGATGTTGGTGGAACTTCA 732

QY 220 rGlnTyrLeuSerLeuLeuCysGluArgIleGlnArgile 233
 DB 733 CCAGTCTCTTTTCCCTACTATGTGAGAGGATCCACCGGATC 772

RESULT 7
 BG195580 816 bp mRNA linear EST 21-APR-2001
 LOCUS RST14773 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.
 DEFINITION BG195580
 ACCESSION BG195580.1 GI:13717267
 VERSION EST.
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 816)

AUTHORS Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.

TITLE Creation of genome-wide protein expression libraries using random activation of gene expression

JOURNAL Nat. Biotechnol. 19 (5), 440-445 (2001)

MEDLINE 21227151

PUBMED 11329013

COMMENT Contact: Scott J. Cain
Athersys, Inc.
3201 Carnegie Ave, Cleveland, OH 44115, USA
Tel: 216 431 9900
Fax: 216 361 9596
Email: scain@atersys.com
High quality sequence stop: 364.

FEATURES
source
1..816
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="HT1080"
/clone_lib="Athersys RAGE Library"
/note="See 'Creation of Genome-wide Protein Expression' Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

ORIGIN
Alignment Scores:
Pred. No.: 5,07e-118 Length: 816
Score: 1122.00 Matches: 220
Percent Similarity: 93.25% Conservative: 1
Best Local Similarity: 92.83% Mismatches: 14
Query Match: 90.41% Indels: 2
DB: 4 Gaps: 0

US-09-914-053A-5 (1-235) x BG195580 (1-816)

QY 1 MetSerIleTrpThrSerGlyArgThrSerSerSerTyArgHisAspGluLysArgAsn 20
DB 72 ATGTTTATGAGCAGGCGGACCTCTTCACTTATAGACATGATGAAAAAGAAAT 131
QY 21 IleTyGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThAlaIeu 40
DB 132 ATTTACCAAGAAATCAGGAGCCATGACCTCTGGACAAAAGGAAACAGTCACAGCACTG 191
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleWet 60
DB 192 AAGCAGGAGAGGACCGAGCTATTCTCTGGAGCTGGCTATGATGGTGTCTCCATCATG 251
QY 61 MetTyRheLeuLeuGlyIleThrLeuLeuArgSerTyMetGlnSerValTrpThrGlu 80
DB 252 ATGTATTTCCTGCTGGGAATCACACTCTGGCTCATACATGCGAGCGTGTGACCGAA 311
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
DB 312 GAGTCTCAATGCACCTTCTGATGCGTCCATCAGGAAACATTTAATGCTCTCTCAGC 371
QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyProCysLeuGlnValTyValAsnLeu 120
DB 372 TGTGTCCAGACTGTCTGGAATCTTCTCAGTACCCCTCCCTCCAGGTACGTAACTG 431
QY 121 ThrSerSerGlyLysLeuLeuLeuTyHisThrGluGluThrIleLysIleAsnGln 140
DB 432 ACTTCTTCGNGGAAAGCTCTCTCTACACACAGAGAGACAATAAATAATCAATCAG 491
QY 141 LysCysSerTyRileProLysCysGlyLysAsnPheGluGluUserMetSerLeuValAsn 160
DB 492 AAGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATCTNCTCTGTGAT 551

QY 161 ValValMetGluAsnPheArgLysTyArgHisPheSerCysTySerAspProGluGly 180
DB 552 GTTGTCTATGAAAACTTCAGGAAGTATCAACTTCTCTCTCTCTCTCTCTCTCTCTCT 611
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTySerSerAsn-ValLeuPheHisSerLe 200
DB 612 AACCAAGAGAGTGTATNCTAACAAACTCTACAGTTCACCGTCCGTCGTCATTCAT 671
QY 200 uPheTrpProThrCysMetMet-AlaGlyGlyValAlaIleValAlaMetValLysLeu 220
DB 672 TCTCTGGCAACCTGTATGATGGCTGGGGCGTGCATAATTGTGCGATGGTGAACCTTA 731
QY 220 hrGlnTyRleuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
DB 732 CACAGACCTCTNCTACTATGCGAGAGATCAACCGCATCANTAGA 778

RESULT 8
BG218411 795 bp mRNA linear EST 21-APR-2001
LOCUS RST38279 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.
DEFINITION BG218411
ACCESSION BG218411
VERSION BG218411.1 GI:13744560
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 795)
AUTHORS Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.
TITLE Creation of genome-wide protein expression libraries using random activation of gene expression
JOURNAL Nat. Biotechnol. 19 (5), 440-445 (2001)
MEDLINE 21227151
PUBMED 11329013
COMMENT Contact: Scott J. Cain
Athersys, Inc.
3201 Carnegie Ave, Cleveland, OH 44115, USA
Tel: 216 431 9900
Fax: 216 361 9596
Email: scain@atersys.com
High quality sequence stop: 483.

FEATURES
source
1..795
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="HT1080"
/clone_lib="Athersys RAGE Library"
/note="See 'Creation of Genome-wide Protein Expression' Libraries using Random Activation of Gene Expression', the Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

ORIGIN
Alignment Scores:
Pred. No.: 1.44e-115 Length: 795
Score: 1100.50 Matches: 222
Percent Similarity: 95.71% Conservative: 1
Best Local Similarity: 95.28% Mismatches: 8
Query Match: 88.68% Indels: 4
DB: 4 Gaps: 1

US-09-914-053A-5 (1-235) x BG218411 (1-795)

QY 3 IleTrpThrSerGlyArgThrSerSerSerTyArgHisAspGluLysArgAsnIleTyR 22

```

Db      78 ATATGACCACCGCGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAATATTTC 137
QY      23 GlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAla 42
Db      138 CAGAAATCAGGACCATGACTCTCTGGACAAAGAAACAGTACAGCATCTGAAGCA 197
QY      43 GlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyr 62
Db      198 GGAGAGGACCGAGCTTTCTCTGGAGCTGGCTATGATGCTGCTCCATCATGATGAT 257
QY      63 PheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGluGluSe 82
Db      258 TTCTCTCTGGGATTT---CTTCTGGCTTCATACATGAGAGCGGTGGACCGAAGATC 314
QY      82 rGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysG1 102
Db      315 TCAATGCACCTTGTGTAATGGCTCCATCAGCAAAACATTTAATTGCTCTTCAGCTGG 374
QY      102 yProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSe 122
Db      375 TCAGACTCTGGAACCTTTCTCAGTACCCCTGCCCTCCAGGTGTACGTAACTGACTTC 434
QY      122 rSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCy 142
Db      435 TTCGGGGGA-AGCTCCCTCTCTACCAACAGAGACATATAAATCAATCAGAAATG 493
QY      142 sSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValva 162
Db      494 CTCCTATATACCTAAATGTGAAAAAATTTGAAGATCCATGTCCTCGGTGAATGTGT 553
QY      162 lMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnG1 182
Db      554 CAITGAAAACTTCAGAAATATCAACACTTCTTCTGCTATTCTGACCCAGAGAAACCA 613
QY      182 nLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTr 202
Db      614 GAAGAGTGTATCTTAACAAAACTCTACAGTTTCCAACTGCTGTCTCCATTTCTG 673
QY      202 pProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTy 222
Db      674 GCAACCTGATGATGGCTGGCGGGTGGCAATTTCTGCCATGGGAAACT-ACACAGTA 732
QY      222 rLeuSerLeuLeuCysGluArgIleGlnArgIleAsn 234
Db      733 CTTTTCCTTACTATGTGAGAGGATCCACGGATCCAT 769

RESULT 9
BU216989
LOCUS
DEFINITION
603107309F1 CSEQCHN04 Gallus gallus linear EST 25-NOV-2002
sequence.
ACCESSION
BU216989
VERSION
BU216989.1 GI:25398033
KEYWORDS
EST.
SOURCE
Gallus gallus (chicken)
ORGANISM
Gallus gallus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 855)
Boardman, P.E., Sanz-Ezquerro, J., Overton, I.M., Burt, D.W., Bosch, E.,
Fong, W.T., Tickle, C., Brown, W.R.A., Wilson, S.A. and Hubbard, S.J.
A Comprehensive Collection of Chicken cDNAs
Curr. Biol. 12 (22), 1965-1969 (2002)
22335534
MEDLINE
12445392
PUBMED
Contact: Simon Hubbard
Department of Biomolecular Sciences
University of Manchester Institute of Science and Technology
(UMIST)
PO Box 88, Manchester, M60 1QD, UK
Tel: 01612008930
Fax: 01612360409

```

```

FEATURES
source
Location/Qualifiers
1..855
/organism="Gallus gallus"
/mol_type="mRNA"
/strain="White Leghorn, Hisex"
/db_xref="taxon:9031"
/clone="ChEST48b4"
/tissue_type="whole embryo"
/dev_stage="20-21"
/lab_host="DH108"
/clone_lib="CSEQCHN04"
Notes: Organ: whole embryo; Vector: pBluescript II KS(+);
Site 1: EcoRI; Site 2: NotI; This normalized library was
constructed from 1 million independent clones. cDNA
synthesis was initiated using an oligo(dT) primer, using
methylated C in the first strand synthesis reaction
Following this first strand reaction, double-stranded cDNA
was bluntended, ligated to NotI adapters, digested with
EcoRI, size-selected, and cloned into the NotI and EcoRI
compatible sites of a custom modified MCS of the
pBluescript (KS+) vector. The library was normalized in 2
rounds using conditions adapted from Soares et al., PNAS
(1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6
(1996): 791, except that a significantly longer
reannealing hybridization was used."
ORIGIN
Alignment Scores:
Pred. No.: 1,03e-114 Length: 855
Score: 1093.50 Matches: 209
Percent Similarity: 93.64% Conservative: 12
Best Local Similarity: 88.56% Mismatches: 7
Query Match: 88.11% Indels: 8
DB: 5 Gaps: 1
US-09-914-053A-5 (1-235) x BU216989 (1-855)
QY      1 MetSerIleTrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
Db      152 ATGTTTATTGGACCATGTCGCGGAGCTCTACATCTTACAGACACGATGAGAAA----- 205
QY      21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db      206 -----AGGATCAGATCTCTGACAAAGAAAGAAACAGTCACAGCCCTA 250
QY      41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
Db      251 AAAGCTGGAGAAACACCGGCCCATCTCTCGGGCTGGCCATCATGCTGCTCATCATG 310
QY      61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80
Db      311 ATGTACTTCTCTGGGAATCACCTGTCGCGGTCTCTACATGACAGAGCTCTGGACAGAA 370
QY      81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db      371 GAGGCTCAGTCTCGCTTCTCAACGCATCCATCACGAAACCTTCAACTGCTCGTTAGC 430
QY      101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
Db      431 TGGCGGCCAGAGTCTGGAAAAATCTCTAGTACCCCTGCTCAGGTGTACATCATCTC 490
QY      121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
Db      491 ACTTCTTCTGGCCAGAGCTTCTGCTTACCACACCGAAGAAACAAATGAAATAATTCT 550
QY      141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
Db      551 GAGTGTGTCATATACCCCAAGTGTGGCAAGAAATACGAGGAATCCATGTCATGTGAAC 610
QY      161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
Db      611 GTTGTGATGGAAAACTTCGGAAGATATCAACGCTTCTCTGCTTCTATGATCTTGAGGC 670

```

Email: Simon.Hubbard@umist.ac.uk.


```

/mol_type="mRNA"
/strain="White Leghorn, Hisex"
/db_xref="taxon:9031"
/clone="ChST43b24"
/tissue_type="whole embryo"
/dev_stage="20-21"
/lab_host="DH10B"
/clone_lib="CSQCHN04"
/site="organ: whole embryo; Vector: pBluescript II KS(+);
Site 1: EcoRI; Site 2: NotI; This normalized library was
constructed from 1 million independent clones. cDNA
synthesis was initiated using an oligo(dT) primer, using
methylated C in the first strand synthesis reaction.
Following this first strand reaction, double-stranded cDNA
was blunt-ended, ligated to NotI adapters, digested with
EcoRI, size-selected, and cloned into the NotI and EcoRI
compatible sites of a custom modified MCS of the
pBluescript (KS+) vector. The library was normalized in 2
rounds using conditions adapted from Soares et al., PNAS
(1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6
(1996): 791, except that a significantly longer
reannealing hybridization was used."

```

ORIGIN

```

Alignment Scores:
Pred. No.: 9 52e-101 Length: 939
Score: 972.50 Matches: 205
Percent Similarity: 88.98% Mismatches: 13
Best Local Similarity: 83.67% Indels: 17
Query Match: 78.36% Gaps: 3
DB: 5

```

US-09-914-053A-5 (1-235) x BU222329 (1-939)

```

Qy 1 MetSerIleTyrThrSerGlyArgHisSerSerSerTyrArgHisAspGluLysArgAsn 20
Db 152 ATGTTATTTCGACGAGTGGCGGAGCTCTACATCTTACACACGATGAGAAA----- 205
Qy 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db 206 -----AGGATCATCGATCTACTGTCACAAAGAAAGAAAGATGACAGCCCTA 250
Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
Db 251 AAAGTGGAGAAGACCGGGCCATATCTCGGGTGGCCATGATGGTGTCTTATCATG 310
Qy 61 MetTyrPheLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80
Db 311 ATGACTTCTTCCTGGGAATCACCTGTGCGGTCTTACATGACGAGCGTCTGGACAGAA 370
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 371 GAGGTCAGTCTGCTCTTCAACGATCCATCACCGAAACCTTCAACTGCTGTTTACG 430
Qy 101 CysGlyProAspCysTyrPheLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
Db 431 TGGCGCCAGACTGCTGAAAATCTTCAGTACCCCTCGCTGCGAGGTACGTCATCTC 490
Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLys-IleAsnGlu 140
Db 491 ACTTCTTCTGCGCAGACCTTCTCTTACACACCGAAGAAACATGAAACATTATTC 550
Qy 140 nLysCysSerTyrIleProLysCysGlyLysAsnPheGluGlnSerMetSerLeuValAs 160
Db 551 TGAGTGTTCGTACATACCAAGTGTGCAAGAAATACGAGAAATCCATGTCATGTGTGAA 610
Qy 160 nValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlu 180
Db 611 CGTTGTGATGAAAACCTCCGAAGATATCAACGCTTCTCTGCTTCTATGATCTGAGGG 670
Qy 180 yAsnGlnLysSerValIleLeuThr-LysLeuTyrSerSer-AsnVal---LeuPheHis 198
Db 671 CACTCAGAAGAACGTGATATTGACCAAACTGTACAGCTCCCAACGCTGGTCTGTTACAC 730

```

```

Qy 199 SerLeuPheTrp--ProThrCysMetMetAlaGlyValAla---IleValAlaMetV 217
Db 731 TCGCTCTTCTGGGCCCCCGTCATGATCGCGGGCGTTCGCCCATTTTTCGGAATGG 790
Qy 217 allys-LeuThrGlnTyrLeu-SerLeuLeuCysGluArgIle-GlnArgIleAsnArg 235
Db 791 TAAAGCGTCACTCAATACCTTTTCTCTCTCGGAGAGATCCCAAGGATCAACAGA 849

```

RESULT 12

```

LOCUS CK903430/c
DEFINITION ie57a02.x5 Melton Normalized Human Islet 4 N4-HIS 1 Homo sapiens
cDNA clone IMAGE:5670818 3', similar to TR:Q9Y691 Q9Y691 MAXIK
CHANNEL BETA 2 SUBUNIT.1, mRNA sequence.

```

ACCESSION

CK903430

VERSION

CK903430.1

KEYWORDS

EST.

SOURCE

Homo sapiens (human)

ORGANISM

Homo sapiens

REFERENCE

1 (bases 1 to 598)

AUTHORS

Melton,D., Meadows,A., Clifton,S., Hillier,L., Marra,M., Pape,D.,

Wyllie,T., Martin,J., Blistain,A., Schmitt,A., Theising,B.,

Ritter,E., Ronko,I., Bennett,J., Cardenas,M., Gibbons,M.,

McCann,R., Cole,R., Tsagarisshvili,R., Williams,T., Jackson,Y. and

Bowers,F.

WashU-Harvard Pancreas EST Project

Unpublished (2000)

Other ESTs: ie57a02.y1

Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue

Endocrine Pancreas Consortium

Harvard University, Howard Hughes Medical Institute

Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,

MA 02138

Tel: 617-495-1812

Fax: 617-495-8557

Email: dmelton@iohnp.harvard.edu

This read is a 3' RESEQUENCE of a previously sequenced pancreas

clone

This resequenced clone has not previously been sequenced on this

end, resequencing from this end represents new data

Seq primer: -40UP from Gibco

High quality sequence stop: 594.

FEATURES

Location/Qualifiers

1..598

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:5670818"

/sex="Both"

/tissue_type="Islets of Langerhans"

/dev_stage="Adult"

/lab_host="DH10B"

/clone_lib="Melton Normalized Human Islet 4 N4-HIS 1"

/note="Organ: Pancreas; Vector: pSPORT1; Site 1: Not 1;

Site 2: Sal 1; Starting library constructed using

SuperScript Plasmid Library kit (Life Technologies). cDNA

made by oligo-dT priming. Size-selected by column

fractionation; average insert size 1.08 kb. Library was

amplified once on solid support and plasmid DNA from

library was prepared. The library DNA was normalized by

method #4 from Bonaldo, Lennon, and Soares 1996 Genome

Research 6:791-806; 0.5 microgram single-stranded library

plasmid DNA was mixed with 5 micrograms PCR product

representing library inserts and hybridized to an Ecot of

20' Single-stranded (unhybridized) plasmids were isolated

by hydroxyapatite chromatography and used to make this

library."

ORIGIN

Alignment Scores:

Pred. No.: 3,77e-69 Length: 598
 Score: 695.00 Matches: 130
 Percent Similarity: 99.24% Conservativeness: 0
 Best Local Similarity: 99.24% Mismatches: 1
 Query Match: 56.00% Indels: 0
 DB: 7 Gaps: 0

US-09-914-053A-5 (1-235) x CK903430 (1-598)

QY 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124
 Db 598 TGCTGGAAATTTCTAGTACCCCTGCTCCAGGTGTACCTTAACCTGACTTCTCCGGG 539
 QY 125 GluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyr 144
 Db 538 GAAAAGCTCTCTCTACACAGAGAGACAAATATAATCAATCAGAGAGTCTCTCTAT 479
 QY 145 IleProLysCysGlyLysAsnPheGluSerMetSerLeuValValMetGlu 164
 Db 478 ATACCTAAATGTGAAAAATTTGAAGATCCATGTCCTGGTGAATGTGTGATGGAA 419
 QY 165 AsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184
 Db 418 AACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGAAACCGAAGAGT 359
 QY 185 ValLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTrpProThr 204
 Db 358 GTTATCTCAACCAACTCTACAGTCCCAAGCTGTGTCTCCATTCACCTTCTGGCCAACC 299
 QY 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224
 Db 298 TGTATGATGGCTGGGGGTGGCAATTTGTGCCATGGTGAACTTACACAGTACCTCTCC 239
 QY 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235
 Db 238 CTACTATGTGAGAGATCCCAACGGATCAATAGA 206

RESULT 13
 CK476300
 LOCUS
 DEFINITION AGNCOURT 17578304 NIH MGC 232 Rattus norvegicus cDNA clone EST 14-JAN-2004
 IMAGE:7122446 5', mRNA sequence.

ACCESSION CK476300
 VERSION CK476300.1 GI:40820398
 KEYWORDS EST.
 SOURCE Rattus norvegicus (Norway rat)
 ORGANISM Rattus norvegicus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
 Rattus.

REFERENCE 1 (bases 1 to 709)
 NIH-MGC <http://mgs.nci.nih.gov/>.
 National Institutes of Health, Mammalian Gene Collection (MGC)
 Unpublished (1999)
 CONTACT: Daniela S. Gerhard, Ph.D.
 Office of Cancer Genomics
 National Cancer Institute / NIH
 Bldg. 31 Rm10A07 Bethesda, MD 20892
 Email: cgaops-remail.nih.gov
 Tissue Procurement: Howard Jacobs
 CDNA Library Preparation: Express Genomics
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Agencourt Bioscience Corporation
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
 Plate: LRAM15008 row: n column: 12
 High quality sequence stop: 710.
 Location/Qualifiers

FEATURES
 source
 1..709
 /organism="Rattus norvegicus"
 /mol_type="mRNA"
 /db_xref="taxon:10116"

ORIGIN

Alignment Scores:
 Pred. No.: 4,87e-69 Length: 709
 Score: 695.00 Matches: 131
 Percent Similarity: 97.78% Conservativeness: 1
 Best Local Similarity: 97.04% Mismatches: 3
 Query Match: 56.00% Indels: 0
 DB: 7 Gaps: 0

US-09-914-053A-5 (1-235) x CK476300 (1-709)

QY 1 MetSerIleTrpThrSerGlyArgThrSerSerTyrArgHisAspGluLysArgAsn 20
 Db 304 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTACAGACAGACAGAGAAAAAAT 363
 QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
 Db 364 ATCTACCAAGAAATCAGGAGCCATGCTCTCTGGACAAAAGGAAACTGTGACACTCTG 423
 QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
 Db 424 AAGGCTGGGAGAGACGGGCAATCTCTGGATGGCCATGATGGTGTCTCCATCATG 483
 QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80
 Db 484 ATGTACTTCTACTGGGAATCACACTGTGCGCTCGTACATGTCAGAGTGTATGGACAGAA 543
 QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
 Db 544 GAAGCCCACTGGCCCTGCTGAATGTGCAATCAGACAGAAACATTTAATCTTCTTCAGC 603
 QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
 Db 604 TGTGGGCTGACTGTGTGAAGCTCTCTCAGTACCTTGCCTGACGATATACGTGAACCTG 663
 QY 121 ThrSerSerGlyLysLeuLeuLeuTyrHisThrGluGluThr 135
 Db 664 ACATCTTCTGGGAGAGCTCTCTCTTACCACAGAGAGACC 708

RESULT 14
 BX729097
 LOCUS
 DEFINITION XCC-tadpole Xenopus tropicalis cDNA clone TTPA078h06 5', mRNA sequence.

ACCESSION BX729097
 VERSION BX729097.1 GI:38401838
 KEYWORDS EST.
 SOURCE Xenopus tropicalis (western clawed frog)
 ORGANISM Xenopus tropicalis
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;
 Xenopodinae; Xenopus; Silurana.

REFERENCE 1 (bases 1 to 852)
 Taylor, J.L., Ashurst, J.L., Zorn, A.M. and Rogers, J.
 Sanger Xenopus tropicalis EST project 2001 (11_2003)
 Unpublished (2003)

/clone="IMAGE:7122446"
 /tissue_type="lung, pooled"
 /lab_host="DH10B_TonA"
 /clone_lib="NIH_MGC_232"
 /note="Organ: lung; Vector: pExpress-1; Site: 1: EcoRV;
 Site 2: NotI; RNA obtained from pooled lung tissue from a
 mix of male and female animals at 8 wk old. Tissues were
 snap-frozen and kept at -80C for two days before RNA
 extraction and purification (Tri-reagent method). cDNA was
 primed using oligo-dT primer:
 5'-pCATAGTCTAGATCGGAGGCGGCCCTT)25-3', and cloned into
 the EcoRV/NotI sites of pExpress-1. Size-selection >1.4kb
 resulted in an average insert size of 2.3 kb. This primary
 library is normalized (non-normalized primary library is
 NIH_MGC 231) and was constructed by Express Genomics
 (Frederick, MD). Note: this is a NIH_MGC library."

COMMENT

Contact: Croning MDR
Sanger Institute
Hinxton, Cambridgeshire, CB10 1SA, UK
Email: trop@anger.ac.uk
Sanger Xenopus tropicalis EST project 2001
TROPICALIS_SEQUENCE_ID: TtpA078h06.plk9p6
Sequencing primer: SP6
This sequence is from a Xenopus Gene Collection (XGC) library
constructed by Nigel Garrett.
cDNA was oligo dT primed from 5' of poly A+ RNA from tadpole
embryos. EcoRI-NotI cut cDNA was then ligated into pCS107 with
EcoRI at the 5' end and NotI at the 3' end.
Vector: pCS107; Site 1: EcoRI; Site 2: NotI
Host: Escherichia coli DH10B.
Location/Qualifiers

FEATURES

source
1..852
/organism="Xenopus tropicalis"
/mol_type="mRNA"
/db_xref="taxon:8364"
/clones="TtpA078h06"
/dev_stages="tadpole (stage 35-40)"
/lab_host="E. coli DH10B"
/clone_lib="XGC-tadpole"
/note="Vector: pCS107; Site 1: EcoRI; Site 2: NotI; cDNA
was oligo dT primed from 5' of poly A+ RNA from tadpole
embryos. EcoRI-NotI cut cDNA was then ligated into pCS107
with EcoRI at the 5' end and NotI at the 3' end"

ORIGIN

Alignment Scores:
Pred. No.: 4..1e-68 Length: 852
Score: 688.00 Matches: 127
Percent Similarity: 95.17% Conservative: 11
Best Local Similarity: 87.59% Mismatches: 7
Query Match: 55.44% Indels: 0
DB: 5 Gaps: 0
US-09-914-053a-5 (1-235) x BX729097 (1-852)

QY 1 MetSerIleTrrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
DB 416 ATGTTTATTTCGACGAGTGGCGGCTCTCGTCATCATACAGCCGATGAAGAAGAAAT 475
QY 21 IleTyrGlnLysIleArgAspHisAspLeuAspLysArgLysThrValThrAlaLeu 40
DB 476 TTCTACCAAAAATCAAGATCATGATCTTCTGACAAAGGAAGAACTGTGCGGCACTA 535
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 536 AAGCAGGAGAGACAGAGCTATATCTCTGGGACTTGCATATGATGGTGTCTCCATTATG 595
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrpThrGlu 80
DB 596 ATGTTATTTCTCTAGGATTAACATTTCTGCGATCATACATGACGCGTATGACAGAA 655
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
DB 656 GAGACACAATGCACATTAATGAATGATCATATACAGAAACCTTCAACTGCTCCTCAGT 715
QY 101 CysGlyPtoAspCysTrrpLysLeuSerGlnTyrProCysLeuGlnValTrrpValAsnLeu 120
DB 716 TGTGGTTCAGATTCTGAGAAATCTTCAGTACCCCTGTCTACAGGTTTATGTAACCTG 775
QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140
DB 776 AATCTTCAGGACAGAGGTCCTTCTCTACACACAGAGAACTATGAAGTAATCT 835
QY 141 LysCysSerTrrpIle 145
DB 836 GAGTNGTCATACATA 850

RESULT 15
CK601161

LOCUS

CK601161 835 bp mRNA linear EST 22-JAN-2004
AGENCOURT 17898293 NIH MGC 234 Rattus norvegicus cDNA clone
IMAGE:7190722 5', mRNA sequence.

ACCESSION

CK601161
VERSION
CK601161.1 GI:41114346
EST.

KEYWORDS

Rattus norvegicus (Norway rat)

SOURCE

Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus

REFERENCE

1 (bases 1 to 835)

AUTHORS

NIH-MGC http://mgc.mci.nih.gov/
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Daniela S. Gerhard, Ph.D.
Office of Cancer Genomics

COMMENT

National Cancer Institute / NIH
Bldg. 31 Rm10A07 Bethesda, MD 20892
Email: cgapbs-remail.nih.gov
Tissue Procurement: Howard Jacobs
cDNA Library Preparation: Express Genomics
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM15048 row: k column: 08
High quality sequence stop: 681.

FEATURES

Location/Qualifiers

1..835
/organism="Rattus norvegicus"
/mol_type="mRNA"
/db_xref="taxon:10116"
/clone="IMAGE:7190722"
/tissue_type="heart, pooled"
/lab_host="DH10B Tona"
/clone_lib="NIH MGC 234"
/note="Organ: heart; Vector: pExpress-1; Site 1: EcoRV;
Site 2: NotI; RNA obtained from pooled heart tissue from a
mix of male and female animals at 8 wk old. Tissues were
snap-frozen and kept at -80C for two days before RNA
extraction and purification (TRI-reagent method). cDNA was
primed using oligo-dT primer:
5'-pGACTAGTTCTAGATCGGCGGCCGCC(T)25-3' and cloned into
the EcoRV/NotI sites of pExpress-1. Size-selection >1.4kb
resulted in an average insert size of 2.2 kb. This primary
library is normalized (non-normalized primary library is
NIH MGC 233) and was constructed by Express Genomics
(Frederick, MD). Note: this is a NIH_MGC library."

ORIGIN

Alignment Scores:
Pred. No.: 1..89e-64 Length: 835
Score: 656.00 Matches: 135
Percent Similarity: 75.54% Conservative: 4
Best Local Similarity: 73.37% Mismatches: 21
Query Match: 52.86% Indels: 24
DB: 7 Gaps: 4

US-09-914-053a-5 (1-235) x CK601161 (1-835)

QY 1 MetSerIleTrrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
DB 298 ATGTTTATATGACAGTGGCGGACCTCTTCACTTACAGACACGACGAGAAAGAAAT 357
QY 21 IleTyrGlnLysIleArgAspHisAspLeuAspLysArgLysThrValThrAlaLeu 40
DB 358 ATCTACCAAGAAATCAGGACCATGACCTCTGACAAAAGAAACTGTGACAGCTCTG 417
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 418 AAGGCTGGGAGGACCGGGCCATCTCTTGGACTGGCCATGATGGTGTCTCCATCATG 477

```
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80
Db 478 ATGTACTTCTTACTGGGAATCACACTGCTGCGTCTGTACATGCAGAGTGTATGGACAGAA 537
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 538 GAAGCCAGTGTGCCCTGCTGAATGTCTCAATCACAGAAACATTTAACTGTTCTTCAGC 597
Qy 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
Db 598 TGTGGGCTCACTGCTGGAAGCTCTCTCACTACCTTGCCTGCAGGTATACGTGAACCTG 657
Qy 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGlu-----GluThrIleLysIle 138
Db 658 ACATCTTCTGGGAGAGCTCTCTCTA---CACACAGAGACATGAGATCATCAAGTG 714
Qy 139 AsnGlnLysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeu 158
Db 715 -----CTC 717
Qy 159 ValAsnValValMetGluAsnPheArgLysTyrGlnHisPheSer-----CysTyrSer 176
Db 718 TATATCTAGTGTGGAAACACTTTGAGATCATGTCCTAGTCTTTTCATCAGACTGCTACGGT 777
Qy 177 AspProGluGly 180
Db 778 GAGACAGCTGGA 789
```

Search completed: November 7, 2004, 03:20:13
Job time : 2967 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: November 6, 2004, 23:41:12 ; Search time 3107 seconds

(without alignments)
3576.788 Million cell updates/sec

Title: US-09-914-053A-5

Perfect score: 1241

Sequence: 1 MSIIWTSGRSTSSSYRHDKRN.....MVKLTQYLSLLCERIQIRINR 235

Scoring table:

BLOSUM62	
Xgapop 10.0 , Xgapext 0.5	
Ygapop 10.0 , Ygapext 0.5	
Fgapop 6.0 , Fgapext 7.0	
Delop 6.0 , Delext 7.0	

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 5053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-Q=/cgn2/1/USPTO.spool.p/US09914053/runat 04112004.183921.18221/app query.fasta_1.391
-DB=GenEmbl -PEMT=fastap -SUFFIX=rge -MINMATCH=0.1 -LOOPT=0 -LOOPT=0
-UNITS=bits -START=1 -END=1 -WATRI-X-blosum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USPR=US09914053@cgn 1.1 5600 @runat 04112004.183921.18221 -NCPU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPEXT=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

GenEmbl.*

1: gb.ba.*

2: gb.htg.*

3: gb.in.*

4: gb.em.*

5: gb.ov.*

6: gb.pat.*

7: gb.ph.*

8: gb.pl.*

9: gb.pr.*

10: gb.ro.*

11: gb.sts.*

12: gb.sy.*

13: gb.un.*

14: gb.vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	1235	99.5	1075	9	AF099137 Homo sapi
2	1235	99.5	1285	9	BC017825 Homo sapi
3	1235	99.5	2574	9	AF209747 Homo sapi
4	1196	96.4	1062	6	C0714334 Sequence

5	1186	95.6	708	10	AY062429	Mus muscu
6	1186	95.6	2947	10	BC046227	Mus muscu
7	1186	95.6	2947	10	BC058957	Mus muscu
8	1185	95.5	708	10	AY191836	Rattus no
9	1117.5	90.0	1546	5	BX950825	Gallus ga
10	1117.5	90.0	1546	5	BX950833	Gallus ga
11	1012	81.5	2098	6	BD223084	98 human
12	1012	81.5	2098	6	AR243782	Sequence
13	821	66.2	487	10	RN0517198	Rattus no
14	510.5	41.1	204899	9	AC117457	Homo sapi
15	509	41.0	815	5	CCU67865	U67865 Coturnix co
16	492.5	39.7	191186	2	AC115077	Mus muscu
17	492	39.6	826	5	AF077369	Gallus ga
18	492	39.6	1290	5	AF420468	Gallus ga
19	487.5	39.3	297398	2	AC097578	Rattus no
20	487.5	38.9	227094	2	AC126508	Rattus no
21	481.5	38.8	1246	6	AR212367	Sequence
22	478.5	38.6	1022	6	C0715541	Sequence
23	478	38.5	1111	6	AR212368	Sequence
24	477.5	38.5	1225	9	AF204159	Homo sapi
25	474.5	38.2	1022	9	AF139471	Homo sapi
26	474.5	38.2	1747	9	AF204161	Homo sapi
27	474	38.2	952	9	AF214561	Homo sapi
28	474	38.2	1160	9	AF170916	Homo sapi
29	474	38.2	1311	9	AF204162	Homo sapi
30	474	38.2	1488	9	AF160968	Homo sapi
31	474	38.2	1620	9	AF204160	Homo sapi
32	421	33.9	576	9	AF026002	Homo sapi
33	421	33.9	576	9	HSU38907	U38907 Human beta-
34	421	33.9	715	9	AY044441	Homo sapi
35	421	33.9	835	9	AY515264	Homo sapi
36	421	33.9	1041	9	HSU42600	Human calci
37	421	33.9	1092	9	HSU61536	Human potas
38	421	33.9	1106	6	AR016453	Sequence
39	421	33.9	1106	6	I45572	Sequence 3
40	421	33.9	1276	6	C0726048	Sequence
41	421	33.9	1277	6	AX337509	Sequence
42	421	33.9	1277	9	HSU25138	U25138 Human MaxiK
43	418	33.7	602	10	RNU46602	Rattus norv
44	418	33.7	1278	10	AF020712	Rattus no
45	415	33.4	680	10	MMCAKBETA	Mus muscu

ALIGNMENTS

RESULT 1	AF099137	1075 bp	linear	PRI 06-APR-1999
LOCUS	AF099137	1075 bp	mRNA	
DEFINITION	Homo sapiens MaxiK channel beta 2 subunit (KCNMB2) mRNA, complete cds.			
ACCESSION	AF099137	GI:4566496		
VERSION	AF099137.1			
KEYWORDS	Homo sapiens (human)			
SOURCE	Homo sapiens			
ORGANISM	Homo sapiens			
REFERENCE	1 (bases 1 to 1075)			
AUTHORS	Wallner,M., Weera,P. and Toro,L.			
TITLE	Molecular basis of fast inactivation in voltage and Ca2+-activated X+ channels: a transmembrane beta-subunit homolog			
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 96 (7), 4137-4142 (1999)			
MEDLINE	99199323			
PubMed	10097176			
REFERENCE	2 (bases 1 to 1075)			
AUTHORS	Wallner,M.			
TITLE	Direct Submission			
JOURNAL	Submitted (16-OCT-1998) Dept. of Anesthesiology, UCLA, BH-612, CHS			
FEATURES	Location/Qualifiers			
source	1..1075			
	/organism="Homo sapiens"			
	/mol_type="mRNA"			

```

/db_xref="taxon:9606"
/clone="IMAGE Consortium ID 1417217"
/tissue_type="neuroendocrine lung carcinoid"
1..1075
/gene="KCNCB2"
CDS
146..853
/gene="KCNCB2"
/function="coexpression with the pore forming Maxik
channel alpha subunit leads to fast inactivating currents
and to an increase in apparent Ca2+ sensitivity"
/note="modulatory subunit of the voltage and Ca2+
activated K+ (Maxik) channel"
/codon_start=1
/product="Maxik channel beta 2 subunit"
/protein_id="AAD23380.1"
/db_xref="GI:4566497"
/translation="MFITWTSRTSSVHDEKRNLYOKIRDHDLDRKTVTALKAGE
DEALLGLAMVCSIMWYFLGILILSYWQSWTERTSQTLINASTETFNCSFSCG
PDCWLSQPCQLQVYNLTSSGEKLLYHIBETIKNKQCSYIPKACGNFEESMLVN
VVMENFRYQHFSQSDPEGNQKSVILTKLYSSNVLPHSLFWPTCMWAGGVAIVAMVK
LTQVLSLCEIRIQINR"
146..202
/misc_feature
/gene="KCNCB2"
/note="intracellular inactivating 'ball' domain;
unclassified site"
287..355
/misc_feature
/gene="KCNCB2"
/note="transmembrane-region site"
728..796
/misc_feature
/gene="KCNCB2"
/note="transmembrane-region site"

ORIGIN
Alignment Scores:
Pred. No.: 9,98e-126 Length: 1075
Score: 1235.00 Matches: 234
Percent Similarity: 99.57% Conservative: 0
Best Local Similarity: 99.57% Mismatches: 1
Query Match: 99.52% Indels: 0
DB: 9 Gaps: 0

US-09-914-053A-5 (1-235) x AF099137 (1-1075)
QY 1 MetSerIleTrrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
DB 146 ATGTTTATATGACGACGAGTGGCGACCTCTCATCTTATGACATGATGAAAAGAAAT 205
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
DB 206 ATTACCAGAAAATCAGGACCATGCTCTGGACAAAAGGAAAACAGTCACGACACTG 265
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 266 AAGCAGAGAGACGACGATCTCTCTGGAGTGGCTATGATGGTGTCTCATCATG 325
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrpThrGlu 80
DB 326 ATGTTATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGGTGGACCGAA 385
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
DB 386 GAGTCTCAATGACCTTGCTGAATGCGTCATCATCGGAAACATTTAACTGCTCTCTCAGC 445
QY 101 CysGlyProAspCysTrrpLysLeuSerGlnTrrpProCysLeuGlnValTrrpValAsnLeu 120
DB 446 TGTGGTCCAGACTGCTGGAACTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTTG 505
QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
DB 506 ACTTCTTCCGGGAAAAGCTCTCTCTTACACACAGAGAGACAAATAAAATCAATCAG 565
QY 141 LysCysSerTrrpIleProLysCysGlyLysAspPheGluSerMetSerLeuValAsn 160

```

566 AAGTGTCTCTATATACCTAAATGTGGAAAAAATTTTGAAGAATCCATGTCCCTGCTGAAT 625
 161 ValValMetGluAspPheArgLysTyrGlnHisPheSerCysTrrpSerAspProGluGly 180
 626 GTTGTCATGGAAACATTCAGGAAGTATCAACACTTCTCTCTGCTATTCGACCAAGA 685
 181 AsnGlnLysSerValIleLeuThrLysLeuTrrpSerSerAsnValLeuPheHisSerLeu 200
 686 AACCAAGAGAGTGTATCTCAACCAACTCTACAGTTCACAGTGTCTGTTCCTCACTC 745
 201 PheTrrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220
 746 TTCTGGCCCAACCTGTATGATGCTGGGGTGTGGCAATTTGTGCCATGTGTGAATTACA 805
 221 GlnTrrpLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
 806 CAGTACTCTCTCTACTATGTGAGAGGATCCACGGAATCAATAGA 850

BC017825 1285 bp mRNA linear PRI 29-JUN-2004
 Homo sapiens potassium large conductance calcium-activated channel,
 subfamily M, beta member 2, transcript variant 1, mRNA (cDNA clone
 MGC:22431 IMAGE:4657825), complete cds.
 BC017825
 BC017825.1 GI:17389593
 MGC.
 Homo sapiens (human)
 SOURCE
 ORGANISM
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 1285)
 Strausberg,R.D., Feingold,E.A., Grouse,L.H., Derge,J.G.,
 Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
 Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
 Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
 Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
 Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
 Schetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
 Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
 Abramson,R.D., Mullany,S.J., Bosak,S.A., McEwan,P.J.,
 McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
 Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
 Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
 Fahey,J., Helton,E., Kettman,M., Madan,A., Rodriguez,S.,
 Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
 Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
 Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
 Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalls,D.E.,
 Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
 Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
 12477932
 2 (bases 1 to 1285)
 Strausberg,R.
 Direct Submission
 Submitted (03-DEC-2001) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA
 NIH-MGC Project URL: <http://mgc.nci.nih.gov>
 Contact: MGC help Desk
 Email: cgabbs-remail.nih.gov
 Tissue procurement: ATCC
 cDNA Library preparation: CLONTECH Laboratories, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNL)
 DNA Sequencing by: Sequencing Group at the Stanford Human Genome
 Center, Stanford University School of Medicine, Stanford, CA 94305
 Web site: <http://www-sngc.stanford.edu>
 Contact: (Dickson, Mark) mcd@paxil.stanford.edu
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
 R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/BLIN at: <http://image.llnl.gov>
Series: IRAL Plate: 36 Row: 1 Column: 8
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 19923319.

FEATURES

Location/Qualifiers
1..1285
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:22431 IMAGE:4657825"
/tissue_type="Testis, embryonal carcinoma"
/clone_lib="NIH_MGC_61"
/lab_host="DH10B"
/notes="vector: pDNR-LIB"
1..1285
/gene="KCMB2"
/notes="synonym: MGC22431"
/db_xref="locusID:10242"
/db_xref="MIM:605214"
344..1051
/gene="KCMB2"
/codon_start=1
/product="calcium-activated potassium channel beta 2 subunit"
/protein_id="AAH17825.1"
/db_xref="GI:17389594"
/db_xref="LocusID:10242"
/db_xref="MIM:605214"
/translations="MTIWTSGRTSSSYRHDENIKYKIRDLKDKRTVTALKAGE
DRAILLGLAMVCSIMMYFLGLITLLRSYMQSVMTESQCTLLNAGITFNCSFCG
PDCWKLKSOYPCLOVYVNTSSGKLLLYHTEETIKINOKCSYIPKCGKNFESMSLVN
VWENPRKYOHPFCSDYDPGNGQSVILTKLYSSNVLPFSLFWPTCMAGGVAIVAMVK
LTQYLSLLCERIQIRNR"

CDS

1..1285
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:22431 IMAGE:4657825"
/tissue_type="Testis, embryonal carcinoma"
/clone_lib="NIH_MGC_61"
/lab_host="DH10B"
/notes="vector: pDNR-LIB"
1..1285
/gene="KCMB2"
/notes="synonym: MGC22431"
/db_xref="locusID:10242"
/db_xref="MIM:605214"
344..1051
/gene="KCMB2"
/codon_start=1
/product="calcium-activated potassium channel beta 2 subunit"
/protein_id="AAH17825.1"
/db_xref="GI:17389594"
/db_xref="LocusID:10242"
/db_xref="MIM:605214"
/translations="MTIWTSGRTSSSYRHDENIKYKIRDLKDKRTVTALKAGE
DRAILLGLAMVCSIMMYFLGLITLLRSYMQSVMTESQCTLLNAGITFNCSFCG
PDCWKLKSOYPCLOVYVNTSSGKLLLYHTEETIKINOKCSYIPKCGKNFESMSLVN
VWENPRKYOHPFCSDYDPGNGQSVILTKLYSSNVLPFSLFWPTCMAGGVAIVAMVK
LTQYLSLLCERIQIRNR"

ORIGIN

Alignment Scores:
Pred. No.: 1.25e-125 Length: 1285
Score: 1235.00 Matches: 234
Percent Similarity: 99.57% Conservative: 0
Best Local Similarity: 99.57% Mismatches: 1
Query Match: 99.52% Indels: 0
DB: 9 Gaps: 0
US-09-914-053A-5 (1-235) x BC017825 (1-1285)
Qy 1 MetSerIleThrSerGlyArgThrSerSerSerTyrrArgHisAspGluLysArgAsn 20
344 ATGTTTATATGACCAATGCGGACCATCTCTTATATAGCATGATGAAAAAGAAAT 403
Qy 21 IletyrglnlyslleArgAspHisAspLeuLeuAspLysArgLysThrValThraLeu 40
404 ATTACCAAGAAATCAGGACCATGACCTCTGACAAAAGGAAACAGTCACGACATG 463
Qy 41 LyslaGlyGluAspArgAlaLeuLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
464 AAGCAGAGAGAGGACCGAGTATTCCTCGGACTGGCTATGATGGTGTCTCATCATG 523
Qy 61 MetTyrrPheLeuLeuGlyIleThrLeuLeuArgSerTyrrMetGlnSerValTrrThrGlu 80
524 ATGATTTTCTGCTGGGAATCACACTCTCGGCTCATCATGACGAGCGTGGACCGAA 583
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
584 GAGTCTCAATGACCTTGTGATGCGTCCATCAGGAAACATTTAACTGCTCTCTCAGC 643
Qy 101 CysGlyProAspCysTrrPysLeuSerGlnTyrrProCysLeuGlnValTrrValAsnLeu 120
644 TGTGGTCCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCAGGGTACGTTACCTG 703
Qy 121 ThrSerSerGlyGluLysLeuLeuLeuTyrrHisThrGluGluThrIleLysIleAsnGln 140

Alignment Scores:

Db 704 ACTTCTTCGGGAAAAAGCTCTCTCTACACACAGAGACAAATAAATCAATCAG 763
Qy 141 LysCysSerTyrrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
Db 764 AAGTCTCTCTATATACCTAAATGTGAAAAAATTTGAAGATCCATCTCCTGTGAAT 823
Qy 161 ValValMetGluAsnPheArgLysTyrrGlnHisPheSerCysTyrrSerAspProGluGly 180
Db 824 GTTGTGATGGAACCTTCTCAGGAAGTATCAACACTTCTCTGCTATCTTGACCCAGAA 883
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrrSerSerAsnValLeuPheHisSerLeu 200
Db 884 AACCAAGAGAGTGTATCTTAACCAAACTCTACAGTTCACACGCTGCTCTCCATTCATC 943
Qy 201 PheTrrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
Db 944 TTCTGCGCAACCTGATGCTGGGGCTGGCAATTTGTGCGATGTTGCGATGTTGAACTTACA 1003
Qy 221 GlnTyrrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db 1004 CAGTACCTCTCCTACTATGTGAGAGGATCCACCGATCAATAGA 1048

RESULT 3

AF209747
LOCUS
DEFINITION
Homo sapiens large conductance calcium-activated potassium channel beta2 subunit (KCMB2) mRNA, complete cds.
ACCESSION
AF209747
VERSION
AF209747.1
GI:7108972
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 2574)
Brenner, R., Jegla, T.J., Wickenden, A., Liu, Y. and Aldrich, R.W.
Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCMB3 and hKCMB4
J. Biol. Chem. 275 (9), 6453-6461 (2000)
JOURNAL
MEDLINE
PUBMED
20158960
10692449
REFERENCE
2 (bases 1 to 2574)
Brenner, R., Jegla, T.J., Wickenden, A., Liu, Y. and Aldrich, R.W.
Direct Submission
Submitted (30-NOV-1999) Molecular and Cell Physiology, Howard Hughes Medical Institute, Stanford School of Medicine, Beckman B173, Stanford, CA 94305, USA
JOURNAL
FEATURES
Location/Qualifiers
1..2574
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue_type="ovary"
1..2574
/gene="KCMB2"
353..1060
/gene="KCMB2"
/note="hKCMB2; large conductance (BK) potassium channel
beta2 subunit"
/codon_start=1
/product="large conductance calcium-activated potassium channel beta2 subunit"
/protein_id="AAF36562.1"
/db_xref="GI:7108973"
/translation="MFIWTSGRTSSSYRHDENIKYKIRDLKDKRTVTALKAGE
DRAILLGLAMVCSIMMYFLGLITLLRSYMQSVMTESQCTLLNAGITFNCSFCG
PDCWKLKSOYPCLOVYVNTSSGKLLLYHTEETIKINOKCSYIPKCGKNFESMSLVN
VWENPRKYOHPFCSDYDPGNGQSVILTKLYSSNVLPFSLFWPTCMAGGVAIVAMVK
LTQYLSLLCERIQIRNR"

gene

CDS

Pred. No.: 2,996-125 Length: 2574
 Score: 1235.00 Matches: 234
 Percent Similarity: 99.57% Conservative: 0
 Best Local Similarity: 99.57% Mismatches: 1
 Query Match: 99.52% Indels: 0
 DB: 9 Gaps: 0

US-09-914-053A-5 (1-235) x AF209747 (1-2574)

QY 1 MetSerIleThrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
 DB 353 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 412

QY 21 IleTyrGlnLysIleArgAspHisAspLeuAspLysThrValThrAlaLeu 40
 DB 413 ATTTACCAAGAAATCAGGAGCATGACCTCTTGACAAAGGAAAAACAGTCACAGCACTG 472

QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
 DB 473 AAGGAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGCTGTGCTCCATCATG 532

QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGlu 80
 DB 533 ATGATATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGAGCGGTGGACCGAA 592

QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
 DB 593 GAGTCTCAATGACCTTGCTGATGCGTCCATCACGGAACATTTAACTGCTCTTCAGC 652

QY 101 CysGlyProAspCysThrPheLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
 DB 653 TGTGCTCCAGACTGCTGGAACCTTTCTCAGTACCCCTCCCTCCAGGTGTACGTTAACTG 712

QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
 DB 713 ACTTCTCCGGGGAAGAGCTCTCTCTACACACAGAGAGACAAATAAAATCATCAG 772

QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
 DB 773 AAGTCTCCTATATACCTAAATATGAAAAAATTTGAAGAAATCCATGCTCCCTGCTGAAT 832

QY 161 ValValMetGluAsnPheArgLysTyrClnHisPheSerCysTyrSerAspProGluGly 180
 DB 833 GTTGTTCATGGAAACTTCAGGAAGTATCAACACTCTCTGCTATTCTGACCCAGGAAGA 892

QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
 DB 893 AACAGAGAAGTGTATCTTAACCAAACTCTACAGTCCCAAGTGTCTTCCATTCATC 952

QY 201 PheThrProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220
 DB 953 TTCTGGCCAACTGATGATGCTGGGGGTGTGCAATTTGTTCATGCTGGAACCTTACA 1012

QY 221 GlnTyrLeuSerLeuLysGluArgIleGlnArgIleAsnArg 235
 DB 1013 CAGTACCTCTCCCTACTATGTGAGAGATCCACGGATCAATAGA 1057

RESULT 4
 CQ714334 1062 bp DNA linear PAT 03-FEB-2004
 LOCUS Sequence 268 from Patent WO02068579.
 DEFINITION CQ714334
 ACCESSION CQ714334.1 GI:42275191
 VERSION
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1
 Venter,C.J., Adams,M.C., Li,P.W. and Myers,E.W.
 TITLE Kites, such as nucleic acid arrays, comprising a majority of
 humanexons or transcripts, for detecting expression and other uses
 thereof

JOURNAL Patent: WO 02068579-A 268 06-SEP-2002;
 PE Corporation (NY) (US)

FEATURES
 source
 1..1062
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

ORIGIN

Alignment Scores:
 Pred. No.: 1,886-121 Length: 1062
 Score: 1196.00 Matches: 234
 Percent Similarity: 98.32% Conservative: 0
 Best Local Similarity: 98.32% Mismatches: 1
 Query Match: 96.37% Indels: 3
 DB: 6 Gaps: 0

US-09-914-053A-5 (1-235) x CQ714334 (1-1062)

QY 1 MetSerIleThrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
 DB 147 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 206

QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysThrValThrAlaLeu 40
 DB 207 ATTTACCAAGAAATCAGGAGCATGACCTCTGGGACAAAGGAAAAACAGTCACAGCACT 266

QY 40 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
 DB 267 GAAGCAGGAGAGGAGCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCAT 326

QY 60 tMetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGlu 80
 DB 327 GATGATATTTCTGCTGGGAATCACACTCTCTGCGCTCATACATGACAGAGCGGTGGACCGA 386

QY 80 uGluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
 DB 387 AGAGTCTCAATGCACCTTGCTGAATGCTGCATACGGAACATTTAACTGCTCTTCAG 446

QY 100 rCysGlyProAspCysThrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLe 120
 DB 447 CTGTGCTCAGACTGCTGGAACCTTCTCAGTACCCCTCCAGGTGTACGTTAACT 506

QY 120 uThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlu 140
 DB 507 GACTTCTTCCGGGGAAGAGCTCTCTCTACACAGAGAGACAAATAAAATCAATCA 566

QY 140 nLysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAs 160
 DB 567 GAAGTCTCTATATACCTAAATGTGAAAAAATTTGAAGAAATCCATGCTCCCTGGTGA 626

QY 160 nValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlu 180
 DB 627 TTTTCTCATGGAACCTTCAGGAAGTATCAACACTCTCTGCTATTCTGACCCAGAGAG 686

QY 180 yAsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLe 200
 DB 687 AAACAGAGAGAGTGTATCTTAACCAAACTCTACAGTTCCAAGCTGCTGTTCATTCAT 746

QY 200 uPheThrProThrCysMetMetAla-GlyGlyValAlaIleValAlaMetValLysLeuT 220
 DB 747 CTCTGCGCAACCTGATGATGCTGGGGGTGTGCAATTTGTGCCATGTGGAACTTA 806

QY 220 hGlnTyrLeuSerLeuLeuCysGluArgIleGlnArg-IleAsnArg 235
 DB 807 CACAGTACCTCTCCCTACTATGTGTAGAGATCCCAACGGGATCAATAGG 854

RESULT 5
 AY062429 708 bp mRNA linear ROD 12-DEC-2001
 LOCUS Mus musculus large conductance calcium-activated K channel beta2
 DEFINITION subunit mRNA, complete cds.
 ACCESSION AY062429

VERSION AV062429.1 GI:17644138
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 708)
AUTHORS Garcia-Valdes J., Eghbali M., Stefani E. and Toro L.
TITLE Mouse kcnmb2 subunit of the large conductance calcium-activated K channel (Maxik, BK)
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 708)
AUTHORS Garcia-Valdes J., Eghbali M., Stefani E. and Toro L.
TITLE Direct Submission
JOURNAL Submitted (14-NOV-2001) Anesthesiology, UCLA, PO Box 957115, BH-509A CHS, Los Angeles, CA 90095-7115, USA
FEATURES
source
1..708
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6"
/db_xref="taxon:10090"
/tissue_type="kidney"
/dev_stage="fetus"
1..708
/notes="inactivating subunit; Maxik; BK; kcnmb2"
/codon_start=1
/product="large conductance calcium-activated K channel beta2 subunit"
/protein_id="AAJ38982.1"
/db_xref="GI:17644139"
/translation="MEFTWTSRTSSRYRQDEKNIYQKIRHDLDPKRTVTKALKE
DRAILLGAMVGSIMVYFLGILTLRSYMQSVTEEAQCALLNITITFNGSFSCG
PDCKLSQYPCLOVYVNLTSGERLLLYHTEETMKINQKCSYIPKGCNNPFESMSIYS
VVENFRHOFHPQYSPDEGNQKSVILTKLYSSNVLFSFLFWPTCNWAGGVAIVAMVK
LTQYLSLLCERIQNRN"

ORIGIN
Alignment Scores:
Pred. No.: 1.41e-120 Length: 708
Score: 1186.00 Matches: 223
Percent Similarity: 97.45% Conservative: 6
Best Local Similarity: 94.89% Mismatches: 6
Query Match: 95.57% Indels: 0
DB: 10 Gaps: 0
US-09-914-053A-5 (1-235) x AY062429 (1-708)
Qy 1 MetSerIleThrSerGlyArgThrSerSerSerTyArgHisAspGluLysArgAsn 20
Db 1 ATGTTTATATGACCAATCAGGACCTCTCTCATCTTACAGACGACGAGAAAGAAAT 60
Qy 21 IletyrglnlyslleAeArgAspHisAspLeuLeuAspLysArgLysThrValThraLeu 40
Db 61 ATCTACCAAGAAATCAGGACCATGACTCTCTGGACAAAGGAAACTGTGACAGCTCTG 120
Qy 41 LyslaGlyGluAspArgAlaalleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
Db 121 AAGGCTGGGAGGACCGGCATCTCTCGGCTGCCATGATGTGTCTCCATCATG 180
Qy 61 MetTyrrPheLeuLeuGlyIleThrLeuLeuArgSerTyrrMetGlnSerValTprThrGlu 80
Db 181 ATGTACTTCTCTGGGAATACACTGCTGGCTCTCTACATGACAGCGGTGGACAGAA 240
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 241 GAAGCCAGTGTGCCCTGTCTGAATGTGTCAATCACAGAAACGTTTAACTGTCTTCAGC 300
Qy 101 CysGlyProAspCysTprLysLeuSerGlnTyrrProCysLeuGlnValTyrrValAsnLeu 120
Db 301 TGTGGGCCCACTGTTGAAGCTCTCTCAGTACCCCTTGCCTGAGGAGTACGTAACCTG 360
Qy 121 ThrSerSerGlyGluLysLeuLeuLeuTyrrHisThrGluGluThrIleLysIleAsnGln 140

Db 361 ACATCTTCGGGAGAGGCTCTCTCTTACACACGAGAGACCATGAATCAATCAA 420
Qy 141 LysCysSerTyrrIleProLysCysGlyLysAsnPheGluGluSerMetSerIleuValAsn 160
Db 421 AAGTGTCTCTATATATCCTAAGTGTGGAACAACACTTGGAGGATCCATGCTCTCTGAGT 480
Qy 161 ValValMetGluAsnPheArgLysTyrrGlnHisPheSerCysTyrrSerAspProGluGly 180
Db 481 GTTCGTATGGAAATTTAGGAGACCAACACTTCCCTGCTATCTTGACCAAGAGA 540
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrrSerSerAsnValLeuPheHisSerIleu 200
Db 541 AACCAAGAGAGTGTCTCTGACCAAACTCTACAGCTCCAATGTCTGTCTCCATTTCTCTC 600
Qy 201 PheTprProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
Db 601 TTCTGGCCAACCTGTATGATGCTGGGTGGCAATCGTGTCTATGTTGAACTAACT 660
Qy 221 GlnTyrrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db 661 CAGTACCTCTCCCTTTGTGAGAGGATCCAAACGATCAACAGA 705
RESULT 6
BC046227 2947 bp mRNA linear ROD 30-JUN-2004
LOCUS Mus musculus potassium large conductance calcium-activated channel,
DEFINITION IMAGE:5703879), complete cds.
ACCESSION BC046227.1 GI:28279339
VERSION Mus musculus (house mouse)
KEYWORDS MGC.
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 2947)
AUTHORS Strausberg R.D., Feingold B.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner D., Shenmen C.W., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Ustin L.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahy J., Helton E., Kettner M., Madan A., Rodriguez S., Sanchez A., Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S., Kzywinski M.I., Skalska U., Smalish D.E., Schnerch A., Schein J.E., Jones S.J. and Marra M.A.
TITLE Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16999-16903 (2002)
PUBMED 12477932
REFERENCE 2 (bases 1 to 2947)
AUTHORS Strausberg R.
TITLE Direct Submission
JOURNAL Submitted (31-JAN-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA
REMARK NIH-MGC Project URL: <http://mgc.ncl.nih.gov>
COMMENT Contact: MGC help desk
Email: cgapbs-re@mail.nih.gov
Tissue Procurement: Dr. Jim Lin, University of Iowa
cDNA Library Preparation: M. Bento Soares, University of Iowa
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: University of Iowa, Dr. M. Bento Soares and Dr.

Thomas L. Casavant.

Web site: <http://genome.uiowa.edu>
 Contact: bento-soares@uiowa.edu; tom-casavant@uiowa.edu
 Bonaldo, M.F., Akabogu, I., Bair, T., Bair, J., Crouch, K., Davis, A.,
 Fishler, K., Keppel, C., Kucaba, T., Lebeck, M., Melo, A., Schaefer, K.,
 Scheetz, T., Smith, C., Snit, E., Tack, D., Trout, K., Walters, J.,
 Casavant, T., Soares, M.B.

Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
 Series: Plate: Row: Column: 0
 This clone was selected for full length sequencing because it
 passed the following selection criteria: matched mRNA gi: 21312299.

FEATURES

source
 1. 2947
 /organism="Mus musculus"
 /mol_type="mRNA"
 /strain="C57BL/6"
 /db_xref="taxon:10090"
 /clone="MGC:57945 IMAGE:5703879"
 /tissue_type="Brain, mouse 15.5 dpc"
 /clone_lib="NIH SWAP_EWC"
 /lab_host="DH10B"
 /note="vector: pYX-ASC"
 1. 2947
 /gene="Kcnmb2"
 /note="synonym: MGC57945"
 /db_xref="LocusID:72413"
 /db_xref="MGI:1919663"
 391..1098
 /gene="Kcnmb2"
 /codon_start=1
 /product="potassium large conductance calcium-activated
 channel, subfamily M, beta member 2"
 /protein_id="AAH46227.1"
 /db_xref="GI:28279340"
 /db_xref="LocusID:72413"
 /db_xref="MGI:1919663"
 /translation="MFVTSSTSSVRQDEKNIYKIRHDLKDKTVALKAGE
 DRAILLGLAMVCSYVFLGILRSYMQSVWTEAQCALLNVSTETFCSPGQ
 PCKNLQYPCLOVYVNLTSGERLLYHTEETKINQKSYIPKCGNFEESKSLVS
 VVMEFRHQRHPCISDPGKQSVILTKYSSNVLPFSLFWPTCMAGGVAIVAVVK
 LTQYLSLCEIRIQINR"

gene

1. 2947
 /gene="Kcnmb2"
 /note="synonym: MGC57945"
 /db_xref="LocusID:72413"
 /db_xref="MGI:1919663"
 391..1098
 /gene="Kcnmb2"
 /codon_start=1
 /product="potassium large conductance calcium-activated
 channel, subfamily M, beta member 2"
 /protein_id="AAH46227.1"
 /db_xref="GI:28279340"
 /db_xref="LocusID:72413"
 /db_xref="MGI:1919663"
 /translation="MFVTSSTSSVRQDEKNIYKIRHDLKDKTVALKAGE
 DRAILLGLAMVCSYVFLGILRSYMQSVWTEAQCALLNVSTETFCSPGQ
 PCKNLQYPCLOVYVNLTSGERLLYHTEETKINQKSYIPKCGNFEESKSLVS
 VVMEFRHQRHPCISDPGKQSVILTKYSSNVLPFSLFWPTCMAGGVAIVAVVK
 LTQYLSLCEIRIQINR"

CDS

1. 2947
 /product="potassium large conductance calcium-activated
 channel, subfamily M, beta member 2"
 /protein_id="AAH46227.1"
 /db_xref="GI:28279340"
 /db_xref="LocusID:72413"
 /db_xref="MGI:1919663"
 /translation="MFVTSSTSSVRQDEKNIYKIRHDLKDKTVALKAGE
 DRAILLGLAMVCSYVFLGILRSYMQSVWTEAQCALLNVSTETFCSPGQ
 PCKNLQYPCLOVYVNLTSGERLLYHTEETKINQKSYIPKCGNFEESKSLVS
 VVMEFRHQRHPCISDPGKQSVILTKYSSNVLPFSLFWPTCMAGGVAIVAVVK
 LTQYLSLCEIRIQINR"

ORIGIN

Alignment Scores:
 Pred. No.: 8 5e-120 Length: 2947
 Scores: 1186.00 Matches: 223
 Percent Similarity: 97.45% Conservative: 6
 Best Local Similarity: 94.89% Mismatches: 6
 Query Match: 95.57% Indels: 0
 DB: 10 Gaps: 0
 US-09-914-053a-5 (1-235) x BC046227 (1-2947)

QY 1 MetSerIleThrThrSerGlyArgThrSerSerSerThrArgHisAspGluLysArgAsn 20
 DB 391 ATGTTTATATGACAGTGGCCGACCTTTCATCTTACAGACGAGGACGAGAAAGAAAT 450
 QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
 DB 451 ATCTACGAGAAATCAGGACCATGACCTCTCTGACAAAGGAAATCTGTGACAGCTCTG 510
 QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
 DB 511 AAGCGTGGGAGGACCGGGCCATCTGCTCGCCCTGGCCCATGATGTTGCTCCATCATG 570
 QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTTPThrGlu 80
 DB 571 ATGACTTCTCTGGGATCAGCTCTGCTGGCTTCTCATGTGACGCGTGTGGACAGAA 630
 QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100

DB 631 GAAGCCAGTGTGCCCTGCTGAATGTGATCATCATCAGAAACGTTTAAGTGTCTTCAGC 690
 QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
 DB 691 TGTGGCCCGAGTGTGGAGGCTCTCTCAGTACCTTGCCTGCAGGTGTACGTGAACCTG 750
 QY 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
 DB 751 ACATCTTCCGGGAGAGGCTCTCTCTTACACAGGAGACCATGAAGTCAATCAA 810
 QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluSerMetSerLeuValAsn 160
 DB 811 AAGTGTCTCATATTCCTAAGTGTGAAACAACTTGAGGAGTCCATGTCTCTCGTGA 870
 QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
 DB 871 GTGTCATGTGAAACCTTCCAGGACACCAACACTTCCCTGCTATCTTGACCCAGAGA 930
 QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
 DB 931 AACCCAGAGAGTGTCTATCTGACCAACTCTACAGCTCCAATGTCTGTCTCCATCTC 990
 QY 201 PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220
 DB 991 TTCTGCCCAACTGTATGATGCTGGGGTGTGGCAATCGTGTGATGTTGAACAACT 1050
 QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
 DB 1051 CAGTACCTTCCCTGCTTGTGAGAGGATCCACGATCCACAGA 1095
 RESULT 7
 BC058957 2947 bp mRNA linear ROD 30-JUN-2004
 LOCUS
 DEFINITION Mus musculus potassium large conductance calcium-activated channel,
 subfamily M, beta member 2, mRNA (CDNA clone MGC:66775
 IMAGE:5703879), complete cds.
 ACCESSION BC058957
 VERSION BC058957.1 GI:37589334
 KEYWORDS MGC.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 2947)
 Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
 Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
 Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
 Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
 Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
 Stapleton, M., Soares, M.B., Bonaldo, M.F., Usdin, T.B., Toshiyuki, S.,
 Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Casavant, T.L.,
 Carninci, P., Prange, C., Raha, S., Loquellano, N.A., Peters, G.J.,
 Abramson, R.D., Mullaly, S.J., Bosak, S.A., McEwan, P.J.,
 McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
 Wootley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
 Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
 Fahey, J., Helton, E., Kettner, M., Madan, A., Rodriguez, S.,
 Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
 Bonfield, W., Blakesley, R.W., Touchman, J.W., Green, E.D.,
 Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
 Butlerfield, Y.S., Krzywicki, M.I., Skalska, U., Smalls, D.E.,
 Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
 Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
 12477932
 2 (bases 1 to 2947)
 Strausberg, R.
 Direct Submission
 Submitted (01-OCT-2003) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA

REMARK
COMMENT

NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgaps-remail.nih.gov
Tissue Procurement: Dr. Jim Lin, University of Iowa
cDNA Library Preparation: M. Bento Soares, University of Iowa
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Genome Sequence Centre,
BC Cancer Agency, Vancouver, BC, Canada
info@bcgsc.bc.ca
Steve Jones, Sarah Barber, Mabel Brown-John, Yaron Butterfield,
Andy Chan, Steve S. Chand, William Chow, Alison Cloutier, Ruth
Featherstone, Malachi Griffith, Obi Griffith, Ran Guin, Nancy Liao,
Kim MacDonald, Amara Masson, Mike R. Mayo, Josh Moran, Ryan Morin,
Teika Olson, Diana Palmquist, Anca Petrescu, Anna Liisa Prabhua,
Parvaneh Saeedi, JR Santos, Angeliue Schnerch, Ursula Skalska,
Duane Smailus, Jeff Stott, Miranda Tsai, George Yang, Jacquie
Schein, Asim Siddiqui, Rob Holt, Marco Marra.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAC Plate: 124 Row: i Column: 16
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 213122399.

FEATURES
source

1. .2947
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6"
/db_xref="taxon:10090"
/clone="MGC:66775 IMAGE:5703879"
/tissue_type="Brain, mouse 15.5 dpc"
/clone_lib="NIH_BMAP_EWO"
/lab_host="DH10B"
/note="Vector: pYX-ASC"
1. .2947
/gene="Kcnmb2"
/note="synonym: MGC57945"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
391. .1098
/gene="Kcnmb2"
/product="potassium large conductance calcium-activated
channel, subfamily M, beta member 2"
/protein_id="AAH58957.1"
/db_xref="GI:37589335"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
/translation="MFEIWTSGRTSSVRODEKRNIVOKIRDHLLDKRTVTALKAGE
DRAILLGMMVCSIMYFLIGITLLRSYQSWTEAQCALLNVSTETENCFSQCG
PDCWKLQYFCLQYVNLTSGERLLIHTETKLNQKCSYIPKCNFNFEESMLVS
VVMENFRHQHPFCYSDPEGNQKSVILTKLYSSNVDPHSLFWPTCMWAGGVAIVAMVK
LTQYLSLLCERIQIRN"

gene

1. .2947
/gene="Kcnmb2"
/note="synonym: MGC57945"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
391. .1098
/gene="Kcnmb2"
/product="potassium large conductance calcium-activated
channel, subfamily M, beta member 2"
/protein_id="AAH58957.1"
/db_xref="GI:37589335"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
/translation="MFEIWTSGRTSSVRODEKRNIVOKIRDHLLDKRTVTALKAGE
DRAILLGMMVCSIMYFLIGITLLRSYQSWTEAQCALLNVSTETENCFSQCG
PDCWKLQYFCLQYVNLTSGERLLIHTETKLNQKCSYIPKCNFNFEESMLVS
VVMENFRHQHPFCYSDPEGNQKSVILTKLYSSNVDPHSLFWPTCMWAGGVAIVAMVK
LTQYLSLLCERIQIRN"

CDS

1. .2947
/gene="Kcnmb2"
/note="synonym: MGC57945"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
391. .1098
/gene="Kcnmb2"
/product="potassium large conductance calcium-activated
channel, subfamily M, beta member 2"
/protein_id="AAH58957.1"
/db_xref="GI:37589335"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
/translation="MFEIWTSGRTSSVRODEKRNIVOKIRDHLLDKRTVTALKAGE
DRAILLGMMVCSIMYFLIGITLLRSYQSWTEAQCALLNVSTETENCFSQCG
PDCWKLQYFCLQYVNLTSGERLLIHTETKLNQKCSYIPKCNFNFEESMLVS
VVMENFRHQHPFCYSDPEGNQKSVILTKLYSSNVDPHSLFWPTCMWAGGVAIVAMVK
LTQYLSLLCERIQIRN"

ORIGIN

Alignment Scores:
Pred. No.: 8.5e-120 Length: 2947
Score: 1186.00 Matches: 223
Percent Similarity: 97.45% Conservative: 6
Best Local Similarity: 94.89% Mismatches: 6
Query Match: 95.57% Indels: 0
DB: 10 Gaps: 0

US-09-914-053A-5 (1-235) x BC058957 (1-2947)
Qy 1 MetSerIleThrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
Db 391 ATGTTATATGACGAGTGGCGGACCTCTTTCATCTTACGACAGGACGAGAAAGAAAT 450
Qy 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db 451 ATCTACGAGAAATCAGGACCATGACCTCTCTGACAAAGAAACTGTGACAGCTCTG 510

Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
Db 511 AAGGCTGGGAGGACCGGGCCATCTCTGCTGGCCCTGGCCATCATGTGTGCTCCATCATG 570
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80
Db 571 ATGTACTTCTCTGCTGGGAATCACACTGTGCTGGCTCTCTACATGTCAGAGGCTGTGGACAG 630
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 631 GAAGCCCTAGTGGCCCTCTGTAATGTGTAATGTCATACAGAAAGCTTTACTGTCTCTTCAGC 690
Qy 101 CysGlyProAspCysTyrPheLeuSerGlnTyrProCysLeuGlnValTrpValAsnLeu 120
Db 691 TGTGGCCCGACTGTGTGAAGCTCTCTCAGTACCCTTGCCTGACGCTGTACGTGAACCTG 750
Qy 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140
Db 751 ACATCTTCGGGGAGAGGCTCTCTCTACCAACGAGAGACCATGAAGATCAATCAA 810
Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluSerMetSerLeuValAsn 160
Db 811 AAGTCTCTCTATATCTTCAAGTGTGAAACAACTTTGAGGAGTCCATGTCTCTCGTGTG 870
Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
Db 871 GTCTGTCATGGAAGAACTTCAGGACACCAACACTTCCCTGCTATTCTGACCCAGAGGA 930
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
Db 931 ACCAGAGAGTGTCTCTGACCAACTCTACAGCTCCATGCTGTGTTCCATCTCTCTC 990
Qy 201 PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220
Db 991 TTCTGCCCAACTGTATGATGCTGGGGGTGTGGCAATCGTTGCTATGCTGTAACAACTA 1050
Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db 1051 CAGTACCTCTCTCTCTGTTGTGAGAGATCCAAACGATCAACAGA 1095
RESULT 8
LOCUS AY191836 708 bp mRNA linear ROD 26-FEB-2003
DEFINITION Rattus norvegicus inactivating beta 2 subunit of large conductance
Ca2+-activated K+ channel mRNA, complete cds.
ACCESSION AY191836
VERSION AY191836.1 GI:28565441
KEYWORDS Rattus norvegicus (Norway rat)
SOURCE Rattus norvegicus
ORGANISM Rattus norvegicus
REFERENCE 1 (bases 1 to 708)
AUTHORS Eghbali,M., Foroughi,S., Toro,L. and Stefani,E.
TITLE Rat inactivating beta 2 subunit of large conductance Ca2+-activated
K+ channel (KCNMB2, rslc beta 2 subunit)
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 708)
AUTHORS Eghbali,M., Foroughi,S., Toro,L. and Stefani,E.
TITLE Direct Submission
JOURNAL Submitted (06-DEC-2002) Anesthesiology, UCLA, PO Box 957115, Room
BH-509A CHS, Los Angeles, CA 90095-7115, USA
FEATURES
source
1. .708
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Sprague-Dawley"
/db_xref="taxon:10116"
/tissue_type="heart; myometrium"
1. .708
/note="KCNMB2; rslc beta 2 subunit"
/codon_start=1
CDS

/product="inactivating beta 2 subunit of large conductance
Ca2+-activated K+ channel"
/protein_id="AA043501.1"
/db_xref="GI:28565442"
/translation="WFIVTSRTSSYRHDKRNIIYQKIRHDLIDRKTWTALKAGE
DRAILGLAMWVCSIMFYLLIGITLIRSYMQSVMTBQAALLNVSITEIFNCFSCG
PCWKLSQPLQVYVNISSGKLLYHTBEETKINQKSYIPKCGNPFESNSLVS
VMENFRHOFPCYSDPEGNQKSVILTKLYSSNVLFHSLEFWPTCMAGGVAIVAMVK
LTQYLSLCCERIQIRNR"
48
variation
/replace="t"
171
variation
/replace="t"
175
variation
/replace="g"
231
variation
/replace="g"
250
variation
/replace="c"

ORIGIN

Alignment Scores:
Pred. No.: 1,82e-120 Length: 708
Score: 1185.00 Matches: 224
Percent Similarity: 97.45% Conservative: 5
Best Local Similarity: 95.33% Mismatches: 6
Query Match: 95.43% Indels: 0
DB: 10 Gaps: 0

US-09-914-053A-5 (1-235) x AY191836 (1-708)

QY 1 MetSerIleTrrThrSerGlyArgThrSerSerTyrArgHisAspGluYeaArgAsn 20
DB 1 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTACACACAGCAGGAGAAAGAAT 60
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
DB 61 ATCTACCAAGAAATCAGGAGCATGACCTCTCGACAAAGAGAAACCTGTGACAGCTCTG 120
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 121 AAGGCTGAGAGAGACCGGCGCATCTGCTTGAGCTGGCCATGATGGTGTCTCCATCATG 180
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrThrGlu 80
DB 181 ATGTACTTCTTACTGGGAATCACACTGCTGGCTCGTACATGCAGAGTGTATGACAGAA 240
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
DB 241 GAAGCCCAAGCTGCTCTCTGAATGTGTCAATCACAGAAACATTTAACTGTCTTCAGC 300
QY 101 CysGlyProAspCysTrrPheLysSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
DB 301 TGTGGCCCTGACTGCTGGAAGCTCTCTCAGTACCCCTTGCCCTGAGGTATACGTGAACCTG 360
QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
DB 361 ACATCTTCTGGGAGAGACTCTCTCTTACCACACAGAGAGACCATGAAGATCAATCAA 420
QY 141 LysCysSerTrrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
DB 421 AAGTGTCTCTATATCTTAAGTGTGGAAACAACTTTGAGAGTCCATGTCCTTGAGT 480
QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
DB 481 GTCGTCAATGAAACCTTCAGGAGACCAACACATCTCCCTGCTATTCTGACCCAGAGGG 540
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
DB 541 AACCAAAAGACGGTCATCTTACCAAACTCTATAGCTTCAATGCTGTGTCTTCTCTC 600
QY 201 PheTrrProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220

DB 601 TTCTGGCCCAACCTGTATGATGCTGGGGGTGTGGCAATCGTTGCTATGTGAACTACT 660
QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
DB 661 CAGTACTCTCCCTGCTGTTTGTAGAGAGATCCCAACGGATCAACAGA 705
RESULT 9
BX950825 1546 bp mRNA linear VRT 17-FEB-2004
LOCUS
DEFINITION
Gallus gallus finished cDNA, clone CHEST48b4.
ACCESSION
BX950825
VERSION
BX950825.1 GI:42600510
KEYWORDS
Gallus gallus (chicken)
ORGANISM
Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus
1 (bases 1 to 1546)
REFERENCE
Boardman,P.E., Bonfield,J.K., Brown,W.R.A., Carder,C., Chalk,S.B.,
Croning,M.D.R., Davies,R.M., Francis,M.D., Graham,D.V.,
Hubbard,S.J., Humphray,S.J., Hunt,P.J., Maddison,M., McLaren,S.R.,
Niblett,D., Overton,I.M., Rogers,J., Scott,C.E., Taylor,R.G.,
Tickle,C. and Wilson,S.A.
Direct Submission
Submitted (16-FEB-2004) Sanger Institute, Hinxton, Cambridgeshire,
CB10 1SA, UK. E-mail enquiries: chickestbms.umist.ac.uk
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST Gallus gallus cDNA
sequencing project.
This sequence is from the
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST cDNA collection,
from a library constructed by Elizabeth Bosch. cDNA was prepared
from RNA extracted from whole embryo, normalised, and poly
A-trimmed. ECoRI-NotI cut cDNA was then ligated into the vector.
Vector: pBluescript II KS(+); Site_1: EcoRI; Site_2: NotI Host:
Escherichia coli DH10B.
FEATURES
Location/Qualifiers
1..1546
/organism="Gallus gallus"
/mol_type="mRNA"
/strain="White Leghorn, Hisex"
/db_xref="taxon:9031"
/clone="CHEST48b4"
/clone_lib="CSQCHN04"
/dev_stage="stage 10"

ORIGIN

Alignment Scores:
Pred. No.: 1,25e-112 Length: 1546
Score: 1117.50 Matches: 210
Percent Similarity: 94.4% Conservative: 12
Best Local Similarity: 89.36% Mismatches: 6
Query Match: 90.05% Indels: 7
DB: 5 Gaps: 1

US-09-914-053A-5 (1-235) x BX950825 (1-1546)

QY 1 MetSerIleTrrThrSerGlyArgThrSerSerTyrArgHisAspGluYeaArgAsn 20
DB 144 ATGTTTATTTGACCAAGTGGCGGAGCTCTACATCTTACACACAGATGAGAA----- 197
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
DB 198 -----AGGGATCACGATCTACTGGCAAAAGAGAAACAGTCACAGCCCTA 242
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 243 AAAGCTGAGAGAGACCGGCGCATACTCTCGGGCTGGCCATGATGGTGTCTTATCATG 302
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrThrGlu 80
DB 303 ATGTACTTCTCTGGGAATCACCTGCTGGCGTCTTACATGCAGAGCGTCTGGACAGAA 362

Qy	81	GlusSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer	100
Db	363	GAGGCTCAGTGGCTGCTTCAACGATCCATCAGCGAAACCTTCAACTGCTCGTTAGC	422
Qy	101	CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu	120
Db	423	TGCGGCCACAGCTGCTGAAAATCTCTCAGTACCCCTGCTGCTGAGGTGTACGTCATCTC	482
Qy	121	ThrSerSerGlyGluLysLeuLeuTyrHisThrGluThrLysIleAsnGln	140
Db	483	ACTTCTTCTGCGCAGAGCTTCTGCTTACACACCGAGAAACAAATGAATAATCTCT	542
Qy	141	LysCysSerTrpIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn	160
Db	543	GAGTGTTCGTACATACCAAGTGTGCAAGATTACGAGGAATCCATGTCATGTTGAC	602
Qy	161	ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly	180
Db	603	GTGTGATGGAAGAACTTCGAAAGATCAACCTTCTCTGCTTCTATGATCCTGAGGC	662
Qy	181	AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu	200
Db	663	ACTCAGAGACGTGATATTGACCAACTGTACAGCTCCACAGCTGCTGTTCCACTCGCTC	722
Qy	201	PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr	220
Db	723	TTCGCGCCACGTGATGATGATCGCGCGCTGTCATTTGTCGATGATAAGCTGACT	782
Qy	221	GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg	235
Db	783	CAATACCTTCTCTCTCTGCGAGAGATCCAAAGAAATCAACAGA	827
US-09-914-053A-5 (1-235) x BX950833 (1-1546)			
Qy	1	MetSerIleTrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn	20
Db	144	ATGTTTATTTGACGAGTGGCGGAGCTTACTATTACAGACACGATGAGAAA-----	197
Qy	21	IleTyrGlnLysIleArgAspHisLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu	40
Db	198	-----AGGATCAGCATCTACTGGGCAAAAGAAAACAGTACACCCCTA	242
Qy	41	LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet	60
Db	243	AAAGCTGGAGAGAACCGGCCATATCTCTGGGCTGGCCATGATGTTGCTCTATCATG	302
Qy	61	MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu	80
Db	303	ATGTACTTCTCTCGGAATCACCTGCTGGGCTCTACATGACAGAGCGTCTGGACAGAA	362
Qy	81	GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer	100
Db	363	GAGGCTCAGTGTCTGCTTCTCAACGATCCATCAGGAAACCTTCAACTGCTGTTAGC	422
Qy	101	CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu	120
Db	423	TGCGGCCACAGCTGCTGAAAATCTCTCAGTACCCCTGCTGCTGAGGTGTACGTCATCTC	482
Qy	121	ThrSerSerGlyGluLysLeuLeuTyrHisThrGluThrLysIleAsnGln	140
Db	483	ACTTCTTCTGCGCAGAGCTTCTGCTTACACACCGAGAAACAAATGAATAATCTCT	542
Qy	141	LysCysSerTrpIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn	160
Db	543	GAGTGTTCGTACATACCAAGTGTGCAAGATTACGAGGAATCCATGTCATGTTGAC	602
Qy	161	ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly	180
Db	603	GTGTGATGGAAGAACTTCGAAAGATCAACCTTCTCTGCTTCTATGATCCTGAGGC	662
Qy	181	AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu	200
Db	663	ACTCAGAGACGTGATATTGACCAACTGTACAGCTCCACAGCTGCTGTTCCACTCGCTC	722
Qy	201	PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr	220
Db	723	TTCGCGCCACGTGATGATGATCGCGCGCTGTCATTTGTCGATGATAAGCTGACT	782
Qy	221	GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg	235
Db	783	CAATACCTTCTCTCTCTGCGAGAGATCCAAAGAAATCAACAGA	827
RESULT 11			
BD223084			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
COMMENT			
FEATURES			
source			
ORIGIN			
ALIGNMENT SCORES:			
Pred. No.:			
Score:			
Percent Similarity:			
Best Local Similarity:			
Query Match:			
DB:			
Length:			
Matches:			
Conservative:			
Mismatch:			
Indels:			
Gaps:			
2098 bp			
DNA			
linear			
PAT 17-JUL-2003			
98 human secretory proteins.			
BD223084			
BD223084			
BD223084.1			
UP 2002521055-A/19.			
Homo sapiens			
ORGANISM			
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
1 (bases 1 to 2098)			
Komatsoulis, G.A., Rosen, C.A., Ruben, S.M., Duan, R., Moore, P.A.,			
Shi, Y., Lafleur, D., Wei, Y.F., Ni, J., Florence, K.A., Young, P.E.,			

Brewer, L.A., Soppet, D.R., Endress, G.A., Ebner, R., Olsen, H.S. and Mucenski, M.
 98 human secretory proteins
 Patent: JP 2002521055-A 19 16-JUL-2002;
 HUMAN GENOME SCIENCES INC
 OS Homo sapiens (human)
 PN JP 2002521055-A/19
 PD 16-JUL-2002
 PF 29-JUL-1999 JP 2000562480
 PR 30-JUL-1998 US 60/094657, 05-AUG-1998 US 60/095486 PR
 06-AUG-1998 US 60/095455, 06-AUG-1998 US 60/095454 PR
 12-AUG-1998 US 60/096319
 PI GEORGE A. KOMATSOUKIS, CRAIG A. ROSEN, STEVEN
 M. RUBEN, ROXANNE DUAN,
 PI PAUL A. MOORE, YANGGU SHI, DAVID LAFLEUR, YING PEI WEI, JIAN NI, PI
 KIMBERLY A. FLORENCE, PAUL E. YOUNG, LAURIE A. BREWER, DANIEL R. PI
 SOPPET,
 PI GREGORY A. ENDRESS, REINHARD EBNER, HENRIK S. OLSEN, MICHAEL PI
 MUCENSKI
 PC C12N15/09, A61K31/713, A61K38/00, A61K48/00, C07K14/47, C07K16/18,
 PC C12N1/15,
 PC C12N1/19, C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/68, G01N33/ PC
 15,
 G01N33/50, G01N33/53//A61P1/18, A61P5/02, A61P5/06, A61P5/14, A61P9/ PC
 10,
 PC A61P11/06, A61P17/06, A61P19/02, A61P25/02, A61P25/14, A61P25/16,
 PC A61P25/24,
 PC A61P25/28, A61P27/02, A61P29/00, A61P31/18, A61P35/02, C12N15/00,
 PC C12N5/00,
 PC A61K37/02
 CC 98 human secretory proteins
 PH key Location/Qualifiers
 FT source 1..2098
 /organism="Homo sapiens (human)"
 /location/Qualifiers
 1..2098
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

ORIGIN

Alignment Scores:
 Pred. No.: 7,01e-101 Length: 2098
 Score: 1012.00 Matches: 191
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 81.55% Indels: 0
 DB: 6 Gaps: 0

US-09-914-053A-5 (1-235) x BD223084 (1-2098)

QY 45 AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64
 DB 10 GACCGAGCTATTCCTGGGACTGGCTATGATGGTGCTCCATCATGATGATTTCTG 69
 QY 65 LeuGlyIleThrLeuLeuAArgSerTyrMetGlnSerValTrpThrGluGluSerGlnCys 84
 DB 70 CTGGGAATCACACTCTCGCTCATACATGCAGACGCTGTGGACCGAAGAGTCTCAATGC 129
 QY 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104
 DB 130 ACCTTGCTGAATGCTCCATCAGGAACATTTAATGCTTCCTTCAGCTGTGGTCCAGAC 189
 QY 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124
 DB 190 TGCTGGAAACTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACCTGACTTCTTCGGG 249
 QY 125 GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr 144
 DB 250 GAAAGCTCTCTCTACACACAGAGAGACAATAAATAATCAATCAGAGAGTCTCTCTAT 309

QY 145 IleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValValMetGlu 164
 DB 310 ATACCTAAATGTGGAAAAATTTTGAAGAATCCATGCTCCCTGGTGAATGTTGTCTATGAA 369
 QY 165 AsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184
 DB 370 AACTTCAGGAAGTATCAACACTTCTCTGCTATTCTGACCCAGAGAAACAGAGAGT 429
 QY 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTrpProThr 204
 DB 430 GTTATCTCAACAAACTCTACAGTTCACAGTTCCTCAATTCCTCTCTGGCCAAAC 489
 QY 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224
 DB 490 TGTATGATGGCTGGGGGTGTGGCAATTTGCAATGTTGCAATGTTGAAACTTACACAGTCTCTCC 549
 QY 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235
 DB 550 CTACTATGTGAGAGGATCCACGGATCAATAGA 582

RESULT 12
 AR243782
 LOCUS
 DEFINITION
 Sequence 20 from patent US 6476195.
 AR243782
 ACCESSION
 AR243782.1 GI:27291275
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM
 Unknown.
 Unclassified.
 REFERENCE
 1 (bases 1 to 2098)
 Komatsoulis, G., Rosen, C.A., Ruben, S.M., Duan, R.D., Moore, P.A.,
 Shi, Y., Lafleur, D.W., Wei, Y.-F., Ni, J., Florence, K.A., Young, P.,
 Brewer, L.A., Soppet, D.R., Endress, G.A., Ebner, R., Olsen, H. and
 Mucenski, M.
 TITLE
 Secreted protein HNPF20
 JOURNAL
 Patent: US 6476195-A 20 05-NOV-2002;
 FEATURES
 Location/Qualifiers
 1..2098
 /organism="unknown"
 /mol_type="genomic DNA"

ORIGIN

Alignment Scores:
 Pred. No.: 7,01e-101 Length: 2098
 Score: 1012.00 Matches: 191
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 81.55% Indels: 0
 DB: 6 Gaps: 0

US-09-914-053A-5 (1-235) x AR243782 (1-2098)

QY 45 AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64
 DB 10 GACCGAGCTATTCCTGGGACTGGCTATGATGGTGCTCCATCATGATGATTTCTG 69
 QY 65 LeuGlyIleThrLeuLeuAArgSerTyrMetGlnSerValTrpThrGluGluSerGlnCys 84
 DB 70 CTGGGAATCACACTCTCGCTCATACATGCAGACGCTGTGGACCGAAGAGTCTCAATGC 129
 QY 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104
 DB 130 ACCTTGCTGAATGCTCCATCAGGAACATTTAATGCTTCCTTCAGCTGTGGTCCAGAC 189
 QY 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124
 DB 190 TGCTGGAAACTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACCTGACTTCTTCGGG 249
 QY 125 GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr 144
 DB 250 GAAAGCTCTCTCTACACACAGAGAGACAATAAATAATCAATCAGAGAGTCTCTCTAT 309

```
QY 145 IleProLysCysGlyLysAsnPhesGluGluSerMetSerLeuValAsnValMetGlu 164
Db 310 ATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTGTTGAATGTTGTCATGGAA 369
QY 165 AsnPhesArgLysTyrGlnHisPhesSerCysTyrSerAspProGluGlyAsnGlnLysSer 184
Db 370 AACTTTCAGGAAGTATCAACACTTCTCTGCTATTCTGACCCAGAGAAACCAAGAGAGT 429
QY 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTyrProThr 204
Db 430 GTTATCTCAACAACACTACAGTTCACAGTCCACAGTGTCTGTTCCATTCACCTCTTCGSCCAACC 489
QY 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224
Db 490 TGTATGATGGCTGGGGGTGTGGCAATTTGTTGCCATGTTGAACTTACACAGTACCTCTCC 549
QY 225 LeuLeuCysGlnArgIleGlnArgIleAsnArg 235
Db 550 CTACTATGTGAGAGATCCACGGATCAATAGA 582

RESULT 13
RNO517198 487 bp mRNA linear ROD 15-DEC-2002
LOCUS Rattus norvegicus partial mRNA for calcium-activated potassium channel beta 2 subunit (Kcnmb2 gene).
DEFINITION
ACCESSION AJ517198.1 GI:26801163
VERSION calcium-activated potassium channel beta 2 subunit; Kcnmb2 gene.
KEYWORDS Rattus norvegicus (Norway rat)
SOURCE Rattus norvegicus
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
REFERENCE 1
AUTHORS Langer, P., Grunder, S. and Rusch, A.
TITLE Expression of Ca2+-activated BK channel mRNA and its splice variants in the rat cochlea
JOURNAL J. Comp. Neurol. 455 (2), 198-209 (2003)
MEDLINE 22342043
PUBMED 12454985
REFERENCE 2 (bases 1 to 487)
AUTHORS Langer, P.
TITLE Direct Submission
JOURNAL Submitted (16-NOV-2002) Langer P., Institute of Physiology II, University of Tuebingen, Gmelinstr. 5, Tuebingen, D-72076, GERMANY
FEATURES
source
Location/Qualifiers
1..487
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Wistar"
/db_xref="taxon:10116"
/tissue_type="brain"
1..487
/gene="Kcnmb2"
<1..>487
/gene="Kcnmb2"
/function="ion channel"
/codon_start=2
/product="calcium-activated potassium channel beta 2 subunit"
/protein_id="CAD56888.1"
/db_xref="GI:26801164"
/db_xref="GOA:Q8CF83"
/db_xref="TrEMBL:Q8CF83"
/translation="LKAGEDRAILLGLAMVCSIMYVFLLGITLLRSYMQSVMTERRAQ
CALLINVSITETFNCSFGGPDCKLSQYPCIQVYVNLTSSEKLLVHTETWKINQ
CSYTPKGNFEESMSLVSVNFRHQHPFCISDPGQKSVILTKLYSSNVLFHS
LF"

gene
CDS
1.04e-80 Length: 487
821.00 Matches: 153

ORIGIN
Alignment Scores:
Pred. No.:
Score:
```

```
Percent Similarity: 97.53% Conservative: 5
Best Local Similarity: 94.44% Mismatches: 4
Query Match: 66.16% Indels: 0
DB: 10 Gaps: 0
US-09-914-053A-5 (1-235) x RNO517198 (1-487)
QY 40 LeuLysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIle 59
Db 2 CTGAAGGCTGGAGAGACCGGGCCATCTGCTTGACTGGCCATGATGGTGTGCTCCATC 61
QY 60 MetMetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThr 79
Db 62 ATGATGATCTTCTACTCTGGGAATCACTGCTGCCCTGTCATCGACAGAGTGTGGACA 121
QY 80 GluGluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPhe 99
Db 122 GAAGAAGCCCACTGTGCTGCTGAATGTGTCATCACAGAAACATTTAACTGTTCTTC 181
QY 100 SerCysGlyProAspCysTyrLysLeuSerGlnTyrProCysLeuGluValTyrValAsn 119
Db 182 AGCTGTGGCCCTGACTGTGGAAAGTCTCTCAGTACCTTGCTCGAGGTATACGTGAAC 241
QY 120 LeuThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsn 139
Db 242 CTGACATCTTCTGGGAGAGAGCTCTCTCTACACACAGAGAGACCATGAATCAAT 301
QY 140 GlnLysCysSerTyrIleProLysCysGlyLysAsnPhesGluGluSerMetSerLeuVal 159
Db 302 CAAAAGTGTCTCTATATTCTTAAGTGTGAAACAACTTTGAGGAGTCCATGTCCTTGG 361
QY 160 AsnValValMetGluAsnPhesArgLysTyrGlnHisPhesSerCysTyrSerAspProGlu 179
Db 362 AGTGTGCTCATGGAAAACCTTCAGGAGACACCAACTTCCCTGCTATTCTGACCCAGAA 421
QY 180 GlyAsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSer 199
Db 422 GGGAAACCAAGAGGCGTCATCTCGACCAACTCTATAGTCCAAATGCTGCTGCTTCCATT 481
QY 200 LeuPhe 201
Db 482 CTCCTC 487

RESULT 14
RNO517457 204899 bp DNA linear PRI 25-FEB-2003
LOCUS Homo sapiens 3 BAC RP11-385J1 (Roswell Park Cancer Institute Human BAC Library) complete sequence.
DEFINITION
ACCESSION AC117457
VERSION AC117457.11 GI:28557825
KEYWORDS HTG.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 204899)
Muzny, D.M., Adams, C., Adio-Oduola, B., Ali-Osman, F.R., Allen, C., Alsbrooks, S.L., Amaral, H.C., Are, J.R., Ayale, M., Banks, T., Barbara, J., Benton, J., Bimage, K., Blankenburg, K., Bonnin, D., Bouck, J., Bowie, S., Brieva, M., Brown, E., Brown, M., Bryant, N.P., Buhay, C., Burch, P., Burkett, C., Burrell, K.L., Byrd, N.C., Caron, T.F., Carter, M., Cavazos, S.R., Chacko, J., Chavez, D., Chen, G., Chen, R., Chen, Z., Chowdhry, I., Christopoulos, C., Cleveland, C.D., Cox, C., Coyle, M.D., Dathorne, S.R., David, R., Davila, M.L., Davis, C., Davy-Carroll, L., Dederich, D.A., Delaney, K.R., Delgado, O., Denn, A.L., Ding, Y., Dinh, H.H., Douthwaite, K.J., Draper, H., Dugan-Rocha, S., Durbin, K.J., Earnhart, C., Edgar, D., Edwards, C.C., Elhaj, C., Escotto, M., Falls, T., Ferraguto, D., Flagg, N., Ford, J., Foster, P., Frantz, P., Gabisi, A., Gao, J., Garcia, A., Garner, T., Garza, N., Gill, R., Gorrell, J.H., Guevara, W., Gunaratne, P., Hale, S., Hamilton, K., Harris, C., Harris, K., Hart, M., Havlak, P., Hawes, A., He, X., Hernandez, J., Hernandez, O., Hodgson, A., Hogues, M., Holloway, C.,
```


Hollins, B., Honsi, F., Howard, S., Huber, J., Hulyk, S., Hume, J., Jackson, L. E., Jacobson, B., Jia, Y., Johnson, R., Jolivet, S., Joudah, S., Karlsson, E., Kelly, S., Khan, U., King, L., Korvan, J., Kovar, C., Kravovic, J., Kresh, A., Landry, N., Leal, B., Lewis, L. C., Lewis, L., Li, J., Li, Z., Lichtarge, O., Lieu, C., Liu, J., Liu, W., Louised, H., Lozano, R. J., Lu, X., Lucier, A., Lucier, R., Luna, R., Ma, J., Maheshwari, M., Mapus, P., Martin, R., Martindale, A., Martinez, E., Massey, B., Mawhney, B., McLeod, M. P., Meador, M., Mei, G., Metzker, M., Miner, G., Miner, Z., Mitchell, T., Mohabhat, K., Moore, S., Moran, M., Moorish, T., Morris, S., Moser, M., Neal, D., Nelson, D., Newton, J., Newton, N., Nguyen, A., Nguyen, N., Nguyen, N., Nickerson, E., Nwokenkwo, S., Oguh, M., Okwuonu, G., Oragunye, N., Oviedo, R., Pace, A., Payton, B., Peery, J., Perez, L., Peters, L., Pickens, R., Primus, E., Fu, L. L., Quiles, M., Ren, Y., Rives, M., Rojas, A., Rojibokan, I., Rolfe, M., Ruiz, S., Savery, G., Scherer, S., Scott, G., Shen, H., Shoohtari, N., Sison, I., Sodergren, E., Sotnik, T., Sparks, A., Stanley, H., Stone, H., Sutton, A., Svatek, A., Tabor, P., Tamerisa, A., Tamerisa, K., Tang, H., Tansey, J., Taylor, C., Taylor, T., Telford, B., Thomas, N., Thomas, S., Umami, K., Vasquez, L., Vera, V., Villalob, D., Vinson, R., Wang, Q., Wang, S., Ward-Moore, S., Warren, R., Washington, C., Watlington, S., Williams, G., Williamson, A., Wleczky, R., Wooden, S., Worley, K., Wu, C., Wu, Y., Wu, Y. F., Zhou, J., Zorrilla, S., Naylor, S. L., Weinstein, G. and Gibbs, R.

Direct Submission
Unpublished
2 (bases 1 to 204899)
Worley, K.C.
Direct Submission
Submitted (10-APR-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
3 (bases 1 to 204899)
Worley, K.C.
Direct Submission
Submitted (22-FEB-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
4 (bases 1 to 204899)
Worley, K.C.
Direct Submission
Submitted (25-FEB-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
On Feb 25 2003 this sequence version replaced gi:28467084.
INFORMATION: <http://www.hgsc.bcm.tmc.edu/> or email gc-help@bcm.tmc.edu

CLONE LENGTH: This sequence does not necessarily represent the entire insert of this clone. Overlapping regions of clones are only sequenced and submitted once, so the sequence for the remainder of the insert may be found in the record for the adjacent clones. Overlapping clones are noted at the beginning and end of the features listing.

ANNOTATION OF FEATURES:

STSs are identified using ePCR (Genome Res. 7:541-550) searches of a local database that includes entries from dbSTS, GDB, and local mapping efforts.

Repeats are identified using RepeatMasker (A. Smit and P. Green, unpublished.) for Human and Mouse sequences.

Genes and region of sequence similarity are identified by BLAST (Nuc. Acids Res. 25:3389-3402) similarity (expect < 1e-34) to the EST and cDNA sequences. Genes demonstrate at least two exons flanked by consensus splice sites that maintained sequence continuity across the splice junctions. Sequences that are not identical matches are annotated as similar.

SEQUENCING READ COVERAGE: Sequencing is completed to a minimum standard of double strand coverage with a minimum of 2 clones and 2 reads with no ambiguities or 2 chemistries with a minimum of 2 clones and 3 reads with no ambiguities. If the sequence quality for a region does not meet this standard, it will be indicated in the

annotation as Low Coverage.

QUALITY OF INDIVIDUAL BASES: This sequence meets stringent quality standards - estimated error rate less than 1 per 10,000 bases. Reports of lowest quality individual bases and measures of base quality are listed below. Description of the metrics can be found at URL:

<http://www.hgsc.bcm.tmc.edu:8088/quality.info/genbank.annotation.ht>

FEATURES	source	Location/Qualifiers
		1..204899
		/organism="Homo sapiens"
		/mol_type="genomic DNA"
		/db_xref="taxon:9606"
		/chromosomes="3"
		/clone="RP11-385J1"
		/complement(1..2000)
		/notes="overlaps bases 1..2000 of clone AC139661"
		/function="clone overlap"
		/complement(501..659)
		/rpt_family="L2"
		/complement(1481..1546)
		/rpt_family="L2"
		1611..1689
		/rpt_family="MLT1B"
		1694..1879
		/rpt_family="MER2"
		1893..1922
		/rpt_family="AT-rich"
		1964..2082
		/rpt_family="MLT1B"
		2083..2421
		/rpt_family="MLT1A1"
		2422..2587
		/rpt_family="MLT1B"
		/complement(2948..3005)
		/rpt_family="L2"
		/complement(4400..4536)
		/rpt_family="L2"
		/complement(5059..5175)
		/rpt_family="MER20"
		/complement(5428..5572)
		/rpt_family="MIR"
		/complement(5578..5707)
		/rpt_family="MIR"
		/complement(7008..7250)
		/rpt_family="MIR"
		7575..7962
		/rpt_family="L2"
		/complement(10792..10921)
		/rpt_family="MIR"
		/complement(11688..11850)
		/rpt_family="MIR"
		/complement(12469..13201)
		/rpt_family="MER49"
		13643..13814
		/rpt_family="L2"
		13815..13840
		/rpt_family="(TTG)n"
		13841..13878
		/rpt_family="L2"
		/complement(13891..13953)
		/rpt_family="L1PA2"
		/complement(14053..14222)
		/rpt_family="FRAM"
		15886..15985
		/rpt_family="MERSB"
		15990..16149
		/rpt_family="MIR"
		/complement(16360..16474)
		/rpt_family="MIR"
		16570..16676
		/rpt_family="L2"


```
repeat_region 16945..17166
/rpt_family="MIR"
repeat_region complement(17322..17473)
/rpt_family="MER33"
repeat_region 17474..18315
/rpt_family="L1PAL6"
repeat_region complement(18329..18510)
/rpt_family="MER33"
repeat_region 18610..19373
/rpt_family="L1MA8"
repeat_region 19374..19673
/rpt_family="AluSp"
repeat_region 19674..19760
/rpt_family="L1MA8"
repeat_region 20088..20127
/rpt_family="MER5B"
repeat_region 20874..20893
/rpt_family="(GA)n"
repeat_region complement(21009..21423)
/rpt_family="MER39"
repeat_region 22482..22503
/rpt_family="AT-rich"
repeat_region 24182..24476
/rpt_family="AluY"
repeat_region 24861..24881
/rpt_family="AT-rich"

Alignment Scores:
Pred. No.: 2,54e-43 Length: 204899
Score: 510.50 Matches: 120
Percent Similarity: 52.00% Conservative: 23
Best Local Similarity: 43.64% Mismatches: 31
Query Match: 41.14% Indels: 103
DE: 9 Gaps: 6

US-09-914-053A-5 (1-235) x AC117457 (1-204899)

Qy 44 GluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyPhe 63
Db 176994 AARGATAAGAGTACTACTACITTCCTCGAGAACTGGTAAGTTTATGTATGTGGAC- 177052
Qy 64 LeuLeuGlyIleThr----- 68
Db 177053 AGATGTGGCAGACAGAAATGATGCGAGATTGACATCTGATTCCTAATAAGAGATGTT 177112
Qy 69 -----LeuLeuAsnGlySerValThrThrGluGlySerValThrGluGlySerValThr 85
Db 177113 CAATAGAAATATATATAAACCCTACATACCTAGTATGCGAAAGAAATCC----- 177163
Qy 86 LeuLeuAsnAlaSerIleThrGluThrPheAsnGlySerPheSerCysGlyProAsp--- 104
Db 177164 -----TGGGAATCATTTAATTTATTTACGATCGAATGGAATGA 177205
Qy 104 ----- 104
Db 177206 TTAATCAAGCTAATTAACATATCTATCATTTTATTTCAATCAATAATAATATATGGGT 177265
Qy 105 -----Cys--- 105
Db 177266 GAGCAATCAAGGACATCTTGGTCAGATACCTTAAACATTTGTTTAAATCAATGTGTTAT 177325
Qy 106 -----TrpLeuLeu 108
Db 177326 TTATTAGGGTTTCCAAAGCCACCAGTTTGAATATGAAAGAAATAACCAATGTTT-ATT 177384
Qy 109 SerGln-----TyrProCysLeuGlnValTyValAsnLeu 120
Db 177385 TCACAGATCACTAATTGGACACATACTCCACCCCTCTAGAGTCTCAACACACATA 177444
Qy 121 ThrSerSerGlyGluLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 140
Db 177445 GTATCTTCTAGTAACAGTTTA-----TCTTATCTCCA 177477
```

